HIV/AIDS surveillance in Europe 2024 : 2023 data.
Date: 2025-01-15
Institutions: European Centre for Disease Prevention and Control, World Health Organization
Subjects: AIDS, activity report, disease prevention, disease surveillance, epidemiology, health control, health statistics, public health

HIV/AIDS surveillance in Europe

2024

2023 data

HIV/AIDS surveillance in Europe

2024

2023 data

Abstract
HIV  infection  continues  to  affect  the  health  and  well-being 
of  nearly  2.6  million  people  in  the  WHO  European  Region, 
particularly  in  the  eastern  part  of  the  Region.  This  report 
is  the  latest  in  a  series  published  jointly  by  the  European 
Centre  for  Disease  Prevention  and  Control  (ECDC)  and  the 
WHO  Regional  Office  for  Europe  that  has  been  reporting 
data  on  HIV  and  AIDS  in  the  WHO  European  Region  and  in 
the  European  Union  and  European  Economic  Area  (EU/EEA) 
since 2007. It finds that while epidemic patterns and trends 
vary  widely  across  European  countries,  nearly  113  000 
people were diagnosed with HIV in the European Region in 
2023, including around 25 000 in the EU/EEA.

Keywords

ACQUIRED IMMUNODEFICIENCY SYNDROME 
– EPIDEMIOLOGY

AIDS – PREVENTION AND CONTROL

DISEASE OUTBREAKS – STATISTICS

HIV INFECTIONS – EPIDEMIOLOGY

POPULATION SURVEILLANCE

© World Health Organization 2024

Creative 

is  available  under 
Some  rights  reserved.  This  work 
Attribution-NonCommercial-
the 
ShareAlike  3.0  IGO  licence  (CC  BY-NC-SA  3.0  IGO;  https://
creativecommons.org/licenses/by-nc-sa/3.0/igo). 

Commons 

Under the terms of this licence, you may copy, redistribute 
and adapt the work for non-commercial purposes, provided 
the  work  is  appropriately  cited,  as  indicated  below.  In 
any  use  of  this  work,  there  should  be  no  suggestion  that 
WHO  endorses  any  specific  organization,  products  or 
services.  The  use  of  the  WHO  logo  is  not  permitted.  If  you 
adapt  the  work,  then  you  must  license  your  work  under 
the  same  or  equivalent  Creative  Commons  licence.  If 
you  create  a  translation  of  this  work,  you  should  add  the 
following  disclaimer  along  with  the  suggested  citation: 
“This  translation  was  not  created  by  the  World  Health 
Organization (WHO). WHO is not responsible for the content 
or accuracy of this translation. The original English edition 
shall be the binding and authentic edition”. 

Any mediation relating to disputes arising under the licence 
shall  be  conducted  in  accordance  with  the  mediation  rules 
of  the  World  Intellectual  Property  Organization.  (http://
www.wipo.int/amc/en/mediation/rules/)

Cataloguing-in-Publication (CIP) data. CIP data are available 
at http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, 
see http://apps.who.int/bookorders. To submit requests for 
commercial  use  and  queries  on  rights  and  licensing,  see 
http://www.who.int/about/licensing. 

Third-party  materials.  If  you  wish  to  reuse  material  from 
this work that is attributed to a third party, such as tables, 
figures  or  images,  it  is  your  responsibility  to  determine 

whether  permission  is  needed  for  that  reuse  and  to  obtain 
permission  from  the  copyright  holder.  The  risk  of  claims 
resulting  from 
infringement  of  any  third-party-owned 
component in the work rests solely with the user.

Maps.  All  maps  included  in  this  publication  are  ©  World 
Health  Organization  2024.  Reproduction  or  translation 
of  substantial  portions  of  the  maps  require  explicit,  prior 
authorization  of  WHO.  To  request  permission  to  use  the 
maps,  please  complete  the  permissions  form  available 
by 
link:  https://www.who.int/about/who-we-are/
publishing-policies/permissions.

this 

General  disclaimers.  The  designations  employed  and  the 
presentation  of  the  material  in  this  publication  do  not 
imply  the  expression  of  any  opinion  whatsoever  on  the 
part  of  WHO  concerning  the  legal  status  of  any  country, 
territory,  city  or  area  or  of  its  authorities,  or  concerning 
the  delimitation  of  its  frontiers  or  boundaries.  Dotted  and 
dashed  lines  on  maps  represent  approximate  border  lines 
for which there may not yet be full agreement.

The  mention  of  specific  companies  or  of  certain 
manufacturers’  products  does  not  imply  that  they  are 
endorsed or recommended by WHO in preference to others 
of  a  similar  nature  that  are  not  mentioned.  Errors  and 
omissions excepted, the names of proprietary products are 
distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify 
the information contained in this publication. However, the 
published material is being distributed without warranty of 
any  kind,  either  expressed  or  implied.  The  responsibility 
for  the  interpretation  and  use  of  the  material  lies  with  the 
reader. In no event shall WHO be liable for damages arising 
from its use. 

The  WHO  Regional  Office  for  Europe  is  responsible  for  the 
accuracy of the translation of the Russian summary.

© European Centre for Disease Prevention and Control 2024

This  publication  follows  WHO  terminological  practice. 
The  names  and  designations  of  countries  used  in  this 
publication  should  not  be  understood  as  an  endorsement 
by  ECDC  of  the  terminology  used.  The  designations  used, 
and the presentation of the maps therein, do not represent 
ECDC’s  official  position  on  the  legal  status  of  any  country, 
territory, city or area or of its authorities, or the delimitation 
of its frontiers and boundaries.

Cover picture: NIAID

Suggested  citation  for  full  report.  WHO  Regional  Office 
for  Europe,  European  Centre  for  Disease  Prevention  and 
Control. HIV/AIDS surveillance in Europe 2024 – 2023 data. 
Copenhagen: WHO Regional Office for Europe; 2024.

Suggested  citation  for  tables  and  figures.  WHO  Regional 
Office  for  Europe,  European  Centre  for  Disease  Prevention 
and  Control.  HIV/AIDS  surveillance  in  Europe  2024  –  2023 
data.

ECDC PDF

ISBN 978-92-9498-757-0

ISSN 2363-3085

doi 10.2900/3113714

TQ-01-24-013-EN-N

WHO  PDF

ISBN 978-92-8906-155-1

ii

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 dataContents

Acknowledgements  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . vi

Abbreviations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . .  .vii

Overview of HIV and AIDS in Europe  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  .ix

Обзор эпидемиологической ситуации по ВИЧ-инфекции/СПИДу в Европе  . . . . . . . . . . . . . . . . . . . . . . . . . . .xvii

1. HIV and AIDS in the EU/EEA  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  .1

1.1 HIV diagnoses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . 1

1.2 Previous positive diagnoses  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7

1.3 Trends in HIV diagnoses. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . 9

1.4 AIDS cases, morbidity and mortality  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .12

1.5 HIV testing. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . 14

2. HIV and AIDS in the WHO European Region  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  .18

2.1 HIV and AIDS diagnoses in the WHO European Region  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .18

2.2 HIV testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .27

2.3 Conclusions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . 28

Tables . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .31

Maps . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61

Annexes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66

Figures

Fig. A. Estimated new HIV infections and reported new HIV diagnoses in the EU/EEA and WHO European Region, 2014–2023   . . . . . . . . . . . . . . . . . . . . . . .x

Fig. B. Proportion of people diagnosed late (CD4 cell count < 350 per mm3) by gender, age and transmission mode,  
WHO European Region, 2023   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . x

Рис. A. Оценочное количество новых случаев и количество зарегистрированных случаев ВИЧ-инфекции в странах ЕС/ЕЭЗ и в 
Европейском регионе ВОЗ, 2014–2023 гг.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xviii

Рис. B. Доля случаев (%) с постановкой диагноза на поздней стадии (CD4 <350 кл/мм3) с разбивкой по полу, возрасту и путям 
передачи, Европейский регион ВОЗ, 2023 г. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xix

Fig. 1.1. Male-to-female ratio in HIV diagnoses, by country, EU/EEA, 2023 (n = 24 481) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1

Fig. 1.2. Age- and gender-specific rates of HIV diagnoses per 100 000 population, EU/EEA, 2023 (n = 24 393) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2

Fig. 1.3. HIV diagnoses, by age group and transmission mode, EU/EEA, 2023 (n = 18 003) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2

Fig. 1.4. Percentage of HIV diagnoses, by country and age group, EU/EEA, 2023 (n = 24 617) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3

Fig. 1.5. Percentage by transmission mode and country, HIV diagnoses with known mode of transmission, EU/EEA, 2023 (n = 17 757) . . . . . . . . . . . . . 4

Fig. 1.6. Percentage of HIV diagnoses among migrants out of all reported cases with known information on the region of origin, by 
country of report, EU/EEA, 2023 (n = 21 230) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5

Fig. 1.7. CD4 cell count cells per mm3 at HIV diagnosis and acute infection, by transmission mode, EU/EEA, 2023  
(n = 11 961)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6

Fig. 1.8. Percentage of people diagnosed late (CD4 cell count < 350 per mm3) by demographic, EU/EEA, 2023 (n=11 961) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6

Fig. 1.9. Linkage to care after HIV diagnosis in the EU/EEA, individuals diagnosed with HIV 2022−2023 (n = 6722) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .7

Fig. 1.10. Percentage of previous positive diagnoses and new HIV diagnoses by country of report, 21 EU/EEA countries, 2023 (n = 15 150)  . . . . . . . 8

Fig. 1.11. Demographic and epidemiological characteristics of previous positive diagnoses and new HIV diagnoses by 21 EU/EEA 
countries, 2023 (n = 15 150)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . 9

Fig. 1.12. Temporal trends in HIV diagnoses reported by 21 EU/EEA countries: comparison of trends including and excluding previous 
positive diagnoses, 2014–2023 (n = 152 157) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  10

iii

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORTFig. 1.13. People diagnosed with HIV, AIDS and AIDS-related deaths reported per 100 000 population, EU/EEA, 2014–2023 . . . . . . . . . . . . . . . . . . . . . . . . 10

Fig. 1.14a. Age-specific trends in HIV diagnoses in women, 2014−2023  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10

Fig. 1.14b. Age-specific trends in HIV diagnoses in men, 2014−2023 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .11

Fig. 1.15. Percentage of diagnoses among people born outside of the reporting country by year of diagnosis and region of origin,  
EU/EEA, 2014−2023 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . 11

Fig. 1.16a. HIV diagnoses, by year of diagnosis and transmission mode, EU/EEA, 2014−2023  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12

Fig. 1.16b. Percentage of HIV diagnoses, by year of diagnosis and transmission mode, EU/EEA, 2014−2023 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12

Fig. 1.17. HIV diagnoses, by year of diagnosis, transmission mode and migration status, EU/EEA, 2014−2023  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12

Fig. 1.18. HIV diagnoses, acute infection or CD4 cell count per mm3 at diagnosis, EU/EEA, 2014−2023   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13

Fig. 1.19. AIDS diagnoses, by transmission mode, EU/EEA, 2014−2023 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14

Fig. 2.1. Percentage of HIV diagnoses by country and age group, WHO European Region, 2023 (n = 112 768)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19

Fig. 2.2. Percentage of HIV diagnoses with known mode of transmission, by transmission route and country, WHO European Region, 
2023 (n = 101 278). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . 20

Fig. 2.3. HIV diagnoses, by age group and transmission mode, WHO European Region, 2023 (n = 100 268) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21

Fig. 2.4. HIV diagnoses, by CD4 cell count per mm3 at diagnosis and transmission mode, WHO European Region, 2023 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23

Fig. 2.5. HIV diagnoses per 100 000 population, by year of diagnosis, WHO European Region, 2014–2023. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24

Fig. 2.6. HIV diagnoses, by transmission mode and year of diagnosis, WHO European Region, 2014–2023  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24

Fig. 2.7. HIV diagnoses, by transmission mode and year of diagnosis, east of the WHO European Region, 2014–2023  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24

Fig. 2.8. HIV diagnoses, by transmission mode and year of diagnosis, centre of the WHO European Region, 2014–2023  . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25

Fig. 2.9. HIV diagnoses, by transmission mode and year of diagnosis, west of the WHO European Region, 2014–2023  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25

Fig. 2.10. AIDS diagnoses per 100 000 population, by subregion and year of diagnosis, WHO European Region, 2014–2023  . . . . . . . . . . . . . . . . . . . . . . . 27

Tables

Table A. Characteristics of new HIV and AIDS diagnoses reported in the WHO European Region, the west, centre and east of the  
WHO European Region, and the EU/EEA, 2023  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ix

Таблица A. Характеристики новых случаев ВИЧ-инфекции и СПИДа, зарегистрированных в Европейском регионе ВОЗ, в странах 
западной, центральной и восточной частях Европейского региона ВОЗ и в странах ЕС/ЕЭЗ, 2023 г. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .xvii

Table 1. HIV diagnoses and rates per 100 000 population, by country and year of diagnosis (2014–2023) and cumulative totals, in EU/EEA 
and other countries of the WHO European Region  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32

Table 2. HIV diagnoses in males and rates per 100 000 male population, by country and year of diagnosis (2014–2023) and cumulative 
totals, in EU/EEA and other countries of the WHO European Region . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34

Table 3. HIV diagnoses in females and rates per 100 000 female population, by country and year of diagnosis (2014–2023) and 
cumulative totals, in EU/EEA and other countries of the WHO European Region . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36

Table 4. HIV diagnoses in males who acquired HIV through sex with men, by country and year of diagnosis  
(2014–2023) and cumulative totals, in EU/EEA and other countries of the WHO European Region . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38

Table 5. HIV diagnoses in people who acquired HIV through injecting drug use, by country and year of diagnosis (2014–2023) and  
cumulative totals, in EU/EEA and other countries of the WHO European Region . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39

Table 6. HIV diagnoses in people who acquired HIV through heterosexual contact, by country and year of diagnosis (2014–2023) and 
cumulative totals, in EU/EEA and other countries of the WHO European Region . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40

Table 7. HIV diagnoses in people who acquired HIV through mother-to-child transmission, by country and year of diagnosis (2014–2023)  
and cumulative totals, in EU/EEA and other countries of the WHO European Region . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41

Table 8. HIV diagnoses in 2023, by country of report, transmission mode and sex, in EU/EEA and other countries of the  
WHO European Region . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . 42

Table 9. HIV diagnoses in 2023, by country of report, age and sex, in EU/EEA and other countries of the  
 WHO European Region . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44

Table 10. Origin of those diagnosed with HIV in 2023 by country of report or region, in EU/EEA and other countries of the  
WHO European Region  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46

Table 11. HIV diagnoses, by geographical area, transmission mode and country or region of origin, in cases  
reported in 2023. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . 48

Table 12. Percentage of HIV diagnoses (2023) among individuals over 14 years old, reported with available CD4 cell count data, 
categorized by CD4 cell count levels (< 200 and < 350 cells per mm³ of blood) and by transmission mode for cases with CD4 < 350, in the 
EU/EEA and other countries within the WHO European Region. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51

Table 13. AIDS diagnoses and rates per 100 000 population, by country and year of diagnosis (2014–2023) and cumulative totals, in EU/
EEA and other countries of the WHO European Region . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52

Table 14. AIDS diagnoses in males and rates per 100 000 male population, by country and year of AIDS diagnosis (2014–2023) and 
cumulative totals, in EU/EEA and other countries of the WHO European Region . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54

Table 15. AIDS diagnoses in females and rates per female 100 000 population, by country and year of diagnosis (2013–2022) and 
cumulative totals, in EU/EEA and other countries of the WHO European Region . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56

iv

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 dataTable 16. The most common AIDS-indicative diseases diagnosed in 2023 ordered by frequency  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58

Table 17. AIDS-related deaths, by country and year of death (2014–2023) and cumulative totals in EU/EEA and other countries of the 
WHO European Region . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . 59

Table 18. Number of HIV tests performed, excluding unlinked anonymous testing and testing of blood donations, by country and year 
(2014–2023) and number of tests per 1000 population in 2023, in EU/EEA and other countries of the WHO European Region  . . . . . . . . . . . . . . . . . . . . . . 60

Maps

Map 1a. HIV diagnoses per 100 000 population, 2023. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62

Map 1b. HIV diagnoses per 100 000 population, 2023, EU/EEA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62

Map 2. HIV diagnoses in men per 100 000 male population, 2023  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63

Map 3. HIV diagnoses in women per 100 000 female population, 2023. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63

Map 4. HIV diagnoses in men who have sex with men per 100 000 male population, 2023  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64

Map 5. HIV diagnoses acquired through heterosexual transmission per 100 000 population, 2023 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64

Map 6. HIV diagnoses acquired through injecting drug use per 100 000 population, 2023 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65

Map 7. AIDS diagnoses reported per 100 000 population, 2023  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65

Fig. A1.1. Geographical/epidemiological division of the WHO European Region  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .68

Annexes

Annex 1.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67

Annex 2  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71

Annex 3  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72

Annex 4a. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73

Annex 4b. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74

Annex 5  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75

Annex 6  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77

v

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORTAcknowledgements

This  report  was  coordinated  by  Juliana  Reyes-Urueña 
(European  Centre  for  Disease  Prevention  and  Control 
(ECDC) and Giorgi Kuchukhidze (WHO Regional Office for 
Europe).

WHO  Regional  Office  for  Europe  and  ECDC  would  like 
to  thank  the  nominated  operational  contact  points  for 
HIV/AIDS  surveillance  from  European  Union/European 
Economic  Area  (EU/EEA)  Member  States  and  the  HIV/
AIDS  surveillance  focal  points  from  the  non-EU/EEA 
Member  States  and  areas  of  the  WHO  European  Region 
for providing data and valuable comments on this report: 

Albania:  Marjeta  Dervishi;  Andorra:  Jennifer  Fernández 
Garcia; Armenia: Anna Mergelyan;  Austria: Ziad El-Khatib, 
Irene  Kászoni-Rückerl;  Azerbaijan:  Gunash  Jafarova, 
Famil  Mammadov,  Natig  Zulfugarov;  Belarus:  Svetlana 
Sergeenko; Belgium: Dominique Van Beckhoven, Jessika 
Deblonde;  Bosnia  and  Herzegovina:  Dalibor  Pejović; 
Bulgaria: Ivailo Alexiev; Croatia: Tatjana Nemeth Blazic; 
Mirjana Lana Kosanovic Licina; Cyprus: Anna Demetriou, 
George  Siakallis,  Fani  Theofanous,  Elena  Xenofontos; 
Czechia:  Marek  Malý,  Vratislav  Němeček,  Hana 
Zákoucká;  Denmark:  Maria  Wessman;  Estonia:  Kristi 
Rüütel,  Jevgenia  Epstein;  Finland:  Henrikki  Brummer-
Korvenkontio,  Kirsi  Liitsola;  France:  Françoise  Cazein, 
Amber  Kunkel,  Florence  Lot;  Georgia:  Otar  Chokoshvili; 
Germany:  Barbara  Gunsenheimer-Bartmeyer;  Greece: 
Georgios  Ferentinos,  Dimitra  Paraskeva,  Chrysa  Tsiara; 
Hungary:  Erika  Fogarassy,  Ágnes  Galgóczi,  Zsuzsanna 

Molnár;  Iceland:  Anna  Margret  Gudmundsdottir,  Erna 
Milunka Kojic; Ireland: Mary Archibald, Derval Igoe, Kate 
O’Donnell;  Israel:  Tali  Wagner;  Italy:  Barbara  Suligoi, 
Maria  Elena  Tosti;  Kazakhstan:  Lolita  Ganina,  Gulnar 
Temirkhanov;  Kyrgyzstan:  Aigul  Solpueva;  Latvia: 
Šarlote  Konova;  Liechtenstein:  Esther  Walser-Domjan; 
Lithuania:  Giedrė  Aleksienė,  Oksana  Jučienė,  Vilnelė 
Lipnickienė,  Jurgita  Pakalniškienė;  Luxembourg:  Pierre 
Braquet,  Patrick  Hoffmann,  Joël  Mossong,  Yolanda 
Pires; Malta: Elaine Lautier, Jackie Maistre Melillo, Tanya 
Melillo;  Monaco:  Julie  Biga;  Montenegro:  Alma  Cicic; 
Netherlands:  Eline  Op  de  Coul,  Birgit  van  Benthem,  Ard 
van Sighem; North Macedonia: Dragan Kocinski; Norway: 
Robert Whittaker; Poland: Marta Niedźwiedzka-Stadnik, 
Magdalena Rosinska; Portugal: Joana Bettencourt, Vítor 
Cabral  Veríssimo,  Helena  Cortes  Martins,  Pedro  Pinto 
Leite;  Republic  of  Moldova:  Silvia  Stratulat;  Romania: 
Mariana  Mardarescu;  the  Russian  Federation: 
Inna 
Kulikova,  Oleg  Sonin,  Elena  Veselova;  San  Marino: 
Mauro  Fiorini,  Andrea  Gualtieri;  Serbia:  Danijela  Simic; 
Slovakia: Alexandra Bražinová, Jana Námešná; Slovenia: 
Irena Klavs, Tanja Kustec; Spain: Asuncion Diaz, Julia Del 
Amo;  Sweden:  Maria  Axelsson,  Anneli  Carlander,  Lena 
Dillner,  Lilian  van  Leest;  Switzerland:  Thibault  Lovey; 
Tajikistan:  Zukhra  Nurlaminova,  Kholnazarov  Ramshed; 
Türkiye:  Nurcan  Ersöz,  Oğuz  Evlice,  Burak  Tunç;  
Ukraine:  Ihor  Kuzin,  Violetta  Martsinovskaya;  United 
Kingdom:  Alison  Brown,  Cuong  Chau,  Amal  Farah; 
Kosovo[1]: Luljeta Gashi.

[1]  All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

vi

Abbreviations

ART 

antiretroviral treatment

COVID-19  

coronavirus disease 

ECDC 

EU/EEA 

MSM 

MTCT 

PrEP 

PWID 

TESSy 

European Centre for Disease Prevention and Control

European Union/European Economic Area

men who have sex with men

mother-to-child transmission 

pre-exposure prophylaxis

people who inject drugs

The European Surveillance System

vii

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORT 
 
 
 
 
 
 
 
Overview of HIV and AIDS in Europe 

This  report  presents  HIV/AIDS  surveillance  data  for 
2023, which  show  significant  variation  in  epidemic 
patterns and trends across the WHO European Region. In 
2023, 112 883 HIV diagnoses were reported in 47 of the 
53  countries  in  the  Region,  including  24 731  from  the 
countries  of  the  European  Union/European  Economic 
Area  (EU/EEA).  This  corresponds  to  a  crude  rate  of  12.7 
HIV  diagnoses  per  100 000  population  in  the  Region 
overall, a slight (2.4%) increase compared with the 2022 
rate  (12.4  per  100  000  population)  but  still  a  19.6% 
decrease  compared  to  the  2019  rate  (15.8  per  100  000 
population):  the  period  before  the  coronavirus  disease 
(COVID-19) pandemic (Table A; Fig. A). In all, 21 out of 47 
countries reported an increase in HIV diagnoses in 2023 
to  2022.  Several  countries1, 
compared 
including 
Azerbaijan,  Finland, 
Ireland,  Kazakhstan, 
Iceland, 
Lithuania,  Malta  and  Montenegro,  recorded  the  highest 
number  of  HIV  diagnoses  in  a  single  year  over  the  past 
decade.

For  the  EU/EEA  countries,  the  rate  in  2023  was  5.3  per 
100 000,  marking  a  15.9%  decrease  from  the  6.3  per 
100 000  rate  observed  in  2014.  However,  focusing  only 
on newly reported cases and excluding previous positive 
diagnoses,2  the  rate  increased  by  11.8%  between  2022 
and 2023 (from 3.4 to 3.8 per 100 000 population).

When  comparing  the  number  of  HIV  diagnoses  made  to 
the  estimated  number  of  new  HIV  infections  acquired 
over  the  past  decade,  it  is  evident  that  an  increasingly 
larger number of individuals are acquiring HIV infection 
than  are  being  diagnosed.  This  indicates  a  growing 
number  of  people  living  with  undiagnosed  HIV  in  the 
Region (Fig. A). In the EU/EEA, the trend differs from that 
of  the  wider  Region  with  slightly  more  diagnoses 
reported than estimated new infections. 

The increase in HIV diagnoses in 2023 can be attributed 
to  various  factors  across  different  subregions.3  In  the 
east of the WHO European Region, countries reported a 
rebound  in  HIV  testing  and  case  detection  since  the 
COVID-19  pandemic  subsided,  focusing  on  increasing 
case  detection  and  introducing  new  testing  policies  to 
close  the  gap  on  undiagnosed  individuals.  In  the  EU/
EEA and the west of the Region, the increase may be a 
increased  diagnoses  among  migrants, 
result  of 
particularly 
from  high-prevalence  countries,  and 
expanded HIV testing services. In contrast, the number 
of HIV diagnoses in the centre of the Region decreased 
in 2023 compared to 2022, mainly due to a reduction in 
previous  positive  diagnoses.  However,  six  out  of  15 
countries  in  the  centre  still  reported  an  increase  in 
2023 compared to 2022.

Table A. Characteristics of new HIV and AIDS diagnoses reported in the WHO European Region, the west, centre and 
east of the WHO European Region, and the EU/EEA, 2023 

WHO European Region

Reporting countries/number of countriesa
Number of new HIV diagnoses 
Rate of HIV diagnoses per 100 000 population
Percentage aged 15–24 years
Percentage aged 50+ years
Male-to-female ratio
Percentage of migrantsb 
Transmission mode
Sex between men
Heterosexual transmission (men)
Heterosexual transmission (women)
Injecting drug use
Mother-to-child transmission
Unknown
AIDS and late HIV diagnosis
Percentage new HIV diagnoses  
CD4 < 350 cells/mm3
Number of new AIDS diagnosesc
Rate of AIDS diagnoses per 100 000 population

47/53
112 883
12.7
5.8%
18.7%
1.8
38.1%

11.7%
33.1%
30.7%
13.6%
0.5%
10.3%

52.4

 7 878 
1.2

West

20/23
27 043
6.2
9.0%
21.1%
2.1
69.9%

33.3%
16.9%
23.7%
3.3%
1.3%
21.1%

45.9

 2 168 
0.6

Centre

14/15
8 239
4.2
12.2%
15.6%
3.9
30.5%

18.1%
16.2%
8.3%
2.3%
0.4%
54.7%

57.0

 874 
0.4

East

13/15
77 601
30.6
4.0%
18.2%
1.6
3.2%

3.4%
40.5%
35.6%
18.4%
0.3%
1.8%

59.5

 4 836 
4.9

EU/EEA 

30/30
24 731
5.3
10.1%
20.5%
2.7
47.9%

46.7%
21.2%
24.8%
4.1%
0.9%
27.6%

52.7

2 690
0.7

a  No data received from Andorra, Bosnia and Herzegovina, Monaco, San Marino, Turkmenistan or Uzbekistan. 
b   Migrants defined as originating from outside of the country in which they were diagnosed. 
c   No data reported by Andorra, Belarus, Bosnia and Herzegovina, Cyprus, Germany, Monaco, North Macedonia, the Russian Federation, San Marino, Sweden, 

Turkmenistan or Uzbekistan. 

1   In this report, the word “countries” refers to “countries, territories and 

areas” without distinction.

2  Previous positive diagnoses are defined as an HIV diagnosis made either 
abroad or in another setting within the reporting country on any occasion 
before the current year of reporting. Some countries report previous 
positive HIV cases as they enter, re-enter or re-engage with the care system 
in the reporting country.

3  Fig. A1.1 in Annex 1 illustrates the division of countries into west, centre 

and east of the WHO European Region.

ix

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORT 
reported 

The  mode  of  transmission  varies  across  subregions, 
once again highlighting the diversity in HIV epidemiology 
within  the  Region.  In  the  EU/EEA,  and  the  west  and 
centre  of  the  Region,  heterosexual  transmission  has 
become  one  of  the  most  prevalent  modes  of  HIV 
diagnoses 
in  2023,  particularly  among 
migrants  or  those  with  a  previous  positive  diagnosis. 
Among people reported with heterosexual transmission 
in  the  west,  13%  had  been  previously  diagnosed,  74% 
were  born  abroad  and  40%  originated  from  countries 
with a high prevalence of HIV. Sex between men is still, 
however,  the  most  prevalent  mode  of  transmission  in 
EU/EEA  countries,  and  a  predominant  transmission 
mode  for  seven  of  the  15  countries  in  the  centre.  As  in 
previous  years,  heterosexual  transmission  remains  the 
main  mode  of  transmission  in  the  east  of  the  Region. 

However,  although  reported  transmission  through  sex 
between men remains low in absolute terms in the east, 
it  has  more  than  doubled  over  the  past  decade:  the 
largest increase in any transmission mode and subregion 
of the Region. The proportion of injecting drug use as a 
reported mode of transmission continues to decline and 
reached a record low rate of 18.4% in the east.

Late  HIV  diagnosis  remains  a  challenge  for  most 
countries in the Region: more than half (52.4%) of those 
diagnosed  in  2023  were  diagnosed  late  (CD4  cell  count 
< 350 cells per mm3). The percentage of people diagnosed 
late  varied  across  transmission  modes  and  age  groups, 
with  the  highest  rates  among  people  infected  through 
heterosexual  contact  (especially  men),  injecting  drug 
use and people in older age groups (Fig. B). 

Fig. A. Estimated new HIV infections and reported new HIV diagnoses in the EU/EEA and WHO European Region, 
2014–2023 

d
n
a
s
e
s
o
n
g
a
i
d
V
H
d
e
t
r
o
p
e
r

I

f
o
r
e
b
m
u
N

s
n
o
i
t
c
e
f
n

i

I

V
H
w
e
n
d
e
t
a
m

i
t
s
e

200 000

150 000

100 000

50 000

0

 WHO European Region estimated infections

WHO European Region diagnoses

 EU/EEA estimated infections

EU/EEA diagnoses

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

Year of diagnosis

Note: the shaded area represents uncertainty intervals around the best estimate. Data from Andorra, Bosnia and Herzegovina, Monaco, San Marino, Turkmenistan 
and Uzbekistan were excluded due to inconsistent reporting or unavailability of estimates during the period. 

Fig. B. Proportion of people diagnosed late (CD4 cell count < 350 per mm3) by gender, age and transmission mode, 
WHO European Region, 2023 

Total

Men
Women
Transgender

15–19
20–24
25–29
30–39
40–49
50+

Heterosexual transmission (men)
Heterosexual transmission (women)
Heterosexual transmission (transgender)
Injecting drug use
Sex between men

r
e
d
n
e
G

p
u
o
r
g
e
g
A

)
s
r
a
e
y
(

n
o
i
s
s
i
m
s
n
a
r
T

e
d
o
m

0

10

20

30

40

50

60

70

Percentage

Note: CD4 data from the Russian Federation was excluded as this was not provided with age, sex and transmission route breakdowns.

x

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 data 
 
 
 
 
 
 
 
 
 
In  2023,  7878  people  were  diagnosed  with  AIDS, 
reported  in  41  countries  of  the  WHO  European  Region 
(Table  A).  The  overall  rate  of  AIDS  diagnoses  in  the 
Region decreased by 50% between 2014 and 2023: from 
2.4  per  100 000  population  (17  363  cases)  to  1.2  per 
100 000.  This  declining  trend  is  evident  across  all  the 
subregions of the Region, including the EU/EEA.

EU/EEA
 In  2023,  a  total  of  24 731  HIV  diagnoses  were  reported 
across 30 EU/EEA countries, resulting in a rate of 5.3 per 
100 000 population. Since 2014, this rate has decreased 
by 15.9%, down from 6.3 per 100 000. Previously positive 
diagnoses  accounted  for  16.3%  (4020)  of  all  cases 
reported  in  2023.  When  focusing  only  on  new  HIV 
diagnoses  –  excluding  previously  positive  cases  to 
capture  only  newly  reported  ones  –  the  2023  rate  was 
3.8  per  100 000,  reflecting  an  11.8%  increase  from  the 
2022 rate of 3.4 per 100 000.

As  in  previous  years,  more  men  than  women  were 
diagnosed  with  HIV  in  2023,  with  17 793  cases  among 
men  and  6688  cases  among  women,  resulting  in  an 
overall male-to-female ratio of 2.7. The overall rate was 
8.0 per 100 000 population for men and 2.9 per 100 000 
population  for  women.  In  addition,  seven  countries 
reported  0.8% 
in  people 
identifying as transgender, while 0.2% (44) of diagnoses 
were reported with an unknown gender.

(206)  of  all  diagnoses 

Sex  between  men  was  the  most  reported  mode  of 
transmission  in  the  EU/EEA  in  2023,  accounting  for 
33.8%  (8367)  of  all  reported  diagnoses  and  46.7%  of 
cases  where  the  mode  of  transmission  was  known. 
Between  2014  and  2023,  the  proportion  of  HIV 
diagnoses  attributed  to  sex  between  men  declined 
from  52.1%  to  46.9%  of  all  diagnoses.  Among  those 
diagnosed in 2023, 51.5% (4306) of men who have sex 
with  men  (MSM)  were  born  in  the  reporting  country, 
while  44.4%  (3712)  were  migrants.  The  number  of  HIV 
diagnoses  among  migrant  MSM  increased  by  37.7%, 
from 2659 in 2014 to 3661 in 2023.

Heterosexual  contact  remains  one  of  the  most  common 
modes of HIV transmission in the EU/EEA, accounting for 
33.4%  (8254)  of  all  HIV  diagnoses  and  46.1%  of 
diagnoses with a known mode of transmission. Of these 
diagnoses, 33.7% (2779) were among people born in the 
reporting country, while most (62.4%; 5153) were among 
migrants. Between 2014 and 2023, the proportion of HIV 
diagnoses  due  to  heterosexual  transmission  rose  from 
41.4%  to  46.2%.  This  increase  was  moderate  among 
men  (rising  from  20.6%  to  21.3%),  but  higher  among 
women, rising from 20.7% to 24.9%. Between 2022 and 
2023,  diagnoses  among  heterosexual  migrants  rose  by 
2.1%,  while  the  increase  among  those  born  in  the 
reporting country was 4.5%.

Transmission  due  to  injecting  drug  use  accounted  for 
4.1%  (1012)  of  all  HIV  diagnoses  in  2023  and  5.7%  of 
diagnoses with a known mode of transmission in 2023. 

Nearly  half  (47.6%)  of  the  people  who  inject  drugs 
reported with an HIV diagnosis in 2023 were migrants.

Mother-to-child  transmission  (MTCT)  during  pregnancy, 
childbirth  or  breastfeeding  accounted  for  0.9%  (217)  of 
all  reported  HIV  diagnoses  and  1.2%  of  cases  with  a 
known  mode  of  transmission.  Of  the  total  cases 
attributed  to  MTCT,  78.8%  (171  cases)  were  among 
migrants,  with  41.5%  originating  from  Sub-Saharan 
Africa.

In  2023,  migrants  (defined  as  people  born  outside  the 
reporting country) comprised 47.9% of all HIV diagnoses 
in  the  EU/EEA.  Among  the  migrant  population,  31.6% 
were from Sub-Saharan Africa, 30.1% from central and 
eastern  Europe,  22.8%  from  Latin  America  and  the 
Caribbean, 5.1% from western Europe, 5.1% from south 
and  south-east  Asia,  and  5.3%  from  other  regions. 
When  excluding  cases  with  an  unknown  region  of 
origin,  the  proportion  of  migrants  among  all  reported 
HIV  diagnoses  in  EU/EEA  countries  rose  from  47.3%  in 
2014 to 55.8% in 2023, reflecting a 17.9% increase over 
this period. This trend was marked by a 32.5% decrease 
in  cases  from  central  and  eastern  Europe  and  a  20.4% 
increase  in  cases  from  Sub-Saharan  Africa  over  the 
past year.

CD4  cell  count  data  at  the  time  of  HIV  diagnosis  were 
available  for  59.8%  adults  and  adolescents  (14 795) 
diagnosed  across  27  countries.  For  the  calculation  of 
late  diagnoses,  children  under  15  years,  acute  cases, 
and  previously  positive  diagnoses  were  excluded, 
resulting  in  11 961  people  with  recorded  CD4  counts. 
Among these, over half (52.7%) were considered to have 
been  diagnosed  several  years  post-infection,  indicated 
by  a  CD4  cell  count  <  350  cells  per  mm³.  This  included 
31.6%  of  people  with  advanced  HIV  infection  (CD4  cell 
count  < 200  cells  per  mm³).  Late  diagnosis  (CD4  cell 
count < 350 cells per mm³) was most frequently observed 
among  women  (58.2%),  older  adults  (up  to  68.5%), 
people infected through heterosexual contact (63.8% of 
men  and  58.2%  of  women),  people  who  inject  drugs 
(52.7%),  and  people  from  south  and  south-east  Asia 
(61.1%) and Sub-Saharan Africa (58.6%).

the  epidemiological  profile  of 

This year marked a significant step forward in terms of 
transgender  people  reporting  within  HIV  surveillance, 
with information from transgender people now included 
in 
reported  HIV 
diagnoses.  In  2023,  206  transgender  people  (0.8%  of 
all  diagnoses)  were  reported  as  diagnosed  with  HIV 
across  seven  EU/EEA  countries.  Of  these,  86.4%  were 
migrants,  primarily 
the 
Caribbean. Among those with CD4 count data available, 
27.1%  were  diagnosed  during  the  acute  stage  of 
infection,  while  29.2%  were  diagnosed  at  a  late  stage 
(CD4 cell count < 350 cells per mm³).

from  Latin  America  and 

In  2023,  2690  AIDS  diagnoses  were  reported  across  26 
EU/EEA  countries,  resulting  in  a  crude  rate  of  0.7  cases 
per  100 000  people.  Over  the  past  decade,  the  rate  of 
reported AIDS cases decreased by 36.4%. 

xi

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORTHowever, cases attributed to heterosexual transmission 
showed  an  increase.  Among  women,  there  was  a  3.1% 
increase in reported AIDS cases over the past year (from 
677  in  2022  to  698  in  2023),  while  men  experienced  an 
1.3%  increase  (from  1955  to  1981  cases).  It  is  worth 
noting that tuberculosis (pulmonary and extrapulmonary) 
accounted 
for  13.6%  of  AIDS-indicative  diseases 
reported in 2023.

Fourteen  countries  consistently  reported  data  on  HIV 
tests performed during the period 2014−2023, excluding 
unlinked  anonymous  testing  and  testing  of  blood 
donations.  The  number  of  tests  performed  in  the 
countries  consistently  reporting  testing  activity  has 
increased  by  15.0%  compared  to  2021  and  14.3% 
compared  to  2022,  representing  a  total  increase  of 
23.6% over the entire period.

WHO European Region
Of the 112 883 people diagnosed with HIV in 2023, 69% 
were  diagnosed  in  the  east  (77 601),  24%  in  the  west 
(27 043), and 7% in the centre of the Region (8239) (see 
Table A). The rate was also highest in the east (30.6 per 
100 000  population):  disproportionately  higher  than  in 
the  west  (6.2  per  100 000  population)  and  the  centre 
(4.2 per 100 000 population) (see Table A).

Rates  of  HIV  diagnoses  varied  widely  across  countries 
in the WHO European Region in 2023. The highest rates 
per  100 000  population  (>  15.0)  were  observed  in  the 
Russian  Federation  (37.9)  followed  by  Ukraine  (31.7), 
the Republic of Moldova (27.0), Malta (21.0), Kazakhstan 
(20.6),  Armenia  (18.0),  Cyprus  (17.6),  Ireland  (17.3), 
Georgia  (16.4),  Kyrgyzstan  (15.6)  and  Belarus  (15.4). 
The  lowest  rates  (<  3.0  and  under)  were  reported  by 
Sweden  (2.9),  Slovakia  (2.6),  Croatia  (2.5),  Hungary 
(2.4), North Macedonia (2.4), Serbia (2.2), Austria (2.1) 
and Slovenia (2.1). 

The overall rate for men was 16.7 per 100 000 population 
and  for  women,  8.9  per  100 000  population;  The  male-
to-female ratio was 1.8, lowest in the east (1.6), higher in 
the  west  (2.1),  and  highest  in  the  centre  (3.9)  of  the 
Region.

The  largest  proportion  of  people  diagnosed  in  the 
Region  were  in  the  age  group  30–39  (36%),  while  6% 
were young people aged 15–24, and 19% were 50 years 
or older at diagnosis. 

The  most  common  reported  mode  of  transmission  was 
heterosexual contact (63.8%), while 13.6% were infected 
through injecting drug use, 11.7% through sex between 
men,  and 
through  MTCT. 
than  one  percent 
Information  on  transmission  mode  was  unknown  or 
missing for 10.3% of the new diagnoses.

less 

Among the HIV diagnoses reported by 13 countries in the 
east for whom the mode of HIV transmission was known, 
76.1% were infected through heterosexual transmission 
and  18.4%  through  injecting  drug  use,  while  reported 
transmission through sex between men remained low, at 
3.4%  of  cases.  Heterosexual  sex  (24.5%)  and  sex 

xii

lacked 

the  main 

(18.1%)  were 

information  on 

between  men 
reported 
transmission  modes  in  the  centre  among  cases  with 
known  modes  of  transmission,  but  54.7%  of  HIV 
the  mode  of 
diagnoses 
transmission.  Sex  between  men  was  the  predominant 
transmission  mode  for  seven  of  the  15  countries  in  the 
centre. In the west, heterosexual transmission emerged 
as the main mode (40.1%); however, of these cases, 13% 
were previously diagnosed, 74% were born abroad, and 
40%  originated  from  generalized  epidemic  countries. 
The  second  most  common  transmission  mode  was  sex 
between men (33.3% of cases). Information on the mode 
of  transmission  was  missing  for  21.1%  of  people 
diagnosed with HIV in 2023.

for 

Consistent  data  on  transmission  mode  were  available 
from  39  countries 
the  period  2014–2023. 
Transmission  in  the  east  was  driven  by  the  number  of 
HIV diagnoses with reported heterosexual transmission. 
Transmission  through  sex  between  men  increased  by 
almost 120%. Although the number of HIV diagnoses in 
people infected through injecting drug use decreased by 
39%  over  the  period,  injecting  drug  use  still  accounted 
for  18.4%  of  all  HIV  diagnoses.  Despite  the  increasing 
trend  in  heterosexual  transmission,  seven  of  the  15 
countries in the centre reported sex between men as the 
predominant mode of transmission. In the west, overall 
HIV diagnosis rates have shown a decline over the past 
decade. This decline is primarily due to a decrease in the 
number  of  diagnoses  among  MSM  in  some  countries. 
However,  even 
if  previously  diagnosed  cases  are 
excluded, there has been an increase in diagnoses in the 
past  year  among  people  infected  through  heterosexual 
contact, particularly among women and migrants.

Among those newly diagnosed and over 14 years old for 
whom  information  on  CD4  cell  count  at  the  time  of  HIV 
diagnosis  was  available,  more  than  half  (52.4%)  were 
diagnosed late, with CD4 cell count < 350 cells per mm3, 
including  31.6%  with  advanced  HIV  infection  (CD4  cell 
count  <  200  cells  per  mm3).  However,  the  regional 
average  does  not 
include  data  from  the  Russian 
Federation,4  where  30.0%  of  those  diagnosed  with  HIV 
are detected once their CD4 cell counts have fallen below 
350 cells per mm3 and 15.1% once their counts are below 
200 cells per mm3.

Late  HIV  diagnosis  remains  a  challenge  in  most  of  the 
countries  of  the  Region.  The  percentage  of  people  who 
were  diagnosed  late  (CD4  cell  count  <  350  per  mm3) 
varied  across  transmission  categories  and  age  groups, 
but  was  highest  for  people  with  reported  heterosexual 
transmission  (56%;  61%  for  men  and  51%  for  women) 
and  people  who  inject  drugs  (52.0%),  and  lowest  for 
MSM  (43.0%)  (Fig. B).  The  percentage  increased  with 
age, ranging from 37.7% among people aged 15–19 years 
at  diagnosis,  to  65.9%  among  those  aged  50  years  or 
above.  In  terms  of  gender,  the  percentage  of  late 
diagnoses  was  53.4%  for  men  and  50.6%  for  women:  

4  Data on CD4 cell count reported from the Russian Federation did not include 
disaggregation by previous positive status and mode of transmission and 
were, therefore, excluded from the subregional and regional analysis.

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 datathe  lower  rate  for  men  compared  to  women  is  due  to  a 
further decrease in late diagnoses among MSM.

In  2023,  7878  people  in  41  countries  of  the  WHO 
European  Region  were  diagnosed  with  AIDS, 
corresponding  to  a  rate  of  1.2  per  100 000  population. 
Overall,  61%  of  AIDS  cases  were  diagnosed  in  the  east 
–  where  the  rate  per  100 000  was  also  highest  (4.9)  – 
28% in the west (with a rate of 0.6 per 100 000) and 12% 
in  the  centre  of  the  Region  (0.4  per  100 000).  Twelve 
percent  of  those  diagnosed  with  AIDS  presented  with 
tuberculosis  as  an  AIDS-defining  illness,  ranging  from 
11% of reports in the west to 12% in the centre and 14% 
in the east. Between 2014 and 2023, the overall rate of 
new AIDS diagnoses in the Region decreased by 50%.

Conclusions
HIV  infection  continues  to  affect  the  health  and  well-
being of millions of people in the WHO European Region. 
Over  the  course  of  the  last  four  decades,  nearly  2.6 
million  people  have  been  diagnosed  and  reported  with 
HIV in the WHO European Region, including over 650 000 
people in the EU/EEA. 

The  overall  trend  in  HIV  diagnoses  largely  reflects  the 
situation  in  the  Russian  Federation,  where  diagnoses 
have decreased since 2019 by 32%. In total, however, 21 
of 47 countries reported an increase in HIV diagnoses in 
2023 compared to 2022, and several countries recorded 
the highest number of HIV diagnoses reported in a single 
year in the last decade. The increase in HIV diagnoses in 
2023  in  these  countries  can  be  attributed  to  a  range  of 
factors. 

In the east, four countries reported an increased number 
of  HIV  diagnoses  in  2023  compared  to  2022.  This  is 
mainly  due  to  a  rebound  in  HIV  testing  since  the 
pandemic  subsided, 
increasing  case 
detection  and  introducing  new  testing  policies  to  close 
the gap on undiagnosed people. 

focusing  on 

Eleven  countries  in  the  west  reported  an  increased 
number  of  HIV  diagnoses,  and  it  is  the  only  subregion 
where HIV diagnoses overall increased in 2023 compared 
to  2022.  This  is  mainly  due  to  an increase  in  the 
proportion  of  HIV  diagnoses  among  people  originating 
from outside the reporting country: from 60.3% in 2022 
to 66.1% in 2023. This figure is significantly higher than 
in the centre (19.4%) and the east (2.0%). This increase 
is  primarily  due  to  a  rise  in  the  number  of  people 
diagnosed with HIV originating from Sub-Saharan Africa 
and continued high rates among people originating from 
central  and  eastern  Europe,  Latin  America  and  the 
Caribbean. Notably, 12.9% of the diagnoses reported in 
the  west  in  2023  were  previously  positive  diagnoses. 
However,  the  number  of  previous  positive  diagnoses  is 
probably  underestimated,  as  the  variable  identifying 
these  cases  had  a  completeness  of  48.6%  in  2023. 
Therefore, it is important to understand the differences 
in  the  epidemiological  profile  of  previously  diagnosed 

and  newly  diagnosed  people,  as  well  as  the  origin  of 
cases,  to  adequately  manage  prevention,  public  health 
and resource planning (1). 

In  contrast,  the  number  of  HIV  diagnoses  in  the  centre 
decreased  in  2023  compared  to  2022,  mainly  due  to  a 
reduction in previous positive diagnoses in large EU/EEA 
countries.  However,  six  out  of  15  countries  in  the  centre 
still reported an increase in 2023 compared to 2022.

Across  the  30  EU/EEA  countries,  there  was  a  15.9% 
decrease in HIV diagnoses from 2014 to 2023, indicating 
a  gradual  decline  in  overall  cases.  However,  when 
previously  diagnosed  cases  are  excluded,  the  rate  of 
new  HIV  diagnoses  in  2023  shows  an  increase  from 
2022.

Epidemiological  profiles  of  new  and  previous  positive 
diagnoses  differ  in  EU/EEA  countries.  Newly  diagnosed 
HIV cases in EU/EEA countries are mostly seen in middle-
aged men, but women now make up 28% of all cases. A 
significant portion of new diagnoses (47.9%) are among 
migrants,  although  38%  of  newly  diagnosed  people 
were born in the reporting country. Sexual transmission 
between men remains a leading mode of transmission in 
the  EU/EEA,  but  heterosexual 
transmission  also 
accounts for a substantial number of new diagnoses. In 
contrast,  previous  positive  diagnoses  show  a  higher 
proportion  of  women,  older  individuals  and  people 
mainly  from  central  and  eastern  Europe,  Sub-Saharan 
Africa,  Latin  America  and 
the  Caribbean,  with 
heterosexual  transmission  being  the  most  common 
mode of transmission for those individuals.

transmission 

the  reported 

Although 
through  sex 
between  men  remains  low  in  absolute  terms  in  the 
east,  it  has  increased  more  than  two-fold  during  the 
decade  –  the  largest  increase  in  any  transmission 
category and any subregion of the Region. Heterosexual 
transmission remains a main transmission route in the 
east. However, there is some evidence to suggest that a 
proportion  of  men  reported  as  heterosexually  infected 
may,  in  fact,  be  MSM  or  people  with  a  history  of  drug 
injection,  which  may  have  been  misclassified  as 
heterosexually infected (2–4). 

through  heterosexual 

The proportion of people infected through heterosexual 
transmission originating outside the reporting countries 
of the centre has increased in recent years, from 13% in 
2021  to  23%  in  2023.  Forty  percent  and  above  of  cases 
from 
infected 
Croatia, Montenegro, Poland and Slovenia, and 70% and 
above from Cyprus, Czechia and Slovakia were reported 
among  migrants.  Despite  the 
in 
heterosexual transmission, seven of the fifteen countries 
in  the  centre  reported  sex  between  men  as  the 
predominant mode of transmission. 

increasing  trend 

transmission 

In the European Region, more than half of HIV diagnoses 
have  a  CD4  cell  count  < 350  cells  per  mm3,  including 
almost a third of cases with advanced HIV infection (CD4 
cell count < 200 per mm3) at the time of diagnosis. 

xiii

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORTis  highest  among  people 

As  in  previous  years,  data  from  2023  indicate  that  late 
HIV  diagnosis 
infected 
heterosexually (particularly men), among those infected 
as  a  result  of  injecting  drug  use,  and  among  those  in 
older  age  groups.  Data  from  this  report  also  indicate 
that  the  gap  between  HIV  diagnoses  and  infections  is 
widening  in  the  Region,  indicating  that  it  will  not  reach 
the  2025  target  of  95%  of  those  living  with  HIV 
diagnosed. 

Interventions  to  control  the  epidemic  should  be  based 
to  national  and 
on  evidence  and  adapted 
local 
epidemiology.  This 
report  provides  an  extensive 
overview of the epidemiology of HIV, indicating that the 
following response efforts should be prioritized: 

•  In  all  countries  in  the  Region:  rapid  scale-up  of  HIV 
testing  is  of  the  utmost  importance  to  improve 
progress  towards  the  95%  target  by  2025.  WHO  has 
issued  a  policy  brief  on  moving  away  from  the  use  of 
western blotting and line immunoassays in HIV testing 
strategies and algorithms and towards the support of 
decentralized  testing  and  rapid  linkage  to  treatment 
(5).  Guidance  from  WHO  and  the  European  Centre  for 
Disease  Prevention  and  Control  (ECDC)  recommends 
innovative  approaches, 
including  self-testing  and 
community  testing  by  lay  providers  using  rapid  tests 
as part of overall HIV testing services, including easily 
accessible  services  for  migrant  populations  (6–8). 
While  the  provision  of  HIV  testing  services  has 
improved  over  time,  and  self-testing  and  community-
based  HIV  testing  have  increased  substantially  in 
recent years, policy monitoring in the Region indicates 
that  some  testing  modes  remain  limited  or  non-
existent  in  many  European  countries  (9).  HIV  testing 
services and strategies should be based on available 
data  describing  the  local  epidemiology,  identifying 
key populations to target. These strategies should be 
these 
tailored 
populations,  supporting 
to  HIV 
prevention,  treatment  and  care.  This  will  ensure 
earlier diagnoses and treatment initiation, resulting in 
improved 
treatment  outcomes  and  reduced  HIV 
incidence,  morbidity  and  mortality  in  support  of  the 
95–95–95 goals and other regional and global targets 
(10–12).  A  robust  body  of  evidence  shows  that  early 
initiation of antiretroviral treatment (ART) is beneficial 
to  the  health  of  the  person  receiving  the  treatment 
and  in  preventing  onward  HIV  transmission  (13–18). 
Nearly 90% of countries in the WHO European Region 
have  a  policy  to  initiate  ART  upon  HIV  diagnosis, 
irrespective of CD4 cell count (19). 

the  specific  needs  of 

to  meet 

linkage 

timely 

•  In the EU/EEA and countries in the west of the Region: 
the  rise  in  new  HIV  diagnoses  may  be  linked  to 
increased  HIV  diagnoses  in  migrants  and  expanded 
testing  services,  reflecting  shifts  in  demographics 
and  improvements  in  detection  and  reporting  across 
the EU/EEA and the west of the Region. To strengthen 
HIV prevention among migrant populations, countries 
should expand primary prevention services – such as 
condom  distribution,  sexual  education  for  youth  and 

xiv

(PrEP)  – 

pre-exposure  prophylaxis 
to  ensure 
accessibility  for  migrants.  Providing  testing  and 
treatment 
irrespective  of  residency  or  migration 
status  supports  effective  prevention  and  care. 
Addressing broader barriers to HIV care and improving 
guidance on health-care access is also essential. Over 
the  past  decade,  sexual  contact  between  men  has 
been  the  primary  transmission  mode  in  the  EU/EEA 
and  the  west  of  the  Region.  Prevention  efforts  for 
MSM should include comprehensive programmes that 
expand  PrEP  access,  remove  eligibility  barriers  and 
broaden  PrEP  availability  across  diverse  settings. 
Integrating  PrEP  with  regular  testing  and  timely 
linkage to care can reduce HIV incidence among MSM 
(20–21).  For  effective  monitoring,  robust  surveillance 
systems  are  essential.  Community-based,  culturally 
tailored  interventions,  self-testing  kits  and  targeted 
social  marketing  can  further  enhance  testing  access 
for  migrant  MSM.  Heterosexual  transmission 
is 
increasing in the west, becoming a significant mode of 
transmission,  with  a  notable  prevalence  of 
late 
diagnoses  among  heterosexual  people.  Expanding 
targeted  testing  including  indicator  condition-guided 
testing,  emergency  department  testing  and  raising 
awareness  among  health-care  workers  to  carry  out 
risk-based  targeted  screening  can  all  improve  early 
HIV detection in this population. 

and  management  of 

•  In  countries  in  the  centre  of  the  Region:  following  an 
unprecedentedly  high  number  of  HIV  diagnoses 
recorded in 2022, the number of HIV diagnoses at the 
centre decreased in 2023, mainly due to a reduction in 
the  number  of  previous  positive  diagnoses  in  large 
EU/EEA  countries.  However,  six  out  of  15  countries  in 
the centre still reported an increase in 2023 compared 
to 2022. Despite the increasing trend in heterosexual 
transmission  due  to  the  factors  described  earlier, 
seven  of  the  15  countries  in  the  centre  reported  sex 
between  men  as 
the  predominant  mode  of 
transmission.  Interventions  to  address  this  situation 
lubricant 
are  needed,  such  as  condom  and 
programming;  diversified  HIV 
testing  services; 
voluntary  partner  notification,  PrEP; 
assisted 
prevention 
co-infections 
(particularly  sexually  transmitted  infections);  and 
rapid  HIV  treatment  initiation.  Services  should  be 
patient-centred 
friendly 
environment,  preferably  with  the  involvement  of  civil 
society  throughout  the  entire  HIV  continuum  of 
services, ranging from HIV prevention to adherence to 
ART. Drug-injection-related transmission remains low, 
but  past  outbreaks 
that  HIV 
prevention  services  for  people  who  inject  drugs 
continue 
these  must  be 
important  and 
maintained  with  sufficient  coverage  to  prevent  such 
outbreaks.  The  percentage  of  young  people  among 
HIV diagnoses is also higher in this part of the Region 
than  elsewhere.  Some  countries  have  undergone  a 
transition  to  domestic  financing  of  the  HIV  response 
after  the  withdrawal  of  funding  from  the  Global  Fund 
to  Fight  AIDS,  Tuberculosis  and  Malaria.  This  has 

(22–26)  suggest 

provided 

to  be 

and 

in 

a 

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 datachallenges, 

sustainability 

posed 
particularly 
regarding the financing of HIV prevention programmes 
and  surveys  among  key  populations  designed  and 
In  addition,  ensuring 
delivered  by  communities. 
access  to  health  services  for  refugees  and  migrant 
populations,  including  HIV  services,  and  promoting 
cross-border  collaboration  and  data  sharing,  remains 
essential to a robust and people-centred public health 
response,  especially  in  countries  heavily  affected  by 
the  influx  of  these  populations.  Increased  political 
will  and  attention and  the  intensified  involvement  of 
civil  society  are  needed  to  mitigate  some  of  these 
challenges and prevent the epidemic from accelerating 
(27). 

services, 

combination-prevention 

•  In  countries  in  the  east  of  the  Region:  several 
countries  in  the  east  of  the  Region  also  recorded  the 
highest number of HIV diagnoses reported in a single 
year.  While  these  countries  have  reported  a  rebound 
in  HIV  testing  and  case  detection  since  the  pandemic 
subsided  due  to  the  introduction  of  new  testing 
policies  to  increase  case  detection,  this  is  still  not 
enough  to  close  the  gap  to  ensure  that  people  know 
their  HIV  status,  and  more  people  need  to  be 
diagnosed.  For  the  countries  in  the  east,  there  is  an 
urgent  need  to  continue  the  scale-up  of  bold, 
evidence-based 
interventions  and  deliver  more 
effective, integrated services through health systems 
that better address the social determinants of health. 
Comprehensive 
and 
innovative  HIV  testing  strategies  are  needed,  with  a 
particular focus on reaching key populations. This can 
be  achieved  through  user-friendly  prevention  and 
testing 
partner 
including 
notification,  PrEP,  HIV  testing  performed  by  trained 
lay  providers  and  self-testing  in  line  with  WHO 
recommendations.  All  of  these  services  should  be 
integrated into national policies and programmes and 
then implemented (6,7,12). Community involvement in 
the  design  and  delivery  of  services  is  essential  for 
reducing the rate of HIV infections and increasing the 
number  of  people  linked  to  care  and  initiated  and 
retained  on  ART.  The  ultimate  aim  is  to  reduce  HIV 
incidence  and  AIDS-related  deaths.  Innovative  HIV 
prevention  interventions  should  address  the  risk  of 
heterosexual  transmission,  particularly  in  couples 
where  one  partner  engages  in  high-risk  behaviour 
(such  as  injecting  drug  use)  or  is  spending  longer 
periods of time working abroad. A substantial number 
of diagnoses in people infected through injecting drug 
use emphasizes the fact that evidence-based policies 
focused  on  key  populations,  including  high  coverage 
of  harm-reduction  programmes  for  people  who  inject 
drugs,  remain  critical  to  the  HIV  response  in  the 
eastern part of the Region.

assisted 

The  HIV  data  for  2023  revealed  significant  issues  with 
data  quality;  completeness  and  lack  of  standardization 
for the variable; differentiating new HIV diagnoses from 
previous  positives;  as  well  as  variables  looking  at  the 
country  of  birth  and  region  of  origin  of  cases.  This,  in 
combination  with  the  increase  in  migration  made  2022 

and 2023 data interpretation very challenging. Achieving 
consensus  among  countries  in  the  Region  on  the 
collection,  recording  and  reporting  of  previous  positive 
cases  is  paramount.  This  is  critical  due  to  the  different 
epidemiological  profiles  and  health-care  needs  of 
refugees,  migrants 
diagnosed 
individuals.  Improving  data  recording  and  reporting 
standards  within  surveillance  systems  for  previous 
positive  cases  will  ensure  accuracy  and  help  plan 
tailored prevention strategies. 

previously 

and 

Due  to  limited  data  availability  among  the transgender 
population,  a  more  comprehensive  understanding  of 
their epidemiological profile remains elusive. 

Conducting  enhanced  HIV  surveillance  increases  the 
possibility for longer-term monitoring of HIV continuum-
of-care  outcomes,  such  as  modelling  the  undiagnosed 
fraction, and measurement of linkage to care, treatment 
and  viral  suppression  following  diagnosis.  It  can  also 
support national and global efforts to monitor progress 
towards  the  95–95–95  goals  and  other  global  and 
regional targets.

WHO  and  ECDC  are  working  with  Member  States  to 
operationalize the Regional action plans for ending AIDS 
and  the  epidemics  of  viral  hepatitis  and  sexually 
transmitted  infections  2022–2030  (12)  and  to  measure 
progress  toward  the  Sustainable  Development  Goal 
target 3.3 on ending AIDS by 2030. Key efforts from both 
WHO and ECDC focus on supporting countries to increase 
the  uptake  of  HIV  testing  and  treatment  guidance  and 
innovative  combination  HIV  prevention  approaches  in 
key  populations.  WHO  and  ECDC  are  also  working  to 
eliminate MTCT of HIV, viral hepatitis B and syphilis and 
to  strengthen  HIV  surveillance  and  reporting  and  other 
key priorities, as highlighted in the action plans (12). 

towards 

WHO and ECDC, together with partners, will continue to 
support  Member  States  in  their  efforts  to  accelerate 
progress 
Sustainable 
achieving 
Development Goals for HIV through dedicated guidance, 
workshops,  training,  webinars  and  other  technical 
support 
surveillance, 
on 
monitoring, treatment and prevention activities.

high-impact 

focused 

the 

References5

1.  Massmann R, Groh T, Jilich D, Bartková D, Bartovská Z, Chmelař J, 
et al. HIV-positive Ukrainian refugees in the Czech Republic. AIDS. 
2023 Oct 1;37(12):1811-1818 (https://doi.org/10.1097/
QAD.0000000000003633).

2.  Dumchev K, Kornilova M, Kulchynska R, Azarskova M, Vitek C. 

Improved ascertainment of modes of HIV transmission in Ukraine 
indicates importance of drug injecting and homosexual risk. BMC 
Public Health 2020;20(1):1288 (https://doi.org/10.1186/
s12889-020-09373-2).

3.  Čakalo JI, Božičević I, Vitek C, Mandel JS, Salyuk T, Rutherford GW. 
Misclassification of men with reported HIV infection in Ukraine. 
AIDS Behav. 2015;19(10):1938–40 (https://doi.org/10.1007/
s10461-015-1112-0).

4.  Dumchev K, Stepanovich-Falke A, Lunchenkov N, Rohde A, 

Danshyna A, Bekbolotov A, et al. Comparison of Registered and 
Survey-based Modes of HIV Transmission in 2021-2023: 
cross- sectional study in the Kyrgyz Republic. 2024; PREPRINT 
(Version 1) (https://doi.org/10.21203/rs.3.rs-4592674/v1).

5  All references were accessed 13 November 2024.

xv

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORT19.  Continuum of HIV care - Monitoring implementation of the Dublin 

Declaration on partnership to fight HIV/AIDS in Europe and Central 
Asia: 2021 progress report. Stockholm: ECDC; 2022 (https://www.
ecdc.europa.eu/en/publications-data/continuum-hiv-care- 
monitoring-implementation-dublin-declaration-partnership-fight). 

20.  HIV Transmission Elimination Amsterdam (H-TEAM) Initiative, Van 
Sighem A, Hendriks S, Deug F, Zantkuijl P, van Bergen JE, et al. A 
95% decline in estimated newly acquired HIV infections, 
Amsterdam, 2010 to 2022. Euro Surveillance. 2023;28(40):2300515 
(https://doi.org/10.2807/1560-7917.ES.2023.28.40.2300515).

21.  Cambiano V, Miners A, Lampe FC, McCormack S, Gill ON, Hart G, et 

al. The effect of combination prevention strategies on HIV 
incidence among gay and bisexual men who have sex with men in 
the UK: a model-based analysis. Lancet HIV. 2023;10(11):e713–22 
(https://doi.org/10.1016/S2352-3018(23)00204-7).

22.  Hedrich D, Kalamara E, Sfetcu O, Pharris A, Noor A, Wiessing L et 

al. Human immunodeficiency virus among people who inject drugs: 
is risk increasing in Europe? Euro Surveill. 2013;18(48) (https://doi.
org/10.2807/1560-7917.ES2013.18.48.20648).

23.  Giese C, Igoe D, Gibbons Z, Hurley C, Stokes S, McNamara S et al. 

Injection of new psychoactive substance snow blow associated 
with recently acquired HIV infections among homeless people who 
inject drugs in Dublin, Ireland, 2016. Euro Surveill. 2016;20(40) 
(https://doi.org/10.2807/1560-7917).

24.  HIV in people who inject drugs – joint technical mission to 

Luxembourg. Stockholm: ECDC/European Monitoring Centre for 
Drugs and Drug Addiction; 2018 (https://sante.public.lu/fr/
publications/h/hiv-joint-technical-mission.html).

25.  McAuley A, Palmateer NE, Goldberg DJ, Trayner KMA, Shepherd SJ, 
Gunson RN, et al. Re-emergence of HIV related to injecting drug use 
despite a comprehensive harm reduction environment: a 
cross-sectional analysis. Lancet HIV. 2019;6(5):e315–24 (https://
doi.org/10.1016/S2352-3018(19)30036-0).

26.  Des Jarlais DC, Sypsa V, Feelemyer J, Abagiu AO, Arendt V, Broz D, 
et al. HIV outbreaks among people who inject drugs in Europe, 
North America, and Israel. Lancet HIV. 2020;7(6):e434–42 (https://
doi.org/10.1016/S2352-3018(20)30082-5).

27.  Lost in transition. Three case studies of Global Fund withdrawal in 
south-eastern Europe. New York: Open Society Foundations; 2017 
(www.opensocietyfoundations.org/publications/lost-transition).

5.  WHO recommends countries move away from the use of western 
blotting and line immunoassays in HIV testing strategies and 
algorithms: policy brief. Geneva: World Health Organization; 2019 
(WHO/CDS/HIV/19.30; https://iris.who.int/handle/10665/329915). 
License: CC BY-NC-SA 3.0 IGO.

6.  Guidelines on HIV self-testing and partner notification: supplement 
to consolidated guidelines on HIV testing services. Copenhagen: 
World Health Organization; 2016 (https://iris.who.int/
handle/10665/251655).

7. 

Consolidated guidelines on HIV testing services, 2019. Geneva: 
World Health Organization; 2020 (https://iris.who.int/han-
dle/10665/336323). License: CC BY-NC-SA 3.0 IGO

8.  Public health guidance on HIV, hepatitis B and C testing in the EU/
EEA. Stockholm: ECDC; 2018 (https://www.ecdc.europa.eu/sites/
default/files/documents/hiv-hep-testing-guidance_0.pdf). 

9.  HIV testing. Monitoring implementation of the Dublin Declaration 
on Partnership to fight HIV/AIDS in Europe and Central Asia: 2017 
progress report. Stockholm: ECDC; 2017 (https://ecdc.europa.eu/
sites/portal/files/documents/HIV%20testing.pdf).

10.  Global health sector strategies on, respectively, HIV, viral hepatitis 

and sexually transmitted infections for the period 2022-
2030. Geneva: World Health Organization; 2022 (https://iris.who.
int/handle/10665/360348). License: CC BY-NC-SA 3.0 IGO.

11.  Global AIDS Strategy 2021–2026 End Inequalities. End AIDS. 
Geneva: UNAIDS; 2021 (www.unaids.org/sites/default/files/
media_asset/global-AIDS-strategy-2021-2026_en.pdf).

12.  World Health Organization. Regional Office for 

Europe. (2023). Regional action plans for ending AIDS and the 
epidemics of viral hepatitis and sexually transmitted infections 
2022–2030. World Health Organization. Regional Office for 
Europe. https://iris.who.int/handle/10665/369243. License: CC 
BY-NC-SA 3.0 IGO.

13.  Consolidated guidelines on the use of antiretroviral drugs for 
treating and preventing HIV infection: recommendations for a 
public health approach, 2nd ed. Geneva: World Health 
Organization; 2016 (https://iris.who.int/handle/10665/208825).

14.  Guideline on when to start antiretroviral therapy and on 
pre-exposure prophylaxis for HIV. Geneva: World Health 
Organization; 2015 (https://iris.who.int/handle/10665/186275).

15. 

INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, 
Emery S, Grund B, et al. Initiation of Antiretroviral Therapy in Early 
Asymptomatic HIV Infection. N Engl J Med. 2015;373(9):795–807 
(https://doi.org/10.1056/NEJMoa1506816). 

16.  Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, 

Kumarasamy N, et al. Prevention of HIV-1 infection with early 
antiretroviral therapy. N Engl J Med. 2011;365(6):493–505 (https://
doi.org/10.1056/NEJMoa1105243).

17.  EACS Guidelines [website]. European AIDS Clinical Society; 2024 
(https://www.eacsociety.org/guidelines/eacs-guidelines/).

18.  Rodger A, Cambiano V, Bruun T, Vernazza P, Collins S, Degan O et 
al. Risk of HIV transmission through condomless sex in serodiffer-
ent gay couples with HIV-positive partner taking suppressive 
antiretroviral therapy (PARTNER): final results of a multicentre, 
prospective, observational study. Lancet. 2019;393(10189):2428–
38 (https://doi.org/10.1016/S0140-6736(19)30418-0).

xvi

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 dataОбзор эпидемиологической ситуации по 
ВИЧ-инфекции/СПИДу в Европе

за 

отчете 

различия 

настоящем 

экономической 

представлены 
ВИЧ-инфекцией/СПИДом 

данные 
В 
эпиднадзора 
в 
Европейском  регионе  ВОЗ  за  2023  г.,  которые 
демонстрируют 
в 
значительные 
эпидемиологической  ситуации  и  соответствующих 
тенденциях  в  разных  странах  Региона.  В  2023  г.  в  47 
из  53  стран  Региона  было  зарегистрировано  112 883 
новых  случая  ВИЧ-инфекции,  в  том  числе  24 731 
новый  случай  в  странах  Европейского  союза/
Европейской 
(ЕС/ЕЭЗ):  в 
среднем,  12,7  случая  ВИЧ-инфекции  на  100 000 
населения  во  всем  Регионе,  что  незначительно  (на 
2,4%)  больше,  чем  в  2022  г.  (12,4  на  100 000 
населения).  Вместе  с  тем,  уровень  заболеваемости 
2023 г. на 19,6% ниже уровня 2019 г. (15,8 на 100 000 
населения), 
пандемии 
коронавирусной  инфекции  (COVID-19)  (таблица  A; 
рис. A).  В  21  из  47  стран,  предоставивших  данные,  в 
2023  г.  было  зарегистрировано  увеличение  числа 
новых случаев ВИЧ-инфекции по сравнению с 2022 г. 
В  нескольких  странах,  включая  Азербайджан, 

ниже, 

зоны 

чем 

т.е. 

до 

Ирландию,  Исландию,  Казахстан,  Литву,  Мальту, 
Финляндию  и  Черногорию,  было  зарегистрировано 
рекордное  за  последнее  десятилетие  число  новых 
случаев  ВИЧ-инфекции,  выявленных  в  течение 
одного года.

В  странах  ЕС/ЕЭЗ  заболеваемость  ВИЧ-инфекцией  в 
2023  г.  составила  5,3  на  100 000  населения,  что 
соответствует снижению заболеваемости на 15,9% по 
сравнению с 2014 г., когда заболеваемость составила 
6,3  на  100 000  населения.  Вместе  с  тем,  в  2023  г,  по 
сравнению  с  2022  г.,  при  вычете  «случаев  с  ранее 
известным 
ВИЧ-статусом», 
наблюдалось увеличение числа впервые выявленных 
случаев  ВИЧ-инфекции  на  11,8%  (c  3,4  до  3,8  на 
100 000 населения).1 

положительным 

При сравнении числа новых случаев ВИЧ-инфекции с 
оценочным  числом  новых  случаев  за  последнее 
десятилетие  становится  очевидным,  что  с  каждым 
годом ВИЧ-инфекцией заражается все больше людей, 

Таблица A. Характеристики случаев ВИЧ-инфекции и СПИДа, зарегистрированных в Европейском регионе ВОЗ, в 
странах в западной, центральной и восточной частях Европейского региона ВОЗ и в странах ЕС/ЕЭЗ, 2023 г. .

Европейский регион 
ВОЗ

Западная часть 

Центральная часть

Восточная часть

ЕС/ЕЭЗ

Кол-во стран, предоставивших данные/
общее кол-во странa
Количество новых случаев ВИЧ-инфекции
Количество случаев ВИЧ-инфекции на  
100 000 населения
Доля (%) в возрасте 15–24 лет
Доля (%) в возрасте 50+ лет
Соотношение заболеваемости у мужчин и 
женщин
Доля (%)b 
Путь передачи
Секс между мужчинами
Гетеросексуальная передача (мужчины)
Гетеросексуальная передача (женщины
Употребление инъекционных наркотиков
Передача от матери к ребенку
Неизвестен
Случаи СПИДа и поздней диагностики 
ВИЧ-инфекции
Доля (%) новых случаев ВИЧ-инфекции при 
CD4 < 350 кл/мм3 c
Количество новых случаев СПИДаd
Заболеваемость СПИДом на 100 000 
населения

47/53

112 883

12,7

5,8%
18,7%

1,8

38,1%

11,7%
33,1%
30,7%
13,6%
0,5%
10,3%

52,4

 7 878 

1,2

20/23

27 043

6,2

9,0%
21,1%

2,1

69,9%

33,3%
16,9%
23,7%
3,3%
1,3%
21,1%

45,9

 2 168 

0,6

14/15

8 239

4,2

12,2%
15,6%

3,9

30,5%

18,1%
16,2%
8,3%
2,3%
0,4%
54,7%

57,0

 874 

0,4

13/15

77 601

30,6

4,0%
18,2%

1,6

3,2%

3,4%
40,5%
35,6%
18,4%
0,3%
1,8%

59,5

 4 836 

4,9

30/30

24 731

5,3

10,1%
20,5%

2,7

47,9%

46,7%
21,2%
24,8%
4,1%
0,9%
27,6%

52,7

2 690

0,7

a  Отсутствуют данные из следующих стран: Андорра, Босния и Герцеговина, Монако, Сан-Марино, Туркменистан, Узбекистан
b  Согласно используемому определению, мигранты - это лица, родившиеся за пределами страны, где им был поставлен диагноз.
c  Отсутствуют данные из следующих стран: Андорра, Беларусь, Босния и Герцеговина, Кипр, Германия, Монако, Сан-Марино, Северная Македония, 

Российская Федерация, Туркменистан, Швеция, Узбекистан.

1  Случаи с ранее известным положительным ВИЧ-статусом – это 

случаи ВИЧ-инфекции, выявленные до отчетного года за пределами 
страны, предоставляющей данные, или случаи ВИЧ-инфекции, 
выявленные до отчетного года в пределах страны, предоставляющей 
данные, но выявленные другим учреждением. Некоторые страны 
предоставляют данные о ранее известном положительном ВИЧ-статусе 
на момент появления или повторного появления пациента в системе 
здравоохранения страны, предоставляющей данные.

xvii

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORTи  число  инфицированных  больше,  чем  число  людей, 
которым ставится соответствующий диагноз. 

Это означает, что в Регионе увеличивается популяция 
людей,  живущих  с  недиагностированной  ВИЧ-
инфекцией 
(рис.  А).  В странах  ЕС/ЕЭЗ  данная 
тенденция  отличается  от  остальных  стран  Региона:  в 
них  число  регистрируемых  новых  случаев  ВИЧ-
инфекции  немного  превышает  число  оценочных 
новых случаев.

быть 

случаев 

ВИЧ-инфекции 

субрегионах  может 

Рост  числа  новых  случаев  ВИЧ-инфекции  в  2023  г.  в 
разных 
объяснен 
различными факторами.2 В восточной части Региона 
со времени ослабления пандемии COVID-19 во многих 
странах были восстановлены объемы тестирования и 
диагностики  новых  случаев  ВИЧ-инфекции,  со 
сосредоточением  усилий  на  выявлении  новых 
случаев  и  введением  новой  политики  тестирования, 
направленной  на  снижение  числа  людей,  живущих  с 
недиагностированной ВИЧ-инфекцией. В странах ЕС/
ЕЭЗ  и  странах  в  западной  части  Региона  рост  числа 
быть 
новых 
результатом  увеличения  числа  новых  случаев  среди 
мигрантов,  особенно  мигрантов  из  стран  с  высокой 
распространенностью ВИЧ-инфекции, а также может 
быть  результатом  увеличения  охвата  тестированием 
на  ВИЧ-инфекцию.  В  странах  в  центральной  части 
Региона  наблюдается  противоположная  картина: 
число  новых  случаев  ВИЧ-инфекции  в  2023  г. 
снизилось по сравнению с 2022 г., главным образом, 
по  причине  снижения  числа  случаев  с  ранее 
известным  положительным  ВИЧ-статусом.  Вместе  с 
тем,  в  6  из  15  стран  в  центральной  части  Региона, 
согласно  предоставленным  ими  данным,  в  2023  г. 
наблюдалось  увеличение  числа  новых  случаев  ВИЧ-
инфекции по сравнению с 2022 г.

может 

ВИЧ-статусом. 

Пути  передачи  ВИЧ-инфекции  в  разных  субрегионах 
разнятся, что еще раз подчеркивает неоднородность 
эпидемиологической  ситуации  по  ВИЧ-инфекции  в 
пределах  Региона.  В  2023  г.  в  странах  ЕС/ЕЭЗ  и 
странах  в  западной  и  центральной  частях  Региона 
одним  из  наиболее  распространенных  путей 
передачи  ВИЧ-инфекции  стал  гетеросексуальный 
путь;  этот  путь  передачи  особенно  распространен 
с  ранее  известным 
среди  мигрантов  и  лиц 
положительным 
лиц, 
Из 
инфицированных 
гетеросексуальным  путем  на 
западе  Региона,  13%  имели  ранее  известный 
положительный  ВИЧ-статус,  74%  были  рождены  за 
пределами страны, предоставляющей данные, и 40% 
происходили из стран с высокой распространенностью 
ВИЧ-инфекции. Вместе с тем, секс между мужчинами 
все  еще  остается  самым  распространенным  путем 
передачи  в  странах  ЕС/ЕЭЗ  и  одним  из  наиболее 
распространенных  путей  передачи  в  7  из  15  стран  в 
центральной  части  Региона.  Как  и  в  прошлые  годы, 
на  востоке  Региона  основным  путем  передачи 
остается  гетеросексуальный.  Хотя  передача  ВИЧ-
инфекции  половым  путем  между  мужчинами  в 
странах в восточной части Региона остается низкой в 
абсолютном  выражении,  ее  значение  за  последнее 
десятилетие увеличилось более чем в два раза – это 
наибольшее увеличение среди всех путей передачи и 
во  всех  субрегионах  Региона.  Доля  инфицирования 
при  приеме  инъекционных  наркотиков  в  качестве 
указанного пути передачи продолжает снижаться и в 
восточной  части  Региона  достигла  рекордно  низкой 
отметки 18,4%.

Для большинства стран Региона серьезной проблемой 
остается  выявление  ВИЧ-инфекции  на  поздней 
стадии: в 2023 г. на поздней стадии (CD4 <350 кл/мм3) 

Рис. A. Оценочное количество новых случаев и количество зарегистрированных случаев ВИЧ-инфекции в 
странах ЕС/ЕЭЗ и в Европейском регионе ВОЗ, 2014–2023 гг.

с
х
ы
в
о
н
х
ы
н
н
а
в
о
р
и
р
т
с
и
г
е
р
а
з
о
в
т
с
е
ч
и
л
о
К

е
о
н
ч
о
н
е
ц
о
и
и
и
ц
к
е
ф
н
и
-
Ч
И
В
в
е
а
ч
у
л

и
и
ц
к
е
ф
н
и
-
Ч
И
В
в
е
а
ч
у
л
с
х
ы
в
о
н
о
в
т
с
е
ч
и
л
о
к

200 000

150 000

100 000

50 000

0

Оценочное число случаев 
ВИЧ-инфекции в 
Европейском регионе ВОЗ

Число зарегистрированных 
новых случаев ВИЧ-инфекции 
в Европейском регионе ВОЗ

Оценочное число случаев 
ВИЧ-инфекции в ЕС/ЕЭЗ

Число зарегистрированных 
новых случаев ВИЧ-инфекции 
в ЕС/ЕЭЗ

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

Год постановки диагноза

Примечание: затененная область представляет интервалы неопределенности вокруг лучшей оценки. По причине нерегулярного предоставления данных или 
отсутствия данных в отчетном периоде были исключены данные следующих стран: Андорра, Босния и Герцеговина, Монако, Сан-Марино, Туркменистан и 
Узбекистан.

xviii

 
 
 
 
 
 
 
 
 
 
 
были  диагностированы  около  половины 
случаев ВИЧ-инфекции.2 

(52,4%) 

Процент случаев с постановкой диагноза на позднем 
стадии  разнится  по  разным  путям  передачи  и 
возрастным 
долю 
наибольшую 
составляют 
гетеросексуальным  путем 
передачи (особенно у мужчин), лица, употребляющие 
инъекционные наркотики, и люди старшего возраста 
(рис. В).

группам, 
лица 

но 

с 

В  2023  г.  в  41  стране  Европейского  региона  ВОЗ  у 
7 878  лиц  был  диагностирован  СПИД  (таблица  А).  С 
2014 г. по 2023 г. общее число новых случаев СПИДа в 

2 

Регионе  уменьшилось  на  50%,  с  2,4  на  100 000 
населения  (17 363  случая)  до  1,2  на  100 000.  Данная 
тенденция к снижению четко прослеживается во всех 
частях Региона, включая ЕС/ЕЭЗ.

ЕС/ЕЭЗ
В  2023  г.  в  30  странах  ЕС/ЕЭЗ  был  зарегистрирован 
24 371  новый  случай  ВИЧ-инфекции:  таким  образом, 
заболеваемость составила 5,3 на 100 000 населения. 
С  2014  г.  этот  показатель  снизился  на  15,9%  (6,3  на 
100 000  населения).  На  долю  случаев  с  ранее 
известным  положительным  ВИЧ-статусом  в  числе 
всех  новых  случаев  ВИЧ-инфекции,  выявленных  в 
2023 г., пришлось 16,3% случаев (4 020 случаев). При 

Рис. B. Доля случаев (%) с постановкой диагноза на поздней стадии (CD4 <350 кл/мм3) с разбивкой по полу, 
возрасту и путям передачи, Европейский регион ВОЗ, 2023 г. 

Всего

Мужчины
Женщины
Трансгендерные люди

15–19
20–24
25–29
30–39
40–49
50+

Гетеросексуальная передача (мужчины)
Гетеросексуальная передача (женщины)
Гетеросексуальная передача  (трансгендеры)
Употребление инъекционных наркотиков
Секс между мужчинами

л
о
П

т
с
а
р
з
о
В

и
ч
а
д
е
р
е
п
ь
т
у
П

Примечание: Данные от Российской Федерации исключены, т.к. отсутствовала разбивка данных по возрасту, полу и путям передачи.

0

10

20

30

40

50

60

70

Процентная доля

вычете  случаев  с  ранее  известным  положительным 
ВИЧ-статусом 
впервые 
заболеваемость 
зарегистрированным случаям в 2023 г. составила 3,8 
на 100 000 населения, что отражает увеличение этого 
показателя  на  11,8%  по  сравнению  с  2022  г.  (3,4  на 
100 000 населения).

по 

составило 

Как  и  в  предыдущие  годы,  заболеваемость  ВИЧ-
инфекцией  в  2023  г.  была  выше  у  мужчин  (17 793 
случая) чем у женщин (6 688 случаев), и соотношение 
заболеваемости  у  мужчин  к  заболеваемости  у 
женщин 
показатель 
2,7. 
заболеваемости составил 8,0 на 100 000 населения у 
мужчин и 2,9 на 100 000 населения у женщин. Кроме 
того,  согласно  данными,  предоставленным  семью 
странами, 
пациенты 
(206) 
самоидентифицировали  себя  как  трансгендерных 
людей,  а  в  0,2%  случаев  (44)  гендерный  статус  был 
неизвестен.

случаев 

Общий 

0,8% 

в 

В 2023 г. в странах ЕС/ЕЭЗ наиболее распространенным 
путем  передачи  ВИЧ-инфекции  был  секс  между 
мужчинами:  на  него  пришлось  33,8%  (8367)  всех 
зарегистрированных  новых  случаев,  и  в  46,7% 
случаев  путь  передачи  инфекции  был  неизвестен.  В 
период  с  2014  г.  по  2023  г.  доля  случаев  ВИЧ-
инфекции, атрибутируемых сексу между мужчинами, 
снизилась с 52,1% до 46,9% от общего числа случаев. 
В  2023 г.  среди  новых  случаев  ВИЧ-инфекции  у 
мужчин,  практикующих  секс  с  мужчинами  (МСМ) 
51,5%  (4 306  случаев)  приходились  на  уроженцев 
страны,  предоставляющей  данные,  а  44,4%  (3 712 
случаев)  приходились  на  мигрантов.  Число  новых 
среди  МСМ-мигрантов 
случаев  ВИЧ-инфекции 
увеличилось  на  37,7%,  с  2 659  в  2014  г.  до  3 661  в 
2023 г.

странах 

наиболее 
В 
распространенных  путей  передачи  ВИЧ-инфекции 
остается  гетеросексуальный:  на  него  приходится 

ЕС/ЕЭЗ 

одним 

из 

2  На Рис. A1.1 в Приложении 1 представлено разделение Европейского 

региона ВОЗ на западную, центральную и восточную части.

xix

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORT 
33,4%  (8  254)  всех  новых  случаев  ВИЧ-инфекции  и 
46,1% случаев с известным путем передачи. 

Из  этих  случаев  33,7%  (2  779)  приходилось  на 
уроженцев  страны,  предоставляющей  данные,  а 
большая часть, то есть 62,4% (5 153), – на мигрантов. 
С  2014  г.  по  2023 г.  доля  случаев  ВИЧ-инфекции, 
полученной  гетеросексуальным  путем,  возросла  с 
41,4%  до  46,2%.  Подобный  прирост  был  умеренным 
среди мужчин (повышение с 20,6% до 21,3%) и более 
высоким  у  женщин,  с  20,7%  до  24,9%.  В  2023  г.,  по 
сравнению  с  2022  г.,  число  новых  случаев  ВИЧ-
инфекции среди мигрантов выросло на 2,1%, а среди 
уроженцев  страны,  предоставляющей  данные,  –  на 
4,5%.

г.  на 

заражение  при 

В  2023 
употреблении 
инъекционных  наркотиков  приходилось  4,1%  (1  012) 
всех  новых  случаев  ВИЧ-инфекции  и  5,7%  случаев  с 
известным  путем  передачи.  Почти  половина  случаев 
(47,6%) заражения ВИЧ-инфекцией при употреблении 
инъекционных  наркотиков  в  2023  г.  приходилась  на 
мигрантов.

На передачу ВИЧ-инфекции от матери ребенку (ПМР) 
во  время  беременности,  при  родах  или  лактации 
приходилось  0,9%  (217)  всех  новых  случаев  ВИЧ-
инфекции  и  1,2%  случаев  с  известным  путем 
передачи.  На  мигрантов  приходилось  78,8%  (171) 
случаев  ПМР,  из  них  41,5%  случаев  касались 
мигрантов из стран Африки к югу от Сахары.

г.  в 

странах  ЕС/ЕЭЗ  на  мигрантов 
В  2023 
(определяемых  как  лица,  рожденные  за  пределами 
страны,  предоставляющей  данные)  пришлось  47,9% 
всех  новых  случаев  ВИЧ-инфекции,  при  этом  31,6% 
мигрантов  происходили  из  стран  Африки  к  югу  от 
Сахары,  30,1%  –  из  стран  Центральной  и  Восточной 
Европы,  22,8%  –  из  стран  Латинской  Америки  и 
Карибского  бассейна,  5,1%  –  из  стран  Западной 
Европы,  5,1%  –  из  стран  Южной  и  Юго-Восточной 
Азии,  и  5,3%  –  из  других  регионов.  При  исключении 
случаев  с  известным  регионом  происхождения  доля 
всех новых случаев ВИЧ-инфекции в странах ЕС/ЕЭЗ, 
приходящаяся на мигрантов, выросла с 47,3% в 2014 
г. до 55,8% в 2023 г., то есть за этот период увеличение 
составило  17,9%.  При  этом  за  прошедший  год  было 
отмечено  снижение  на  32,5%  числа  случаев, 
происходящих  из  стран  Центральной  и  Восточной 
Европы,  и  увеличение  на  20,4%  числа  случаев, 
происходящих из стран Африки к югу от Сахары. 

для 

ВИЧ-инфекции 

Информацию  о  количестве  CD4-клеток  на  момент 
диагностирования 
59,8% 
взрослых  и  подростков  (14 795)  предоставили  27 
стран.  Для  вычисления  доли  случаев  постановки 
диагноза  на  поздней  стадии  были  исключены  дети 
младше  15  лет,  острые  случаи  и  случаи  с  ранее 
известным положительным ВИЧ-статусом, что в итоге 
дало  популяцию  с  известным  количеством  CD4-
клеток  в  количестве  11 961  человека.  У  более  чем 
половины 
(52,7%)  из  них  ВИЧ-инфекция  была 
выявлена через несколько лет после инфицирования, 

xx

что  подтверждалось  количеством  CD4-клеток  <350 
кл/мм3. Данная популяция включала в себя 31,6% лиц 
с  ВИЧ-инфекцией  продвинутой  стадии  (количество 
CD4-клеток  <200  кл/мм3).  Постановка  диагноза  на 
поздней  стадии  (количество  CD4-клеток  <350  кл/мм3) 
наиболее  часто  наблюдалась  у  женщин  (58,2%), 
пожилых  людей  (до  68,5%),  у  лиц,  инфицированных 
гетеросексуальным  путем  (63,8%  мужчин  и  58,2% 
женщин),  у  лиц,  употребляющих  инъекционные 
наркотики  (52,7%),  а  также  у  мигрантов  из  стран 
Южной и Юго-Восточной Азии (61,1%) и стран Африки 
к югу от Сахары (58,6%). 

в 

эпидемиологический 

В  2023  г.  был  отмечен  значительный  прогресс  в 
отношении  отчетных  данных  по  трансгендерным 
людям  в  рамках  эпиднадзора  за  ВИЧ-инфекцией: 
информация  по  трансгендерным  людям  теперь 
профиль 
включается 
зарегистрированных  случаев  ВИЧ-инфекции.  В  2023 
г. в семи странах ЕС/ЕЭЗ среди трансгендерных людей 
было  зарегистрировано  206  случаев  ВИЧ-инфекции 
(0,8%  от  числа  всех  случаев).  Из  них  86,4%  были 
мигрантами, в основном из стран Латинской Америки 
и  Карибского  бассейна.  Среди  лиц,  по  которым 
имелись  данные  о  количестве  CD4-клеток,  27,1% 
были диагностированы на острой стадии инфекции, в 
то  время  как  29,2%  были  диагностированы  на 
поздней стадии (количество CD4-клеток <350 кл/мм3).

В 2023 г. в 26 странах ЕС/ЕЭЗ было зарегистрировано 
2  690  случаев  СПИДа  –  0,7  случая  на  100 000 
населения.  За  последнее  десятилетие  показатель 
зарегистрированных  случаев  СПИДа  снизился  на 
36,4%.  Вместе  с  тем  возросло  число  случаев  СПИДа, 
атрибутируемых гетеросексуальному пути передачи. 
За  прошедший  год  отмечалось  увеличение  числа 
зарегистрированных  случаев  СПИДа  у  женщин  на 
3,1% (с 677 в 2022 г. до 698 в 2023 г.), а у мужчин –на 
1,3% (с 1 955 до 1 981 случая). Следует отметить, что в 
2023 
заболеваниями, 
случаев 
указывающими  на  возможное  наличие  СПИДа, 
пришлось на туберкулез (легочный и внелегочный).

13,6% 

г. 

с 

В  2014–2023  гг.  14  стран  регулярно  предоставляли 
данные  о  тестировании  на  ВИЧ,  за  исключением 
и 
анонимного 
непересекаемого 
тестирования  донорской  крови.  Количество  тестов, 
проведенных в странах, регулярно предоставлявших 
данные  о  тестировании,  увеличилось  на  15,0%  по 
сравнению  с  2021  г.  и  на  14,3%  по  сравнению  с  2022 
г.,  что  отражает  общее  увеличение  показателей 
тестирования на 23,6% за весь период.

тестирования 

112 883  новых 

Европейский регион ВОЗ
В  2023  г.  в  Европейском  регионе  ВОЗ  было 
зарегистрировано 
случая  ВИЧ-
инфекции;  69%  случаев  пришлось  на  восточную 
часть (77 601), 24% – на западную часть (27 043) и 7% 
–  на  центральную  часть  Региона  (8  239)  (таблица  A). 
Наиболее высокие показатели заболеваемости также 
были  отмечены  в  восточной  части  (30,6  на  100 000 
населения),  что  непропорционально  выше,  чем  в 

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 dataзападной (6,2 на 100 000 населения) и в центральной 
части Региона (4,2 на 100 000 населения) (таблица A).

В  2023  г.  уровень  заболеваемости  ВИЧ-инфекции  в 
разных  странах  Региона  значительно  разнился. 
Наиболее  высокие  значения  заболеваемости  на 
100 000  населения  (>15,0)  наблюдались  в  Российской 
Федерации (37,9), Украине (31,7), Республике Молдова 
(27,0),  Мальте  (21,0),  Казахстане  (20,6),  Армении 
(18,0),  Кипре  (17,6),  Ирландии  (17,3),  Грузии  (16,4), 
Кыргызстане 
(15,4).  Наиболее 
низкие  значения  (<3,0)  были  зарегистрированы  в 
Швеции (2,9), Словакии (2,6), Хорватии (2,5), Венгрии 
(2,2), 
(2,4),  Северной  Македонии 
Австрии (2,1) и Словении (2,1). 

(15,6)  и  Беларуси 

(2,4),  Сербии 

Общая  заболеваемость  у  мужчин  составила  16,7  на 
100 000  населения,  а  у  женщин  –  8,9  на  100 000 
населения. Соотношение заболеваемости у мужчин к 
заболеваемости  у  женщин  в  среднем  составило  1,8; 
наиболее  низкое  соотношение  было  отмечено  в 
восточной  части  (1,6),  более  высокое  (2,1)  –  в 
западной части, и самое высокое (3,9) – в центральной 
части Региона.

Наибольшая  доля  новых  случаев  ВИЧ-инфекции  в 
Регионе (36%) пришлась на возрастную группу 30-39 
лет,  6%  –  на  возрастную  группу  15-24  лет  и  19%  –  на 
возрастную  группу  50  лет  и  старше  на  момент 
постановки диагноза.

данным, 

полученным 

гетеросексуальный 

Согласно 
наиболее 
распространенными путями передачи ВИЧ-инфекции 
были 
(63,8%), 
инфицирование 
инъекционных 
наркотиков (13,6%), секс между мужчинами (11,7%) и 
–  менее  1%  –ПМР.  Путь  передачи  инфекции  был 
неизвестен  или  информация  о  нем  отсутствовала  в 
10,3% новых случаев.

приеме 

путь 

при 

а 

от 

3,4% 

числа 

(18,1%) 

общего 

мужчинами 

В  восточной  части  Региона,  согласно  данным  из  13 
стран,  из  новых  случаев  ВИЧ-инфекции  с  известным 
путем передачи 76,1% пришлись на гетеросексуальный 
путь,  18,4%  –  на  инфицирование  при  приеме 
инъекционных 
число 
наркотиков, 
зарегистрированных  случаев  инфицирования  при 
сексе  между  мужчинами  оставалось  низким,  на 
уровне 
случаев. 
Гетеросексуальный  путь  передачи  (24,5%)  и  секс 
между 
наиболее 
распространенными  путями  передачи  инфекции  в 
центральной чести Региона для случаев с известным 
путем  передачи,  но  у  54,7%  новых  случаев  ВИЧ-
инфекции 
передачи 
отсутствовала. Секс между мужчинами был наиболее 
распространенным  путем  передачи  инфекции  в  7  из 
15  стран  в  центральной  части  Региона.  В  западной 
части  Региона  основным  путем  передачи  ВИЧ-
инфекции  был  гетеросексуальный  путь 
(40,1%); 
вместе  с  тем,  13%  из  этих  случаев  имели  ранее 
известный 
74% 
приходились  на  мигрантов,  и  40%  происходили  из 
генерализованной  эпидемией.  Вторым 
стран  с 

положительный 

информация 

ВИЧ-статус, 

были 

пути 

о 

наиболее  распространенным  путем  передачи  был 
секс между мужчинами (33,3% случаев). Информация 
о  пути  передачи  отсутствовала  для  21,1%  новых 
случаев ВИЧ-инфекции, выявленных в 2023 г.

являлся 

Региона 

В  2014–2023  гг.  данные  о  пути  передачи  ВИЧ-
инфекции регулярно поступали из 39 стран Региона. 
Основным  путем  передачи  инфекции  в  восточной 
гетеросексуальный. 
части 
Показатели  передачи  при  сексе  между  мужчинами 
увеличились почти на 120%. Хотя число случаев ВИЧ-
инфекции, приобретенной при приеме инъекционных 
наркотиков, за этот период снизилось на 39%, на этот 
путь  передачи  все  еще  приходится  18,4%  случаев 
ВИЧ-инфекции. Несмотря на тенденцию к повышению 
роли  передачи  гетеросексуальным  путем,  в  7  из  15 
стран  в  центральной  части  Региона  секс  между 
наиболее 
мужчинами 
распространенный  путь  передачи.  В  западной  части 
Региона  за  прошедшее  десятилетие  отмечается 
снижение  общей  заболеваемости  ВИЧ-инфекцией, 
что  главным  образом  объясняется  снижением  числа 
случаев  среди  МСМ  в  некоторых  странах.  Вместе  с 
тем, даже при исключении случаев с ранее известным 
положительным  ВИЧ-статусом  за  прошедший  год 
отмечается 
случаев 
заражения  гетеросексуальным  путем,  особенно  у 
женщин и у мигрантов.

числа  новых 

увеличение 

отмечался 

как 

диагноза 

постановки 

Среди  лиц  старше  14  лет,  которым  впервые  был 
поставлен диагноз «ВИЧ-инфекция» и для которых на 
было  известно 
момент 
количество  CD4-клеток,  более  чем  в  половине 
случаев  (52,4%)  отмечалась  постановка  диагноза  на 
поздней  стадии,  с  количеством  CD4-клеток  <350  кл/
мм3,  в  том  числе  в  31,6%  случаев  –  с  продвинутыми 
(количество  CD4-клеток 
стадиями  ВИЧ-инфекции 
<200  кл/мм3).  Вместе  с  тем,  среднее  значение  по 
Региону  не  включает  данные  по  Российской 
Федерации,3  где  в  30,0%  случаев  ВИЧ-инфекция 
была диагностирована, когда количество CD4-клеток 
составляло  <350  кл/мм3  и  в  15,1%  случаев  –  когда 
количество CD4-клеток составляло <200 кл/мм3.

Выявление  ВИЧ-инфекции  на  поздней 
стадии 
остается  серьезной  проблемой  в  большинстве  стран 
Региона.  Доля  людей  с  постановкой  диагноза  на 
поздней  стадии  (количество  CD4-клеток  <350  кл/мм3) 
разнится  по  разным  категориям  передачи  и 
возрастным  группам,  но  наиболее  высокая  доля 
отмечается  у  лиц,  зараженных  гетеросексуальным 
путем  (56%;  61%  у  мужчин  и  51%  у  женщин)  и  у  лиц, 
употребляющих  инъекционные  наркотики  (52,0%),  а 
наименьшая  доля  –  у  МСМ  (43,0%)  (рис. B).  Эта  доля 
увеличивается  с  возрастом  и  составляет  от  37,7%  у 
лиц  в  возрасте  15–19  лет  на  момент  постановки 
диагноза до 65,9% у лиц в возрасте 50 лет и старше. В 
гендерной  разбивке  доля  случаев  постановки 
диагноза  на  поздней  стадии  составила  53,4%  у 

3   Данные по количеству CD4-клеток из Российской Федерации не 

включали разбивку данных по ранее известному положительному 
ВИЧ-статусу и путям передачи и поэтому были исключены из 
субрегионального и регионального анализа.

xxi

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORTмужчин и 50,6% у женщин: более низкий показатель 
у  мужчин  по  сравнению  с  женщинами  обусловлен 
дальнейшим  снижением  числа  случаев  постановки 
диагноза на поздней стадии среди МСМ.

стране 

Европейского 

заболеваемости 

региона  ВОЗ, 
1,2  на 

В 2023 г. СПИД был диагностирован у 7 878 человек в 
что 
41 
соответствует 
100 000 
населения.  Из  общего  числа  диагностированных 
случаев  СПИДа,  61%  случаев  были  диагностированы 
в  восточной  части  Региона,  где  заболеваемость  на 
100 000  населения  также  была  наиболее  высокой 
(4,9), 28% – в западной части Региона (заболеваемость 
0,6  на  100 000  населения)  и  12%  –  в  центральной 
части Региона (0,4 на 100 000 населения). У 12% лиц, 
у  которых  был  диагностирован  СПИД,  СПИД-
индикаторным  заболеванием  был  туберкулез  (11%  в 
западной  части,  12%  в  центральной  части  и  14%  в 
восточной части Региона). В период с 2014 г. по 2023 
г.  общее  число  диагностированных  случаев  СПИДа  в 
Регионе снизилось на 50%.

ВОЗ 

регионе 

Европейском 

Выводы
В 
ВИЧ-инфекция 
по-прежнему  остается  угрозой  для  здоровья  и 
благополучия  миллионов  людей.  За  последние 
четыре 
была 
диагностирована  почти  у  2,6  миллиона  жителей 
Региона,  в  том  числе  у  более  чем  650 000  человек  в 
странах ЕС/ЕЭЗ.

ВИЧ-инфекция 

десятилетия 

степени 

ситуацию 

отражает 
где  с  2019 

Общая  тенденция  в  выявлении  ВИЧ-инфекции  в 
значительной 
в 
Российской  Федерации, 
г.  число 
выявленных случаев снизилось на 32%. Вместе с тем, 
21 из 47 стран сообщила об увеличении числа новых 
случаев ВИЧ-инфекции в 2023 г. по сравнению с 2022 
г.,  а  в  нескольких  странах  было  зарегистрировано 
самое  большое  за  последнее  десятилетие  число 
новых случаев ВИЧ-инфекции, выявленных в течение 
одного года. Рост числа случаев ВИЧ-инфекции в этих 
странах в 2023 г. может быть объяснен целым рядом 
факторов.

В восточной части Региона четыре страны сообщили 
об  увеличении  числа  новых  случаев  ВИЧ-инфекции 
в 2023 г. по сравнению с 2022 г. Это главным образом 
объемов 
объясняется 
восстановлением 
тестирования  на  ВИЧ-инфекцию 
времени 
ослабления  пандемии  COVID-19,  сосредоточением 
усилий  на  выявлении  новых  случаев  и  введением 
новой  политики  тестирования,  направленной  на 
снижение числа лиц, живущих с недиагностированной 
ВИЧ-инфекцией.

со 

Одиннадцать  стран  в  западной  части  Региона 
сообщили  об  увеличении  числа  новых  случаев  ВИЧ-
инфекции;  это  единственный  субрегион,  где  число 
новых  случаев  ВИЧ-инфекции  в  2023  г.  увеличилось 
по  сравнению  с  2023  г.  Это  объясняется  главным 
образом  увеличением  доли  новых  случаев  ВИЧ-
инфекции  среди  мигрантов,  с  60,3%  в  2022  г.  до 

xxii

высоких 

происходящих 

сохранение 
у 

66,1%  в  2023  г.  Это  число  значительно  выше,  чем  в 
центральной (19,4%) и восточной части Региона (2,0). 
Основной  причиной  для  такого  увеличения  является 
рост  числа  лиц,  у  которых  была  выявлена  ВИЧ-
инфекция,  происходящих  из  стран  Африки  к  югу  от 
показателей 
Сахары,  и 
заболеваемости 
из 
людей, 
Центральной  и  Восточной  Европы  и  из  Латинской 
Америки.  Следует  отметить,  что  12,9%  случаев 
инфекции,  выявленных  в  западной  части  Региона  в 
2023  г.,  приходится  на  людей  с  ранее  известным 
положительным  ВИЧ-статусом.  При  этом,  вероятно, 
имеет  место  недооценка  числа  случаев  с  ранее 
известным положительным ВИЧ-статусом, поскольку 
полнота  данных  для  переменной  выявления  таких 
случаев  в  2023  г.  составила  48,6%.  Следовательно, 
для 
мер 
профилактики, вмешательств в сфере общественного 
здравоохранения  и  планирования  ресурсов  важно 
понимать  различия  в  эпидемиологическом  профиле 
случаев  с  ранее  известным  положительным  ВИЧ-
случаев 
статусом 
таких 
ВИЧ-инфекции,  а 
случаев (1).

также  происхождение 

организации 

выявленных 

адекватной 

впервые 

целей 

и 

В странах в центральной части Региона наблюдается 
противоположная  картина:  число  новых  случаев 
ВИЧ-инфекции  в  2023  г.  снизилось  по  сравнению  с 
2022 г.,  главным  образом,  по  причине  уменьшения 
числа  случаев  с  ранее  известным  положительным 
ВИЧ-статусом.  Вместе  с  тем,  в  6  из  15  стран  в 
согласно 
центральной 
предоставленным ими данным, в 2023 г. наблюдалось 
увеличение  числа  новых  случаев  ВИЧ-инфекции  по 
сравнению с 2022 г.

Региона, 

части 

В  30  странах  ЕС/ЕЭЗ  за  период  2014–2023  гг.  число 
случаев  ВИЧ-инфекции  снизилось  на  15,9%,  что 
указывает  на  постепенное  снижение  общего  числа 
случаев. Вместе с тем, в 2023 г., по сравнению с 2022 
с  ранее  известным 
г.,  при  вычете 
положительным 
отмечается 
увеличение  числа  впервые  выявленных  случаев 
ВИЧ-инфекции.

ВИЧ-статусом 

случаев 

в 

время 

ЕС/ЕЭЗ 

странах 

приходится 

Эпидемиологические  профили  впервые  выявленных 
случаев и случаев с ранее известным положительным 
ВИЧ-статусом 
значительно 
различаются.  Впервые  выявленные  случаи  ВИЧ-
инфекции  в  странах  ЕС/ЕЭЗ  в  основном  приходятся 
на  мужчин  среднего  возраста,  и  28%  всех  случаев  в 
настоящее 
женщин. 
Значительная  часть  впервые  выявленных  случаев 
ВИЧ-инфекции  (47,9%)  приходится  на  мигрантов,  а 
38%  впервые  выявленных  случаев  –на  уроженцев 
страны,  предоставляющей  данные.  В  странах  ЕС/ЕЭЗ 
секс  между  мужчинами  остается  ведущим  путем 
передачи  ВИЧ-инфекции,  но  значительное  число 
новых 
на 
также 
гетеросексуальный  путь.  Среди  случаев  с  ранее 
поставленным 
наблюдается 
диагнозом 
здесь  наблюдается 
противоположная  картина: 

приходится 

случаев 

на 

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 dataболее  высокая  доля  женщин,  людей  старшего 
возраста  и  мигрантов  из  Центральной  и  Восточной 
Европы,  Африки  к  югу  от  Сахары  и  Латинской 
Америки; для таких лиц наиболее распространенным 
путем передачи является гетеросексуальный.

Хотя  число  зарегистрированных  случаев  передачи 
ВИЧ-инфекции  половым  путем  среди  МСМ  в 
восточной  части  Региона  в  абсолютном  выражении 
остается  низким,  за  последнее  десятилетие  оно 
увеличилось  более  чем  в  два  раза  –  это  самое 
значительное  увеличение  для  всех  путей  передачи  и 
всех  субрегионов.  Гетеросексуальный  путь  передачи 
ВИЧ-инфекции  остается  в  восточной  части  Региона 
основным.  Вместе  с  тем  имеются  определенные 
данные,  позволяющие  предположить,  что  для  части 
мужчин  путь  заражения  мог  быть  ошибочно 
классифицирован как гетеросексуальный, тогда как 
на  самом  деле  они  могут  относиться  к  МСМ  или 
иметь  в  анамнезе  употребление  инъекционных 
наркотиков (2-4).

мигрантов, 

инфицированных 
Доля 
гетеросексуальным  путем,  в  центральной  части 
Региона в последние годы увеличилась, с 13% в 2021 
г. до 23% в 2023 г. Среди инфицированных мигрантов 
из  Хорватии,  Черногории,  Польши  и  Словении  более 
40%  были  заражены  гетеросексуальным  путем,  а 
среди инфицированных мигрантов из Кипра, Чехии и 
Словакии  этот  показатель  составил  более  70%. 
Несмотря  на 
увеличению  роли 
гетеросексуального пути заражения, в 7 из 15 стран в 
центральной части Региона самым распространенным 
путем  передачи  ВИЧ-инфекции  был  секс  между 
мужчинами.

тенденцию  к 

В  Европейском  регионе  ВОЗ  у  более  половины 
выявленных  случаев  ВИЧ-инфекции  число  CD4-
клеток составляет <350 кл/мм3, при этом почти треть 
таких  случаев  была  выявлена  на  продвинутых 
стадиях  инфекции  (количество  CD4-клеток  <200  кл/
мм3  на  момент  диагностики).  Как  и  в  предыдущие 
годы, данные 2023 г. указывают на то, что выявление 
ВИЧ-инфекции на поздней стадии преобладает у лиц, 
инфицированных 
путем 
(особенно  у  мужчин),  у  лиц,  инфицированных  при 
приеме  инъекционных  наркотиков  и  у  людей 
старшего возраста. Данные настоящего отчета также 
указывают  на  то,  что  в  Регионе  расширяется  разрыв 
между  выявленными  и  невыявленными  случаями 
ВИЧ-инфекции,  и  что  Регион  не  сможет  к  2025  г. 
достичь  цели,  предполагающей  диагностику  95% 
людей, живущих с ВИЧ-инфекцией.

гетеросексуальным 

эпидемии  должны 
Мероприятия  по  контролю 
основываться  на  фактических  данных  и  быть 
адаптированы  к  эпидемиологической  ситуации  на 
уровне  стран  и  на  локальном  уровне.  В  настоящем 
отчете 
обзор 
эпидемиологической ситуации по ВИЧ-инфекции, и в 
соответствии  с  этими  данными  приоритет  должен 
отдаваться следующим мерам реагирования:

представлен 

подробный 

ВИЧ, 

подходов, 

годы 
на 

улучшились 
и 

•  Во  всех  странах  Региона:  быстрое  увеличение 
объемов  тестирования  на  ВИЧ-инфекцию  имеет 
важнейшее  значение  для  ускорения  прогресса  на 
пути  к  достижению  цели  выявления  к  2025  г.  95% 
лиц,  инфицированных  ВИЧ.  ВОЗ  выпустила 
аналитическую 
рекомендующую 
записку, 
отказаться в стратегиях и алгоритмах тестирования 
на ВИЧ-инфекцию от вестерн-блоттинга и линейных 
политику 
и 
иммуноанализов 
поддерживать 
децентрализованного 
тестирования  и  раннего 
привлечения  к  лечению  (5).  В  руководстве  ВОЗ  и 
Европейского  центра  профилактики  и  контроля 
заболеваний  даны  рекомендации  по  применению 
инновационных 
включая 
самотестирование  и  тестирование  на  уровне 
сообществ,  проводимое  лицами  без  формального 
образования, а также организацию легкодоступных 
(6–8).  В 
служб  тестирования  для  мигрантов 
показатели 
последние 
тестирования 
показатели 
самотестирования  и  тестирования  на  уровне 
сообществ  значительно  выросли,  однако  данные 
мониторинга  политики  в  Регионе  свидетельствуют 
о том, что в некоторых странах Региона некоторые 
виды  тестирования  по-прежнему  недостаточно 
доступны  или  практически  отсутствуют 
(9). 
Тестирование  на  ВИЧ-инфекцию  должно  быть 
преимущественно  направлено  на  охват  ключевых 
групп 
местной 
в 
эпидемиологической  ситуации.  Стратегии  должны 
быть  адаптированы  к  конкретным  потребностям 
обеспечивать 
этих 
своевременное  оказание  услуг  профилактики, 
лечения и ухода при ВИЧ-инфекции. Это обеспечит 
более  раннюю  диагностику  и  начало  лечения,  что 
приведет  к  улучшению  результатов  лечения  и 
снижению  распространенности,  заболеваемости  и 
смертности 
будет 
способствовать  достижению  целей  «95-95-95»  и 
других  региональных  и  глобальных  целей  (10–12). 
Научные  данные  убедительно  доказывают,  что 
раннее  начало  антиретровирусной  терапии  (АРТ) 
благотворно  влияет  на 
здоровье  пациента, 
получающего  такую  терапию,  и  способствует 
профилактике  передачи  ВИЧ-инфекции  (13–18). 
Почти  90%  стран  в  Регионе  следуют  политике, 
предписывающей  начинать  АРТ  независимо  от 
количества CD4-клеток (19).

ВИЧ-инфекции 

населения 

населения 

условиях 

групп 

от 

и 

и 

тестирования, 

•  В  странах  ЕС/ЕЭЗ  и  странах  в  западной  части 
Региона:  увеличение  числа  новых  случаев  ВИЧ-
инфекции может быть связано с ростом выявления 
случаев  инфекции  у  мигрантов  и  повышением 
объемов 
отражает 
демографические сдвиги и улучшение диагностики 
и  выявления  случаев  ВИЧ-инфекции  в  странах  ЕС/
ЕЭЗ  и  странах  в  западной  части  Региона.  Для 
улучшения 
в 
популяциях  мигрантов  страны  должны  изучить 
возможности  для  расширения  первичных  услуг 
профилактики, включая программы предоставления 
сексуального 
презервативов, 

ВИЧ-инфекции 

профилактики 

программы 

что 

xxiii

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORTпросвещения молодежи и программы доконтактной 
профилактики  (ДКП),  и  обеспечить  для  мигрантов 
доступ  к  этим  программам.  Предоставление  услуг 
от 
лечения 
тестирования 
миграционного статуса способствует осуществлению 
эффективной профилактики и лечения. 

независимо 

и 

(20-21). 

эпиднадзора. 

Для 
тестирования 

•  Страны  также  должны  устранять  барьеры  более 
широкого  характера,  затрудняющие  доступ  к 
необходимой помощи, и улучшать информирование 
о получении доступа к системе здравоохранения. В 
последнее  десятилетие  основным  путем  передачи 
ВИЧ-инфекции  среди  мигрантов  в  странах  ЕС/ЕЭЗ 
остается  секс  между  мужчинами.  Меры  по 
профилактике  передачи  инфекции  для  МСМ 
должны  включать  комплексные  программы  с 
расширенным  доступом  к  ДКП  и  устранением 
ограничений для доступа к ДКП во всех контекстах. 
Предоставление  ДКП  в  сочетании  с  расширенным 
регулярным  тестированием  и  привлечением  к 
лечению  может  помочь  снизить  заболеваемость 
ВИЧ-инфекцией 
Для 
среди  МСМ 
эффективного мониторинга необходимы надежные 
дальнейшего 
системы 
доступности 
повышения 
для 
мигрантов, 
необходимы 
являющихся  МСМ, 
мероприятия,  проводимые  с  опорой  на  местные 
сообщества  и  с  учетом  культурной  специфики, 
предоставление  наборов  для  самотестирования  и 
социального 
проведение 
маркетинга. 
Региона 
западной 
увеличивается  число  случаев  инфицирования 
гетеросексуальным  путем:  этот  путь  передачи 
становится одним из основных, и для него является 
характерным  большой  процент  случаев,  когда 
диагноз  ставится  на  поздней  стадии.  Такие  меры, 
как расширение программ целевого тестирования, 
включая тестирование при наличии показаний при 
тестирование  в 
соответствующих  состояниях, 
отделениях 
повышение 
помощи 
осведомленности  медицинских  работников  о 
важности  проведения  целевого  скрининга  на 
основании  имеющихся  факторов  риска,  способны 
улучшить  показатели  раннего  выявления  ВИЧ-
инфекции в этой группе населения.

кампаний 

целевых 

скорой 

части 

В 

и 

г. 

в 
2023 
снизилось, 

•  В странах в центральной части Региона: после того, 
как  в  2022  г.  в  центральной  части  Региона  было 
выявлено  беспрецедентно  высокое  число  новых 
случаев  ВИЧ-инфекции, 
число 
главным 
поставленных  диагнозов 
образом,  в  связи  со  снижением  числа  случаев  с 
ранее  известным  положительным  ВИЧ-статусом  в 
странах  ЕС/ЕЭЗ.  Тем  не  менее,  в  2023  г.  6  из  15 
стран в центральной части Региона также сообщили 
об  увеличении  числа  новых  случаев  инфекции  по 
сравнению  с  2022  г.  Несмотря  на  тенденцию  к 
инфицирования 
увеличению 
гетеросексуальным 
обусловленную 
вышеуказанными  факторами,  в  7  из  15  стран  в 
центральной 
самым 
распространенным путем передачи был секс между 
мужчинами.  В  связи  с  этим  необходимы  такие 

случаев 
путем, 

Региона 

числа 

части 

xxiv

вспышек 

партнера 

инфекций 

сочетанных 

необходимо 

вмешательства,  как  программы  предоставления 
презервативов  и  лубрикантов,  диверсификация 
услуг  тестирования  на  ВИЧ-инфекцию,  помощь  в 
о 
уведомлении 
добровольном 
положительном ВИЧ-статусе, ДКП, профилактика и 
ведение 
(особенно 
передаваемых  половым  путем)  и  ранее  начало 
лечения  ВИЧ-инфекции.  Услуги  должны  быть 
пациентоориентированными  и  предоставляться  в 
комфортной  обстановке,  предпочтительно  –  с 
вовлечением  организаций  гражданского  общества 
на  всех  этапах  предоставления  услуг,  связанных  с 
ВИЧ-инфекцией,  от  профилактики  ВИЧ-инфекции 
до  соблюдения  схемы  АРТ.  Показатели  передачи 
ВИЧ-инфекции  при  употреблении  инъекционных 
наркотиков  остаются  низкими,  но  из  опыта 
прошлых вспышек (22–26)  можно сделать вывод о 
том,  что  услуги  профилактики  ВИЧ-инфекции  для 
людей,  употребляющих  инъекционные  наркотики, 
сохраняют свою актуальность, и для профилактики 
таких 
обеспечить 
достаточный  охват  этими  услугами.  Также  в  этой 
части  Региона  выше,  чем  где-либо  еще  в  Регионе, 
доля молодых людей среди лиц с диагностированной 
ВИЧ-инфекцией. 
прекращения 
финансирования со стороны Глобального фонда по 
борьбе  со  СПИДом,  туберкулезом  и  малярией  в 
некоторых  странах  был  осуществлен  перевод  мер 
реагирования  на  ВИЧ-инфекцию  на  внутреннее 
финансирование.  Это  подорвало  устойчивость 
финансирования  программ  профилактики  ВИЧ-
инфекции  и  создало  препятствия  для  проведения 
среди ключевых групп населения опросов целиком 
силами  местных  сообществ.  Кроме  того,  для 
осуществления 
надежных 
пациентоориентированных  мер  реагирования, 
особенно  в  странах,  сильно  затронутых  притоком 
мигрантов  и  беженцев,  необходимым  являются 
обеспечение  доступа  к  услугам  здравоохранения 
(включая услуги, связанные с ВИЧ-инфекцией) для 
международному 
содействие 
этих 
сотрудничеству  и  обмену  данными.  Для  решения 
этих  проблем  и  предотвращения  обострения 
эпидемии  требуется  твердая  политическая  воля  и 
приоритетное  внимание  к  этой  проблеме,  а  также 
больше  широкое 
гражданского 
общества (27).

вовлечение 

После 

лиц 

и 

объемов 

•  В странах в восточной части Региона: в нескольких 
также 
странах  в  восточной  части  Региона 
отмечалось  рекордное  число  новых  случаев  ВИЧ-
инфекции,  выявленных  в  течение  одного  года. 
то,  что  эти  страны  отмечают 
Несмотря  на 
восстановление 
и 
показателей  выявления  случаев  ВИЧ-инфекции 
после  ослабления  пандемии  COVID-19  благодаря 
внедрению  новой  политики  тестирования  для 
повышения 
этого 
недостаточно  для  того,  чтобы  устранить  разрыв  и 
обеспечить,  чтобы  люди  знали  свой  ВИЧ-статус: 
необходимо увеличить охват диагностикой. Страны 
в  восточной  части  Региона  должны  далее 

тестирования 

показателей 

выявления, 

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 dataна 

научными 

увеличения 

воздействием 

данными  мер 

наращивать  осуществление  инновационных  и 
обоснованных 
и 
предоставление  эффективных  интегрированных 
услуг  через  системы  здравоохранения,  с  более 
эффективным 
социальные 
детерминанты здоровья. Необходимы комплексные 
стратегии  по  профилактике  и  инновационным 
методам тестирования на ВИЧ-инфекцию, с особым 
группам  населения. 
вниманием  к  ключевым 
Важную  роль 
здесь  играет  предоставление 
пациентоориентированных  услуг  профилактики  и 
тестирования,  включая  помощь  в  уведомлении 
партнера  о  ВИЧ-статусе,  ДКП,  тестирование  на 
ВИЧ-инфекцию,  проводимое  сотрудниками  без 
формального  образования  и  самотестирование  в 
соответствии  с  рекомендациями  ВОЗ.  Все  эти 
услуги  должны  быть  включены  в  национальные 
стратегии  и  программы,  с  последующей  их 
реализацией (6,7,12). Для снижения заболеваемости 
ВИЧ-инфекций  и 
людей, 
привлеченных  к  лечению,  а  также  начавших  и 
продолжающих  АРТ,  крайне  важно  вовлечение 
сообществ в планирование и предоставление услуг. 
Конечной 
снижение 
заболеваемости  ВИЧ-инфекцией  и  смертности, 
связанной 
Инновационные 
СПИДом. 
мероприятия  по  профилактике  ВИЧ-инфекции 
должны  быть  направлены  на  снижение  риска 
гетеросексуальной  передачи,  особенно  для  пар,  в 
которых  один  из  партнеров  склонен  к  поведению 
высокого 
употребляет 
инъекционные  наркотики)  или  в  течение  долгих 
периодов  времени  работает  за  границей.  Большое 
число диагностированных случаев ВИЧ-инфекции у 
людей,  употребляющих  инъекционные  наркотики, 
указывает  на  то,  что  обоснованные  научными 
данными  меры  политики,  направленные  на 
ключевые группы населения, включая обеспечение 
высокого охвата программами снижения вреда для 
людей,  употребляющих  инъекционные  наркотики, 
по-прежнему  имеет  решающее  значение  для 
борьбы  с  ВИЧ-инфекцией  в  восточной  части 
Региона.

(например, 

является 

целью 

риска 

числа 

со 

Для  данных  о  ВИЧ-инфекции  2023  г.  характерны 
серьезные проблемы, касающиеся качества, полноты 
и  степени  стандартизации  переменных,  различения 
впервые  диагностированных  случаев  ВИЧ-инфекции 
и  случаев  с  ранее  известным  положительным  ВИЧ-
статусом,  а  также  в  отношении  таких  переменных, 
как  страна  рождения  и  регион  инфицирования.  Эти 
факторы,  в  сочетании  с  увеличением  миграции 
населения,  сделали  интерпретацию  данных  2022  г.  и 
2023  г.  крайне  затруднительной.  Огромное  значение 
имеет достижение среди стран Региона консенсуса в 
отношении  сбора,  регистрации  и  предоставления 
отчетных  данных  о  случаях  с  ранее  известным 
положительным 
для 
ВИЧ-статусом, 
беженцев,  мигрантов  и  людей  с  ранее  известным 
положительным  ВИЧ-статусом  характерны  разные 
эпидемиологические профили и разные медицинские 
потребности.  Улучшение  стандартов  регистрации 

поскольку 

данных  и  предоставления  отчетности  в  системах 
эпидназдора  поможет  обеспечить  необходимую 
точность и осуществлять эффективное планирование 
стратегий 
адаптированных 
специально 
профилактики.

ограниченной 

Из-за 
по 
трансгендерным  людям  более  полное  понимание  их 
остается 
эпидемиологического 
затрудненным.

доступности 

профиля 

данных 

с 

моделированием 
случаев 

Усиление  эпиднадзора  за  ВИЧ-инфекцией  создает 
возможность для осуществления более долгосрочного 
мониторинга  результатов  каскада  лечения  ВИЧ-
инфекции, 
доли 
недиагностированных 
измерением 
эффективности  привлечения  к  лечению,  лечения  и 
подавления  вирусной  нагрузки  после  постановки 
диагноза. 
способствовать 
также  может 
осуществлению  на  уровне  стран  и  на  глобальном 
уровне мониторингу прогресса на пути к достижению 
целей 
и 
«95–95–95» 
региональных целей.

глобальных 

других 

Это 

и 

и 

3.3, 

развития 

вирусных 

эпидемий 

гепатитов 

ВОЗ  и  Европейский  центр  профилактики  и  контроля 
заболеваний  во  взаимодействии  с  государствами-
членами ВОЗ занимаются практической реализацией 
Региональных  планов  действий  по  ликвидации 
СПИДа, 
и 
заболеваний, предаваемых половым путем, на 2022-
2030  гг.  (12),  а  также  работают  над  измерением 
прогресса  на  пути  к  достижению  Цели  в  области 
устойчивого 
предполагающей 
ликвидацию СПИДа к 2030 г. Ключевые мероприятия 
ВОЗ и Европейского центра профилактики и контроля 
заболеваний  сосредоточены  на  поддержке  стран  в 
наращивании  масштабов  тестирования  на  ВИЧ  и 
выполнении  рекомендаций  по  лечению  и  сочетанию 
инновационных  подходов  к  профилактике  ВИЧ-
инфекции  в  отношении  ключевых  групп  населения. 
центр 
Помимо 
профилактики  и  контроля  заболеваний  занимаются 
вопросами 
ВИЧ-инфекции, 
вирусного  гепатита  В  и  сифилиса,  улучшения 
эпиднадзора  за  ВИЧ-инфекцией  и  предоставления 
отчетных  данных,  а  также  другими  ключевыми 
приоритетами, установленными в планах действий.

Европейский 

элиминации 

этого, 

ПМР 

ВОЗ 

и 

с 

совместно 

ВОЗ  и  Европейский  центр  профилактики  и  контроля 
заболеваний 
партнерскими 
организациями  продолжат  оказывать  поддержку 
государствам-членам  ВОЗ  в  реализации  мер  по 
ускорению  прогресса  на  пути  к  достижению  Целей  в 
области  устойчивого  развития,  касающихся  ВИЧ-
подготовки 
посредством 
инфекции, 
специализированных 
документов, 
проведения  семинаров,  тренингов  и  вебинаров  и 
предоставления  иной  технической  поддержки  для 
обеспечения  высокой  эффективности  эпиднадзора, 
мониторинга, лечения и профилактики. 

руководящих 

xxv

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2021 – 2020 data

SURVEILLANCE REPORT

Литература4

1.  Massmann R, Groh T, Jilich D, Bartková D, Bartovská Z, Chmelař J, 
et al. HIV-positive Ukrainian refugees in the Czech Republic. AIDS. 
2023 Oct 1;37(12):1811-1818 (https://doi.org/10.1097/
QAD.0000000000003633).

2.  Dumchev K, Kornilova M, Kulchynska R, Azarskova M, Vitek C. 

Improved ascertainment of modes of HIV transmission in Ukraine 
indicates importance of drug injecting and homosexual risk. BMC 
Public Health 2020;20(1):1288 (https://doi.org/10.1186/
s12889-020-09373-2).

3.  Čakalo JI, Božičević I, Vitek C, Mandel JS, Salyuk T, Rutherford GW. 
Misclassification of men with reported HIV infection in Ukraine. 
AIDS Behav. 2015;19(10):1938–40 (https://doi.org/10.1007/
s10461-015-1112-0).

4.  Dumchev K, Stepanovich-Falke A, Lunchenkov N, Rohde A, 

Danshyna A, Bekbolotov A, et al. Comparison of Registered and 
Survey-based Modes of HIV Transmission in 2021-2023: 
cross- sectional study in the Kyrgyz Republic. 2024; PREPRINT 
(Version 1) (https://doi.org/10.21203/rs.3.rs-4592674/v1).

5.  WHO recommends countries move away from the use of western 
blotting and line immunoassays in HIV testing strategies and 
algorithms: policy brief. Geneva: World Health Organization; 2019 
(WHO/CDS/HIV/19.30; https://iris.who.int/handle/10665/329915). 
License: CC BY-NC-SA 3.0 IGO.

6.  Guidelines on HIV self-testing and partner notification: supplement 
to consolidated guidelines on HIV testing services. Copenhagen: 
World Health Organization; 2016 (https://iris.who.int/
handle/10665/251655).

7. 

Сводное руководство по тестированию на ВИЧ, 2019. Женева: 
Всемирная организация здравоохранения; 2020 https://iris.
who.int/bitstream/handle/10665/329966/WHO-CDS-HIV-19.31-rus.
pdf). Лицензия: CC BY-NC-SA 3.0 IGO

8.  Public health guidance on HIV, hepatitis B and C testing in the EU/

EEA. Stockholm: ECDC; 2018 (www.ecdc.europa.eu/en/
publications-data/public-health-guidance-hiv-hepatitis-b- 
and-c-testing-eueea). 

9.  HIV testing. Monitoring implementation of the Dublin Declaration 
on Partnership to fight HIV/AIDS in Europe and Central Asia: 2017 
progress report. Stockholm: ECDC; 2017 (https://ecdc.europa.eu/
sites/portal/files/documents/HIV%20testing.pdf).

10.  Глобальные стратегии сектора здравоохранения по ВИЧ, 

вирусному гепатиту и инфекциям, передаваемым половым 
путем, на 2022–2030 гг. Женева: Всемирная организация 
здравоохранения; 2022 (https://iris.who.int/bitstream/han
dle/10665/361970/9789240053878-rus.pdf). Лицензия: CC 
BY-NC-SA 3.0 IGO.

11.  Глобальная стратегия по СПИДу на 2021-2026 годы. 

Ликвидировать неравенство. Покончить со СПИДом. Женева: 
ЮНЭЙДС; 2021 (https://www.unaids.org/sites/default/files/
media_asset/global-AIDS-strategy-2021-2026_ru.pdf).

12.  Региональные планы действий по ликвидации СПИДа и 

эпидемий вирусных гепатитов и инфекций, передаваемых 
половым путем, на 2022–2030 гг. Всемирная организация 
здравоохранения. Европейское региональное бюро (2023).  
https://iris.who.int/bitstream/handle/10665/372674/9789289060264- 
rus.pdf. Лицензия: CC BY-NC-SA 3.0 IGO.

13.  Сводное руководство по использованию антиретровирусных 
препаратов для лечения и профилактики ВИЧ-инфекции: 
рекомендации с позиций общественного здравоохранения, 
второе издание.  Женева: Всемирная организация здравоохра-
нения; 2016 (https://iris.who.int/bitstream/handle/10665/112474/ 
9789244505724_rus.pdf?sequence=1&isAllowed=y).

14.  Руководство о времени назначения антиретровирусной 

терапии и по доконтактной профилактике ВИЧ-инфекции. 
Женева: Всемирная организация здравоохранения; 2015 

4  Все ссылки состоянию на 18 ноября 2024 г.

(https://iris.who.int/bitstream/handle/10665/343785/ 
9789289051415-rus.pdf?sequence=3&isAllowed=y).

15. 

INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, 
Emery S, Grund B, et al. Initiation of Antiretroviral Therapy in Early 
Asymptomatic HIV Infection. N Engl J Med. 2015;373(9):795–807 
(https://doi.org/10.1056/NEJMoa1506816). 

16.  Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, 

Kumarasamy N, et al. Prevention of HIV-1 infection with early 
antiretroviral therapy. N Engl J Med. 2011;365(6):493–505 (https://
doi.org/10.1056/NEJMoa1105243).

17.  EACS Guidelines [website]. European AIDS Clinical Society; 2024 
(https://www.eacsociety.org/guidelines/eacs-guidelines/).

18.  Rodger A, Cambiano V, Bruun T, Vernazza P, Collins S, Degan O et 

al. Risk of HIV transmission through condomless sex in 
serodifferent gay couples with HIV-positive partner taking 
suppressive antiretroviral therapy (PARTNER): final results of a 
multicentre, prospective, observational study. Lancet. 
2019;393(10189):2428–38 (https://doi.org/10.1016/
S0140-6736(19)30418-0).

19.  Continuum of HIV care - Monitoring implementation of the Dublin 

Declaration on partnership to fight HIV/AIDS in Europe and Central 
Asia: 2021 progress report. Stockholm: ECDC; 2022 (https://www.
ecdc.europa.eu/en/publications-data/continuum-hiv-care- 
monitoring-implementation-dublin-declaration-partnership-fight). 

20.  HIV Transmission Elimination Amsterdam (H-TEAM) Initiative, Van 
Sighem A, Hendriks S, Deug F, Zantkuijl P, van Bergen JE, et al. A 
95% decline in estimated newly acquired HIV infections, 
Amsterdam, 2010 to 2022. Euro Surveillance. 2023;28(40):2300515 
(https://doi.org/10.2807/1560-7917.ES.2023.28.40.2300515).

21.  Cambiano V, Miners A, Lampe FC, McCormack S, Gill ON, Hart G, et 

al. The effect of combination prevention strategies on HIV 
incidence among gay and bisexual men who have sex with men in 
the UK: a model-based analysis. Lancet HIV. 2023;10(11):e713–22 
(https://doi.org/10.1016/S2352-3018(23)00204-7).

22.  Hedrich D, Kalamara E, Sfetcu O, Pharris A, Noor A, Wiessing L et 

al. Human immunodeficiency virus among people who inject drugs: 
is risk increasing in Europe? Euro Surveill. 2013;18(48) (https://doi.
org/10.2807/1560-7917.ES2013.18.48.20648).

23.  Giese C, Igoe D, Gibbons Z, Hurley C, Stokes S, McNamara S et al. 

Injection of new psychoactive substance snow blow associated 
with recently acquired HIV infections among homeless people who 
inject drugs in Dublin, Ireland, 2016. Euro Surveill. 2016;20(40) 
(https://doi.org/10.2807/1560-7917).

24.  HIV in people who inject drugs – joint technical mission to 

Luxembourg. Stockholm: ECDC/European Monitoring Centre for 
Drugs and Drug Addiction; 2018 (https://sante.public.lu/fr/
publications/h/hiv-joint-technical-mission.html).

25.  McAuley A, Palmateer NE, Goldberg DJ, Trayner KMA, Shepherd SJ, 
Gunson RN, et al. Re-emergence of HIV related to injecting drug use 
despite a comprehensive harm reduction environment: a 
cross-sectional analysis. Lancet HIV. 2019;6(5):e315–24 (https://
doi.org/10.1016/S2352-3018(19)30036-0).

26.  Des Jarlais DC, Sypsa V, Feelemyer J, Abagiu AO, Arendt V, Broz D, 
et al. HIV outbreaks among people who inject drugs in Europe, 
North America, and Israel. Lancet HIV. 2020;7(6):e434–42 (https://
doi.org/10.1016/S2352-3018(20)30082-5).

27.  Lost in transition. Three case studies of Global Fund withdrawal in 
south-eastern Europe. New York: Open Society Foundations; 2017 
(www.opensocietyfoundations.org/publications/lost-transition).

xxvi

SURVEILLANCE REPORT

HIV/AIDS surveillance in Europe 2024–2023 data

1. HIV and AIDS in the EU/EEA

1.1 HIV diagnoses
In  2023,  24 731  HIV  diagnoses  were  reported  in  30 
countries  of  the   EU/EEA,  resulting  in  a  rate  of  5.3  per 
100 000  population  (Table 1).  The  highest  rates  were 
reported by Malta (21.0; 114 cases) and Cyprus (17.6; 162 
cases),  and  the  lowest  by  Slovenia  (2.1;  44  cases)  and 
Austria  (2.1;  194  cases)  (Table  1;  Map  1).  Of  the  HIV 
diagnoses  reported  in  2023,6  16.3%  (4020  diagnoses) 
were  among  individuals  with  a  previous  positive  HIV 
diagnosis.7  Section  1.2  will  describe  previous  positive 
diagnoses  in  more  detail.  Unless  otherwise  specified, 
data presented in this section includes all HIV diagnoses 
reported,  including  both  individuals  with  a  previous 
positive HIV diagnosis and those diagnosed for the first 
time.

As  in  previous  years,  more  men  than  women  were 
diagnosed  with  HIV 
(17 793  and  6688, 
in  2023 
respectively),  resulting  in  an  overall  male-to-female 
ratio  of  2.7  (Fig.  1.1.;  Table  2,  Table  3).  This  ratio  was 
highest in Malta (21.6), Slovenia (13.6) and Spain (6.2) 
(Fig. 1.1). 

The overall rate of diagnoses in men was 8.0 per 100 000 
population  (Table 2;  Map  3)  and  for  women  2.9  per 
100 000  population  (Table 3;  Map  4).  In  addition  to  the 
24 481  cases  identified  as  either  men  or  women,  206 
people (0.8%) identifying as transgender and 44 people 
(0.2%) with an unknown gender were reported in 2023. 

Fig. 1.1. Male-to-female ratio in HIV diagnoses, by country, EU/EEA, 2023 (n = 24 481)

Malta
Slovenia
Spain
Croatia
Hungary
Bulgaria
Netherlands
Austria
Romania
Greece
Italy
Cyprus
Slovakia
Iceland
Poland
Total EU/EEA
Luxembourg
Portugal
Germany
Latvia
Belgium
Denmark
Czechia
Lithuania
Ireland
Sweden
France
Norway
Estonia
Finland

0

5

10

15

20

25

Male-to-female ratio

Note: Liechtenstein reported only one case in 2023 and is excluded from the figure.

6  Reported HIV diagnoses refer to all HIV diagnoses made and reported by 
a country within a specific year, encompassing both previous positive 
diagnoses and individuals who were diagnosed with HIV for the first time.

7  Previous positive diagnoses are defined as HIV diagnoses made either 

abroad or in another setting within the reporting country, on any occasion 
before the current year of reporting. Some countries report previous 
positive HIV cases as they enter, re-enter or re-engage with the care system 
in the reporting country. 

1

Countries  reporting  HIV  diagnoses  among  transgender 
people  include  Belgium  (1.9%;  21  cases),  France  (2.6%; 
130  cases),  Germany  (0.3%;  11  cases),  Greece  (0.4%; 
three  cases),  Ireland  (0.9%;  eight  cases),  Netherlands 
(3.5%; 30 cases) and Portugal (0.3%; three cases).

Age-specific rates were lowest among children under 15 
years  (0.2  per  100 000  population  for  both  male  and 
female) (Fig. 1.2). In all other age groups, men had higher 
age-specific  HIV  diagnosis  rates  than  women.  The 
highest  overall  age-specific  rate  was  observed  in  the 
age  group  30–39  years  (13.1  per  100 000  population). 
Among men, the highest rate was in the age group 25–29 
years (19.6 per 100 000), while for women, it was in the 
age group 30–39 years (7.2 per 100 000) (Fig. 1.2). 

The  overall  mean  age  at  diagnosis  was  39.1  years;  the 
mean age at diagnosis was lower for  men who have sex 

with men (MSM) (36.6 years) than for cases attributed to 
injecting drug use (42.1 years overall, and similar in both 
women  and  men)  or  heterosexual  transmission  (41.2 
years  overall,  39.4  in  women  and  42.1  in  men).  For 
transgender people, the mean age at diagnosis was 33.4 
years.  The  highest  proportion  of  transgender  people 
(39.8%) were diagnosed between the ages of 30 and 39 
years, followed by 24.3% in the age group 25–29 years, 
15.5%  in  the  age  group  20–24  years,  13.6%  aged 
between 40 and 49 years, 5.3% among those aged over 
50 years, and 1.5% in the age group 15–19 years.

The  age  group  30–39  years  accounted  for  the  largest 
proportion of HIV diagnoses overall (32.3%), with 33.0% 
among  MSM  and  31.6%  among 
reporting 
heterosexual  contact.  In  contrast,  among  people  who 
inject  drugs  (PWID),  most  diagnoses  (38.9%)  were 
reported in the age group 40–49 years (Fig. 1.3). 

those 

Fig. 1.2. Age- and gender-specific rates of HIV diagnoses per 100 000 population, EU/EEA, 2023 (n = 24 393)

Women

Men

n
o
i
t
a
l
u
p
o
p
0
0
0
0
0
1

r
e
p
s
e
s
o
n
g
a
i
d
V
H

I

20

15

10

5

0

< 15

15–19  

20–24

25–29

30–39

40–49

50+

Age category (years)

Note: A total of 206 transgender people and 44 people with an unknown gender category reported in 2023 have been excluded from the calculations.

Fig. 1.3. HIV diagnoses, by age group and transmission mode, EU/EEA, 2023 (n = 18 003)

Heterosexual contact

e
d
o
m
n
o
i
s
s
i
m
s
n
a
r
T

Injecting drug use

Sex between men

15–19 years

20–24 years

25–29 years

30–39 years

40–49 years

50+ years

n = 8 463

n = 1 112

n = 8 428

0

20

40

60

80

100

Percentage

Note: Estonia, Latvia and Poland were excluded from the figure as more than 50% of their reported cases did not include information on the mode of transmission. 

2

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 data 
 
 
 
 
 
 
One  third  (33.0%)  of  diagnoses  attributed  to  sex 
between men were made before the age of 30, while over 
half  (52.1%  and  57.6%)  of  the  HIV  infections  reported 
among  men  and  women  who  had  heterosexual  contact 
and  among  people  who  were  infected  through  injecting 
drug  use,  respectively,  were  diagnosed  at  40  years  or 
above. 

(34.1%),  and  Portugal  (32.6%),  approximately  one  third 
of reported HIV diagnoses were among people under 30 
years  old.  In  contrast,  in  Latvia  (61.7%),  Italy  (54.4%), 
Estonia  (53.3%),  Norway  (52.4%),  Finland  (51.4%),  and 
Lithuania  (50.2%),  over  half  of  the  HIV  diagnoses  
were  reported  in  people  over  40  years  of  age  (Fig.  1.4;  
Table 9). 

The  age  distribution  of  HIV  diagnoses  varied  across 
countries.  In  Cyprus  (37.3%),  Romania  (34.6%),  Iceland 

Fig. 1.4. Percentage of HIV diagnoses, by country and age group, EU/EEA, 2023 (n = 24 617)

< 15 years

15–19 years

20–24 years

25–29 years

30–39 years

40–49 years

50+ years

Cyprus
Romania
Iceland
Portugal
Slovakia
France
Bulgaria
Spain
Hungary
Croatia
Malta
Luxembourg
Belgium
Greece
Poland
EU/EEA
Austria
Germany
Netherlands
Czechia
Ireland
Slovenia
Sweden
Italy
Norway
Lithuania
Estonia
Denmark
Finland
Latvia

0

20

40

60

80

100

Percentage

Note: Liechtenstein reported one case for 2023. Unknown age is excluded from the proportions presented here. The figure is organized in descending order, from the 
highest to the lowest percentage of diagnoses among individuals younger than 30 years.

Data  on  transmission  mode  provide  information  on  the 
groups  in  the  EU/EEA  who  are  most  affected  by  HIV 
(Fig. 1.5; Tables 4–8):

•  Sex  between  men  is  the  most  reported  mode  of 
transmission  in  the  EU/EEA,  accounting  for  33.8% 
(8367)  of  all  reported  HIV  diagnoses  in  2023.  Sex 
between  men  was  one  of  the  predominant  modes  of 
transmission  (46.7%)  where  mode  of  transmission 
was  known  (Fig. 1.5;  Table 4,  Table  8;  Map  5)  and 
accounted  for  more  than  50%  of  reported  HIV 
diagnoses in eight countries (Austria, Croatia, Greece, 
Hungary,  Malta,  Netherlands,  Slovenia  and  Spain) 
(Fig.  1.5).  The  majority  (51.5%;  4306)  of  people 
diagnosed  with  HIV  attributed  to  sex  between  men 
were born in the reporting country. Among the 44.4% 
(3712) of MSM diagnosed with HIV who were migrants, 
46.9%  (1740)  originated  from  Latin  America  and  the 
Caribbean,  17.08%  (634)  from  central  or  eastern 

Europe,  10.6%  (392)  from  Sub-Saharan  Africa,  9.6% 
(358) from western Europe, 7.5% (279) from south and 
south-east  Asia,  and  8.3%  (309)  from  other  regions 
(Table 11). 

•  Sex between men and women remains one of the most 
common  modes  of  HIV  transmission  reported  in  the 
EU/EEA,  accounting  for  33.4%  (8254)  of  all  HIV 
diagnoses and 46.0% of diagnoses where the route of 
transmission  was  known  (Fig.  1.5;  Table 6,  Table  8; 
Map  6).  Among  those  with  reported  heterosexual 
transmission  there  are  more  women  (53.8%;  4437); 
than  men  (46.0%;  3796).  Heterosexual  transmission 
accounts for more than 50% of all reported HIV cases 
in  13  EU/EEA  countries  (Bulgaria,  Cyprus,  Czechia, 
Denmark, 
Lithuania, 
Luxembourg,  Norway,  Portugal,  Romania  and 
Slovakia). 

Finland, 

France, 

Italy, 

3

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORTFig. 1.5. Percentage by transmission mode and country, HIV diagnoses with known mode of transmission, EU/EEA, 
2023 (n = 17 757)

Sex between men

Heterosexual transmission (men)

Heterosexual transmission (women)

Injecting drug use

Other

Lithuania
Finland
Norway
Romania
Denmark
Slovakia
Bulgaria
Cyprus
France
Czechia
Luxembourg
Sweden
Italy
Germany
Portugal
Ireland
EU/EEA
Belgium
Iceland
Austria
Poland
Greece
Netherlands
Spain
Hungary
Malta
Croatia
Slovenia

0

20

40

60

80

100

Percentage

Note: Liechtenstein reported one case for 2023 and is excluded from the figure. Estonia, Latvia and Poland were excluded from the figure as more than 50% of their 
reported cases did not include information on the mode of transmission. A total of 6824 people with an unknown mode of transmission have been excluded from the 
proportions presented for the countries included in the figure. This figure is organized by proportion of diagnoses due to sex between men in descending order.

•  One  third  (33.7%;  2779)  of  reported  diagnoses 
attributed  to  heterosexual  transmission  were  among 
people born in the reporting country. More than half of 
the  reported  diagnoses  (62.4%;  5153)  were  among 
migrants.  Half  of  these  were  among  people  born  in 
Sub-Saharan Africa (50.0%; 2738), followed by people 
from  central  and  eastern  Europe  (26.6%;  1454)  and 
people  from  Latin  America  and  the  Caribbean  (9.5%, 
521) (Table 11).

•  Around four per cent (4.1%; 1012 cases) of all reported 
HIV diagnoses and 5.7% of those with a known mode 
of  HIV  transmission  were  attributed  to  injecting  drug 
use (Fig. 1.5; Table 5, Table 8). Injecting drug use was 
the probable mode of transmission for 19.3% of cases 
diagnosed  in  Lithuania,  18.6%  in  Greece,  13.7%  in 
Austria, 12.4% in Finland, 11.4 in Germany, and 11.3% 
in Norway (Fig. 1.5; Map 7). Almost half of those with a 
reported  diagnosis  attributed  to  injecting  drug  use 
were  born  outside  of  the  reporting  country  (47.6%; 
482  cases).  Of  these,  83.8%  (404  cases)  were  from 
other countries in central and eastern Europe.

•  Mother-to-child 

(MTCT) 

during 
transmission 
pregnancy,  childbirth  or  breastfeeding  accounted  for 
0.9% of all reported HIV diagnoses and 1.2% of cases 
with a known mode of HIV transmission (Table 7, Table 
11).  Most  of  these  cases  were  reported  by  France 
(28.1%),  Germany  (18.0%),  Poland  (6.9%)  and  Ireland 

(6.9%). Most of the people diagnosed with HIV due to 
MTCT  were  born  outside  of  the  reporting  country 
(78.8%; 171 cases), with 41.5% (90) coming from Sub-
Saharan Africa. 

•  Forty-three diagnoses (0.2%) were reported to be due 
to contaminated transfusion of blood and its products, 
and  14  cases  due  to  hospital-acquired  infections 
(Table  8).  Most  of  the  transfusion-related  cases 
(44.2%;  19)  and  nosocomial  acquired 
infections 
(50.0%;  seven)  were  reported  in  people  originating 
from central and eastern Europe (Table 11). 

•  Transmission  mode  was  reported  as  unknown  for 
27.6%  (6824)  of  diagnoses,  with  a  wide  variation 
among  countries:  less  than  5%  of  diagnoses  were 
in 
reported  with  unknown 
Bulgaria,  Cyprus,  Iceland  and  Romania  and  over  50% 
in Estonia, Latvia and Poland (Table 8).

transmission  mode 

In  2023,  28  EU/EEA  countries  provided  data  on  the 
country of birth, nationality or region of origin for 85.8% 
(21 230)  of  HIV  diagnoses  (Table  10).  Among  these, 
47.9%  of  total  HIV  diagnoses  and  55.8%  of  those  with 
known  origin  information  (11 837  cases)  were  reported 
among  migrants  (Fig.  1.6).  Of  these,  31.8%  (3770)  were 
from  Sub-Saharan  Africa,  30.0%  (3548)  (from  central 
and  eastern  Europe,  and  22.8%  (2703)  from  Latin 
America  and  the  Caribbean.  In  addition,  5.1%  (605) 

4

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 dataFig. 1.6. Percentage of HIV diagnoses among migrants out of all reported cases with known information on the region 
of origin, by country of report, EU/EEA, 2023 (n = 21 230)

Sub-Saharan Africa

Central and eastern Europe

Western Europe

Latin America and the Caribbean

South and south-east Asia

Other

Iceland
Ireland
Norway
Sweden
Denmark
Netherlands
Belgium
Luxembourg
Finland
Czechia
Cyprus
Slovakia
France
Estonia
Germany
EU/EEA
Portugal
Austria
Spain
Slovenia
Croatia
Greece
Lithuania
Poland
Italy
Hungary
Bulgaria
Romania

0

20

40

60

80

100

Percentage

Note: Latvia and Malta were excluded from the figure as more than 50% of their reported cases did not include information on the mode of transmission. Liechtenstein 
is not included in the figure, as its single case was reported as being from the reporting country. A total of 3501 cases were reported with unknown region of origin. 
The figure is organized from countries with the highest proportion of migrants to those with the lowest.

originated  from  another  western  European  country, 
5.0%  (587)  from  south  and  south-east  Asia,  and  5.3% 
(624) (from other regions (Fig. 1.6; Table 10). 

The countries with more than half of their HIV diagnoses 
among people originating from outside of the reporting 
country  were  Austria,  Belgium,  Cyprus,  Czechia, 
Denmark,  Estonia,  Finland,  France,  Germany,  Ireland, 
Luxembourg,  Netherlands,  Norway,  Portugal,  Slovakia, 
Spain and Sweden.

For  HIV  diagnoses  reported  among  transgender  people 
in  2023,  86.4%  (178)  originated  from  a  country  outside 
of  the  reporting  country,  12.1%  (25)  were  born  in  the 
reporting  country,  and  in  1.5%  of  cases  (three),  the 
region  of  origin  was  unknown.  Among  those  whose 
regions of origin were known and who were born abroad, 
74.7% (133) came from Latin America and the Caribbean, 
11.8%  (21)  from  Sub-Saharan  Africa,  7.9%  (14)  from 
central  and  eastern  Europe,  2.8%  (five)  from  south  and 
south-east  Asia,  1.7%  (three)  from  other  regions,  and 
1.1% (two) from other western European countries.

for  59.8% 

Information on CD4 cell count at the time of HIV diagnosis 
was  available 
(14 795)  of  adults  and 
adolescents diagnosed across 27 countries. Twenty-one 
countries  were  able  to  provide  CD4  cell  counts  for  50% 
or  more  of  their  reported  cases,  however  Germany, 
Greece,  Iceland,  Ireland,  Latvia  and  Slovakia  were 

unable  to  do  so.  Hungary,  Malta  and  Poland  did  not 
provide CD4 cell counts for 2023. 

To  calculate  late  diagnoses,  children  under  15  years  of 
age, acute cases and previously positive diagnoses were 
excluded from calculations (Table 12), resulting in a final 
total  of  11 961  cases.  More  than  half  of  these  cases 
(52.7%) were considered to have been diagnosed several 
years after infection, with a CD4 cell count < 350 cells per 
mm3.  This  included  31.6%  of  cases  considered  to  have 
advanced  HIV  infection  (CD4  cell  count  < 200 cells  per 
mm3) (Table 12). The proportion diagnosed late (CD4 cell 
count  < 350  cells  per  mm3)  was  above  60%   in  Slovenia 
(68.8%),  Denmark  (67.8%),  Latvia  (64.5%),  Greece 
(64.2%),  Bulgaria  (61.7%),  Croatia  (60.9%),  Czechia 
(60.1%) and Italy (60.1%).

Among  all  cases  diagnosed  in  2023  with  available 
information  on  CD4  cell  count  (11 961)  and  excluding 
previous  positive  cases,  10.8%  were  diagnosed  during 
acute  infection8  and  24.0%  were  identified  as  recent 
infections (with a CD4 cell count of 500+ cells per mm3 at 
diagnosis).  More  specifically,  among  MSM  diagnosed  in 
2023,  15.6%  were  reported  as  acute  infections,  and 
26.4%  had  a  CD4  cell  count  of  500+  cells  per  mm3  at 
diagnosis (Fig. 1.7).

8  Acute infection status was reported by countries using one or more criteria 

for acute infection, including HIV negative test in the last six months, 
evidence of seroconversion illness, p24 antigen or an indication based on 
any other clinical or laboratory criteria. 

5

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORTWhen analysing CD4 cell count,  the highest proportions 
of  people  presenting  at  a  later  stage  of  HIV  infection 
(CD4  cell  count  < 350  cells  per  mm3,  excluding  those 
previously diagnosed or with evidence of acute infection) 
 were  among  women  (58.2%),  older  adults  (68.5%  in 
those  over  50  years,  59.7%  in  the  40–49  age  group), 
men or women infected through heterosexual sex (63.8% 
and  58.2%,  respectively),  people  who  acquired  HIV 
through  injecting  drug  use  (47.0%),  and  people  coming 

from south and south-east Asia (61.1%) and Sub-Saharan 
Africa (58.6%) (Fig. 1.8). 

The lowest proportions of late diagnosis (CD4 cell count 
< 350 cells per mm3) were observed among younger age 
groups  (40.8%  of  those  aged  15–19  years),  men  who 
acquired HIV through sex with another man (43.2%) and 
people coming from countries in western Europe (48.7%) 
(Fig. 1.8). 

Fig. 1.7. CD4 cell count cells per mm3 at HIV diagnosis and acute infection, by transmission mode, EU/EEA, 2023  
(n = 11 961)

e
g
a
t
n
e
c
r
e
P

100

80

60

40

20

0

Heterosexual contact

Injecting drug use

Sex between men

Transmission mode

Acute

500+

350  to < 500

200 to < 350

< 200

Notes: This graph excludes cases with unknown CD4 cell count per mm3 and those defined as previous positive diagnosis. Hungary, Liechtenstein, Malta and Poland 
did not provide CD4 cell count per mm3 for 2023, therefore are not included in the figure.

Fig. 1.8. Percentage of people diagnosed late (CD4 cell count < 350 per mm3) by demographic, EU/EEA, 2023 (n=11 961)

Total

Men

Women

15–19

20–24

25–29

30–39

40–49

50+

Heterosexual men

Heterosexual women

Injecting drug use

Sex between men

Native to reporting country

Central and eastern Europe

Latin America and the Caribbean

South and south-east Asia

Sub-Saharan Africa

Western Europe

r
e
d
n
e
G

)
s
r
a
e
y
(
p
u
o
r
g
e
g
A

e
d
o
m
n
o
i
s
s
i
m
s
n
a
r
T

n
i
g
i
r
o
f
o
n
o
i
g
e
R

0

10

20

30

40

50

60

70

Percentage

Note: This figure excludes cases with an unknown CD4 cell count, people with acute infection, those classified as previous positives cases, children younger than 15 
years old and cases reported by countries that did not report CD4 cell counts.

6

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 data 
 
 
 
 
Information  regarding  CD4  cell  count  was  available  for 
46.6% (96) of all transgender people reported (206). Of 
these,  27.1%  (26)  were  diagnosed  at  the  stage  of  acute 
infection, 33.3% (32) were identified as recent infections 
(with a CD4 cell count of 500+ cells per mm3) and 29.2% 
(28)  presented  at  a  late  stage  of  HIV  infection  (CD4  cell 
count < 350 cells per mm3), with 13.5% (13) (considered to 
have advanced HIV infection at diagnosis (CD4 cell count 
< 200 cells per mm3).

The interval between the date of diagnosis and the date 
of  the  CD4  cell  count  was  used  as  a  proxy  for  time  to 
linkage  to  care  and,  among  cases  diagnosed  in  recent 
years (2022−2023) where CD4 data and date of diagnosis 
were  reported,  81.3%  were  linked  to  care  within  four 
days  of  HIV  diagnosis  and  97.2%  were  linked  to  care 
within three months (Fig. 1.9).

Fig. 1.9. Linkage to care after HIV diagnosis in the EU/EEA, individuals diagnosed with HIV 2022−2023 (n = 6722)

e
d
o
m
n
o
i
s
s
i
m
s
n
a
r
T

Injecting drug use

Heterosexual contact

Sex between men

Total

0–4 days

5–28 days

29–91 days

> 91 days

0
0

20
20

40
40

60
60

80
80

100
100

Percentage

Note: cases with no data or missing data on CD4 cell count or date of diagnosis, previous positive cases and those who died within 91 days of diagnosis are excluded 
from this figure.

1.2 Previous positive diagnoses
In  2023,  previous  positive  diagnoses  accounted  for 
16.3%  (4020)  of  the  24 731  reported  HIV  diagnoses, 
reflecting  a  18.2%  decrease  from  2022,  when  the 
proportion  was  19.5%  (4912  out  of  25 124).  However, 
these  figures  are  probably  underestimated,  as  the 
variable identifying the HIV status as a previous positive 
or first-time diagnosis had a completeness of 57.1%. 

Bulgaria,  Finland,  Hungary,  Italy,  Lithuania,  Malta, 
Poland,  Romania  and  Spain  were  excluded  from  this 
analysis,  as  more  than  half  of  their  HIV  diagnoses 
reported  in  2023  did  not  have  data  on  this  variable  
(Fig.  1.10).  When  only  considering  the  data  from  the  21 
countries  with  sufficient  reporting  on  this  variable,  the 
proportion  of  previous  positive  diagnoses  increased  to 
22.9%  (3463)  of  all  HIV  diagnoses  reported  by  these 
countries in 2023 (Fig. 1.10). In five countries, more than 
50% of the HIV diagnoses reported in 2023 were previous 
positives:  Norway  (65.7%),  Iceland  (61.4%),  Ireland 
(55.9%), Sweden (52.6%) and Denmark (51.5%).

When  comparing  people  with  previous  positive  HIV 
diagnoses to those newly diagnosed, a higher proportion 
are  women  (34.8%  versus  28.3%),  and  a  higher 
proportion  are  over  30  years  of  age  (80.4%  versus 
73.2%). In addition, among those reported as previously 
positive  compared  to  newly  diagnosed  there  is  a  larger 
percentage of people born outside the reporting country 
(86.1%  versus  52.3%)  and  a  higher  proportion  coming 

from  central  and  eastern  Europe  (27.3%  versus  15.2%) 
and Sub-Saharan Africa (28.6% versus 20.8%) (Fig. 1.11).

In  terms  of  transmission  mode,  among  people  with 
previous  positive  diagnoses,  heterosexual  contact  was 
the  primary  route  (39.2%),  with  a  higher  prevalence  in 
women  (25.5%)  than  in  men  (13.6%).  Transmission 
through  sexual  contact  between  men  is  less  common 
among those with previous positive diagnoses (33.0%). 
In  addition,  MTCT  was  reported  at  a  higher  rate  among 
those with previous positive diagnoses (2.7%) compared 
to newly diagnosed people (0.7%).

1.3 Trends in HIV diagnoses
Between  2014  and  2023,  the  trend  in  reported  HIV 
diagnoses showed a decline, with the rate in consistently 
reporting EU/EEA countries dropping from 6.3 to 5.3 per 
100 000  population,  representing  a  15.8%  decrease.  In 
2023, 24 731 HIV diagnoses were reported in 30 EU/EEA 
countries,9  corresponding  to  a  rate  of  5.3  per  100 000 
population  (Table  1).  When  compared  to  2022,  the  rate 
remained unchanged at 5.3 per 100 000 population. 

As  outlined  in  Section  1.2,  a  key  factor  contributing  to 
the stabilization of reported cases in 2023, compared to 
2022  HIV  diagnoses,  is  the  inclusion  of  previously 
diagnosed positive cases. 

9 

All EU/EEA countries reported data for 2023.

7

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORT 
Fig. 1.10. Percentage of previous positive diagnoses and new HIV diagnoses by country of report, 21 EU/EEA countries, 
2023 (n = 15 150)

New HIV diagnoses

Previous positive diagnoses 

Unknown 

Ireland

Slovakia

Norway

Croatia

Slovenia

Iceland

Sweden

Denmark

Netherlands

France

Cyprus

Belgium

Czechia

Estonia

Average EU/EEA

Luxembourg

Portugal

Greece

Germany

Austria

Latvia

Liechtenstein

0

20

40

60

80

100

Percentage

Note: Countries with more than 50% unknown for the variable identifying the HIV status as a previous positive or first-time diagnosis are excluded from the figure. 
Countries included in the figure:  Austria, Belgium, Croatia, Cyprus, Czechia, Denmark, Estonia, France, Germany, Greece, Iceland, Ireland, Latvia, Liechtenstein, 
Luxembourg, Netherlands, Norway, Portugal, Slovakia, Slovenia and Sweden.

When  considering  only  new  HIV  diagnoses  reported 
between  2014  and  2023  (and  excluding  previously 
reported  positive  cases  from  countries  with  sufficient 
data) the rate for 2023 is 3.8 per 100 000. This marks an 
11.3% increase on the 2022 rate of 3.4 per 100 000, but 
a  19.2%  decrease  on  the  2014  rate  of  4.1  per  100 000 
(Fig. 1.12, Fig. 1.13). 

In  addition,  as  noted  in  Section  1.2,  the  number  of 
previously  positive  cases  decreased  by  18.2%  in  2023, 
which  may  account  for  the  stabilization  of  the  overall 
rate  in  2023,  at  5.3  per  100 000  (see  Fig.  1.13),  when 
previously  positive  cases  are  included  in  the  trend 
analysis.

The number of AIDS diagnoses has remained stable and 
unchanged  in  recent  years,  with  the  rate  consistently 
between  1.0  and  1.1  per  100 000  since  2019.  The  only 
change  in  morbidity  is  related  to  AIDS-related  deaths. 
The death rate in 2023, at 0.14 per 100 000 population, 
reflects a decrease of 14.3% on the 2022 rate of 0.16 per 
100 000 population.

Trends vary by gender and age group. Age-specific rates 
declined  from  2014  to  2020,  followed  by  a  plateau 
between 2020 and 2021, and a sudden increase in 2022 
across  most  age  groups  for  both  women  and  men.  The 

only group that continued to see an increase from 2022 
to  2023  was  women  aged  15  to  24  years,  with  a  rise  of 
15.8%.  Among  men,  the  increase  was  most  notable  in 
those aged 15 to 19 years, where the rate rose by 20.6%, 
from 1.9 in 2022 to 2.3 in 2023 (Fig. 1.14a, Fig. 1.14b).

HIV  diagnoses  among  people  born  outside  of  the 
reporting  country,  excluding  Finland,  Latvia,  Malta  and 
Slovakia  (where  more  than  50%  of  reported  cases  have 
an unknown region of origin), accounted for 44.6% of all 
diagnoses  in  2014.  This  proportion  increased  over  time 
to  50.1%  in  2020,  then  slightly  decreased  to  46.3%  in 
2021, before rising again to 53.6% in 2022 and declining 
to 47.9% in 2023. When analysing data excluding cases 
with  an  unknown  region  of  origin,  the  proportion  of 
migrants among HIV diagnoses increased from 47.3% in 
2014  to  55.8%  in  2023,  representing  a  17.9%  rise  over 
the  period.  However,  compared  to  2022,  there  was  a 
decrease  of  19.0%,  down  from  68.9%.  In  particular, 
there was a 20.4% increase in diagnoses among people 
coming  from  Sub-Saharan  Africa,  rising  from  2566 
reported diagnoses in 2022 to 3090 in 2023. In contrast, 
there was a 32.5% decrease in diagnoses among people 
coming  from  central  and  eastern  Europe,  with  cases 
dropping from 4131 in 2022 to 2789 in 2023 (Fig. 1.15). 

8

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 dataFig. 1.11. Demographic and epidemiological characteristics of previous positive diagnoses and new HIV diagnoses by 
21 EU/EEA countries, 2023 (n = 15 150)

r
e
d
n
e
G

)
s
r
a
e
y
(
p
u
o
r
g
e
g
A

Female 

Male 

Trangender 

< 15 years

15–19

20–24

25–29

30–39

40–49

50+

Central and eastern Europe

Latin America and the Caribbean

n
i
g
i
r
o
f
o
n
o
i
g
e
R

e
d
o
m
n
o
i
s
s
i
m
s
n
a
r
T

Other

Reporting country 

South and south-east Asia

Sub-Saharan Africa

Unknown

Western Europe

Heterosexual contact (males)

Heterosexual contact (females)

Injecting drug use

Sex between men

MTCT

Unknown

New HIV diagnoses

Previous positive diagnoses

0

10

20

30

40

50

60

70

80

Percentage

Note: Countries with more than 50% unknown for the variable identifying the HIV status as a previous positive or first-time diagnosis are excluded from the figure. 
Countries included in the figure:  Austria, Belgium, Croatia, Cyprus, Czechia, Denmark, Estonia, France, Germany, Greece, Iceland, Ireland, Latvia, Liechtenstein, 
Luxembourg, Netherlands, Norway, Portugal, Slovakia, Slovenia and Sweden.

9

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORT 
 
 
 
 
Fig. 1.12. Temporal trends in HIV diagnoses reported by 21 EU/EEA countries: comparison of trends including and 
excluding previous positive diagnoses, 2014–2023 (n = 152 157)

16 000

14 000

12 000

New HIV and previous positive diagnoses

New HIV diagnoses

Previous positive diagnoses

Unknown HIV status 

s
e
s
a
c
f
o
r
e
b
m
u
N

10 000

8000

6000

4000

2000

0

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

Year of diagnosis

Note: Countries with more than 50% unknown for the variable identifying the HIV status as a previous positive or first-time diagnosis are 
excluded from the figure. Countries included in the figure:  Austria, Belgium, Croatia, Cyprus, Czechia, Denmark, Estonia, France, Germany, 
Greece, Iceland, Ireland, Latvia, Liechtenstein, Luxembourg, Netherlands, Norway, Portugal, Slovakia, Slovenia and Sweden.

Fig. 1.13. People diagnosed with HIV, AIDS and AIDS-related deaths reported per 100 000 population, EU/EEA, 
2014–2023

7

6

5

4

3

2

1

0

n
o
i
t
a
l
u
p
o
p
0
0
0
0
0
1

r
e
p
e
t
a
R

HIV diagnoses 
(including previous positive diagnoses)

New HIV diagnoses 

AIDS 

AIDS-related deaths 

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

Year of diagnosis

Note: rates exclude countries not reporting consistently over the period: Germany and Sweden (AIDS diagnosis and AIDS deaths). The newly diagnosed cases rate was 
calculated by removing previous positive cases from the 21 EU/EEA countries with sufficient reporting on this variable to exclude these cases (see Chapter 1.2 for 
more details). AIDS diagnosis and AIDS-related death rates were not impacted by previous positive cases and these rates are not adjusted.

Fig. 1.14a. Age-specific trends in HIV diagnoses in women, 2014−2023

30–39 years
25–29 years
40–49 years

20–24 years

15–19 years
50+ years
< 15 years

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

Year of diagnosis

10

8

6

4

2

0

n
o
i
t
a
l
u
p
o
p
0
0
0
0
0
1

r
e
p
s
e
s
o
n
g
a
i
D

10

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 data 
 
 
 
 
 
 
 
 
 
Fig. 1.14b. Age-specific trends in HIV diagnoses in men, 2014−2023

n
o
i
t
a
l
u
p
o
p
0
0
0
0
0
1

r
e
p
s
e
s
o
n
g
a
i
D

25

20

15

10

5

0

25–29 years
30–39 years

40–49 years
20–24 years

50+ years
15–19 years

< 15 years

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

Year of diagnosis

Fig. 1.15. Percentage of diagnoses among people born outside of the reporting country by year of diagnosis and region 
of origin, EU/EEA, 2014−2023

e
g
a
t
n
e
c
r
e
P

80

70

60

50

40

30

20

10

0

Sub-Saharan Africa

Central and eastern Europe

Western Europe

Latin America and the Caribbean

South and south-east Asia

Other

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

Year of diagnosis

Note: HIV reported diagnoses from Finland, Latvia, Malta and Slovakia have been excluded from this figure as more than 50% of reported cases in these countries 
have an unknown region of origin. From 2014 to 2023, a total of 122 293 reported HIV diagnoses were excluded from the countries included in the figure due to  
an unknown region of origin. The proportions are calculated based on the total number of cases reported with a known region of origin for the entire period  
(n = 118 786).

Since  2014,  most  of  the  EU/EEA  countries  have 
maintained consistent reporting on transmission routes. 
However,  for  the  transmission  analysis,  HIV  diagnoses 
reported  by  Estonia,  Latvia  and  Poland  were  excluded 
due  to  incomplete  reporting  on  transmission  mode 
during  some  years  of  the  previous  decade.  When 
focusing  on  data  from  those  countries  that  have 
consistently reported over the past decade (2014–2023) 
and  analysing  data  with  known  routes  of  transmission, 
the following trends become evident:

•  The proportion of HIV diagnoses with a known route of 
transmission  attributed 
to  sex  between  men 
decreased  from  52.1%  in  2014  to  46.9%  in  2023.  A 
slight  decrease  in  reported  HIV  diagnoses  among 
MSM was observed in 2021 (7575 diagnoses), followed 
by  an  increase  in  2022  (8207  diagnoses),  with  the 
number  remaining  relatively  stable  in  2023  (8078 
diagnoses)  (Fig.  1.16a,  Fig.  1.16b).  Among  MSM  who 
were  migrants,  there  was  a  37.7%  increase  in  HIV 
diagnoses,  rising  from  2659  in  2014  to  3661  in  2023 
(Fig. 1.17). 

to 

transmission 

•  The  proportion  of  HIV  diagnoses  with  a  known  mode 
heterosexual 
attributed 
of 
transmission in both women and men increased from 
41.4%  in  2014  to  46.2%  in  2023.  Among  men,  this 
proportion  showed  a  slight  increase,  from  20.6%  to 
21.3% over the period. In contrast, the increase among 
women  was  more  pronounced,  rising  from  20.7%  to 
24.9%  of  HIV  diagnoses  with  known  transmission 
information  (Fig. 1.16b).  A  smaller  increase  was  also 
observed  among  heterosexual  migrants,  with 
diagnoses  rising  from  4889  in  2014  to  4990  in  2023, 
representing a 2.1% increase. 

the  number  of 

•  It is also worth noting that there was a 4.5% increase 
in 
reported  diagnoses  among 
heterosexual  people  born  in  the  reporting  country 
from  2022  (2560  cases)  to  2023  (2676  cases)  (Fig. 
1.17). 

•  The overall number of HIV diagnoses reported among 
PWID  slightly  decreased,  from  1401  cases  in  2014  to 
1212  cases  in  2023  (see  Fig.  1.16a,  Fig.  1.17;  Table  5), 

11

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORT 
 
 
 
Fig. 1.16a. HIV diagnoses, by year of diagnosis and transmission mode, EU/EEA, 2014−2023

12 000

10 000

s
e
s
a
c
f
o
r
e
b
m
u
N

8000

6000

4000

2000

0

Sex between men

Heterosexual transmission (women)
Heterosexual transmission (men)

Injecting drug use
Mother to child transmission

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

Year of diagnosis

Note: HIV diagnoses reported by Estonia, Latvia and Poland were excluded due to incomplete reporting on transmission mode during a portion of the previous 
decade. 

Fig. 1.16b. Percentage of HIV diagnoses, by year of diagnosis and transmission mode, EU/EEA, 2014−2023

100

80

60

40

20

0

s
e
g
a
t
n
e
c
r
e
P

Mother to child transmission

Injecting drug use

 Heterosexual transmission (men) 

 Heterosexual transmission (women) 

 Sex between men  

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

Year of diagnosis

Note: cases where transmission route was “Unknown” or “Other” are not presented here. HIV diagnoses reported by Estonia, Latvia and Poland were excluded due to 
incomplete reporting on transmission mode during some years of the previous decade. 

Fig. 1.17. HIV diagnoses, by year of diagnosis, transmission mode and migration status, EU/EEA, 2014−2023

10 000

8000

s
e
s
o
n
g
a
i
d
V
H

I

6000

4000

2000

Heterosexual (foreign-born)

Sex  between men (born in reporting country)

Sex  between men (foreign-born)

Heterosexual (born in reporting country)

Injecting drug use (born in reporting country)

Injecting drug use (foreign-born)

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

Year of diagnosis

Note: data from Estonia, Finland, Latvia, Malta, Poland and Slovakia were excluded from the figure due to over 50% of their reported cases having either an unknown 
region of origin or an unknown mode of transmission during some years of the previous decade.

12

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 data 
 
 
although  there  was  an  increase  observed  in  2022, 
when the number was 1113.

•  The proportion of HIV diagnoses reported to be due to 
MTCT  of  HIV  increased  from  0.8%  to  1.1%  between 
2014  and  2023,  although  the  number  declined  from 
274 in 2022 to 196 in 2023 (see Fig. 1.16a). 

The trends for both late diagnoses and acute infections 
remained  stable  throughout  the  period.  However,  when 
analysing  the  trend  in  CD4  cell  count  data,  a  23.0% 
decline  was  observed  in  the  number  of  unknown  CD4 
cell count values, decreasing from 9659 in 2014 to 7434 
in 2023 (Fig. 1.18).

Fig. 1.18. HIV diagnoses, acute infection or CD4 cell count per mm3 at diagnosis, EU/EEA, 2014−2023 

100

80

60

40

20

0

s
e
s
o
n
g
a
i
d
f
o
e
g
a
t
n
e
c
r
e
P

Acute infection

500+

350  to < 500

200 to < 350

< 200

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

Year of diagnosis

Note: Bulgaria, Finland, Italy, Hungary, Lithuania, Malta, Poland, Romania and Spain were excluded from this figure as more than 50% of their cases had unknown 
values in the HIV status variables. In addition, previously positive cases were excluded from the countries included in the figure, along with children under 15 years. 
Only individuals with CD4 cell counts recorded at the time of diagnosis were included. 

1.4 AIDS cases, morbidity and 
mortality
Although  there  have  been  improvements  in  the  early 
diagnosis of HIV, 2690 diagnoses of AIDS were reported 
by  26  EU/EEA  countries  in  2023  –  a  crude  rate  of  0.7 
AIDS  diagnoses  per  100 000  population 
(Table 13; 
Map 8). The highest rate was reported by Latvia (2.4 per 
100 000 population; 45 cases) followed by Romania (1.4 
per 100 000; 267 cases). 

The rate of reported AIDS cases has decreased by 36.4% 
over  the  past  decade  (excluding  Cyprus,  Germany, 
Liechtenstein  and  Sweden  which  did  not 
report 
consistently  over  the  period),  a  reduction  from  the  1.1 
per 100 000 reported in 2014 (Table 13). 

This decline is noted in both men and women; however, 
it  is  more  pronounced  in  men.  Among  men,  the  rate 
decreased from 1.7 per 100 000 population in 2014 to 1.1 
per  100 000  population  in  2023,  while  among  women, 
the decline was from 0.6 per 100 000 population in 2014 
to  0.3  per  100 000  in  2023  (Tables  14–15).  When 
considering different transmission modes, a decrease is 
observed  across  all  cases  with  a  known  mode  of 
transmission,  except  for  those  where  heterosexual 
transmission  may  be  the  mode  of  transmission.  Among 
women,  there  was  a  6.3%  increase  in  reported  cases, 
rising from 505 in 2022 to 537 in 2023. Similarly, among 

men there was an 11.2% increase, with cases rising from 
694 in 2022 to 772 in 2023 (Fig. 1.19). 

The most common AIDS-indicative conditions diagnosed 
in  2023  in  the  EU/EEA  were  Pneumocystis  jirovecii 
pneumonia  (22.1%  of  all  AIDS-indicative  diseases), 
wasting  syndrome  due  to  HIV  (11.4%)  and  oesophageal 
candidiasis  (11.0%)  (Table  16).  Combined  pulmonary 
and/or  extrapulmonary   tuberculosis  made  up  13.6%  of 
AIDS-indicative diseases.

Twenty-six  EU/EEA  countries  (all  but  Cyprus,  Germany, 
Liechtenstein  and  Sweden)  reported  data  on  deaths  of 
those  diagnosed  with  AIDS.  Overall,  663  people  were 
reported to have died due to AIDS-related causes during 
2023  (Table  17),  although  these  data  are  affected  by 
under-reporting due to the challenges in many countries 
in linking to death registries. AIDS-related death reports 
have  declined  by  63.0%  since  2014,  when  there  were 
1792  deaths.  However,  delays  in  reporting  affect  the 
latest  figures  and  under-reporting  has  affected  the 
reporting  of  AIDS  deaths  throughout  the  previous 
decade.  From  the  beginning  of  the  HIV  epidemic  to  the 
end  of  2023,  the  cumulative  total  of  people  diagnosed 
with  AIDS  in  the  EU/EEA  was  349 976  (Table  13).  The 
cumulative  total  of  cases  reported  as  known  to  have 
died  from  AIDS-related  causes  by  the  end  of  2023  was 
179 260 (Table 17). 

13

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORT 
 
Fig. 1.19. AIDS diagnoses, by transmission mode, EU/EEA, 2014−2023

s
e
s
o
n
g
a
i
d
S
D
A

I

1200

1000

800

600

400

200

0

Heterosexual transmission (males)

Sex between men

Heterosexual transmission (females)

Other/undetermined 

Injecting drug use

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

Year of diagnosis

Note: data from Cyprus, Germany, Liechtenstein and Sweden are excluded due to inconsistent reporting during the previous decade. HIV diagnoses reported by 
Poland are excluded due to incomplete reporting on transmission mode during some years of the previous decade.

Iceland, 

1.5 HIV testing
Fourteen  countries  –  Belgium,  Czechia,  Denmark, 
Estonia,  France,  Greece, 
Ireland,  Latvia, 
Lithuania, Portugal, Romania and Slovenia – consistently 
reported data on HIV tests performed from 2014 to 2023, 
excluding  unlinked  anonymous 
testing  and  blood 
donation  testing.  Poland  also  reported  data  but  was 
unable  to  exclude  unlinked  anonymous  testing  from  its 
figures. The number of tests performed in the countries 
consistently  reporting  testing  activity  has  increased  by 
15.0%  compared  to  2021  and  14.3%  compared  to  2022 
(Table 18). It is important to note that numbers provided 
are  collected  in  a  heterogeneous  manner  and  therefore 
comparisons  between  country  testing  rates  should  be 
undertaken  with  caution.  However,  these  data  can 
indicate  large  changes  in  overall  testing  policy  or  be 
used to support the interpretation of HIV cases notified. 

1.6 Conclusions

this 

In  2023,  30  EU/EEA  countries  reported  a  total  of  24 731 
HIV  diagnoses,  yielding  a  reporting  rate  of  5.3  per 
100 000  population.  This  represents  a  15.9%  decrease 
from  the  2014  rate  of  6.3  per  100 000,  suggesting  a 
gradual  reduction  in  HIV  diagnosis  rates  over  the  past 
decade.  However, 
figure  may  be  slightly 
overestimated,  as  previously  known  positive  diagnoses 
are included in these figures. When focusing exclusively 
on  new  HIV  diagnoses  (excluding  previously  diagnosed 
cases  to  better  capture  recent  infections),  the  rate  for 
2023  was  3.8  per  100 000.  This  reflects  an  11.8% 
increase  from  the  2022  rate  of  3.4  per  100 000, 
highlighting an upward trend in new diagnoses over the 
past  year.  This  increasing  trend  may  be  explained  by 
increased  migration  into  and  within  EU/EEA  countries, 
driven by conflicts and economic challenges, along with 
the  expansion  of  HIV  testing  services.  Many  migrants 
arrive from regions with higher HIV prevalence and may 

14

face  barriers  to  early  testing  and  health-care  access, 
heightening  transmission  risks.  At  the  same  time, 
improved  testing  availability  and  integration  within 
health-care  services  have  led  to  the  identification  of 
previously  undiagnosed  cases,  thereby  increasing  the 
number  of  new  diagnoses  reported.  Together,  these 
factors  reflect  both  shifting  population  dynamics  and 
advancements in HIV detection and reporting across the 
Region.

it 

as 

each 

group 

presents 

The  inclusion  in  the  analysis  of  previously  positive  HIV 
diagnoses  has  influenced  the  overall  epidemiological 
profile  and  trends  among  those  reported  in  2023  when 
counted  alongside  newly  diagnosed  cases.  However,  to 
in  EU/EEA 
fully  understand  the  HIV  epidemiology 
to  distinguish  between 
countries, 
is  essential 
those  newly 
previously  diagnosed  people  and 
diagnosed, 
distinct 
epidemiological  characteristics.  Newly  diagnosed  HIV 
cases  are  predominantly  middle-aged  men,  although 
women  now  represent  a  growing  proportion  at  28%.  A 
greater  portion  of  new  diagnoses  are  among  migrants 
(47.9%);  however,  a  significant  number  of  those  newly 
diagnosed  (38%)  were  born  in  the  reporting  country. 
While sexual transmission between men remains one of 
the most prevalent modes of transmission, heterosexual 
transmission  also  accounts  for  a  significant  portion  of 
new  diagnoses.  In  addition,  late  diagnoses  are  a  major 
concern,  affecting  more  than  half  of  newly  diagnosed 
people  for  whom  CD4  cell  count  data  are  available.  In 
contrast,  previous  positive  diagnoses  have  a  higher 
proportion  of  women,  older  age  groups,  and  people 
primarily from central and eastern Europe, Sub-Saharan 
Africa,  and    Latin  America  and  the  Caribbean,  with 
heterosexual  transmission  being  the  most  common 
mode of transmission. 

AIDS  and  AIDS-related  death  rates  in  the  EU/EEA  have 
significantly declined over the past decade, but there is 
evidence of a recent increase. 

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 data 
During this period, the rate of reported AIDS cases has 
decreased by 36.4%, with the decline observed in both 
men  and  women,  although  it  is  more  pronounced 
is 
among  men.  When  the  mode  of  transmission 
described,  it  is  evident  that  AIDS  diagnoses  have 
decreased  for  most  transmission  modes,  except  in 
cases where heterosexual contact was identified as the 
primary  mode  of  transmission.  Among  women,  there 
was  a  6.3%  increase  in  reported  AIDS  diagnoses  from 
2022 to 2023, and an 11.2% increase among men during 
the  same  period.  These  increases  are  of  concern,  as 
they  are  linked  to  rising  health-care  costs,  morbidity 
and  mortality,  despite  being  largely  preventable.  In 
contrast, 
reports  of  AIDS-related  deaths  have 
decreased by 63.0% since 2014.

In 2023, heterosexual transmission accounted for 33.4% 
of  all  HIV  diagnoses  and  46.1%  of  cases  with  a  known 
transmission  route.  The  increase  between  2022  and 
2023  was  more  pronounced  among  women  than  men. 
Heterosexual transmission was the most prevalent mode 
of  HIV  transmission  in  over  50%  of  cases  in  13  EU/EEA 
countries,  with  33.7%  of  these  cases  occurring  among 
people  born  in  the  reporting  country,  and  62.4% 
involving  people  born  abroad,  primarily  from  regions 
such as Sub-Saharan Africa, central and eastern Europe 
and Latin America and the Caribbean. This upward trend 
is particularly noteworthy, as a recent study documented 
a  significant  reduction  in  HIV  testing  by  sexual  health 
services  among  heterosexuals  during  2020  due  to  the 
coronavirus  disease  (COVID-19)  pandemic,  with  a  33% 
decline  compared  to  a  7%  reduction  among  gay  and 
bisexual  men 
the 
importance  of  the  increasing  number  of  HIV  diagnoses 
among  heterosexuals,  especially  considering 
the 
uncertainty  regarding  the  full  recovery  of  HIV  testing 
services targeting this group in the post-COVID-19 era. It 
is  also  important  to  highlight  that  61%  of  heterosexual 
people are significantly more likely to be diagnosed at a 
late stage of HIV infection than MSM. In 2023, late-stage 
diagnoses were observed in 63.8% of men and 58.2% of 
women, compared to 42.7% among MSM. This disparity 
may be influenced by a widespread misconception, often 
reinforced 
that 
heterosexual people are at lower risk of HIV (2).

(1).  This  context  underscores 

professionals, 

health-care 

by 

Since  2014,  HIV  diagnoses  among  MSM  born  in  EU/EEA 
countries have declined, with a 51% reduction observed 
during  the  period.  In  contrast,  there  was  a  37.7% 
in  HIV  diagnoses  among  MSM  migrants 
increase 
between 2014 and 2023, particularly noticeable in 2023, 
with a rise in cases among migrants from Latin America 
and the Caribbean, and central and eastern Europe. This 
underscores  the  importance  of  reinforcing  and  tailoring 
HIV prevention and testing programmes for MSM. These 
initiatives  should  prioritize  regular,  accessible  HIV 
testing  with  immediate  linkage  to  care,  distribution  of 
condoms, and access to pre-exposure prophylaxis (PrEP) 
for  high-risk  HIV-negative  people,  as  part  of 
comprehensive  sexual  health  services.  This  approach 
has  demonstrated  success  in  achieving  higher  rates  of 

viral  suppression  and  reducing  HIV  transmission  (3,4). 
Expanding  PrEP  access  remains  critical,  particularly  in 
countries where its implementation is limited or absent, 
despite rising HIV rates among MSM (4,5). In addition, to 
effectively  reach  migrant  MSM,  community-based  and 
culturally tailored interventions – such as peer-to-peer 
involvement,  cultural  and  language  mediation  and 
cultural sensitivity training – are essential for improving 
HIV testing uptake. The offering of self-testing kits, the 
removing  of  health-care  access  barriers,  and  the 
employment  of  targeted  social  marketing  campaigns 
can  all  further  enhance  privacy,  convenience  and 
awareness  which  help  to  increase  testing  rates  in  this 
key population (6,7).

In  particular, 

In  2023,  migrants  (people  born  outside  the  reporting 
country) constituted 47.9% of total HIV diagnoses in the 
EU/EEA,  and  55.8%  of  cases  where  origin  information 
was available. During the period from 2014 to 2023, the 
proportion  of  HIV  diagnoses  among  migrants  increased 
by  54.6%.  However,  there  was  a  slight  decline  of  1.8% 
between  2022  and  2023. 
in  2023, 
diagnoses among people from Sub-Saharan Africa saw a 
sharp  increase  of  20.4%,  while  diagnoses  from  central 
and eastern Europe decreased by 32.5%. Given the high 
proportion of HIV diagnoses among migrants in 2023, it 
is crucial to develop, implement and scale up strategies 
that improve access to HIV testing and linkage to care in 
host  countries.  Evidence  indicates  that  a  significant 
number of migrants, even those from regions with high 
HIV prevalence, acquire HIV after arriving in the EU/EEA 
(8–10).  This  highlights  the  importance  of  providing 
targeted,  non-stigmatizing  HIV  prevention  campaigns 
for  migrants  immediately  upon  arrival,  including  the 
offer of HIV testing as part of routine health assessments 
for new arrivals in the EU/EEA (11), as well as continuously 
providing  sexual  health  and  HIV  prevention  and  testing 
for migrant populations.

findings  underscore 

HIV  transmission  among  PWID  remains  at  consistently 
low levels across most EU/EEA countries, with a further 
decrease  observed  in  2023.  This  decline  is  probably 
attributable  to  the  presence  of  well-established  and 
effective  harm-reduction  programmes  in  many  of  these 
countries.  These 
the  critical 
importance of maintaining sufficient scale and coverage 
of harm-reduction services, as trends can rapidly reverse 
in the absence of robust prevention efforts delivered on 
a  large  scale  (12,13).  In  addition  to  HIV  prevention, 
expanding  access  to  testing  for  other  bloodborne 
infections, such as hepatitis B and C, is an essential and 
integrated  strategy  for  this  population.  Addressing 
these  infections,  which  are  highly  prevalent  among 
PWID,  is  crucial  to  the  achievement  of  the  Sustainable 
Development Goals for this key population by 2030 (14).

This  year  marked  a  significant  step 
in 
transgender  reporting  within  HIV  surveillance,  with 
206  transgender  people 
(0.8%  of  all  diagnoses) 
identified across seven EU/EEA countries. 

forward 

15

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORTOf  these,  86.4%  were  migrants,  primarily  originating 
from  Latin  America  and  the  Caribbean.  Among  those 
with available CD4 cell count data, 27.1% were diagnosed 
during  the  acute  stage  of  infection  and  29.2%  at  a  late 
stage.  Despite  these  insights,  it  remains  difficult  to 
draw  comprehensive  conclusions  about  HIV  prevention 
and  control  for  transgender  populations  due  to  limited 
data. Many EU/EEA countries still do not collect specific 
data on transgender people. Improving data collection is 
crucial  to  gaining  a  clearer  understanding  of  this 
population’s  epidemiological  profile  and  developing 
more 
the 
targeted  prevention  strategies.  Despite 
scarcity of data, it is important to highlight that research 
indicates 
transgender  communities 
through  trans-led  organizations,  and  integrating  HIV 
services  with  gender-affirming  care  has  been  effective 
in  enhancing  care  engagement  and  retention  (15). 
Furthermore, gender-affirming PrEP systems, along with 
integrated  health-care  services,  have  been  shown  to 
increase  PrEP  adherence  and  reduce  HIV  risk  among 
transgender people (16).

that  engaging 

It  is  estimated  that  about  778 237  people  are  living 
with HIV in the EU/EEA, of which around 706 541 (91%) 
have  been  diagnosed  (17).  While  a  comparison  of 
modelled  data  on  HIV  infections  with  the  number  of 
people  diagnosed  with  HIV  appears  to  indicate  that, 
over  time,  fewer  people  are  living  with  undiagnosed 
HIV  in  the  EU/EEA,  around  one  in  nine  people  living 
with HIV in the EU/EEA are still unaware of their status 
(14). Modelled estimates also indicate that it takes an 
average of 2.9 years from HIV infection to diagnosis in 
the  EU/EEA,  varying  by  geographical  area  from  2.2  to 
3.6 years (18). In addition to the clinical and personal 
benefits  for  the  person  diagnosed,  early  diagnosis 
and  effective  antiretroviral  treatment  (ART)  can  also 
help  sexual  and 
inhibiting 
onward HIV transmission (19). 

injecting  partners  by 

Almost  half  of  those  newly  diagnosed  in  a  non-acute 
stage (52.7%) have a CD4 cell count < 350 cells per mm3, 
including  31.6%  of  cases  with  advanced  HIV  infection 
(CD4 cell count < 200 cells per mm3). These data indicate 
that people were infected many years before, suggesting 
problems  with  access  to,  and  uptake  of  HIV  testing  for 
some  segments  of  the  population,  and  indicating  the 
need to improve testing programmes to diagnose people 
living with HIV at an earlier stage. 

To reduce the high proportion of people diagnosed late, 
it  is  essential  to  diversify  HIV  testing  by  increasing 
routine testing for health conditions associated with HIV 
(indicator  condition-guided  testing),  augmenting  HIV 
testing  during  screening  for  other  sexually  transmitted 
infections,  and  continuing  to  expand  community-based 
testing, 
partner 
notification. The development of European Standards of 
HIV  Care  and  European  guidance  on  setting-based 
approaches for HIV and viral hepatitis testing, including 
best practices for effective implementation, can promote 
more  uniform  and  improved  care  quality  across  the 
Region,  and  can  help  countries  seeking  to  implement 

self-testing/home-sampling 

and 

16

more  effective  testing  programmes  (20,21).  Testing  not 
only  provides  a  gateway  to  HIV  treatment  for  people 
found to be positive but can also serve as an entry point 
for high-risk HIV-negative people to effective prevention, 
including PrEP.

Despite  clear  evidence  of  the  benefits  for  the  health  of 
HIV-positive people of introducing ART early (22) and the 
fact that this should serve as an incentive for people to 
know  their  HIV  status,  many  continue  to  be  diagnosed 
with  HIV  years  after  becoming  infected,  at  an  advanced 
stage  of  illness.  Overall,  more  than  95%  of  AIDS 
diagnoses  were  reported  to  have  been  made  within  90 
days  of  the  HIV  diagnosis,  indicating  that  most  AIDS 
cases  in  the  EU/EEA  are  due  to  late  diagnosis  of  HIV 
infection.  Stigma  towards  people  living  with  HIV  and 
members  of  key  population  groups  disproportionately 
affected  by  HIV  is  a  documented  contributing  factor  to 
delayed  HIV  test-seeking  (23).  Stigma  reduction  efforts 
within  health-care  and  community  settings  could 
increase care seeking and reduce late diagnosis.

Once tested, rapid linkage to high-quality care (including 
ART) is essential. In recent years, around 97.2% of those 
diagnosed  who  had  evidence  of  linkage  to  care  were 
linked  to  care  within  three  months  of  HIV  diagnosis. 
Timely linkage to care following HIV diagnosis is crucial, 
as  delayed  access  can  result  in  poor  patient  outcomes 
(14).  Once  linked  to  care,  there  is  evidence  that  high 
proportions of people diagnosed with HIV in the EU/EEA 
have access to ART and achieve viral suppression (14). 

The  changing  epidemiology  of  HIV  infections  observed 
in the EU/EEA over the last year indicates that it is crucial 
to  sustain,  and  in  some  places  strengthen,  evidence-
based HIV prevention interventions tailored to the local 
epidemiological  context  and  targeting  those  most  at 
risk.  The  European  Centre  for  Disease  Prevention  and 
Control (ECDC) will continue to support EU/EEA countries 
in  their  efforts  to  accelerate  progress  towards  reaching 
the  Sustainable  Development  Goal  for  HIV  through 
dedicated  workshops,  webinars,  guidance  and  other 
technical  support  focused  on  high-impact  surveillance, 
monitoring and prevention activities. 

Prevention  and  control  programmes  tailored  to  key 
populations  are  essential  for  managing  HIV  infection 
effectively.  For  most  EU/EEA  countries,  these  efforts 
should  focus  strongly  on  women,  transgender  people 
and  MSM.  Migrants  are  another  key  vulnerable 
population  requiring  targeted  prevention  and  control 
measures,  especially  given  the  increasing  evidence  of 
post-migration  HIV 
acquisition.  Migrant-sensitive 
services  for  prevention,  testing  and  linkage  to  care 
should  be  accessible  in  all  EU/EEA  countries  to  ensure 
equitable  access  to  HIV  services.  The  rising  proportion 
of heterosexual people affected by HIV also underscores 
the  need  to  expand  accessible  sexual  health  services 
and  prompt  testing  for  this  group  to  support  sexual 
health  and  early  diagnosis.  In  addition,  harm-reduction 
programmes  for  PWID  and  their  injecting  or  sexual 
partners are crucial. 

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 dataThese  programmes  must  be  maintained  and  scaled  up, 
especially in areas with low coverage or changing drug-
use patterns.

The  analysis  of  HIV  data  from  2023  was  limited  by 
significant  data  incompleteness,  particularly  regarding 
the HIV transmission route, with 27.6% of cases missing 
this  key  information.  Accurate  transmission  data  is 
for  guiding  HIV  prevention  efforts  and 
essential 
programme  planning. 
Improving  collaboration  with 
clinicians  and  follow-up  with  data  providers  could  help 
address  this  gap.  In  addition,  the  lack  of  standardized 
collection  of  HIV  status  data,  which  distinguishes 
between  first-time  and  previously  positive  diagnoses, 
further  complicates  data  interpretation.  Establishing 
consensus 
among  
 EU/EEA countries on the inclusion of this information is 
critical  for  understanding  the  distinct  epidemiological 
profiles  and  health-care  needs  of 
these  groups. 
Enhancing  data  collection  practices  will  lead  to  more 
accurate insights and enable better-targeted prevention 
strategies for diverse populations.

References10

1. 

Kirby T. UK HIV transmission drops in the wake of COVID-19. Lancet 
HIV. 2023;10(4):e217-e218 (https://doi.org/10.1016/S2352- 
3018(23)00055-3).

2.  Martinez V, Ormel H, Op de Coul ELM. Barriers and enablers that 
influence the uptake of HIV testing among heterosexual migrants 
in the Netherlands. PLoS One. 2024;19(10):e0311114 (https://doi.
org/10.1371/journal.pone.0311114). 

3.  Brown AE, Mohammed H, Ogaz D, Kirwan PD, Yung M, Nash SG. Fall 
in new HIV diagnoses among men who have sex with men (MSM) at 
selected London sexual health clinics since early 2015: testing or 
treatment or pre-exposure prophylaxis (PrEP)? Euro Surveill. 
2017;22(25):30553 (https://doi.org/10.2807/1560-7917.
ES.2017.22.25.30553).

4.  Nwokolo N, Whitlock G, MacOwan A. Not just PrEP: other reasons 
for London’s HIV decline. Lancet HIV. 2017;4(4):e153 (https://doi.
org/10.1016/S2352-3018(17)30044-9).

5. 

ECD Evidence Brief: Pre-exposure prophylaxis for HIV prevention in 
Europe. Stockholm: ECDC; 2023 (https://www.ecdc.europa.eu/en/
publications-data/ecdc-evidence-brief-pre-exposure-prophylaxis- 
hiv-prevention-europe).

6.  HIV and migrants - Monitoring the implementation of the Dublin 

Declaration on partnership to fight HIV/AIDS in Europe and Central 
Asia: 2022 progress report. Stockholm: ECDC; 2022 (https://www.
ecdc.europa.eu/sites/default/files/documents/HIV_and_
migrants_0.pdf).

7. 

Shobowale O, Schmidt AJ, Meireles P, Rojas Castro D, Detandt S, 
Stutterheim SE, et al. Determinants of HIV Testing Among Migrant 
Men Who Have Sex With Men from Sub-Saharan Africa and Other 
Regions Residing in 10 European Countries. AIDS Behav. 
2024;28:488–506 (https://doi.org/10.1007/s10461-023-04239-1).

8.  Rice BD, Elford J, Yin Z, Delpech VC. A new method to assign 

country of HIV infection among heterosexuals born abroad and 
diagnosed with HIV. AIDS. 2012;26(15):1961–6 (https://doi.
org/10.1097/QAD.0b013e3283578b80).

9.  Pantazis N, Rosinska M, van Sighem A, Quinten C, Noori T, Burns F, 
et al. Discriminating Between Premigration and Postmigration HIV 
Acquisition Using Surveillance Data. J Acquir Immune Defic Syndr. 
2021;88(2):117–124 (https://doi.org/10.1097/
QAI.0000000000002745).

10  All references were accessed 14 November 2024.

10.  Fakoya I, Alvarez-del Arco D, Woode-Owusu M, Monge S, 

Rivero-Montesdeoca Y, Delpech V, et al. A systematic review of 
post-migration acquisition of HIV among migrants from countries 
with generalised HIV epidemics living in Europe: implications for 
effectively managing HIV prevention programmes and policy. BMC 
Public Health 2016;15:561 (https://doi.org/10.1186/s12889- 
015-1852-9).

11.  Public health guidance on screening and vaccination for infectious 
diseases in newly arrived migrants in the EU/EEA. Stockholm: 
ECDC; 2019 (https://www.ecdc.europa.eu/en/publications-data/
public-health-guidance-screening-and-vaccination-infectious-
diseases-newly).

12.  ECDC and EMCDDA technical guidance on prevention and control of 
infectious diseases among people who inject drugs. Stockholm: 
ECDC; 2012 (www.ecdc.europa.eu/en/publications-data/
ecdc-and-emcdda-technical-guidance-prevention-and-control-
infectious-diseases-0).

13.  ECDC and European Monitoring Centre for Drugs and Drug 

Addiction. Prevention and control of infectious diseases among 
people who inject drugs - 2023 update. Stockholm: ECDC/European 
Monitoring Centre for Drugs and Drug Addiction; 2023 (https://
www.ecdc.europa.eu/en/publications-data/prevention-and- 
control-infectious-diseases-among-people-who-inject-
drugs-2023).

14.  Continuum of HIV care - Monitoring implementation of the Dublin 

Declaration on partnership to fight HIV/AIDS in Europe and Central 
Asia: 2022 progress report. Stockholm: ECDC; 2023. (https://www.
ecdc.europa.eu/en/publications-data/continuum-hiv-care- 
monitoring-implementation-dublin-declaration-partnership-0).

15.  Restar A, Minalga BJ, Quilantang MI, Adamson T, Dusic E, van der 

Merwe LA, et al. Mapping Community-Engaged Implementation 
Strategies with Transgender Scientists, Stakeholders, and 
Trans-Led Community Organizations. Curr HIV/AIDS Rep. 
2023;20(3):160-169 (https://doi.org/10.1007/s11904- 
023-00656-y).

16.  Downing J, Yee K, Sevelius JM. PrEP Use and Adherence Among 

Transgender Patients. AIDS Behav. 2022;26(4):1251–1259 (https://
doi.org/10.1007/s10461-021-03482-8).

17.  Progress towards reaching the Sustainable Development Goals 

related to HIV in the European Union and European Economic Area. 
Monitoring the implementation of the Dublin Declaration on 
partnership to fight HIV/AIDS in Europe and Central Asia – 2023 
progress report. Stockholm: ECDC; 2024 (https://www.ecdc.
europa.eu/en/publications-data/evidence-brief-progress-towards- 
reaching-sustainable-development-goals-related).

18.  van Sighem A, Pharris A, Quinten C, Noori T, Amato-Gauci AJ, the 

ECDC HIV/AIDS Surveillance and Dublin Declaration Monitoring 
Networks. Reduction in undiagnosed HIV infection in the European 
Union/European Economic Area, 2012 to 2016. Euro Surveill. 
2017;22(48):pii=17-00771 (https://doi.org/10.2807/1560-7917.
ES.2017.22.48.17-00771). 

19.  Paraskevis D, Nikolopoulos G, Tsiara C, Paraskeva D, Antoniadou A, 
Lazanas M, et al. HIV-1 outbreak among injecting drug users in 
Greece, 2011: a preliminary report. Euro Surveill. 
2011;16(36):19962 (https://doi.org/10.2807/ese.16.36.19962-en).

20.  Consolidated guidelines on the use of antiretroviral drugs for 
treating and preventing HIV infection: recommendations for a 
public health approach, 2nd ed. Geneva: World Health 
Organization; 2016 (https://iris.who.int/handle/10665/208825).

21.  Public health guidance on HIV, hepatitis B and C testing in the EU/
EEA. Stockholm: ECDC; 2018 (www.ecdc.europa.eu/en/publica-
tions-data/public-health-guidance-hiv-hepatitis-b-and-c- 
testing-eueea).

22.  INSIGHT START Study Group; Lundgren JD, Babiker AG, Gordin F, 

Emery S, Grund B, et al. Initiation of Antiretroviral Therapy in Early 
Asymptomatic HIV Infection. N Engl J Med. 2015;373(9):795–807 
(https://doi.org/10.1056/NEJMoa1506816).

23.  Earnshaw VA, Smith LR, Chaudoir SR, Lee IC, Copenhaver MM. 
Stereotypes about people living with HIV: Implications for 
perceptions of HIV risk and testing frequency among at-risk 
populations. AIDS Educ Prev. 2012;24:574–581 (https://doi.
org/10.1521/aeap.2012.24.6.574).

17

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORT2. HIV and AIDS in the WHO European Region

2.1 HIV and AIDS diagnoses in 
the WHO European Region
2.1.1 HIV diagnoses 

In  2023,  112 883  people  in  the  WHO  European  Region 
were diagnosed with HIV, corresponding to a rate of 12.7 
per  100 000  population  (see  Table  A,  Table  1).  This 
number includes HIV diagnoses reported by 47 countries11 
to  the  joint   ECDC  and  WHO  Regional  Office  for  Europe 
surveillance system. It brings the cumulative number of 
reported  HIV  diagnoses  in  the  Region  since  reporting 
began  in  the  1980s  to  2 573 110.  As  in  previous  years, 
most (69%) of the 112 883 people diagnosed with HIV in 
2023  were  from  the  east  of  the  Region  (77 601),12  24% 
(27 043)  were  from  the  west,  and  7%  (8239)  were from 
the  centre.  The  rate  was  also  highest  in  the  east  (30.6 
per  100 000  population),  five  times  higher  than  in  the 
west  (6.2  per  100 000),  and  more  than  seven  times 
higher than in the centre (4.2 per 100 000) (see Table A, 
Table  1).  For  men,  the  average  rate  across  the  Region 
was  16.7  per  100 000  population  (Table 2),  and  for 
women, 8.9 per 100 000 population (Table 3).

Rates of HIV diagnoses varied widely across countries in 
the WHO European Region in 2023. The highest rates per 
100 000  population  (more  than  15.0)  were  observed  in 
the Russian Federation (37.9) followed by Ukraine (31.7), 
the Republic of Moldova (27.0), Malta (21.0), Kazakhstan 
(20.6),  Armenia  (18.0),  Cyprus  (17.6),  Ireland  (17.3), 
Georgia (16.4), Kyrgyzstan (15.6) and Belarus (15.4). The 
lowest  rates  (3.0  and  under)  were  reported  by  Sweden 
(2.9),  Slovakia  (2.6),  Croatia  (2.5),  Hungary  (2.4),  North 
Macedonia (2.4), Serbia (2.2), Austria (2.1) and Slovenia 
(2.1).

  The  largest  proportion  of  people  diagnosed  in  the  47 
reporting  countries  was  in  the  age  group  30–39  years 
(33.6%),  while  5.8%  were  young  people  aged  15–24 
years,  and  19%  were  50  years  or  above  at  diagnosis 
(Fig 2.1; see Table A, Table 9). 

The  male-to-female  ratio  was  1.8,  lowest  in  the  east 
(1.6),  higher  in  the  west  (2.1),  and  highest  in  the  centre 
(3.9). The highest male-to-female ratios (more than 10.0) 
at the country level among countries with more than 10 
cases were observed in Malta (21.6), Slovenia (13.7) and 
North  Macedonia  (11.5),  and  the  lowest  in  the  United 
Kingdom  (1.2),  the  Russian  Federation,  Finland  (1.4 

11  No data were received from Andorra, Bosnia and Herzegovina, Monaco, San 
Marino, Turkmenistan or Uzbekistan. Liechtenstein is an EEA Member State 
but not a WHO Member State, so its data are included in the totals for the 
EU/EEA, but not for the WHO European Region.

each),  Estonia,  Republic  of  Moldova  and  Belarus  (1.5 
each).

Data  on  transmission  mode,  which  was  available  for  47 
countries13  (Fig  2.2;  see  Table  A,  Tables  4–8)  provide 
information  on  risk  exposure  among  people  diagnosed 
with HIV. The data for 2023 indicate the following:

WHO European Region

•  Heterosexual  contact  was  still  the  main  reported 
mode  of  HIV  transmission  in  the  WHO  European 
Region,  accounting 
(72 033)  of  people 
for  64% 
diagnosed in 2023 and  71% of HIV diagnoses in 2023 
with a known mode of transmission (Table 6). Among 
those, 15% originated from countries with generalized 
epidemics (data not shown).

•  Injecting  drug  use  was  the  second  most  common 
transmission mode, accounting for 14% (15 357) of HIV 
diagnoses  and  15%  of  HIV  diagnoses  with  a  known 
mode of transmission (Table 5).

•  Sex  between  men  accounted  for  12%  (13 152)  of 
diagnoses  overall  and  13%  of  HIV  diagnoses  with  a 
known mode of transmission (Table 4).

•  Less  than  one  percent  (0.54%,  612)  of  cases  were 
infected through MTCT (0.60% of those with a known 
mode of transmission) (Table 7) and 0.1% (124) through 
infection, 
other  transmission  routes 
transfusion or use of other blood products) (Table 8).

(nosocomial 

•  Transmission  mode  was  reported  as  unknown  or 
missing  for  10%  (11 605  cases)  (Table  8).  Reporting 
completeness  regarding  transmission  mode  varies 
greatly across the Region, with information lacking for 
2%  of  HIV  diagnoses  in  the  east,  55%  in  the  centre, 
and 21% in the west. 

West

•  Overall, 41% of all people diagnosed in 2023 and 52% 
of  those  with  a  known  mode  of  transmission  (10 983) 
were infected heterosexually (Table 6). Of these, 13% 
were  previously  diagnosed,  74%  were  born  abroad 
and  40%  originated  from  countries  with  generalized 
epidemics (Table 11).

•  In total, 33% of all people diagnosed in 2023 and 42% 
of  those  with  a  known  mode  of  transmission  (9010) 
were infected through sex between men (Table 4).

•  Of  all  those  diagnosed  in  2023,  3%  (881)  were 
(Table 5). 

injecting  drug  use 

infected 

through 

12  Fig. A1.1 in Annex 1 illustrates the division of countries into west, centre 

and east of the WHO European Region.

13  Data on transmission mode was not reported by Andorra, Bosnia and 
Herzegovina, Monaco, San Marino, Turkmenistan and Uzbekistan.

18

Fig. 2.1. Percentage of HIV diagnoses by country and age group, WHO European Region, 2023 (n = 112 768)

0–14 years

15–19 years

20–24 years

25–29 years

30–39 years

40–49 years

50+ years

Ukraine
Russian Federation
East
Latvia
Finland
Belarus
Israel
Armenia
Denmark
WHO European Region
Estonia
Lithuania
Republic of Moldova
Norway
Italy
Sweden
Slovenia
Ireland
Kazakhstan
Czechia
United Kingdom
Netherlands
Switzerland
Germany
Georgia
Austria
West
Poland
Greece
Belgium
Luxembourg
Kyrgyzstan
Malta
Croatia
Hungary
Spain
Azerbaĳan
Bulgaria
France
Tajikistan
Slovakia
Centre
Albania
Türkiye
Serbia
Portugal
Iceland
Romania
Montenegro
North Macedonia
Cyprus

0

20

40

60

80

100

Percentage
Percentage

Note: the graph organizes countries in order of proportion of population < 30 years. Liechtenstein reported 1 case for 2023 and is not included in the graph. Unknown 
age is excluded from the proportions presented here. 

•  MTCT accounted for 1.3% of all diagnoses and 1.6% of 
those with a known route of transmission (347) (Table 
7).  Of  these,  27%  were  previously  diagnosed,  88% 
were born abroad and 54% originated from countries 
with a generalized epidemic (Table 11). 

•  Transmission  mode  was  unknown  for  21%  (5712)  of 

all diagnoses in 2023.

Centre

•  Overall, 24% of those diagnosed in 2023 and 54% of 
diagnoses  with  a  known  route  of  transmission  were 
infected  through  heterosexual  transmission  (2014) 
(Table 6),  which  was  the  main  mode  of  transmission 
reported  by  seven  countries  (Albania,  Bulgaria, 
Cyprus,  Czechia,  Romania,  Slovakia  and  Türkiye) 
(Fig. 2.2). 

19

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORT•  Of these, 12% were previously diagnosed, 23% were 
born  abroad  and  3%  originated  from  countries  with 
generalized epidemics (Table 11).

•  In total, 18% of those diagnosed with HIV in 2023 and 
40%  of  HIV  diagnoses  with  a  known  route  of 
transmission 
through  sex 
between men (Table 4). In 2023, sex between men was 
the  predominant  mode  of  transmission  reported  by 

(1488)  were 

infected 

seven countries (Croatia, Hungary, Montenegro, North 
Macedonia, Serbia, Slovenia and Poland) (Fig. 2.2).

•  A  total  of  2%  of  those  diagnosed  and  5%  of  HIV 
diagnoses  with  a  known  route  of  transmission  (190) 
were infected through injecting drug use (Table 5).

•  Of  those  with  a  known  mode  of  transmission,  0.9% 

(32) were infected through MTCT (Table 7).

Fig. 2.2. Percentage of HIV diagnoses with known mode of transmission, by transmission route and country, WHO 
European Region, 2023 (n = 101 278)

Heterosexual contact

Injecting drug use

Sex between men

Mother-to-child transmission

Other

Liechtenstein
Slovenia
Greece
Croatia
Malta
Netherlands
Spain
Austria
Hungary
Serbia
Poland
Montenegro
North Macedonia
Iceland
Germany
Belgium
Sweden
Ireland
Switzerland
Luxembourg
Bulgaria
West
Czechia
Portugal
Italy
Centre
France
Norway
Israel
Slovakia
Cyprus
Denmark
Finland
Romania
Lithuania
Latvia
Albania
United Kingdom
Türkiye
WHO European Region
Kazakhstan
Ukraine
Georgia
Estonia
East
Azerbaĳan
Russian Federation
Belarus
Armenia
Kyrgyzstan
Tajikistan
Republic of Moldova

0

20

40

60

80

100

Percentage
Percentage

Note: the graph organizes countries in order of increasing proportion of heterosexual mode of transmission. No data from Andora, Bosnia and Herzegovina, Monaco, 
San Marino, Turkmenistan and Uzbekistan. 

20

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 data•  Transmission  mode  was  unknown  for  55%  (4505)  of 
those diagnosed in 2023 (Table 8). The two countries 
with  the  highest  number  of  HIV  diagnoses  in  2023 
(Poland and Türkiye) together accounted for 70% of all 
HIV diagnoses reported in the centre and also had the 
highest percentage of HIV diagnoses with an unknown 
transmission mode (Poland 78% and Türkiye 71%). 

East

•  In  total,  76%  of  those  diagnosed  in  2023  and  78%  of 
diagnoses  with  a  known  mode  of  transmission 
(59 036) were infected heterosexually, making this the 
main route of transmission reported in all countries in 
the east (Table 6). 

•  Overall,  18%  of  those  diagnosed  in  2023  and  19%  of 
HIV  diagnoses  with  a  known  route  of  transmission 
(14 286)  were  infected  through  injecting  drug  use 
(Table  5),  with  transmission  through  injecting  drug 
use  accounting  for  20%  or  more  of  diagnoses  with  a 
known transmission mode in Ukraine (25%) and Latvia 
(24%). 

•  In  total,  3%  (2654)  of  those  diagnosed  were  infected 
through  sex  between  men 
(Table  4).  However, 
Armenia,  Azerbaijan,  Estonia,  Georgia,  Latvia  and 
Lithuania  reported  that  sex  between  men  accounted 
for  10%  or  more  of  HIV  diagnoses  with  a  known 
transmission mode.

•  The  percentage  of  cases  diagnosed  as 

infected 
through MTCT was 0.3% (233) (Table 7), and only four 
cases were infected through other transmission routes 
(nosocomial  infection,  transfusion  or  use  of  other 
blood products).

•  Transmission  mode  was  reported  as  unknown  or 
missing for only 2% (1388) of those diagnosed across 

in 

the  east  of 

the  13  countries 
the  Region. 
Nevertheless,  at  the  country  level,  transmission-
mode  information  was  lacking  for  15%  or  more  of 
cases in three countries: Estonia (67%), Latvia (52%) 
and Lithuania (15%). 

Analysis  of  the  HIV  diagnoses  by  age  group  and 
transmission mode for the 47 reporting countries in the 
WHO European Region (Fig. 2.3) shows that 40–49-year-
olds  accounted  for  most  HIV  diagnoses  among  those 
infected  through  injecting  drug  use  (46%)  and  reported 
heterosexual  transmission  (33%)  and  30–39-year-olds 
are the majority among MSM (34%). Conversely, people 
aged over 50 years accounted for 21% of all heterosexual 
transmission but only 13% and 9% of sex between men 
and injecting drug use, respectively (Fig. 2.3). 

Forty-six countries provided information on the country 
of  birth,  country  of  nationality,  or  region  of  origin  for 
93.2% (53 976) HIV diagnoses in 2023 (Table 10).14 In the 
WHO European Region, 31.0% of the total HIV diagnoses 
and 33.2% of those with known information on region of 
origin  (17 930)  were  reported  among  people  originating 
from outside the reporting country. This is slightly more 
than  a  15%  increase  compared  to  2022,  driven  by  the 
increase in diagnoses among people of foreign origin in 
the  west  of  the  Region,  which  increased  from  60.3%  to 
66.1%.  In  the  centre  and  the  east,  it  decreased from 
29.9% to 21.8% and from 2.2% to 2.0%, respectively.

While  overall,  most  of  the  diagnoses  originated  from 
four regions: Sub-Saharan Africa; Latin America and the 
Caribbean; and south and south-east Asia, the share of 
diagnoses  among  those  originating  from  Sub-Saharan 
Africa increased substantially in 2023 compared to 2022 
(41.3% in 2023 versus 28.8% in 2022). 

Fig. 2.3. HIV diagnoses, by age group and transmission mode, WHO European Region, 2023 (n = 100 268)

Injecting drug use

Heterosexual contact

Sex between men

e
d
o
m
n
o
i
s
s
i
m
s
n
a
r
T

15–19 years

20–24 years

25–29 years

30–39 years

40–49 years

50+ years

n = 15 354

n = 71 776

n = 13 138

0
0

20
20

40
40

60
60

80
80

100
100

Percentage

Note: no data from Andora, Bosnia and Herzegovina, Monaco, San Marino, Turkmenistan and Uzbekistan. 

14  Aggregated data reported from the Russian Federation did not include 

information about the country of birth, country of nationality or region of 
origin and is not included in the denominator.

21

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORT 
Of  7402  HIV  diagnoses  in  2023  originating  from  this 
subregion,  97.4%  (7212)  were  diagnosed  in  the  EU/EEA 
countries and the United Kingdom.

Forty-three  countries  provided  information  on  CD4  cell 
count at the time of HIV diagnosis in 2023.15 Information 
was  reported  for  32 065  people  over  14  years  of  age  at 
diagnosis  (covering  74.2%  of  all  HIV  diagnoses  in  the 
reporting countries) (Table 12). 

More  than  half  (52.4%)  of  all  individuals  diagnosed  in 
2023, where a CD4 cell count at diagnosis was reported, 
were  considered  to  have  been  diagnosed  late,  with  a 
CD4  cell  count  < 350  cells  per  mm3,  including  31.6%  of 
cases  considered  to  have  advanced  HIV  infection  (CD4 
cell  count  < 200  cells  per  mm3),  which  is  comparable  to 
the  results  from  previous  years,  albeit  with  a  slight 
decrease.  However,  the  regional  average  excludes  data 
from  the  Russian  Federation,  where  a  CD4  cell  count  at 
diagnosis was reported among 96.1% of HIV diagnoses, 
and  only  30.0%  are  detected  once  their  CD4  cell  count 
has  fallen  to  <  350  cells  per  mm3  and  15.1%  <  200  cells 
per  mm3.  The  percentage  of  those  diagnosed  late  (CD4 
cell  count <  350  cells  per  mm3)  varied  across  the 
countries. Those countries with the highest percentages 
of  late  diagnoses  (60%  or  more,  in  countries  with  more 
than  five  cases)  were  Slovenia  (68.8%),  Denmark 
(67.8%), Latvia (64.5%), Greece (64.2%), Albania (61.9%), 
Bulgaria  (61.7%),  Serbia  (61.7%),  Ukraine  (61.5%)  and 
Croatia  (60.9%).  Those  with  the  lowest  percentages 
(40%  or  less)  were  Slovakia  (26.9%),  United  Kingdom 
(30.0%) and Luxembourg (31.6%). 

The  percentage  of  late  diagnoses  also  varied  across 
transmission categories and was highest for people with 
reported  heterosexual  transmission  (56%;  61%  for  men 
and 51% for women) and as a result of injecting drug use 
(52%) and lowest for men infected through sex with men 
(43%) (see Fig. B, Fig. 2.4; Table 12). Late diagnosis was 
more common in the east (60%) than in the centre (57%) 
and  west  (47%).  In  the  centre  and  east,  the  high 
proportion of late diagnoses is mainly driven by the high 
proportion  of  people  infected  through  heterosexual 
contact. 

The  percentage  of  people  diagnosed  with  a  CD4  cell 
count  < 350  cells  per  mm3  increased  with  age,  ranging 
from  38%  among  people  aged  15–19  years  at  diagnosis 
to  66%  among  people  aged  50  years  or  above.  Overall, 
the  percentage  of  late  diagnoses  by  gender  was  51% 
among  women  and  53%  among  men,  but  this  is 
confounded  by  transmission  mode  and,  for  men,  it 
conceals  the  difference  between  MSM  (who  tend  to  be 
diagnosed  earlier)  and  men  with  reported  heterosexual 
transmission  (who  tend  to  be  diagnosed  later)  (see  Fig. 
B).

15  Data on CD4 cell count reported from the Russian Federation did not 

include disaggregation by mode of transmission, and data from Azerbaijan, 
Kazakhstan, and Tajikistan labelled all HIV diagnoses as previously 
positive, therefore, data from these countries were excluded from 
subregional and regional analysis.

22

2.1.2 Trends in HIV diagnoses

The  rate  of  HIV  diagnoses  in  the  WHO  European  Region 
was  mostly  stable  during  the  period  2014–2019,  with 
minor  fluctuations  between  16  and  18  per  100 000 
population.  However,  it  fell  sharply  in  2020  to  12.2  per 
100 000  (Fig.  2.5).  A  slight  yearly  increase  has  been 
observed  since  then  reaching  12.7  per  100  000 
population  in  2023.  The  decline  observed  in  2020  is 
probably due, in part, to decreased case detection as a 
result  of  the  public  health  and  social  measures 
introduced  by  countries  in  response  to  the  COVID-19 
pandemic.  Meanwhile,  a  slight  upward  trend  in  the 
subsequent  years  could  have  been  due  to  a  rebound  in 
HIV  testing  and  case  detection  after  the  pandemic 
subsided, and the increased movement of people within 
and  from  outside  of  the  European  Region.  For  this 
reason,  while  we  still  compare  2023  data  to  previous 
years,  trends  presented  in  this  chapter  should  be 
interpreted with caution. 

The number of diagnosed women and men decreased by 
27% in the WHO European Region, from 55 912 in 2014 to 
40 681  in  2023  and  from  98 013  to  71 922,  respectively 
(Tables  2  and  3).  The  overall  trend  largely  reflects  the 
situation  in  the  Russian  Federation,  which  accounts  for 
the  vast  majority  of  HIV  diagnoses  reported  in  2023, 
where  diagnoses  have  decreased  since  2019  by  32%. 
Other  countries  have  seen  significant  variations,  with 
the number  of  countries 
in 
diagnosed cases in 2023 compared to 2014. For example, 
the number of women diagnosed in Cyprus, Czechia and 
Iceland  was  almost  six  times  higher  in  2023  than  in 
2014.  A  large  (over  100%)  increase  between  2014  and 
2023  was  observed  in  Cyprus,  Iceland,  Ireland  and 
Montenegro  in  both  males  and  females.  Conversely,  a 
large (over 40%) decrease among males was observed in 
Italy, Portugal, Latvia and Luxembourg. Among females, 
the  largest  decrease  between  2014  and  2023  was 
observed in Portugal, Romania, Sweden, Latvia, Austria 
and Luxembourg.

increases 

reporting 

Thirty-nine  countries  consistently  reported  data  on 
transmission  mode  for  the  period  2014–2023  (Fig. 
2.6−2.9).

Data  on  transmission  mode  from  the  countries  with 
consistent data indicate the following (Fig. 2.6−2.9):

WHO European Region

•  The  proportion  of  all  HIV  diagnoses  attributed  to 
heterosexual  contact  increased  from  49%  of  cases  in 
2014  to  55%  in  2022.  The  number  of  HIV  diagnoses 
in  countries 
attributed 
reporting consistently showed an increasing trend up 
until 2019, followed by a decline in 2020 and a further 
upward trend starting in 2021.

to  heterosexual  contact 

•  The  proportion  of  all  HIV  diagnoses  attributed  to  sex 
between  men  decreased  from  27%  to  21%  over  the 
same period. 

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 dataFig. 2.4. HIV diagnoses, by CD4 cell count per mm3 at diagnosis and transmission mode, WHO European Region, 2023 

0
0

20
20

40
40

60
60

80
80

100
100

Percentage

0
0

20
20

40
40

60
60

80
80

100
100

Percentage

West

Centre

East

e
s
u
g
u
r
d
g
n
i
t
c
e
j
n
I

WHO European Region

West

Centre

East

n
o
i
s
s
i
m
s
n
a
r
t

l
a
u
x
e
s
o
r
e
t
e
H

WHO European Region

West

Centre

East

n
e
m
n
e
e
w
t
e
b
x
e
S

WHO European Region

n = 410

< 200 cells/mm3

200 to < 350 cells/mm3

350 to < 500 cells/mm3

n = 100

500+ cells/mm3

n = 2773

n = 3283

n = 7805

< 200 cells/mm3

200 to < 350 cells/mm3

350 to < 500 cells/mm3

n = 936

500+ cells/mm3

n = 10 193

n = 18 934

n = 5 781

< 200 cells/mm3

200 to < 350 cells/mm3

350 to < 500 cells/mm3

n = 678

500+ cells/mm3

n = 589

n = 7048

0
0

20
20

40
40

60
60

80
80

100
100

Percentage

Note: No data from Andorra, Bosnia and Herzegovina, Hungary, Lithuania, Malta, Monaco, North Macedonia, Poland, San Marino, Turkmenistan or Uzbekistan. Data 
from the Russian Federation was excluded due to incomplete reporting on transmission mode. Data from Portugal was not published at the country’s request.

23

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORT 
 
 
 
 
Fig. 2.5. HIV diagnoses per 100 000 population, by year of diagnosis, WHO European Region, 2014–2023

n
o
i
t
a
l
u
p
o
p
0
0
0
0
0
1

r
e
p
s
e
s
o
n
g
a
i
d
V
H

I

50

40

30

20

10

0

West

Centre

East

WHO European Region 

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

Year of diagnosis

Note: includes data from 49 countries. Data from Andorra, Monaco, Turkmenistan and Uzbekistan are excluded due to inconsistent reporting during the period.

Fig. 2.6. HIV diagnoses, by transmission mode and year of diagnosis, WHO European Region, 2014–2023

30 000

25 000

20 000

15 000

10 000

5000

0

s
e
s
o
n
g
a
i
d
V
H

I

f
o
r
e
b
m
u
N

Heterosexual transmission

Sex between men

Other/undetermined
Injecting drug use

Mother-to-child transmission

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

Year of diagnosis

Note: data from Andorra, Bosnia and Herzegovina, Estonia, Iceland, Israel, Malta, Monaco, Poland, the Russian Federation, San Marino, Switzerland, Türkiye, 
Turkmenistan and Uzbekistan are excluded due to inconsistent reporting during the period.

Fig. 2.7. HIV diagnoses, by transmission mode and year of diagnosis, east of the WHO European Region, 2014–2023

20 000

s
e
s
o
n
g
a
i
d
V
H

I

f
o
r
e
b
m
u
N

15 000

10 000

5000

0

Sex between men

Heterosexual transmission

Injecting drug use

Mother-to-child transmission

Other/undetermined

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

Year of diagnosis

Note: data from Estonia, the Russian Federation, Turkmenistan and Uzbekistan are excluded due to inconsistent reporting during the period.

24

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 data 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.8. HIV diagnoses, by transmission mode and year of diagnosis, centre of the WHO European Region, 2014–2023

1500

1000

500

0

s
e
s
o
n
g
a
i
d
V
H

I

f
o
r
e
b
m
u
N

Sex between men

Heterosexual transmission

Injecting drug use

Mother-to-child transmission

Other/undetermined

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

Year of diagnosis

Note: data from Bosnia and Herzegovina, Poland and Türkiye are excluded due to inconsistent reporting during the period.

Fig. 2.9. HIV diagnoses, by transmission mode and year of diagnosis, west of the WHO European Region, 2014–2023

s
e
s
o
n
g
a
i
d
V
H

I

f
o
r
e
b
m
u
N

15 000

10 000

5000

0

Sex between men

Heterosexual transmission

Injecting drug use

Mother-to-child transmission

Other/undetermined

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

Year of diagnosis

Note: data from Andorra, Monaco, Israel, San Marino and Switzerland are excluded due to incomplete/inconsistent reporting during the period.

•  Overall, the number of HIV diagnoses reported among 
MSM  in  countries  reporting  consistently  declined 
between 2015 and 2020 but has remained stable since 
then.

•  While  the  number  of  diagnoses  in  people  infected 
through injecting drug use has shown a stable decline 
since 2014, it increased by 38% in 2020 compared to 
2019, with a reversal decrease in 2021. The decreasing 
trend continued in 2022 and in 2023, reaching 10% of 
all diagnoses. 

•  The  number  of  HIV  diagnoses  in  children  infected 
through  MTCT  decreased  by  15%  over  the  previous 
decade, from 568 in 2014 to 485 in 2023, representing 
0.9% of all diagnoses in 2023. 

•  Of  the  diagnoses  in  people  infected  by  other  means, 
nosocomial  infections  increased  from  32  cases  in 
2014 to 79 in 2023, while HIV diagnoses attributed to 
transfusion of blood and its products decreased from 
100 cases in 2014 to 79 cases in 2023. 

•  The  number  of  HIV  diagnoses  for  which  information 
on  transmission  mode  was  unknown  or  missing 
increased by 21%, from 5202 in 2014 to 6 310 in 2023 
–  representing  9%  of  all  HIV  diagnoses  in  2014  and 
12% in 2023.

West

•  HIV diagnoses of people infected through sex between 
men  decreased  by  38%,  from  13 968  in  2014  to  8702 
in  2022.  The  percentage  of  HIV  diagnoses  attributed 
to  sex  between  men  decreased  from  46%  in  2014  to 
33% in 2023.

•  HIV  diagnoses  of  people  with  reported  heterosexual 
transmission  slightly  decreased  from  10 818  to 
10 641.  The  percentage  of  HIV  diagnoses  attributed 
to  heterosexual  contact  increased  from  35%  of 
cases  in  2014  to  41%  in  2023.  The  proportion  of 
people  infected  through  heterosexual  transmission 
originating 
country  
the 
increased  from  66%  in  2021  to  74%  in  2023.  

reporting 

outside 

25

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORT 
 
 
 
 
 
 
 
The  share  of  previously  diagnosed  individuals  also 
increased from 19% in 2021 to 26% in 2023.

•  HIV  diagnoses  of  people  infected  through  injecting 
drug use decreased by 16%, from 1021 in 2014 to 860 
in  2023,  representing  3%  of  HIV  diagnoses  in  both 
2014 and 2023.

•  Diagnoses  of  children 

infected 

through  MTCT 
decreased  consistently  between  2014  and  2021,  but 
increased  dramatically  in  2022  and  2023,  reaching 
340  cases.  This  may  be  due  to  the  increasing  trend 
among previous positive individuals; however, when 
analysing  data  on  known  previous  positive  status, 
the  share  of  previously  diagnosed  children  did  not 
change substantially, increasing from 56% in 2021 to 
57% in 2023.

•  The number of HIV diagnoses with missing information 
on transmission mode increased from 4426 in 2014 to 
5515  in  2023, corresponding to 14%  of HIV diagnoses 
in  2014  and  21%  in  2023.  Delays  in  the  reporting  of 
probable  modes  of  transmission  to  national  and 
European surveillance systems intensify the increase.

Centre

•  Following the general decline in reported HIV cases in 
2020,  the  number  of  HIV  diagnoses  in  those  infected 
through  heterosexual  transmission  increased  sharply 
in 2022. It remained high in 2023, resulting in a 49% 
increase  between  2014  and  2023  (from  753  to  1122). 
The  percentage  of  HIV  diagnoses  attributed  to 
heterosexual transmission was 34% in 2014 and 46% 
in  2023.  The  proportion  of  people  infected  through 
heterosexual  transmission  originating  outside  the 
reporting country has increased in recent years, from 
13% in 2021 to 23% in 2023. In all, 40% and above of 
cases reported from Croatia, Montenegro, Poland and 
Slovenia,  and  70%  and  above  from  Cyprus,  Czechia 
and  Slovakia  were  among  migrants.  The  share  of 
previously  diagnosed  individuals  has  also  increased 
− from 3% in 2019 to 15% in 2023. 

•  The number of diagnoses in those infected as a result 
of  sex  between  men  increased  from  908  in  2014  to 
934 in 2023. However, the percentage of HIV diagnoses 
attributed  to  sex  between  men  decreased  slightly, 
from  41% 
in  2023.  This  was 
the predominant  mode  of  transmission  in  the  centre 
up  until  2022,  when  heterosexual 
transmission 
became more common.

in  2014  to  38% 

•  The  number  of  HIV  diagnoses  in  those  infected  as  a 
result of injecting drug use was 291 in 2014 and 138 in 
2023.  The  percentage  of  HIV  diagnoses  attributed  to 
injecting drug use was 13% in 2013 and 6% in 2023. It 
is  interesting  to  note  that  in  2021,  the  proportion  of 
people infected through injection drug use originating 
outside the reporting country was 14%, while in 2023, 
this proportion was 29%.

•  The  number  of  HIV  diagnoses  as  a  result  of  MTCT 
decreased consistently between 2014 and 2020 before 
increasing rapidly in the last two years, from 14 cases 

26

in  2020  to  46  in  2022,  mainly  due  to  a dramatic 
increase in previous positive cases. It went down to 13 
cases in 2023.

•  Among  countries  with  consistent  reporting,  the 
number  of  HIV  diagnoses  reported  with  unknown 
transmission  mode  in  2023  was  244.  The  percentage 
of  HIV  diagnoses  with  missing 
information  on 
transmission  mode  decreased  from  11%  in  2014  to 
10% in 2024 for the 12 countries included in the trend 
assessment.

East 

•  The number of HIV diagnoses in people with reported 
heterosexual  transmission  increased  slightly  (3%), 
from  16  178  in  2014  to  16 666  in  2023.  At  the  same 
time, the percentage of all HIV diagnoses attributed to 
heterosexual  contact  increased  from  66%  of  cases  in 
2014 to 73% in 2023.

•  The  number  of  diagnoses  in  people  infected  through 
injecting  drug  use  decreased  by  39%,  from  6832  in 
2014  to  4149  in  2023.  The  percentage  of  all  HIV 
diagnoses  attributed  to  injecting  drug  use  decreased 
from 28% in 2014 to 18% in 2023. 

•  The  number  of  diagnoses  in  people  infected  through 
sex between men increased more than two-fold, from 
537 in 2014 to 1180 in 2023. Yet despite this increase, 
the  percentage  of  all  HIV  diagnoses  attributed  to  sex 
between men has remained low, at 2% in 2014 and 5% 
in 2023.

•  The  number  of  children 

infected  through  MTCT 
decreased  by  39%,  from  291  in  2014  to  132  in  2023, 
representing 1.2% of HIV diagnoses in 2014 and 0.6% 
in 2023.

•  The  number  of  HIV  diagnoses  for  which  the  mode  of 
transmission  was  unknown  slightly  increased  from 
557 in 2014 to 599 in 2023, although the percentage of 
HIV  diagnoses  with  unknown  mode  of  transmission 
remained  low  and  stable  overall  at  2–3%  between 
2014 and 2023. 

2.1.3 AIDS cases, morbidity and mortality

In  2023,  7878  people  in  41  countries  of  the  WHO 
European  Region16  were  diagnosed  with  AIDS,  which 
corresponds  to  a  rate  of  1.2  per  100 000  population 
(Table 13). Of the 7878 people who received a diagnosis 
of AIDS in 2023, 61% (4836) were diagnosed in the east, 
28% (2168) in the west and 11% (874) in the centre of the 
Region.  The  rate  was  also  highest  in  the  east  (4.9  per 
100 000 population), eight times higher than that in the 
west  (0.6  per  100 000)  and  12  times  higher  than  in  the 
centre (0.4 per 100 000 population). 

The  rate  of  AIDS  diagnoses  varied  widely  among  the 
countries, with the highest rates (3.0 or above) reported 
in Ukraine (9.1), Armenia (8.0), Republic of Moldova (7.3) 
and  Georgia  (6.7)  and  the  lowest  rates  (under  0.3) 

16  No data were reported from Andorra, Bosnia and Herzegovina, Germany, 

Monaco, North Macedonia, the Russian Federation, Sweden, Turkmenistan 
or Uzbekistan. Data from Portugal not published at the country’s request. 

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 datareported in Slovakia (0.1), Israel (0.2), Finland (0.2), the 
United  Kingdom  (0.3),  Switzerland  (0.3),  Norway  (0.3) 
and Ireland (0.3). Malta reported zero cases.

Tuberculosis  represented  13%  of  all  reported  AIDS-
defining  illness  events  in  2023,  ranging  from  11%  of 
reports in the west to 16% in the centre and 18% in the 
east. 

In  the  41  countries  with  consistent  AIDS  data17,  the 
overall  rate  of  AIDS  diagnoses  in  the  Region  decreased 
by  53%  between  2014  and  2023,  from  3.4  per  100 000 
population (16 417 cases) to 1.6 per 100 000 (7846 cases) 
(Fig. 2.10). 

AIDS  trends  varied  across  the  three  subregions.  In  the 
east, the rate increased from 4.3 in 2022 to 4.8 in 2023; 
however,  it  was  a  57%  decrease  compared  to  2014.  In 
the centre, the rate decreased by 11%, from 0.9 in 2014 
to  0.8  in  2023.  In  the  west,  the  steady  downward  trend 
continued, with a 47% decrease from 1.5 in 2014 to 0.8 
in 2023 (Fig. 2.10). 

in  the  Region18  provided 
A  total  of  41  countries 
information  on  AIDS-related  deaths  or  deaths  among 
people  previously  diagnosed  with  AIDS,19  with  2775 
people  reported  to  have  died  during  2023.  This 
represents  a  55%  decrease  compared  with  the  6105 
deaths  reported  for  the  same  countries  in  2014.  Of  the 
2775 deaths in 2023, 72% were reported from the east of 
the  Region,  20%  from  the  west  and  8%  from  the  centre 
(Table 17). It is important to note that delays in reporting 

and  under-reporting  have  a  significant  impact  on  these 
numbers  at  the  European  level,  particularly  when  the 
death  occurs  long  after  the  HIV  or  AIDS  diagnosis.  The 
numbers  presented  here  should  therefore  not  be 
interpreted as representative of the true AIDS mortality 
burden  in  the  European  Region.  According  to  a  country 
survey  from  2006,  only  about  one  third  of  countries  in 
the  WHO  European  Region  were  able  to  match  their 
HIV/ AIDS registries with their national mortality or vital 
statistics registries (1).

2.2 HIV testing
Data  on  the  number  of  HIV  tests  can  support  the 
interpretation  of  trends  in  diagnosed  HIV  infections. 
However,  it  is  worth  noting  that  the numbers  provided 
are  collected 
in  a  heterogeneous  manner,  and 
comparisons  between  country  testing  rates  should  be 
made  with  caution.  In  2023,  a  total  of  79 722 304  HIV 
tests were reported by 29 countries (12 in the east, nine 
in the centre, and eight in the west). These tests do not 
include  unlinked  anonymous  testing  and  all  countries 
except the Russian Federation also exclude the HIV tests 
performed  as  part  of  blood-donor  screening.  In  2023, 
the Russian Federation reported a total of 51 002 495 HIV 
tests, accounting for 64% of all HIV tests reported in the 
Region  for  that  year.  Countries  in  the  east  tended  to 
report  higher  testing  rates  than  those  in  the  west  and 
centre, but rates varied greatly across countries from all 
parts of the Region, and more data were available from 
countries  in  the  east  than  the  centre  and  the  west  
(Table 18). 

Fig. 2.10. AIDS diagnoses per 100 000 population, by subregion and year of diagnosis, WHO European Region, 
2014–2023

12

10

8

6

4

2

0

n
o
i
t
a
l
u
p
o
p
0
0
0
0
0
1

r
e
p
s
e
s
o
n
g
a
i
d
S
D
A

I

West

Centre

East

WHO European Region 

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

Year of diagnosis

Note: no data received from Andorra, Belarus, Bosnia and Herzegovina, Germany, Monaco, North Macedonia, the Russian Federation, Sweden, Turkmenistan or 
Uzbekistan.

17  Data from Andorra, Belarus, Bosnia and Herzegovina, Cyprus, Germany, 
Monaco, North Macedonia, Portugal, the Russian Federation, Sweden, 
Turkmenistan and Uzbekistan are excluded, or not reported.

18  No data were received from Andorra, Bosnia and Herzegovina, Germany, 

North Macedonia, Monaco, the Russian Federation, Sweden, Turkmenistan 
or Uzbekistan. Data from Portugal not published at country request.

19  In countries and years for which cause of death (AIDS or non-AIDS related) 

was unknown or could not be reported, deaths among persons (ever) 
diagnosed with AIDS were included.

27

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORT 
 
 
 
 
 
       
Although  the  overall  number  of  tests  performed  in  the 
Region  increased  by  55%,  from  51 188 357  in  2014  to 
79 149 316  in  2023,  in  the  27  countries  with  data 
available  throughout  the  decade,  the  number  of  tests 
performed  decreased  by  15%  between  2019  and  2020, 
but  then  increased  by  35%  between  2020  and  2023 
(Table 18). This is probably a consequence of a reduction 
in HIV testing services during 2020 due to the COVID-19 
pandemic  and  the  subsequent  lift  of  the  COVID-related 
restrictions  starting  in 2021  and  onwards.  Increases  in 
large  countries  with  high  numbers  tested,  such  as 
Belarus,  France,  Kazakhstan,  the  Russian  Federation 
and  Türkiye,  have  had  a  considerable  impact  on  the 
overall  increase  since  2014.  The  number  of  tests  more 
than  doubled  in  a  few  countries,  although  information 
on  testing  yield  or  coverage  among  key  populations  at 
higher  risk  of  HIV  infection  was  not  collected  from 
countries.

The  number  of  HIV  tests  from  the  11  consistently  
reporting  countries  in  the  east  of  the  Region  increased 
by 65%, from 36 582 586 in 2014 to 60 440 812 in 2023 
(Table 18). Information on the types of population tested 
is  not  available,  but  an  increased  number  of  HIV  tests 
does  not  necessarily  generate  higher  testing  yields  if 
large numbers of HIV tests are performed among people 
at low risk of HIV infection.

Over the last decade, the number of HIV tests increased 
by  19%  (from  7 747 456  in  2014  to  9 215 335  in  2023)  in 
the  nine  countries  for  which  consistent  data  were 
available.20 

The  number  of  HIV  tests  conducted  in  the  west  is  not 
reported separately here. In contrast to countries in the 
east and centre, many in the west do not systematically 
collect data on the number of HIV tests performed. This 
results in data being too sparse to allow for meaningful 
interpretation.

2.3 Conclusions
The 2023 HIV surveillance data indicate a wide variation 
in  epidemic  patterns  and  trends  across  the  WHO 
European  Region.  Overall,  HIV  diagnoses  slightly 
increased  in  the  WHO  European  Region  in  2023,  with  a 
rate  of  12.7  per  100 000  population,  a  2.4%  increase 
compared with the 2022 rate but still a 19.6% decrease 
compared  to  the  2019  rate.  However,  this  overall  trend 
masks  very  different  trends  across  the  Region.  The 
overall trend largely reflects the situation in the Russian 
Federation,  which  accounts  for  the  vast  majority  of  HIV 
diagnoses  reported  in  2023,  where  diagnoses  have 
decreased since 2019 by 32%. However, in total, 21 of 47 
countries reported an increase in HIV diagnoses in 2023 
compared  to  2022,  and  several  countries,  namely 
Azerbaijan,  Finland, 
Ireland,  Kazakhstan, 
Iceland, 
Lithuania,  Malta  and  Montenegro,  recorded  the  highest 
number of HIV diagnoses, reported in a single year in the 
last decade.

20 The nine countries are Albania, Czechia, Montenegro, North Macedonia, 

Poland, Romania, Serbia, Slovenia and Türkiye. 

28

When  comparing  the  number  of  HIV  diagnoses  with  the 
estimated  number  of  new  HIV  infections  over  the  past 
decade,  it  is  evident  that  more  people  are  becoming 
infected  with  HIV  than  are  being  diagnosed.  This 
indicates  that  the  number  of  people 
living  with 
undiagnosed  HIV  in  the  Region  is  increasing.  The 
widening  gap  between  estimated  new  infections  and 
actual  diagnoses  can  be  addressed  by  further  scale-up 
of  testing  to  reach  the  right  populations,  especially  in 
the east, which is lagging behind in case detection.

The increase in HIV diagnoses in 2023 can be attributed 
to  a  range  of  factors,  including  expanded  and  more 
targeted  HIV  testing  services  in  some  settings  and  the 
implementation  of  new  testing  strategies  to  identify 
those  who  are  undiagnosed,  as  well  as  the  observed 
increase  in  HIV  diagnoses  in  the  west  in  the  number  of 
people  originating  from  outside  the  reporting  country, 
primarily  due  to  increase  of  share  of  diagnosed  people 
from  Sub-Saharan  Africa  and  continued  high  rates  of 
those  originating  from  central  and  eastern  Europe  and 
Latin  America  and  the  Caribbean.  In  all,  12.9%  of  the 
diagnoses reported in the west in 2023 were previously 
positive.  However,  the  number  of  previous  positives  is 
probably  underestimated,  as  the  variable  identifying 
them  had  a  completeness  of  48.6%  in  2023.  This 
individuals  who  had  previously 
category 
received  an  HIV  diagnosis,  either  in  another  country  or 
within a different setting in the reporting country before 
the current reporting year. Most of these infections were 
probably  acquired  abroad  and  may  not  reflect  a  rise  in 
transmission in the reporting countries. 

includes 

Previously positive individuals have had a considerable 
impact  on  the  epidemiological  profile  and  the  trends 
among  those  reported  in  2023,  specifically  for  the  EU/
EEA countries from the west and centre of the Region. A 
sub-analysis  of  the  previous  positive  diagnoses  shows 
that they include a higher proportion of women in older 
age groups, originating mainly from central and eastern 
Europe  and  Sub-Saharan  Africa,  who  were  primarily 
infected  through  heterosexual  contact.  Additionally, 
MTCT  was  reported  at  a  higher  rate  among  those  with 
previous  positive  diagnoses  compared 
to  newly 
diagnosed  people.  Consequently,  trends  in  reported 
modes of transmission from EU/EEA countries and from 
the west should be interpreted with caution. 

In  the  east,  Azerbaijan  and  Kazakhstan  recorded  the 
highest  number  of  HIV  diagnoses  reported  in  a  single 
year.  None  of  these  countries  reported  a  substantial 
increase in the number of cases originating from outside 
the  country,  and  over  95%  of  their  HIV  diagnoses 
originate  from  the  reporting  country.  The  countries 
reported  a  rebound  in  HIV  testing  and  case  detection 
since  the  pandemic  subsided  because  of  their  focus  on 
increasing  case  detection  by  introducing  new  testing 
policies to close the gap on undiagnosed people.

transmission 

the  main 
Heterosexual 
transmission  route  in  the  east.  Although  the  reported 
transmission  through  sex  between  men  remains  low  in 
absolute  terms  in  the  east,  it  has  increased  more  than 

remains 

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 datatwo-fold during the decade – the largest increase in any 
transmission category and any subregion of the Region. 
There  is  some  evidence  to  suggest  that  a  proportion  of 
men reported as heterosexually infected may, in fact, be 
men who have sex with men or people with a history of 
drug  injection,  which  may  have  been  misclassified  as 
heterosexually  infected  (2,3).  With  the  support  of  the 
Robert  Koch  Institute,  a  WHO  Collaborating  Centre  for 
viral hepatitis and HIV, WHO’s Regional Office for Europe 
is supporting countries in conducting studies to assess 
the  quality  of  the  reported  modes  of  transmission.  A 
study  conducted  in  Kyrgyzstan  in  2023  also  found 
significant  misclassification  in  the  categorization  of 
reported modes of transmission.21

the 

increasing 

Despite 
in  heterosexual 
transmission due to the factors described earlier, seven 
of  the  15  countries  in  the  centre  reported  sex  between 
men as the predominant mode of transmission. 

trend 

treatment 

interventions 

Drug-injection-related  transmission  remains  low,  but 
past  outbreaks  (4–8)  suggest  that  HIV  prevention 
services  for  people  who  inject  drugs  continue  to  be 
important  and  must  be  maintained  with  sufficient 
coverage  to  prevent  further  outbreaks.  The  percentage 
of young people among the new diagnoses is also higher 
in this part of the Region than elsewhere. HIV prevention, 
should 
diagnostics  and 
accommodate the needs of key populations, particularly 
interventions. 
MSM,  with  relevant  evidence-based 
These 
lubricant 
programming; diversified HIV testing services; assisted 
voluntary  partner  notification,  PrEP;  prevention  and 
(particularly  sexually 
management  of  co-infections 
transmitted 
treatment 
rapid  HIV 
infections)  and 
initiation.  Services  should  be  patient-centred  and 
provided  in  a  friendly  environment,  preferably  with  the 
involvement  of  civil  society  along  the  entire  HIV 
continuum  of  services,  ranging  from  HIV  prevention  to 
adherence to ART.

include  condom  and 

interventions 

In the west subregion, there has been a clear decline in 
the  overall  rate  of  HIV  diagnoses  during  the  previous 
decade, resulting primarily from decreases in diagnoses 
among  MSM  in  specific  countries  (Austria,  Belgium, 
Denmark,  Netherlands,  Norway,  Spain,  and  the  United 
Kingdom)  and  among  people  infected  heterosexually, 
particularly  women  and  people  originating 
from 
countries  with  generalized  HIV  epidemics.  However, 
surveillance  data  indicate  a  considerable  increase  in 
reported HIV diagnoses in 2022 and 2023 from this part 
of  the  Region.  This  is  due  to  a  combination  of  different 
factors.  In  countries  where  migration  is  common  and 
takes  various  forms,  the  public  health  challenge  of 
for  migrant 
ensuring  access 
populations,  including  HIV  services  and  promoting 
cross-border  collaboration  and  data  sharing,  remains 
essential  to  a  robust  and  people-centred  public  health 
response.  The 
living  with  HIV, 
particularly from Ukraine, has introduced new challenges 
to HIV care, as this population may have different needs 

to  health  services 

influx  of  people 

21  the paper, Dumchev, et al. 2024, with the results is under peer review.

in  EU/EEA  countries) 

for mental health and social support and require special 
considerations around transitioning to new ART regimens 
(many  were  on  treatment  regimens  that  were  not 
In  addition, 
available 
individuals  who  are  aware  of  their  HIV-positive  status 
may  hesitate  to  seek  care  in  the  health  system  due  to 
challenges  to  access  or  concerns  related  to  stigma  and 
discrimination  (10).  An  increase  is  observed  among 
people  originating  from  outside  reporting  countries, 
with their proportion reaching 56% among HIV diagnoses 
in EU/EEA countries.

(9). 

More  than  half  of  HIV  diagnoses  have  a  CD4  cell  count 
< 350  cells  per  mm3,  including  almost  a third  of  cases 
with  advanced  HIV  infection  (CD4  cell  count  < 200  cells 
per mm3). Once again, it is significant that the 2023 data 
provide  information  on  variations  in  late  diagnoses 
according  to  geography,  transmission  mode  and  age. 
The  data  also  suggest  problems  with  access  to  and 
uptake  of  HIV  testing  for  some  populations,  indicating 
the  need  to  improve  testing  programmes  to  diagnose 
people living with HIV at an earlier stage. The data also 
confirm that the proportion diagnosed at a late stage of 
infection 
infected 
heterosexually  (particularly  men) or  as  a  result  of 
injecting drug use and among those in older age groups.

highest 

people 

among 

is 

Late diagnosis reflects insufficient access to and uptake 
of  appropriate  HIV  testing  and  counselling  by  those  at 
greater risk of acquiring HIV. HIV testing strategies must 
be  reconsidered  and  diversified  to  include  innovative 
approaches  involving  community-based  organizations 
and  focusing  on  key  population  groups.  Multiple  entry 
points  to  HIV  testing  should  be  available  through  HIV 
self-testing,  HIV  testing  performed  by  trained 
lay 
providers  and  civil  society,  home  sampling,  routine 
indicator  condition-guided  HIV  testing  offered  in  the 
health  system,  and  assisted  partner  notifications.  HIV 
testing  should  also  be  available  in  settings  such  as 
prisons,  drug-dependence 
treatment  programmes, 
sexual  and  reproductive  health  clinics,  and  migrant 
health services, depending on the local context. Support 
for timely linkage to HIV treatment and care is essential 
to  reduce  late  diagnosis  and  ensure  progress  towards 
the  Joint  United  Nations  Programme  on  HIV/AIDS  and 
WHO  95–95–95  targets,  improving  treatment  outcomes 
and reducing HIV transmission.

It  is  estimated  that  around  3 100 000  (95%  confidence 
interval:  2 800 000–3 400 000)  people  are  living  with 
HIV  in  the  WHO  European  Region,  around  2 170 000 
(70%) of whom know their status (11). 

Similar  to  the  2022  data,  2023  HIV  data  reveals  a 
significant  issue  with  data  quality,  completeness  and 
lack  of  standardization  for  the  HIV  Status  variable, 
differentiating  new  HIV  diagnoses 
from  previous 
positives. This complicates the 2023 data interpretation. 
Achieving  consensus  among  countries  in  the  Region  on 
the  collection,  recording  and  reporting  of  previous 
positive  cases  is  paramount.  This  is  critical  due  to  the 
different epidemiological profiles and health-care needs 
of  previously  diagnosed  individuals.  Improving  data 

29

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORTrecording  and  reporting  standards  within  surveillance 
systems will ensure accuracy and help with the planning 
of tailored prevention strategies.

Since  the  adoption  of  the  Regional  action  plans  for 
ending  AIDS  and  the  epidemics  of  viral  hepatitis  and 
sexually  transmitted  infections  2022–2030  (12),  WHO 
and partners have been working with Member States on 
their national adoption and implementation of the action 
plans,  with  a  particular  focus  on  strengthening  HIV 
surveillance; 
capacity; 
alignment  and  uptake  of  HIV  testing  and  treatment 
guidance;  and  innovative  combination  HIV  prevention 
approaches  in  key  populations;  efforts  to  eliminate 
MTCT of HIV viral hepatitis B and syphilis, and other key 
priorities, as highlighted within the plans. 

analytical 

reporting 

and 

To  accelerate  implementation  of  the  action  plans,  the 
WHO Regional Office for Europe, jointly with the Ministry 
of Health of Spain and partners, held a series of regional 
events  to  disseminate  WHO  guidelines  and  secure 
political  engagement  to  eliminate  discrimination.  A 
ministerial  session  entitled,  "Keeping  the  promise  on 
ending  AIDS  and  the  epidemics  of  viral  hepatitis  and 
sexually transmitted infections", held on 22 July 2024 in 
Munich,  Germany,  prior  to  the  25th  International  AIDS 
Conference,  gathered  ministers,  decision-makers  and 
civil  society  organizations  from  across  the  Region  and 
beyond to renew commitments to the 2025 targets of the 
action  plans.  The  WHO  Regional  Office  for  Europe  also 
announced  the  triple  elimination  initiative  in  central 
Asia,  encouraging  countries  to  simultaneously  commit 
to  the  elimination  of  MTCT  of  HIV,  syphilis  and  the 
hepatitis  B  virus  and  aiming  to  mobilize  support  to 
further push the agenda for integrated service delivery.

infection  programmes, 
verification 

Technical  support  was  provided  to  Member  States  to 
review  their  national  HIV  responses,  their  national 
guidelines  and  HIV,  viral  hepatitis  and  sexually 
implement 
transmitted 
strengthen 
diagnostic 
surveillance  and  data  on  key  populations  and  to  boost 
country  capacity  to  proactively  interpret  and  analyse 
data.  The  WHO  Regional  Office  for  Europe  also  helped 
countries  apply  for  support  from  the  Global  Fund,  with 
10  successful  applications  raising  US$  337  million  for 
2024–2027.

studies, 

to 

to 

Sustainable  Development  Goals 
through 
dedicated  guidance,  workshops,  webinars  and  other 
technical  support  focused  on  high-impact  surveillance, 
monitoring, treatment and prevention activities.

for  HIV 

References22

1. 

 EuroHIV 2006 survey on HIV and AIDS surveillance in the WHO 
European Region. Saint-Maurice: Santé publique France; 2007 
(https://www.santepubliquefrance.fr/maladies-et-traumatismes/
infections-sexuellement-transmissibles/vih-sida/documents/
rapport-synthese/eurohiv-2006-survey-on-hiv-and-aids- 
surveillance-in-the-who-european-region).

2.  Čakalo JI, Božičević I, Vitek CR, Mandel JS, Salyuk TO, Rutherford 
GW. Misclassification of men with reported HIV infection in 
Ukraine. AIDS Behav. 2015;19:1938–40 (https://doi.org/10.1007/
s10461-015-1112-0).

3.  Dumchev K, Kornilova M, Kulchynska R, Azarskova M, Vitek C. 

Improved ascertainment of modes of HIV transmission in Ukraine 
indicates importance of drug injecting and homosexual risk. BMC 
Public Health 2020;20(1):1288 (https://doi.org/10.1186/
s12889-020-09373-2).

4.  Hedrich D, Kalamara E, Sfetcu O, Pharris A, Noor A, Wiessing L, et 

al. Human immunodeficiency virus among people who inject drugs: 
is risk increasing in Europe? Euro Surveill. 2013;18(48) (https://doi.
org/10.2807/1560-7917).

5.  Giese C, Igoe D, Gibbons Z, Hurley C, Stokes S, McNamara S, et al. 
Injection of new psychoactive substance snow blow associated 
with recently acquired HIV infections among homeless people who 
inject drugs in Dublin, Ireland, 2016. Euro Surveill. 2016;20(40) 
(https://doi.org/10.2807/1560-7917).

6. 

ECDC/European Monitoring Centre for Drugs and Drug Addiction. 
HIV in people who inject drugs – Joint technical mission to 
Luxembourg. Stockholm: ECDC/European Monitoring Centre for 
Drugs and Drug Addiction; 2018 (https://sante.public.lu/fr/
publications/h/hiv-joint-technical-mission.html).

7.  McAuley A, Palmateer NE, Goldberg DJ, Trayner KMA, Shepherd SJ, 
Gunson RN, et al. Re-emergence of HIV related to injecting drug use 
despite a comprehensive harm reduction environment: a 
cross-sectional analysis. Lancet HIV 2019;6(5):e315–24 (https://
doi.org/10.1016/S2352-3018(19)30036-0).

8.  Des Jarlais DC, Sypsa V, Feelemyer J, Abagiu AO, Arendt V, Broz D, 
et al. HIV outbreaks among people who inject drugs in Europe, 
North America, and Israel. Lancet HIV. 2020;7(6):e434–42 (https://
doi.org/10.1016/S2352-3018(20)30082-5).

9.  Massmann R, Groh T, Jilich D, Bartková D, Bartovská Z, Chmelař J, 
et al. HIV-positive Ukrainian refugees in the Czech Republic. AIDS. 
2023 Oct 1;37(12):1811–1818 (https://doi.org/10.1097/
QAD.0000000000003633).

10.  Standardized protocol for clinical management and medical 
data-sharing for people living with HIV among refugees from 
Ukraine. Copenhagen: WHO Regional Office for Europe; 
2022 (https://iris.who.int/handle/10665/353083). License: CC 
BY-NC-SA 3.0 IGO.

11.  The path that ends AIDS: UNAIDS Global AIDS Update 2024. 
Geneva: Joint United Nations Programme on HIV/AIDS; 2024 
(https://www.unaids.org/sites/default/files/
media_asset/2023-unaids-global-aids-update_en.pdf).

12.  Regional action plans for ending AIDS and the epidemics of viral 
hepatitis and sexually transmitted infections 2022–2030. 
Copenhagen: WHO Regional Office for Europe; 2023 (https://iris.
who.int/handle/10665/369243). License: CC BY-NC-SA 3.0 IGO.

WHO  Regional  Office  for  Europe,  with  ECDC  and  other 
partners,  will  continue  to  support  Member  States  in 
their efforts to accelerate progress toward reaching the 

22 All references were accessed on 14 November 2024.

30

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 dataTables

31

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORTTable 1. HIV diagnoses and rates per 100 000 population, by country and year of diagnosis (2014–2023) and cumulative 
totals, in EU/EEA and other countries of the WHO European Region

Area

Country, territory or areaa

Year of 
start of 
reporting

2014

N

EU/EEA
Austria
West
West
Belgium
Centre Bulgaria
Centre Croatia
Centre Cyprus
Centre Czechia
Denmark
West
Estonia
East
Finland
West
France
West
Germany
West
West
Greece
Centre Hungary
Iceland
West
Ireland
West
Italy
West
Latvia
East
Liechtenstein
West 
Lithuania
East
Luxembourgc
West
Malta
West
Netherlands
West
Norway
West
Poland
Centre
Portugal
West
Centre Romania
Centre Slovakia
Centre Slovenia
West
West

Spain
Sweden
Total EU/EEA

Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco

Non-EU/EEA
Centre Albania
Andorra
West
Armenia
East
Azerbaijan
East
East
Belarus
Centre Bosnia and Herzegovina
East
West
East
East
West
Centre Montenegro
Centre North Macedonia
East
East
West
Centre Serbia
Centre
Centre
West
East
Centre
East
East
West
East

Serbia excluding Kosovo[1]
Kosovo[1]
Switzerland
Tajikistan
Türkiye
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Total non-EU/EEA

Republic of Moldova
Russian Federationd
San Marino

WHO European Region
West
Centre
East
Total WHO European Region

1980
1985
1986
1985
1986
1985
1990
1988
1980
2003
1993
1984
1985
1983
1985
1985
1987
1985
1988
1983
2001
1980
1984
1985
1985
1987
1985
1985
2003
1983

1993
2004
1988
1987
1981
1986
1989
1981
1987
1987
1987
1993
1987
1987
2009
1985
1984
1984
1999
1985
1991
1985
1990
1987
1981
1981

321
1 124
247
92
56
232
256
291
181
5 702
3 536
785
271
11
370
3 853
358
1
141
166
40
1 022
267
1 136
1 609
937
86
50
4 535
473
28 149

79
5
334
604
1 811
23
564
462
2 341
647
1
20
1
831
92 613
3
144
138
6
528
986
1 838
–
15 796
6 383
–
126 014

31 633
5 212
117 317
154 162

2015

N

340
1 111
227
117
80
266
277
270
174
5 321
3 653
776
271
12
487
3 623
408
0
157
159
61
1 048
221
1 278
1 721
921
86
48
4 308
447
27 868

96
3
294
727
2 305
15
717
414
2 475
619
1
19
25
818
100 220
2
188
185
3
550
1 149
2 107
–
13 000
6 233
–
131 977

30 942
5 744
123 159
159 845

Rate

4.0
9.9
3.2
2.8
9.4
2.5
4.9
20.5
3.2
8.0
4.5
7.1
2.7
3.6
10.4
6.0
20.5
0.0
5.3
28.2
13.9
6.2
4.3
3.4
16.6
4.6
1.6
2.3
9.3
4.6
6.2

3.3
4.2
10.2
7.4
23.8
0.4
19.0
5.2
13.9
10.5
2.7
3.0
1.2
25.0
69.3
6.0
2.0
2.5
0.2
6.6
13.5
2.6
–
30.4
9.6
–
30.8

7.3
2.9
48.2
18.2

Rate

3.8
10.1
3.5
2.2
6.5
2.2
4.5
22.1
3.3
8.6
4.4
7.2
2.7
3.4
8.0
6.4
17.9
2.7
4.7
30.2
9.3
6.1
5.2
3.0
15.4
4.7
1.6
2.4
9.8
4.9
6.3

2.7
7.0
11.6
6.2
18.7
0.6
14.9
5.9
13.3
11.1
2.8
3.2
0.0
24.9
64.2
9.0
1.5
1.8
0.3
6.4
11.8
2.4
–
35.0
9.9
–
29.4

7.5
2.7
45.7
17.6

2016

N

312
1 005
202
108
80
286
244
229
180
5 447
3 399
652
228
28
502
3 726
374
2
214
168
63
951
220
1 317
1 696
815
88
63
4 399
429
27 427

127
3
303
556
2 391
24
718
371
2 898
748
0
34
30
832
86 855
2
187
176
11
545
1 038
2 437
–
14 229
5 416
–
119 744

29 758
6 026
111 385
147 169

Rate

3.6
8.9
2.9
2.6
9.4
2.7
4.3
17.4
3.3
8.2
4.1
6.0
2.3
8.4
10.6
6.2
19.0
5.3
7.3
29.2
14.0
5.6
4.2
3.5
16.4
4.1
1.6
3.1
9.5
4.4
6.1

4.4
4.1
10.6
5.6
24.6
0.7
19.0
4.5
16.0
12.4
0.0
5.4
1.4
25.8
59.9
5.9
2.0
2.3
0.6
6.5
11.9
3.0
–
33.4
8.2
–
27.7

6.9
3.1
43.5
16.7

2017

N

330
961
241
106
85
254
242
219
158
5 391
3 178
650
223
24
488
3 619
381
2
263
141
45
1 005
213
1 425
1 594
844
72
42
4 319
434
26 949

94
6
358
567
2 468
15
631
419
3 012
836
3
26
44
835
85 802
1
190
187
3
465
1 205
2 844
–
15 603
4 813
–
120 237

28 499
6 505
112 180
147 184

Rate

3.8
8.5
3.5
2.6
9.9
2.4
4.2
16.6
2.9
8.1
3.9
6.0
2.3
7.1
10.2
6.0
19.5
5.3
9.1
23.9
9.8
5.9
4.1
3.8
15.5
4.3
1.3
2.0
9.3
4.3
6.0

3.3
8.1
12.6
5.6
25.4
0.4
16.7
5.0
16.4
13.7
8.1
4.1
2.1
26.3
59.0
2.9
2.1
2.5
0.2
5.5
13.5
3.5
–
36.8
7.3
–
27.7

6.6
3.3
43.7
16.6

2018

N

Rate

2019

N

Rate

2020

N

Rate

2021

N

2022

N

Rate

2023

N

Cumulative 

totalb

Rate

Country, territory or areaa

231
958
311
94
78
208
219
190
153
5 110
2 892
728
229
38
523
3 038
334
0
160
116
73
967
191
1 214
1 441
778
102
42
4 063
481
24 962

102
12
429
656
2 386
24
672
455
3 213
866
0
23
45
905
85 995
3
195
187
8
443
1 421
3 248
–
15 648
4 727
–
121 468

26 862
6 693
112 875
146 430

2.6
8.4
4.6
2.3
9.0
2.0
3.8
14.4
2.8
7.6
3.5
6.8
2.3
10.9
10.8
5.1
17.3
0.0
5.6
19.3
15.3
5.6
3.6
3.2
14.0
4.0
1.9
2.0
8.7
4.8
5.5

3.5
16.0
15.1
6.5
24.6
0.7
17.8
5.4
17.3
13.9
0.0
3.6
2.1
28.8
59.0
8.8
2.1
2.5
0.4
5.2
15.6
3.9
–
37.1
7.1
–
27.9

6.2
3.4
43.8
16.5

261

993

258

103

100

222

190

178

148

5 137

3 133

677

238

28

533

2 510

306

0

151

107

80

979

172

1 557

1 411

784

104

42

3 939

449

24 790

101

– 

448

721

2 137

33

668

410

3 667

843

–

26

66

922

80 124

0

229

224

5

428

1 320

3 229

16 236

4 286

–

–

115 894

25 871

7 092

107 721

140 684

177

766

199

75

106

251

161

147

134

3 577

2 472

631

201

34

434

1 470

257

1

139

65

82

708

137

965

529

103

35

1 073

2 980

360

18 269

96

–

369

559

17

530

375

1 427

3 468

674

–

15

29

680

59 598

0

134

132

2

295

1 084

2 076

15 478

3 333

–

–

2.9

8.7

3.9

2.6

11.4

2.1

3.3

13.4

2.7

7.6

3.8

6.3

2.4

7.8

10.9

4.2

15.9

0.0

5.3

17.4

16.2

5.7

3.2

4.1

13.7

4.0

1.9

2.0

8.4

4.4

5.5

3.5

–

15.9

7.0

22.1

1.0

17.7

4.8

19.6

13.3

–

4.1

3.1

29.7

55.0

0.0

2.5

3.0

0.3

5.0

14.1

3.9

–

38.7

6.4

–

26.5

6.0

3.6

41.8

15.8

200

793

237

77

149

233

139

125

162

3 675

2 263

592

226

20

397

1 914

212

1

121

94

45

713

102

1 461

1 200

652

115

39

3 155

352

19 464

104

–

425

690

37

530

409

1 496

3 589

841

–

13

43

792

58 340

0

188

179

9

327

922

2 920

15 333

3 464

–

–

2.0

6.6

3.0

1.9

11.9

2.3

2.8

11.1

2.4

5.3

3.0

5.9

2.1

9.3

8.7

2.5

13.5

2.6

4.9

10.4

15.9

4.1

2.6

2.5

10.4

2.7

1.9

1.7

6.3

3.5

4.0

3.3

–

13.2

5.4

14.8

0.5

14.1

4.3

18.3

10.5

–

2.4

1.4

22.0

40.9

0.0

1.5

1.8

0.1

3.4

11.4

2.5

–

37.1

5.0

–

4.4

2.4

32.7

12.2

19 264

4 831

84 410

108 505

20 016

6 494

83 416

109 926

Rate

2.2

6.9

3.6

2.0

16.6

2.2

2.4

9.4

2.9

5.4

2.7

5.5

2.3

5.4

7.9

3.2

11.2

2.6

4.3

14.8

8.7

4.1

1.9

3.9

11.7

3.4

2.1

1.8

6.7

3.4

4.3

3.6

–

15.2

6.7

15.6

1.1

14.1

4.6

18.7

12.9

–

2.1

2.0

25.9

40.2

0.0

2.1

2.5

0.5

3.8

9.5

3.4

–

37.0

5.1

–

20.6

4.6

3.3

32.4

12.3

197

1 058

328

113

218

870

258

250

271

4 237

3 279

599

224

40

880

2 140

229

1

252

76

60

996

245

989

696

203

57

2 604

3 308

446

25 124

98

–

535

766

54

617

477

1 644

4 006

1 091

929

55 573

–

40

41

172

171

1

1

358

1 037

3 824

12 183

4 379

–

–

87 825

24 294

9 542

79 112

112 948

0.8

6.1

5.1

2.9

24.1

8.3

4.4

18.8

4.9

6.2

3.9

5.7

2.3

10.6

17.4

3.6

12.2

2.5

9.0

11.8

11.5

5.7

4.5

7.1

9.6

3.7

3.7

2.7

7.0

4.3

5.3

3.4

–

19.2

7.4

17.2

1.7

16.5

5.3

20.7

16.5

–

6.4

2.0

28.4

38.4

3.0

1.9

2.4

0.1

4.1

10.4

4.5

29.7

6.5

–

–

20.0

5.3

4.8

30.7

12.4

194

1 119

253

97

162

402

227

183

282

4 981

3 321

680

228

44

911

2 349

188

1

267

60

114

834

332

924

703

142

44

2 189

3 196

304

24 731

123

–

500

919

–

612

418

1 463

4 040

1 054

928

54 689

–

54

50

–

197

177

20

351

1 100

3 595

11 658

6 402

–

–

27 043

8 239

77 601

112 883

EU/EEA

11 294 Austria

38 074 Belgium

4 333 Bulgaria

2 096 Croatia

1 961 Cyprus

5 346 Czechia

8 785 Denmark

10 784 Estonia

5 061

Finland

110 621

France

82 841 Germany

18 442 Greece

4 913 Hungary

589 Iceland

12 498 Ireland

57 948 Italy

8 914 Latvia

73 Liechtenstein

4 102 Lithuania

3 637 Luxembourgc

886 Malta

31 592 Netherlands

7 470 Norway

32 918 Poland

68 627 Portugal

28 008 Romania

1 640 Slovakia

1 095 Slovenia

71 424 Spain

14 961 Sweden

650 933 Total EU/EEA

Non-EU/EEA

1 725 Albania

96 Andorra

5 614 Armenia

11 055 Azerbaijan

35 104 Belarus

10 391 Georgia

12 192 Israel

54 515 Kazakhstan

13 289 Kyrgyzstan

40 Monaco

425 Montenegro

440 Bosnia and Herzegovina

Serbia excluding Kosovo[1]

432 North Macedonia

17 008 Republic of Moldova

1 109 458 Russian Federationd

94 San Marino

4 946 Serbia

4 788

158

Kosovo[1]

38 288 Switzerland

16 129 Tajikistan

34 881

Türkiye

2 Turkmenistan

348 895 Ukraine

183 070 United Kingdom

24 018 Uzbekistan

WHO European Region

778 530 West

125 159 Centre

1 669 421 East

2 573 110 Total WHO European Region

2.1

9.5

3.9

2.5

17.6

3.7

3.8

13.4

5.1

7.3

3.9

6.5

2.4

11.3

17.3

4.0

10.0

2.5

9.3

9.1

21.0

4.7

6.0

6.0

8.8

3.7

2.6

2.1

6.6

2.9

5.3

4.3

–

18.0

8.8

15.4

–

16.4

4.6

20.6

15.6

–

8.6

2.4

27.0

37.9

–

2.2

2.5

1.1

4.0

10.8

4.2

31.7

9.5

–

–

6.2

4.2

30.6

12.7

90 237

20.6

90 463

88 153

20.3

1 922 250 Total non-EU/EEA

a   Country/territory/area specific comments are in Annex 5.
b   Cumulative total is the total number of cases reported by the country since the start of reporting.
c   The numbers displayed here may not fully align with the numbers in the country’s national statistics as these are presented by the “date of notification” instead of the 

“date of diagnosis” as here. 

d   Due to discrepancies in the methodology used for calculating the population rates by the Russian Federal Statistics Service and the United Nations Population Division,  
rates on overall HIV diagnoses, as well as data disaggregated by sex, presented in the report in Tables 1, 2 and 3 and elsewhere in the report may differ from the data 
presented in national statistics.

32

[1]  All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 dataTable 1. HIV diagnoses and rates per 100 000 population, by country and year of diagnosis (2014–2023) and cumulative 

totals, in EU/EEA and other countries of the WHO European Region

Area

Country, territory or areaa

Year of 

start of 

reporting

2014

N

2015

N

2016

N

2017

N

2018

N

Rate

2019

N

Rate

2020

N

Rate

2021

N

Rate

2022

N

Rate

2023

N

Cumulative 
totalb

Rate

Country, territory or areaa

261
993
258
103
100
222
190
178
148
5 137
3 133
677
238
28
533
2 510
306
0
151
107
80
979
172
1 557
1 411
784
104
42
3 939
449
24 790

101
– 
448
721
2 137
33
668
410
3 667
843
–
26
66
922
80 124
0
229
224
5
428
1 320
3 229
–
16 236
4 286
–
115 894

25 871
7 092
107 721
140 684

2.9
8.7
3.9
2.6
11.4
2.1
3.3
13.4
2.7
7.6
3.8
6.3
2.4
7.8
10.9
4.2
15.9
0.0
5.3
17.4
16.2
5.7
3.2
4.1
13.7
4.0
1.9
2.0
8.4
4.4
5.5

3.5
–
15.9
7.0
22.1
1.0
17.7
4.8
19.6
13.3
–
4.1
3.1
29.7
55.0
0.0
2.5
3.0
0.3
5.0
14.1
3.9
–
38.7
6.4
–
26.5

6.0
3.6
41.8
15.8

177
766
199
75
106
251
161
147
134
3 577
2 472
631
201
34
434
1 470
257
1
139
65
82
708
137
965
1 073
529
103
35
2 980
360
18 269

96
–
369
559
1 427
17
530
375
3 468
674
–
15
29
680
59 598
0
134
132
2
295
1 084
2 076
–
15 478
3 333
–
90 237

19 264
4 831
84 410
108 505

2.0
6.6
3.0
1.9
11.9
2.3
2.8
11.1
2.4
5.3
3.0
5.9
2.1
9.3
8.7
2.5
13.5
2.6
4.9
10.4
15.9
4.1
2.6
2.5
10.4
2.7
1.9
1.7
6.3
3.5
4.0

3.3
–
13.2
5.4
14.8
0.5
14.1
4.3
18.3
10.5
–
2.4
1.4
22.0
40.9
0.0
1.5
1.8
0.1
3.4
11.4
2.5
–
37.1
5.0
–
20.6

4.4
2.4
32.7
12.2

200
793
237
77
149
233
139
125
162
3 675
2 263
592
226
20
397
1 914
212
1
121
94
45
713
102
1 461
1 200
652
115
39
3 155
352
19 464

104
–
425
690
1 496
37
530
409
3 589
841
–
13
43
792
58 340
0
188
179
9
327
922
2 920
–
15 333
3 464
–
90 463

20 016
6 494
83 416
109 926

2.2
6.9
3.6
2.0
16.6
2.2
2.4
9.4
2.9
5.4
2.7
5.5
2.3
5.4
7.9
3.2
11.2
2.6
4.3
14.8
8.7
4.1
1.9
3.9
11.7
3.4
2.1
1.8
6.7
3.4
4.3

3.6
–
15.2
6.7
15.6
1.1
14.1
4.6
18.7
12.9
–
2.1
2.0
25.9
40.2
0.0
2.1
2.5
0.5
3.8
9.5
3.4
–
37.0
5.1
–
20.6

4.6
3.3
32.4
12.3

197
1 058
328
113
218
870
258
250
271
4 237
3 279
599
224
40
880
2 140
229
1
252
76
60
996
245
2 604
989
696
203
57
3 308
446
25 124

98
–
535
766
1 644
54
617
477
4 006
1 091
–
40
41
929
55 573
1
172
171
1
358
1 037
3 824
–
12 183
4 379
–
87 825

24 294
9 542
79 112
112 948

0.8
6.1
5.1
2.9
24.1
8.3
4.4
18.8
4.9
6.2
3.9
5.7
2.3
10.6
17.4
3.6
12.2
2.5
9.0
11.8
11.5
5.7
4.5
7.1
9.6
3.7
3.7
2.7
7.0
4.3
5.3

3.4
–
19.2
7.4
17.2
1.7
16.5
5.3
20.7
16.5
–
6.4
2.0
28.4
38.4
3.0
1.9
2.4
0.1
4.1
10.4
4.5
–
29.7
6.5
–
20.0

5.3
4.8
30.7
12.4

194
1 119
253
97
162
402
227
183
282
4 981
3 321
680
228
44
911
2 349
188
1
267
60
114
834
332
2 189
924
703
142
44
3 196
304
24 731

123
–
500
919
1 463
–
612
418
4 040
1 054
–
54
50
928
54 689
–
197
177
20
351
1 100
3 595
–
11 658
6 402
–
88 153

27 043
8 239
77 601
112 883

2.1
9.5
3.9
2.5
17.6
3.7
3.8
13.4
5.1
7.3
3.9
6.5
2.4
11.3
17.3
4.0
10.0
2.5
9.3
9.1
21.0
4.7
6.0
6.0
8.8
3.7
2.6
2.1
6.6
2.9
5.3

4.3
–
18.0
8.8
15.4
–
16.4
4.6
20.6
15.6
–
8.6
2.4
27.0
37.9
–
2.2
2.5
1.1
4.0
10.8
4.2
–
31.7
9.5
–
20.3

6.2
4.2
30.6
12.7

EU/EEA
11 294 Austria
38 074 Belgium
4 333 Bulgaria
2 096 Croatia
1 961 Cyprus
5 346 Czechia
8 785 Denmark
10 784 Estonia
Finland
France

5 061
110 621
82 841 Germany
18 442 Greece
4 913 Hungary
589 Iceland
12 498 Ireland
57 948 Italy
8 914 Latvia

73 Liechtenstein

4 102 Lithuania
3 637 Luxembourgc

886 Malta

31 592 Netherlands
7 470 Norway
32 918 Poland
68 627 Portugal
28 008 Romania
1 640 Slovakia
1 095 Slovenia
71 424 Spain
14 961 Sweden

650 933 Total EU/EEA
Non-EU/EEA

1 725 Albania
96 Andorra
5 614 Armenia
11 055 Azerbaijan
35 104 Belarus

440 Bosnia and Herzegovina

10 391 Georgia
12 192 Israel
54 515 Kazakhstan
13 289 Kyrgyzstan
40 Monaco
425 Montenegro
432 North Macedonia
17 008 Republic of Moldova
1 109 458 Russian Federationd
94 San Marino

4 946 Serbia
4 788
158

Serbia excluding Kosovo[1]
Kosovo[1]
38 288 Switzerland
16 129 Tajikistan
34 881

Türkiye
2 Turkmenistan

348 895 Ukraine
183 070 United Kingdom
24 018 Uzbekistan

1 922 250 Total non-EU/EEA

WHO European Region

778 530 West
125 159 Centre

1 669 421 East
2 573 110 Total WHO European Region

a   Country/territory/area specific comments are in Annex 5.

b   Cumulative total is the total number of cases reported by the country since the start of reporting.

c   The numbers displayed here may not fully align with the numbers in the country’s national statistics as these are presented by the “date of notification” instead of the 

[1]  All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

d   Due to discrepancies in the methodology used for calculating the population rates by the Russian Federal Statistics Service and the United Nations Population Division,  

rates on overall HIV diagnoses, as well as data disaggregated by sex, presented in the report in Tables 1, 2 and 3 and elsewhere in the report may differ from the data 

33

Rate

3.8

10.1

3.5

2.2

6.5

2.2

4.5

22.1

3.3

8.6

4.4

7.2

2.7

3.4

8.0

6.4

17.9

2.7

4.7

30.2

9.3

6.1

5.2

3.0

15.4

4.7

1.6

2.4

9.8

4.9

6.3

2.7

7.0

11.6

6.2

18.7

0.6

14.9

5.9

13.3

11.1

2.8

3.2

0.0

24.9

64.2

9.0

1.5

1.8

0.3

6.4

11.8

2.4

–

35.0

9.9

–

29.4

7.5

2.7

45.7

17.6

340

1 111

227

117

80

266

277

270

174

5 321

3 653

776

271

12

487

3 623

408

0

157

159

61

1 048

221

1 278

1 721

921

86

48

96

3

294

727

15

717

414

2 305

2 475

619

1

19

25

818

2

188

185

3

550

1 149

2 107

13 000

6 233

–

–

131 977

30 942

5 744

123 159

159 845

4 535

473

28 149

4 308

447

27 868

92 613

100 220

1980

1985

1986

1985

1986

1985

1990

1988

1980

2003

1993

1984

1985

1983

1985

1985

1987

1985

1988

1983

2001

1980

1984

1985

1985

1987

1985

1985

2003

1983

1993

2004

1988

1987

1981

1986

1989

1981

1987

1987

1987

1993

1987

1987

2009

1985

1984

1984

1999

1985

1991

1985

1990

1987

1981

1981

321

1 124

247

92

56

232

256

291

181

5 702

3 536

785

271

11

370

3 853

358

1

141

166

40

1 022

267

1 136

1 609

937

86

50

79

5

334

604

1 811

23

564

462

2 341

647

20

1

1

831

3

144

138

6

528

986

1 838

15 796

6 383

–

–

126 014

31 633

5 212

117 317

154 162

Rate

4.0

9.9

3.2

2.8

9.4

2.5

4.9

3.2

8.0

4.5

7.1

2.7

3.6

20.5

10.4

6.0

20.5

0.0

5.3

28.2

13.9

6.2

4.3

3.4

16.6

4.6

1.6

2.3

9.3

4.6

6.2

3.3

4.2

10.2

7.4

23.8

0.4

19.0

5.2

13.9

10.5

2.7

3.0

1.2

25.0

69.3

6.0

2.0

2.5

0.2

6.6

13.5

2.6

–

30.4

9.6

–

30.8

7.3

2.9

48.2

18.2

312

1 005

5 447

3 399

3 726

202

108

80

286

244

229

180

652

228

28

502

374

2

214

168

63

951

220

1 317

1 696

815

88

63

4 399

429

27 427

127

3

303

556

24

718

371

2 391

2 898

748

0

34

30

832

86 855

2

187

176

11

545

1 038

2 437

14 229

5 416

–

–

29 758

6 026

111 385

147 169

Rate

3.6

8.9

2.9

2.6

9.4

2.7

4.3

3.3

8.2

4.1

6.0

2.3

8.4

17.4

10.6

6.2

19.0

5.3

7.3

29.2

14.0

5.6

4.2

3.5

16.4

4.1

1.6

3.1

9.5

4.4

6.1

4.4

4.1

10.6

5.6

24.6

0.7

19.0

4.5

16.0

12.4

0.0

5.4

1.4

25.8

59.9

5.9

2.0

2.3

0.6

6.5

11.9

3.0

–

33.4

8.2

–

6.9

3.1

43.5

16.7

330

961

241

106

85

254

242

219

158

5 391

3 178

650

223

24

488

3 619

381

2

263

141

45

1 005

213

1 425

1 594

844

72

42

4 319

434

26 949

2 468

3 012

836

94

6

358

567

15

631

419

3

26

44

835

1

190

187

3

465

1 205

2 844

15 603

4 813

–

–

85 802

28 499

6 505

112 180

147 184

Rate

3.8

8.5

3.5

2.6

9.9

2.4

4.2

2.9

8.1

3.9

6.0

2.3

7.1

16.6

10.2

6.0

19.5

5.3

9.1

23.9

9.8

5.9

4.1

3.8

15.5

4.3

1.3

2.0

9.3

4.3

6.0

3.3

8.1

12.6

5.6

25.4

0.4

16.7

5.0

16.4

13.7

8.1

4.1

2.1

26.3

59.0

2.9

2.1

2.5

0.2

5.5

13.5

3.5

–

36.8

7.3

–

6.6

3.3

43.7

16.6

231

958

311

94

78

208

219

190

153

728

229

38

523

334

0

160

116

73

967

191

5 110

2 892

3 038

1 214

1 441

778

102

42

4 063

481

24 962

102

12

429

656

24

672

455

2 386

3 213

866

0

23

45

905

85 995

3

195

187

8

443

1 421

3 248

15 648

4 727

–

–

26 862

6 693

112 875

146 430

119 744

27.7

120 237

27.7

121 468

2.6

8.4

4.6

2.3

9.0

2.0

3.8

2.8

7.6

3.5

6.8

2.3

14.4

10.9

10.8

5.1

17.3

0.0

5.6

19.3

15.3

5.6

3.6

3.2

14.0

4.0

1.9

2.0

8.7

4.8

5.5

3.5

16.0

15.1

6.5

24.6

0.7

17.8

5.4

17.3

13.9

0.0

3.6

2.1

28.8

59.0

8.8

2.1

2.5

0.4

5.2

15.6

3.9

–

37.1

7.1

–

27.9

6.2

3.4

43.8

16.5

EU/EEA

West

West

Austria

Belgium

Centre Bulgaria

Centre Croatia

Centre Cyprus

Centre Czechia

Denmark

Estonia

Finland

France

Germany

Greece

Iceland

Ireland

Italy

Latvia

Centre Hungary

West

East

West

West

West

West

West

West

West

East

East

West

West

West

West

West 

Liechtenstein

Lithuania

Luxembourgc

Malta

Netherlands

Norway

Centre

Poland

West

Portugal

Centre Romania

Centre Slovakia

Centre Slovenia

West

West

Spain

Sweden

Total EU/EEA

Non-EU/EEA

Centre Albania

Andorra

Armenia

Azerbaijan

Belarus

Georgia

Israel

Kazakhstan

Kyrgyzstan

Monaco

Centre Bosnia and Herzegovina

West

East

East

East

East

West

East

East

West

East

East

West

Centre

Centre

West

East

East

East

West

East

West

Centre

East

Centre Montenegro

Centre North Macedonia

Republic of Moldova

Russian Federationd

San Marino

Centre Serbia

Serbia excluding Kosovo[1]

Kosovo[1]

Switzerland

Tajikistan

Centre

Türkiye

Turkmenistan

Ukraine

United Kingdom

Uzbekistan

Total non-EU/EEA

WHO European Region

Total WHO European Region

“date of diagnosis” as here. 

presented in national statistics.

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORTTable 2. HIV diagnoses in males and rates per 100 000 male population, by country and year of diagnosis (2014–2023) 
and cumulative totals, in EU/EEA and other countries of the WHO European Region

Area

Country, territory or areaa

2014
N

EU/EEA
Austria
West
West
Belgium
Centre Bulgaria
Centre Croatia
Centre Cyprus
Centre Czechia
Denmark
West
Estonia
East
Finland
West
France
West
Germany
West
West
Greece
Centre Hungary
Iceland
West
Ireland
West
Italy
West
Latvia
East
Liechtenstein
West
Lithuania
East
Luxembourgc
West
Malta
West
Netherlands
West
Norway
West
Poland
Centre
West
Portugal
Centre Romania
Centre Slovakia
Centre Slovenia
West
West

Spain
Sweden
Total EU/EEA

Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco

Non-EU/EEA
Centre Albania
Andorra
West
Armenia
East
Azerbaijan
East
East
Belarus
Centre Bosnia and Herzegovina
East
West
East
East
West
Centre Montenegro
Centre North Macedonia
East
East
West
Centre Serbia
Centre
Centre
West
East
Centre
East
East
West
East

Serbia excluding Kosovo[1]
Kosovo[1]
Switzerland
Tajikistan
Türkiye
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Total non-EU/EEA

Republic of Moldova
Russian Federation
San Marino

WHO European Region
West
Centre
East
Total WHO European Region

248
789
201
83
49
209
196
182
138
3 829
2 865
681
216
9
269
3 060
246
1
90
109
36
848
199
934
1 156
660
75
45
3 870
273
21 566

61
5
217
375
1 052
20
413
330
1 334
365
1
17
1
452
55 469
3
127
121
6
392
557
1 497
–
8 991
4 769
–
76 448

24 075
4 195
69 743
98 013

2015
N

291
766
194
111
72
248
205
167
131
3 561
2 886
683
196
10
373
2 809
273
0
115
121
53
850
145
1 084
1 279
675
76
41
3 691
276
21 382

67
3
205
495
1 395
14
545
291
1 442
342
1
17
24
462
62 118
2
182
180
2
423
680
1 770
–
7 519
4 754
–
82 751

23 604
4 771
75 758
104133

Rate

6.9
13.9
5.7
5.5
17.5
4.8
7.3
27.2
4.9
11.1
7.2
13.0
4.2
6.1
16.1
9.6
30.0
0.0
8.5
42.9
24.0
10.2
5.6
5.9
26.0
7.0
2.9
4.0
16.2
5.7
9.8

4.6
8.3
15.6
10.2
31.1
0.8
30.7
7.3
16.9
11.8
5.5
5.5
2.3
29.6
92.6
12.2
4.0
5.0
0.2
10.3
15.9
4.4
–
32.7
14.8
–
39.6

11.3
4.9
61.8
24.3

2016
N

259
713
169
104
65
262
191
139
121
3 587
2 667
537
171
22
390
2 865
236
2
165
128
51
796
157
1 149
1 241
600
81
59
3 738
269
20 934

104
3
212
355
1 490
22
552
257
1 684
434
0
32
28
471
53 689
2
171
160
11
425
621
2 065
–
8 366
4 118
–
75 101

22 537
5 082
68 414
96 033

Rate

6.1
12.8
5.0
5.2
15.8
5.1
6.7
22.5
4.5
11.1
6.6
10.3
3.6
13.2
16.7
9.8
26.1
10.7
12.3
44.3
22.5
9.5
6.0
6.3
25.3
6.2
3.1
5.8
16.4
5.5
9.5

7.2
8.2
16.3
7.2
33.2
1.3
31.1
6.3
19.5
14.7
0.0
10.4
2.7
30.7
79.8
12.2
3.8
4.5
1.2
10.2
14.2
5.1
–
42.4
12.7
–
36.2

10.7
5.2
57.1
22.5

Rate

6.0
14.4
5.8
4.1
11.7
4.0
7.0
29.6
5.1
11.9
7.2
12.8
4.6
5.5
11.7
10.5
26.8
5.4
6.6
39.6
16.8
10.2
7.8
5.1
23.3
6.8
2.8
4.4
16.9
5.7
9.9

4.2
13.8
16.4
7.8
23.5
1.1
23.2
8.5
15.9
12.8
5.6
5.5
0.1
28.5
82.9
18.5
2.8
3.3
0.7
9.7
13.3
3.8
–
43.1
15.0
–
37.2

11.6
4.4
58.1
23.1

2017
N

272
647
218
101
65
230
192
146
101
3 510
2 512
535
149
21
371
2 748
247
2
220
107
35
840
155
1 260
1 159
629
66
40
3 680
273
20 531

69
3
253
359
1 540
15
492
298
1 818
490
3
24
44
468
53 209
1
179
176
3
357
735
2 389
–
9 296
3 556
–
75 598

21 376
5 478
69 273
96 127

Rate

6.3
11.6
6.6
5.2
15.6
4.4
6.7
23.6
3.7
10.9
6.2
10.2
3.2
12.3
15.7
9.4
27.6
10.7
16.5
36.1
15.1
9.9
5.9
6.9
23.7
6.6
2.5
3.9
16.1
5.4
9.3

4.8
8.0
19.5
7.2
34.3
0.9
27.7
7.2
20.7
16.3
16.5
7.8
4.2
30.9
78.8
6.0
4.0
4.9
0.3
8.5
16.4
5.8
–
47.3
10.9
–
36.2

10.1
5.6
57.6
22.4

2018
N

190
659
276
88
65
186
170
131
104
3 266
2 242
581
195
24
411
2 382
227
0
117
84
62
782
122
1 051
1 045
584
94
40
3 482
306
18 966

76
8
293
437
1 499
22
506
299
2 004
535
0
21
45
537
52 720
2
181
174
7
341
874
2 717
–
9 512
3 497
–
76 126

20 059
5 641
69 392
95 092

Rate

4.4
11.7
8.5
4.6
15.4
3.6
5.9
21.1
3.8
10.1
5.5
11.2
4.2
13.5
17.2
8.2
25.5
0.0
8.9
27.8
25.8
9.2
4.6
5.7
21.5
6.1
3.5
3.9
15.2
6.0
8.6

5.3
21.0
22.8
8.7
33.5
1.3
28.5
7.1
22.5
17.5
0.0
6.8
4.3
35.9
78.0
12.0
4.1
4.9
0.8
8.1
19.0
6.5
–
48.6
10.7
–
36.3

9.5
5.8
57.5
22.1

2019

N

2020

N

2021

N

2022

N

2023

N

Cumulative 

totalb

Rate

Country, territory or areaa

Rate

5.0

12.1

6.8

5.1

16.1

3.7

5.1

18.1

4.1

10.1

6.0

10.0

4.4

12.6

16.3

6.9

21.1

0.0

8.5

25.9

21.8

9.0

4.2

7.2

20.7

6.1

3.5

3.5

14.8

5.6

8.5

5.1

–

24.6

9.4

30.3

1.8

28.6

6.3

26.8

15.8

–

7.8

6.1

36.8

72.6

0.0

4.7

5.8

0.5

7.8

16.4

6.6

50.9

9.6

–

–

34.6

9.1

6.1

54.9

21.3

145

531

168

66

87

203

133

88

99

2 406

1 899

505

166

28

343

1 164

162

1

97

48

67

562

91

805

792

404

90

30

70

–

251

386

899

14

403

263

2 562

226

13 968

2 293

383

–

14

29

398

36 659

0

125

124

1

230

644

1 763

9 810

2 452

–

–

57 086

14 546

4 034

52 473

71 053

Rate

3.3

9.3

5.3

3.5

20.0

3.9

4.6

14.0

3.6

7.4

4.6

9.7

3.5

15.0

14.0

4.0

18.4

5.2

7.5

15.2

25.2

6.5

3.4

4.4

16.3

4.3

3.4

2.9

11.0

4.3

6.3

4.9

–

19.8

7.6

20.2

0.9

22.7

6.0

25.1

12.1

–

4.6

2.8

27.2

54.2

0.0

2.8

3.5

0.1

5.4

13.4

4.2

–

43.8

7.4

–

26.7

6.8

4.1

42.3

16.3

167

586

205

71

115

201

115

80

119

2 446

1 783

480

182

14

307

1 524

136

1

93

71

41

578

64

1 203

857

503

100

32

2 683

232

14 989

73

–

297

472

926

35

403

289

2 346

513

–

12

41

455

33 543

0

181

173

8

244

574

2 445

9 796

2 462

–

–

55 107

15 062

5 399

49 634

70 095

1 689

1 786

Rate

3.8

10.3

6.5

3.8

26.3

3.9

4.0

12.7

4.4

7.5

4.3

9.2

3.9

7.4

12.4

5.3

15.5

5.2

7.2

22.2

15.4

6.7

2.4

6.7

17.6

5.4

3.8

3.0

11.6

4.4

6.8

5.1

–

23.6

9.3

21.0

2.2

22.8

6.5

25.4

16.0

–

3.9

3.9

31.3

49.8

0.0

4.1

4.9

0.9

5.7

11.7

5.8

–

51.0

7.4

–

26.1

7.1

5.5

41.1

16.2

2 738

2 251

161

687

215

90

154

435

149

130

170

467

179

30

577

154

1

152

47

55

714

136

1 751

738

554

122

45

2 821

265

17 677

71

–

390

524

1 028

50

454

310

2 689

658

–

34

35

537

159

158

1

1

251

666

3 181

8 078

2 751

–

–

55 263

17 008

7 075

48 856

72 939

Rate

3.6

12.0

6.9

4.8

34.9

8.4

5.1

20.5

6.2

8.3

5.5

9.1

3.9

15.5

23.0

5.9

17.7

5.1

11.6

14.5

20.4

8.2

5.0

9.8

15.0

6.0

4.6

4.3

12.1

5.0

8.0

5.0

–

31.2

10.3

23.4

3.1

25.8

6.9

28.8

20.2

–

11.1

3.4

34.5

49.7

6.1

3.7

4.6

0.1

5.8

13.3

7.4

42.5

8.2

–

–

26.1

7.9

7.3

40.5

16.9

3 107

2 325

157

757

206

83

122

270

154

109

166

522

178

33

590

131

1

178

43

108

654

205

1 612

660

551

107

41

2 741

196

17 793

2 771

95

–

346

651

889

–

472

280

651

–

40

46

561

–

179

159

20

245

693

2 997

7 562

3 465

–

–

18 194

6 527

47 201

71 922

33 396

32 187

220

685

217

98

69

192

146

113

111

523

208

23

397

187

0

110

80

55

770

112

3 277

2 438

2 004

1 322

1 006

583

93

36

3 407

288

18 770

74

–

313

473

1 354

30

508

270

2 412

491

–

24

64

544

49 177

0

210

206

4

331

771

2 748

9 904

3 156

–

–

72 854

19 299

5 968

66 357

91 624

EU/EEA

8 679 Austria

24 518 Belgium

3 463 Bulgaria

1 852 Croatia

1 459 Cyprus

4 200 Czechia

6 427 Denmark

7 149 Estonia

3 596 Finland

71 379 France

64 792 Germany

15 264 Greece

3 832 Hungary

433 Iceland

7 694 Ireland

44 328 Italy

6 013 Latvia

47 Liechtenstein

3 149 Lithuania

2 663 Luxembourgc

723 Malta

25 139 Netherlands

5 004 Norway

25 743 Poland

49 506 Portugal

17 517 Romania

1 365 Slovakia

961 Slovenia

59 541 Spain

9 951 Sweden

476 387 Total EU/EEA

1 257 Albania

78 Andorra

3 909 Armenia

7 874 Azerbaijan

21 348 Belarus

7 780 Georgia

8 098 Israel

35 561 Kazakhstan

8 396 Kyrgyzstan

26 Monaco

365 Montenegro

384 Bosnia and Herzegovina

Serbia excluding Kosovo[1]

399 North Macedonia

9 868 Republic of Moldova

665 379 Russian Federation

74 San Marino

4 131 Serbia

4 007

124

Kosovo[1]

24 658 Switzerland

10 270 Tajikistan

28 484 Türkiye

1

Turkmenistan

210 398 Ukraine

127 961 United Kingdom

16 234 Uzbekistan

560 532 West

95 412 Centre

1 013 398 East

1 669 342 Total WHO European Region

3.5

13.1

6.6

4.5

27.2

5.1

5.2

16.8

6.0

9.4

5.6

10.3

3.8

16.5

22.7

6.2

15.0

5.1

13.3

12.9

37.9

7.4

7.4

9.1

13.1

5.9

4.0

3.9

11.6

3.7

8.0

6.7

–

27.7

12.7

20.3

–

26.9

6.1

29.3

19.7

–

13.1

4.4

34.2

48.0

–

4.2

4.6

2.3

5.6

13.6

7.0

45.1

10.3

–

–

8.4

6.8

39.8

16.7

54 130

26.0

1 193 002 Total non-EU/EEA

a  Country/territory/area specific comments are in Annex 5.
b  Cumulative total is the total number of cases reported by the country since the start of reporting.
c  The numbers displayed here may not fully align with the numbers in the country’s national statistics as these are presented by the “date of notification” instead of 

the “date of diagnosis” as here. 

[1]  All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999). 

34

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. HIV diagnoses in males and rates per 100 000 male population, by country and year of diagnosis (2014–2023) 

and cumulative totals, in EU/EEA and other countries of the WHO European Region

Area

Country, territory or areaa

2014

N

2015

N

2016

N

2017

N

2018

N

2019
N

220
685
217
98
69
192
146
113
111
3 277
2 438
523
208
23
397
2 004
187
0
110
80
55
770
112
1 322
1 006
583
93
36
3 407
288
18 770

74
–
313
473
1 354
30
508
270
2 412
491
–
24
64
544
49 177
0
210
206
4
331
771
2 748
–
9 904
3 156
–
72 854

19 299
5 968
66 357
91 624

EU/EEA

West

West

Austria

Belgium

Centre Bulgaria

Centre Croatia

Centre Cyprus

Centre Czechia

Centre Hungary

West

East

West

West

West

West

West

West

West

East

West

East

West

West

West

West

Denmark

Estonia

Finland

France

Germany

Greece

Iceland

Ireland

Italy

Latvia

Liechtenstein

Lithuania

Luxembourgc

Malta

Netherlands

Norway

Centre

Poland

West

Portugal

Centre Romania

Centre Slovakia

Centre Slovenia

West

West

Spain

Sweden

Total EU/EEA

Non-EU/EEA

Centre Albania

Centre Bosnia and Herzegovina

Andorra

Armenia

Azerbaijan

Belarus

Georgia

Israel

Kazakhstan

Kyrgyzstan

Monaco

West

East

East

East

East

West

East

East

West

East

East

West

Centre

Centre

West

East

East

East

West

East

West

Centre

East

Centre Montenegro

Centre North Macedonia

Republic of Moldova

Russian Federation

San Marino

Centre Serbia

Kosovo[1]

Switzerland

Tajikistan

Centre

Türkiye

Turkmenistan

Ukraine

United Kingdom

Uzbekistan

Total non-EU/EEA

WHO European Region

Total WHO European Region

Serbia excluding Kosovo[1]

Rate

6.0

14.4

5.8

4.1

11.7

4.0

7.0

29.6

5.1

11.9

7.2

12.8

4.6

5.5

11.7

10.5

26.8

5.4

6.6

39.6

16.8

10.2

7.8

5.1

23.3

6.8

2.8

4.4

16.9

5.7

9.9

4.2

13.8

16.4

7.8

23.5

1.1

23.2

8.5

15.9

12.8

5.6

5.5

0.1

28.5

82.9

18.5

2.8

3.3

0.7

9.7

13.3

3.8

43.1

15.0

–

–

37.2

11.6

4.4

58.1

23.1

291

766

194

111

72

248

205

167

131

3 561

2 886

683

196

10

373

2 809

273

0

115

121

53

850

145

1 084

1 279

675

76

41

3 691

276

21 382

67

3

205

495

14

545

291

1 395

1 442

342

1

17

24

462

62 118

2

182

180

2

423

680

1 770

7 519

4 754

–

–

82 751

23 604

4 771

75 758

104133

Rate

6.9

13.9

5.7

5.5

17.5

4.8

7.3

27.2

4.9

11.1

7.2

13.0

4.2

6.1

16.1

9.6

30.0

0.0

8.5

42.9

24.0

10.2

5.6

5.9

26.0

7.0

2.9

4.0

16.2

5.7

9.8

4.6

8.3

15.6

10.2

31.1

0.8

30.7

7.3

16.9

11.8

5.5

5.5

2.3

29.6

92.6

12.2

4.0

5.0

0.2

10.3

15.9

4.4

32.7

14.8

–

–

39.6

11.3

4.9

61.8

24.3

259

713

169

104

65

262

191

139

121

3 587

2 667

537

171

22

390

2 865

236

2

165

128

51

796

157

1 149

1 241

600

81

59

3 738

269

20 934

1 490

1 684

434

104

3

212

355

22

552

257

0

32

28

471

2

171

160

11

425

621

53 689

2 065

8 366

4 118

–

–

75 101

22 537

5 082

68 414

96 033

Rate

6.1

12.8

5.0

5.2

15.8

5.1

6.7

22.5

4.5

11.1

6.6

10.3

3.6

13.2

16.7

9.8

26.1

10.7

12.3

44.3

22.5

9.5

6.0

6.3

25.3

6.2

3.1

5.8

16.4

5.5

9.5

7.2

8.2

16.3

7.2

33.2

1.3

31.1

6.3

19.5

14.7

0.0

10.4

2.7

30.7

79.8

12.2

3.8

4.5

1.2

10.2

14.2

5.1

–

42.4

12.7

–

36.2

10.7

5.2

57.1

22.5

3 510

2 512

272

647

218

101

65

230

192

146

101

535

149

21

371

247

2

220

107

35

840

155

2 748

1 260

1 159

629

66

40

3 680

273

20 531

69

3

253

359

1 540

15

492

298

1 818

490

3

24

44

468

53 209

1

179

176

3

357

735

2 389

9 296

3 556

–

–

75 598

21 376

5 478

69 273

96 127

Rate

6.3

11.6

6.6

5.2

15.6

4.4

6.7

23.6

3.7

10.9

6.2

10.2

3.2

12.3

15.7

9.4

27.6

10.7

16.5

36.1

15.1

9.9

5.9

6.9

23.7

6.6

2.5

3.9

16.1

5.4

9.3

4.8

8.0

19.5

7.2

34.3

0.9

27.7

7.2

20.7

16.3

16.5

7.8

4.2

30.9

78.8

6.0

4.0

4.9

0.3

8.5

16.4

5.8

47.3

10.9

–

–

36.2

10.1

5.6

57.6

22.4

190

659

276

88

65

186

170

131

104

581

195

24

411

0

117

84

62

782

122

3 266

2 242

2 382

227

1 051

1 045

584

94

40

3 482

306

18 966

76

8

293

437

22

506

299

1 499

2 004

535

52 720

0

21

45

537

2

181

174

7

341

874

2 717

9 512

3 497

–

–

76 126

20 059

5 641

69 392

95 092

248

789

201

83

49

209

196

182

138

3 829

2 865

681

216

9

269

3 060

246

1

90

109

36

848

199

934

1 156

660

75

45

3 870

273

21 566

61

5

217

375

1 052

20

413

330

1 334

365

17

1

1

452

55 469

3

127

121

6

392

557

1 497

8 991

4 769

–

–

76 448

24 075

4 195

69 743

98 013

Rate

4.4

11.7

8.5

4.6

15.4

3.6

5.9

21.1

3.8

10.1

5.5

11.2

4.2

13.5

17.2

8.2

25.5

0.0

8.9

27.8

25.8

9.2

4.6

5.7

21.5

6.1

3.5

3.9

15.2

6.0

8.6

5.3

21.0

22.8

8.7

33.5

1.3

28.5

7.1

22.5

17.5

0.0

6.8

4.3

35.9

78.0

12.0

4.1

4.9

0.8

8.1

19.0

6.5

48.6

10.7

–

–

36.3

9.5

5.8

57.5

22.1

2020
N

145
531
168
66
87
203
133
88
99
2 406
1 899
505
166
28
343
1 164
162
1
97
48
67
562
91
805
792
404
90
30
2 562
226
13 968

70
–
251
386
899
14
403
263
2 293
383
–
14
29
398
36 659
0
125
124
1
230
644
1 763
–
9 810
2 452
–
57 086

14 546
4 034
52 473
71 053

Rate

3.3
9.3
5.3
3.5
20.0
3.9
4.6
14.0
3.6
7.4
4.6
9.7
3.5
15.0
14.0
4.0
18.4
5.2
7.5
15.2
25.2
6.5
3.4
4.4
16.3
4.3
3.4
2.9
11.0
4.3
6.3

4.9
–
19.8
7.6
20.2
0.9
22.7
6.0
25.1
12.1
–
4.6
2.8
27.2
54.2
0.0
2.8
3.5
0.1
5.4
13.4
4.2
–
43.8
7.4
–
26.7

6.8
4.1
42.3
16.3

2021
N

167
586
205
71
115
201
115
80
119
2 446
1 783
480
182
14
307
1 524
136
1
93
71
41
578
64
1 203
857
503
100
32
2 683
232
14 989

73
–
297
472
926
35
403
289
2 346
513
–
12
41
455
33 543
0
181
173
8
244
574
2 445
–
9 796
2 462
–
55 107

15 062
5 399
49 634
70 095

Rate

3.8
10.3
6.5
3.8
26.3
3.9
4.0
12.7
4.4
7.5
4.3
9.2
3.9
7.4
12.4
5.3
15.5
5.2
7.2
22.2
15.4
6.7
2.4
6.7
17.6
5.4
3.8
3.0
11.6
4.4
6.8

5.1
–
23.6
9.3
21.0
2.2
22.8
6.5
25.4
16.0
–
3.9
3.9
31.3
49.8
0.0
4.1
4.9
0.9
5.7
11.7
5.8
–
51.0
7.4
–
26.1

7.1
5.5
41.1
16.2

2022
N

161
687
215
90
154
435
149
130
170
2 738
2 251
467
179
30
577
1 689
154
1
152
47
55
714
136
1 751
738
554
122
45
2 821
265
17 677

71
–
390
524
1 028
50
454
310
2 689
658
–
34
35
537
33 396
1
159
158
1
251
666
3 181
–
8 078
2 751
–
55 263

17 008
7 075
48 856
72 939

Rate

3.6
12.0
6.9
4.8
34.9
8.4
5.1
20.5
6.2
8.3
5.5
9.1
3.9
15.5
23.0
5.9
17.7
5.1
11.6
14.5
20.4
8.2
5.0
9.8
15.0
6.0
4.6
4.3
12.1
5.0
8.0

5.0
–
31.2
10.3
23.4
3.1
25.8
6.9
28.8
20.2
–
11.1
3.4
34.5
49.7
6.1
3.7
4.6
0.1
5.8
13.3
7.4
–
42.5
8.2
–
26.1

7.9
7.3
40.5
16.9

Rate

5.0
12.1
6.8
5.1
16.1
3.7
5.1
18.1
4.1
10.1
6.0
10.0
4.4
12.6
16.3
6.9
21.1
0.0
8.5
25.9
21.8
9.0
4.2
7.2
20.7
6.1
3.5
3.5
14.8
5.6
8.5

5.1
–
24.6
9.4
30.3
1.8
28.6
6.3
26.8
15.8
–
7.8
6.1
36.8
72.6
0.0
4.7
5.8
0.5
7.8
16.4
6.6
–
50.9
9.6
–
34.6

9.1
6.1
54.9
21.3

2023
N

Cumulative 
totalb

Rate

Country, territory or areaa

157
757
206
83
122
270
154
109
166
3 107
2 325
522
178
33
590
1 786
131
1
178
43
108
654
205
1 612
660
551
107
41
2 741
196
17 793

95
–
346
651
889
–
472
280
2 771
651
–
40
46
561
32 187
–
179
159
20
245
693
2 997
–
7 562
3 465
–
54 130

18 194
6 527
47 201
71 922

3.5
13.1
6.6
4.5
27.2
5.1
5.2
16.8
6.0
9.4
5.6
10.3
3.8
16.5
22.7
6.2
15.0
5.1
13.3
12.9
37.9
7.4
7.4
9.1
13.1
5.9
4.0
3.9
11.6
3.7
8.0

6.7
–
27.7
12.7
20.3
–
26.9
6.1
29.3
19.7
–
13.1
4.4
34.2
48.0
–
4.2
4.6
2.3
5.6
13.6
7.0
–
45.1
10.3
–
26.0

8.4
6.8
39.8
16.7

EU/EEA
8 679 Austria
24 518 Belgium
3 463 Bulgaria
1 852 Croatia
1 459 Cyprus
4 200 Czechia
6 427 Denmark
7 149 Estonia
3 596 Finland
71 379 France
64 792 Germany
15 264 Greece
3 832 Hungary
433 Iceland
7 694 Ireland

44 328 Italy

6 013 Latvia

47 Liechtenstein

3 149 Lithuania
2 663 Luxembourgc

723 Malta

25 139 Netherlands
5 004 Norway
25 743 Poland
49 506 Portugal
17 517 Romania
1 365 Slovakia
961 Slovenia

59 541 Spain
9 951 Sweden
476 387 Total EU/EEA

1 257 Albania
78 Andorra
3 909 Armenia
7 874 Azerbaijan
21 348 Belarus

384 Bosnia and Herzegovina

7 780 Georgia
8 098 Israel
35 561 Kazakhstan
8 396 Kyrgyzstan
26 Monaco
365 Montenegro
399 North Macedonia
9 868 Republic of Moldova
665 379 Russian Federation
74 San Marino

4 131 Serbia
4 007
124

Serbia excluding Kosovo[1]
Kosovo[1]
24 658 Switzerland
10 270 Tajikistan
28 484 Türkiye

1

Turkmenistan

210 398 Ukraine
127 961 United Kingdom
16 234 Uzbekistan

1 193 002 Total non-EU/EEA

560 532 West

95 412 Centre

1 013 398 East
1 669 342 Total WHO European Region

a  Country/territory/area specific comments are in Annex 5.

b  Cumulative total is the total number of cases reported by the country since the start of reporting.

c  The numbers displayed here may not fully align with the numbers in the country’s national statistics as these are presented by the “date of notification” instead of 

the “date of diagnosis” as here. 

[1]  All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999). 

[1]  All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

35

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. HIV diagnoses in females and rates per 100 000 female population, by country and year of diagnosis  
(2014–2023) and cumulative totals, in EU/EEA and other countries of the WHO European Region

Area

Country, territory or areaa

2014
N

EU/EEA
Austria
West
West
Belgium
Centre Bulgaria
Centre Croatia
Centre Cyprus
Centre Czechia
Denmark
West
Estonia
East
Finland
West
France
West
Germany
West
West
Greece
Centre Hungary
Iceland
West
Ireland
West
Italy
West
Latvia
East
West 
Liechtenstein
Lithuania
East
Luxembourgc
West
Malta
West
Netherlands
West
Norway
West
Poland
Centre
West
Portugal
Centre Romania
Centre Slovakia
Centre Slovenia
West
West

Spain
Sweden
Total EU/EEA

Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco

Non-EU/EEA
Centre Albania
Andorra
West
Armenia
East
Azerbaijan
East
East
Belarus
Centre Bosnia and Herzegovina
East
West
East
East
West
Centre Montenegro
Centre North Macedonia
East
East
West
Centre Serbia
Centre
Centre
West
East
Centre
East
East
West
East

Serbia excluding Kosovo[1]
Kosovo[1]
Switzerland
Tajikistan
Türkiye
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Total non-EU/EEA

Republic of Moldova
Russian Federation
San Marino

WHO European Region
West
Centre
East
Total WHO European Region

73
334
46
9
7
23
60
109
43
1 846
660
101
20
2
101
793
112
0
51
57
4
162
68
189
453
277
11
4
665
198
6 478

18
0
117
229
759
3
151
130
1 007
282
0
3
0
379
37 144
0
17
17

128
429
341
–
6 683
1 614
–
49 434

7 492
968
47 452
55 912

2015
N

Rate

2016
N

Rate

2017
N

Rate

2018
N

Rate

2019

N

Rate

2020

N

Rate

2021

N

Rate

2022

N

2023

N

Cumulative 

totalb

Rate

Country, territory or areaa

47
338
33
6
8
18
72
103
43
1 719
755
93
26
2
113
814
135
0
42
38
8
173
76
175
442
246
10
7
617
171
6 330

29
0
89
232
910
1
172
121
1 033
277
0
2
1
356
38 102
0
6
5
1
121
469
337
–
5 481
1 458
–
49 197

7 221
905
47 401
55 527

1.1
5.9
0.9
0.3
1.8
0.3
2.5
14.7
1.5
5.0
1.8
1.7
0.5
1.2
4.8
2.6
12.6
0.0
2.6
13.5
3.6
2.0
3.0
0.9
8.1
2.4
0.4
0.7
2.6
3.5
2.8

2.0
0.0
5.7
4.6
17.4
0.1
8.6
3.0
11.1
9.2
0.0
0.6
0.1
20.7
49.1
0.0
0.1
0.1
0.1
2.9
11.0
0.8
–
27.7
4.4
–
22.4

3.3
0.9
35.7
12.3

53
292
33
4
15
24
53
90
59
1 813
720
112
21
6
112
861
138
0
49
40
11
143
63
141
455
215
7
4
661
160
6 355

23
0
91
201
901
2
166
110
1 214
314
0
2
1
361
33 166
0
16
16

113
417
372
–
5 863
1 273
–
44 606

7 110
880
42 971
50 961

1.2
5.1
0.9
0.2
3.4
0.4
1.8
12.9
2.1
5.3
1.7
2.0
0.4
3.6
4.7
2.8
13.0
0.0
3.1
13.9
4.9
1.7
2.4
0.7
8.4
2.1
0.3
0.4
2.8
3.3
2.8

1.6
0.0
5.8
4.0
17.3
0.1
8.3
2.7
12.9
10.2
0.0
0.6
0.1
21.3
42.6
0.0
0.3
0.4
0.0
2.7
9.6
0.9
–
25.6
3.8
–
20.0

3.3
0.9
31.5
11.2

56
311
23
5
20
24
50
73
57
1 814
652
109
18
3
115
871
134
0
43
34
10
144
58
162
433
215
6
2
639
161
6 242

25
3
105
208
928
0
139
119
1 191
346
0
1
0
367
32 593
0
11
11

102
470
455
–
6 307
1 227
–
44 597

6 968
967
42 904
50 839

1.3
5.4
0.7
0.2
4.6
0.4
1.7
10.5
2.0
5.3
1.6
2.0
0.4
1.8
4.8
2.8
12.7
0.0
2.7
11.6
4.4
1.7
2.2
0.8
8.0
2.1
0.2
0.2
2.7
3.2
2.7

1.7
8.2
6.7
4.1
17.8
0.0
7.0
2.9
12.5
11.1
0.0
0.3
0.0
22.0
41.8
0.0
0.2
0.3
0.0
2.4
10.6
1.1
–
27.7
3.7
–
20.1

3.2
1.0
31.4
11.2

39
294
35
6
13
22
49
59
49
1 767
638
142
8
14
106
656
107
0
43
32
11
155
69
153
394
194
8
2
581
175
5 821

26
4
136
219
887
2
166
154
1 209
331
0
2
0
368
33 275
1
14
13
1
97
547
531
–
6 136
1 210
–
45 315

6 637
1 016
43 483
51 136

0.9
5.1
1.0
0.3
2.9
0.4
1.7
8.5
1.8
5.1
1.5
2.6
0.2
8.2
4.3
2.1
10.2
0.0
2.8
10.7
4.7
1.8
2.6
0.8
7.3
1.9
0.3
0.2
2.4
3.5
2.5

1.8
10.8
8.8
4.3
17.0
0.1
8.3
3.6
12.5
10.4
0.0
0.6
0.0
22.3
42.6
5.7
0.3
0.3
0.1
2.3
12.1
1.3
–
27.1
3.6
–
20.1

3.0
1.0
31.8
11.2

1 136

459

1 395

1 006

1 744

5 848

4 252

6 688

169 174 Total EU/EEA

1 780

40

303

41

5

31

30

44

65

37

683

150

16

5

133

506

119

0

41

27

15

181

60

228

403

201

11

6

526

161

27

–

135

248

783

3

160

140

1 254

352

–

2

2

378

30 947

0

19

18

1

90

549

481

–

6 332

1 113

–

43 015

6 397

1 103

41 363

48 863

11.5

0.9

5.2

1.2

0.2

6.9

0.6

1.5

9.3

1.3

5.1

1.6

2.7

0.3

2.9

5.4

1.6

0.0

2.7

8.8

6.2

2.1

2.3

1.2

7.4

2.0

0.4

0.6

2.2

3.2

2.5

1.9

–

8.7

4.8

15.0

0.2

8.0

3.2

12.9

10.9

–

0.6

0.2

23.2

39.7

0.0

0.4

0.5

0.1

2.1

11.8

1.2

–

28.1

3.3

–

18.9

2.9

1.1

30.2

10.7

1 093

560

124

31

226

31

9

19

48

28

59

35

306

15

6

86

95

0

42

15

15

124

46

153

279

125

11

5

415

134

4 135

26

–

118

173

528

3

127

112

1 173

291

–

1

0

0

9

8

1

282

22 939

60

440

313

–

5 668

872

–

33 135

4 567

768

31 935

37 270

0.7

3.9

0.9

0.4

4.2

0.9

1.0

8.4

1.3

3.1

1.3

2.3

0.3

3.4

3.4

1.0

9.3

0.0

2.8

4.8

6.0

1.4

1.7

0.8

5.1

1.3

0.4

0.5

1.7

2.6

1.8

1.8

–

7.7

3.3

10.2

0.2

6.4

2.5

11.9

8.9

–

0.3

0.0

17.4

29.4

0.0

0.2

0.2

0.1

1.4

9.3

0.7

–

29.3

2.6

–

14.8

2.1

0.8

23.8

8.2

33

196

32

6

34

32

24

45

43

390

111

19

5

82

76

0

28

23

4

112

38

238

341

149

14

6

457

119

31

–

128

218

570

2

127

120

1 243

328

337

24 797

–

1

2

0

7

6

1

78

348

475

–

5 537

991

–

35 340

4 762

1 048

33 782

39 592

0.7

3.3

0.9

0.3

7.4

0.6

0.8

6.4

1.5

3.3

1.1

2.0

0.4

2.8

3.2

1.3

7.5

0.0

1.9

7.3

1.6

1.3

1.4

1.2

6.3

1.5

0.5

0.6

1.9

2.3

1.8

2.2

–

8.3

4.2

11.0

0.1

6.4

2.7

12.5

9.9

–

0.3

0.2

21.0

31.9

0.0

0.1

0.2

0.1

1.8

7.2

1.1

–

24.9

2.9

–

15.5

2.2

1.0

24.7

8.6

36

333

113

23

64

435

109

120

101

128

26

10

296

451

75

0

100

29

5

256

109

834

250

142

78

11

479

181

7 195

27

–

145

242

616

4

163

167

1 317

433

392

22 177

–

6

4

0

13

13

0

104

371

643

–

4 105

1 610

–

32 539

7 055

2 423

30 256

39 734

Rate

0.8

5.7

3.4

1.1

13.8

8.2

3.7

17.2

11.6

3.6

4.0

2.4

2.4

0.5

5.5

1.5

7.5

0.0

6.7

9.1

2.0

2.9

4.1

4.4

4.6

1.4

2.8

1.0

2.0

3.5

3.1

1.9

–

9.5

4.6

12.0

0.2

8.2

3.7

13.1

12.8

–

1.9

0.4

22.9

28.6

0.0

0.3

0.3

0.0

2.4

7.5

1.5

–

18.7

4.7

–

14.3

3.2

2.4

22.1

8.7

37

339

47

14

39

132

73

74

116

982

153

38

11

313

563

57

0

89

17

5

150

127

564

261

152

35

3

445

108

28

–

154

268

574

–

140

136

–

13

4

–

18

18

0

1 269

403

367

22 502

101

407

592

–

4 096

2 921

–

33 993

8 602

1 679

30 400

40 681

EU/EEA

2 598 Austria

13 171 Belgium

870 Bulgaria

244 Croatia

501 Cyprus

1 146 Czechia

2 357 Denmark

3 623 Estonia

1 465

Finland

38 347 France

17 096 Germany

3 129 Greece

484 Hungary

155

Iceland

3 561

Ireland

13 616 Italy

2 901

Latvia

23 Liechtenstein

953 Lithuania

962 Luxembourgc

151 Malta

6 061 Netherlands

2 466 Norway

6 481 Poland

19 081 Portugal

10 491 Romania

269 Slovakia

131 Slovenia

11 841 Spain

5 000 Sweden

Non-EU/EEA

468 Albania

18 Andorra

1 705 Armenia

3 181 Azerbaijan

13 756 Belarus

2 611 Georgia

3 970 Israel

18 948 Kazakhstan

4 886 Kyrgyzstan

14 Monaco

58 Montenegro

53 Bosnia and Herzegovina

27 North Macedonia

7 140 Republic of Moldova

444 079 Russian Federation

20 San Marino

815 Serbia

781

34

Kosovo[1]

Serbia excluding Kosovo[1]

10 866 Switzerland

5 859 Tajikistan

6 389 Türkiye

1

Turkmenistan

136 589 Ukraine

54 942 United Kingdom

7 783 Uzbekistan

724 252 Total non-EU/EEA

WHO European Region

210 887 West

28 427 Centre

654 089 East

893 403 Total WHO European Region

0.8

5.7

1.4

0.7

8.3

2.4

2.4

10.3

4.1

5.0

2.3

2.9

0.8

5.9

11.7

1.9

5.6

0.0

5.8

5.2

1.9

1.7

4.7

3.0

4.7

1.6

1.3

0.3

1.8

2.1

2.9

2.0

–

10.1

5.1

11.2

–

7.1

3.0

12.5

11.8

–

4.0

0.4

20.4

29.1

–

0.4

0.5

0.0

2.3

8.1

1.4

–

20.5

8.5

–

15.2

3.8

1.7

22.5

8.9

Rate

1.7
5.9
1.3
0.4
1.6
0.4
2.1
15.6
1.6
5.4
1.6
1.8
0.4
1.2
4.3
2.5
10.3
0.0
3.2
20.8
1.9
1.9
2.7
1.0
8.3
2.7
0.4
0.4
2.8
4.1
2.8

1.3
0.0
7.5
4.6
14.6
0.2
7.6
3.3
11.0
9.5
0.0
0.9
0.0
21.6
48.0
0.0
0.4
0.4
0.0
3.1
10.3
0.9
–
27.5
4.9
–
22.4

3.5
1.0
34.7
12.4

a  Country/territory/area specific comments are in Annex 5.
b  Cumulative total is the total number of cases reported by the country since the start of reporting.
c  The numbers displayed here may not fully align with the numbers in the country’s national statistics as these are presented by the “date of notification” instead of 

the “date of diagnosis” as here. 

[1]  All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

36

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 dataTable 3. HIV diagnoses in females and rates per 100 000 female population, by country and year of diagnosis  

(2014–2023) and cumulative totals, in EU/EEA and other countries of the WHO European Region

Area

Country, territory or areaa

2014

N

2015

N

Rate

2016

N

Rate

2017

N

Rate

2018

N

Rate

2019
N

Rate

2020
N

Rate

2021
N

Rate

2022
N

Rate

2023
N

Cumulative 
totalb

Rate

Country, territory or areaa

40
303
41
5
31
30
44
65
37
1 780
683
150
16
5
133
506
119
0
41
27
15
181
60
228
403
201
11
6
526
161
5 848

27
–
135
248
783
3
160
140
1 254
352
–
2
2
378
30 947
0
19
18
1
90
549
481
–
6 332
1 113
–
43 015

6 397
1 103
41 363
48 863

0.9
5.2
1.2
0.2
6.9
0.6
1.5
9.3
1.3
5.1
1.6
2.7
0.3
2.9
5.4
1.6
11.5
0.0
2.7
8.8
6.2
2.1
2.3
1.2
7.4
2.0
0.4
0.6
2.2
3.2
2.5

1.9
–
8.7
4.8
15.0
0.2
8.0
3.2
12.9
10.9
–
0.6
0.2
23.2
39.7
0.0
0.4
0.5
0.1
2.1
11.8
1.2
–
28.1
3.3
–
18.9

2.9
1.1
30.2
10.7

31
226
31
9
19
48
28
59
35
1 093
560
124
15
6
86
306
95
0
42
15
15
124
46
153
279
125
11
5
415
134
4 135

26
–
118
173
528
3
127
112
1 173
291
–
1
0
282
22 939
0
9
8
1
60
440
313
–
5 668
872
–
33 135

4 567
768
31 935
37 270

0.7
3.9
0.9
0.4
4.2
0.9
1.0
8.4
1.3
3.1
1.3
2.3
0.3
3.4
3.4
1.0
9.3
0.0
2.8
4.8
6.0
1.4
1.7
0.8
5.1
1.3
0.4
0.5
1.7
2.6
1.8

1.8
–
7.7
3.3
10.2
0.2
6.4
2.5
11.9
8.9
–
0.3
0.0
17.4
29.4
0.0
0.2
0.2
0.1
1.4
9.3
0.7
–
29.3
2.6
–
14.8

2.1
0.8
23.8
8.2

33
196
32
6
34
32
24
45
43
1 136
459
111
19
5
82
390
76
0
28
23
4
112
38
238
341
149
14
6
457
119
4 252

31
–
128
218
570
2
127
120
1 243
328
–
1
2
337
24 797
0
7
6
1
78
348
475
–
5 537
991
–
35 340

4 762
1 048
33 782
39 592

0.7
3.3
0.9
0.3
7.4
0.6
0.8
6.4
1.5
3.3
1.1
2.0
0.4
2.8
3.2
1.3
7.5
0.0
1.9
7.3
1.6
1.3
1.4
1.2
6.3
1.5
0.5
0.6
1.9
2.3
1.8

2.2
–
8.3
4.2
11.0
0.1
6.4
2.7
12.5
9.9
–
0.3
0.2
21.0
31.9
0.0
0.1
0.2
0.1
1.8
7.2
1.1
–
24.9
2.9
–
15.5

2.2
1.0
24.7
8.6

36
333
113
23
64
435
109
120
101
1 395
1 006
128
26
10
296
451
75
0
100
29
5
256
109
834
250
142
78
11
479
181
7 195

27
–
145
242
616
4
163
167
1 317
433
–
6
4
392
22 177
0
13
13
0
104
371
643
–
4 105
1 610
–
32 539

7 055
2 423
30 256
39 734

0.8
5.7
3.4
1.1
13.8
8.2
3.7
17.2
3.6
4.0
2.4
2.4
0.5
5.5
11.6
1.5
7.5
0.0
6.7
9.1
2.0
2.9
4.1
4.4
4.6
1.4
2.8
1.0
2.0
3.5
3.1

1.9
–
9.5
4.6
12.0
0.2
8.2
3.7
13.1
12.8
–
1.9
0.4
22.9
28.6
0.0
0.3
0.3
0.0
2.4
7.5
1.5
–
18.7
4.7
–
14.3

3.2
2.4
22.1
8.7

37
339
47
14
39
132
73
74
116
1 744
982
153
38
11
313
563
57
0
89
17
5
150
127
564
261
152
35
3
445
108
6 688

28
–
154
268
574
–
140
136
1 269
403
–
13
4
367
22 502
–
18
18
0
101
407
592
–
4 096
2 921
–
33 993

8 602
1 679
30 400
40 681

0.8
5.7
1.4
0.7
8.3
2.4
2.4
10.3
4.1
5.0
2.3
2.9
0.8
5.9
11.7
1.9
5.6
0.0
5.8
5.2
1.9
1.7
4.7
3.0
4.7
1.6
1.3
0.3
1.8
2.1
2.9

2.0
–
10.1
5.1
11.2
–
7.1
3.0
12.5
11.8
–
4.0
0.4
20.4
29.1
–
0.4
0.5
0.0
2.3
8.1
1.4
–
20.5
8.5
–
15.2

3.8
1.7
22.5
8.9

EU/EEA
2 598 Austria
13 171 Belgium
870 Bulgaria
244 Croatia
501 Cyprus
1 146 Czechia
2 357 Denmark
3 623 Estonia
Finland
1 465
38 347 France
17 096 Germany
3 129 Greece
484 Hungary
Iceland
155
Ireland
3 561
13 616 Italy
2 901

Latvia
23 Liechtenstein
953 Lithuania
962 Luxembourgc
151 Malta

6 061 Netherlands
2 466 Norway
6 481 Poland
19 081 Portugal
10 491 Romania
269 Slovakia
131 Slovenia

11 841 Spain
5 000 Sweden

169 174 Total EU/EEA
Non-EU/EEA

468 Albania
18 Andorra
1 705 Armenia
3 181 Azerbaijan

13 756 Belarus

53 Bosnia and Herzegovina

2 611 Georgia
3 970 Israel
18 948 Kazakhstan
4 886 Kyrgyzstan
14 Monaco
58 Montenegro
27 North Macedonia
7 140 Republic of Moldova
444 079 Russian Federation
20 San Marino
815 Serbia
781
34

Serbia excluding Kosovo[1]
Kosovo[1]
10 866 Switzerland
5 859 Tajikistan
6 389 Türkiye

1

Turkmenistan

136 589 Ukraine
54 942 United Kingdom
7 783 Uzbekistan

724 252 Total non-EU/EEA

WHO European Region

210 887 West
28 427 Centre

654 089 East
893 403 Total WHO European Region

[1]  All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

37

EU/EEA

West

West

Austria

Belgium

Centre Bulgaria

Centre Croatia

Centre Cyprus

Centre Czechia

Denmark

Estonia

Finland

France

Germany

Greece

Iceland

Ireland

Italy

Latvia

Centre Hungary

West

East

West

West

West

West

West

West

West

East

East

West

West

West

West

West 

Liechtenstein

Lithuania

Luxembourgc

Malta

Netherlands

Norway

Centre

Poland

West

Portugal

Centre Romania

Centre Slovakia

Centre Slovenia

West

West

Spain

Sweden

Total EU/EEA

Non-EU/EEA

Centre Albania

Andorra

Armenia

Azerbaijan

Belarus

Georgia

Israel

Kazakhstan

Kyrgyzstan

Monaco

Centre Bosnia and Herzegovina

West

East

East

East

East

West

East

East

West

East

East

West

Centre

Centre

West

East

East

East

West

East

West

Centre

East

Centre Montenegro

Centre North Macedonia

Republic of Moldova

Russian Federation

San Marino

Centre Serbia

Serbia excluding Kosovo[1]

Kosovo[1]

Switzerland

Tajikistan

Centre

Türkiye

Turkmenistan

Ukraine

United Kingdom

Uzbekistan

Total non-EU/EEA

WHO European Region

Total WHO European Region

6 478

6 330

6 355

6 242

5 821

Rate

15.6

1.7

5.9

1.3

0.4

1.6

0.4

2.1

1.6

5.4

1.6

1.8

0.4

1.2

4.3

2.5

10.3

0.0

3.2

20.8

1.9

1.9

2.7

1.0

8.3

2.7

0.4

0.4

2.8

4.1

2.8

1.3

0.0

7.5

4.6

14.6

0.2

7.6

3.3

11.0

9.5

0.0

0.9

0.0

21.6

48.0

0.0

0.4

0.4

0.0

3.1

10.3

0.9

27.5

4.9

–

–

22.4

3.5

1.0

34.7

12.4

47

338

33

6

8

18

72

103

43

1 719

755

93

26

2

113

814

135

0

42

38

8

173

76

175

442

246

10

7

617

171

29

0

89

232

910

1

172

121

1 033

277

356

38 102

0

2

1

0

6

5

1

121

469

337

–

5 481

1 458

–

49 197

7 221

905

47 401

55 527

1 846

660

73

334

46

9

7

23

60

109

43

101

20

2

101

793

112

0

51

57

4

162

68

189

453

277

11

4

665

198

18

0

117

229

759

3

151

130

0

3

0

0

17

17

1 007

282

379

37 144

128

429

341

–

6 683

1 614

–

49 434

7 492

968

47 452

55 912

1 813

1 814

14.7

1.1

5.9

0.9

0.3

1.8

0.3

2.5

1.5

5.0

1.8

1.7

0.5

1.2

4.8

2.6

12.6

0.0

2.6

13.5

3.6

2.0

3.0

0.9

8.1

2.4

0.4

0.7

2.6

3.5

2.8

2.0

0.0

5.7

4.6

17.4

0.1

8.6

3.0

11.1

9.2

0.0

0.6

0.1

20.7

49.1

0.0

0.1

0.1

0.1

2.9

11.0

0.8

–

27.7

4.4

–

3.3

0.9

35.7

12.3

53

292

33

4

15

24

53

90

59

720

112

21

6

112

861

138

0

49

40

11

143

63

141

455

215

7

4

661

160

23

0

91

201

901

2

166

110

0

2

1

0

16

16

1 214

314

361

33 166

113

417

372

–

5 863

1 273

–

7 110

880

42 971

50 961

22.4

44 606

12.9

1.2

5.1

0.9

0.2

3.4

0.4

1.8

2.1

5.3

1.7

2.0

0.4

3.6

4.7

2.8

13.0

0.0

3.1

13.9

4.9

1.7

2.4

0.7

8.4

2.1

0.3

0.4

2.8

3.3

2.8

1.6

0.0

5.8

4.0

17.3

0.1

8.3

2.7

12.9

10.2

0.0

0.6

0.1

21.3

42.6

0.0

0.3

0.4

0.0

2.7

9.6

0.9

–

25.6

3.8

–

20.0

3.3

0.9

31.5

11.2

56

311

23

5

20

24

50

73

57

652

109

18

3

115

871

134

0

43

34

10

144

58

162

433

215

6

2

639

161

25

3

105

208

928

0

139

119

1 191

346

0

1

0

0

11

11

367

32 593

102

470

455

–

6 307

1 227

–

44 597

6 968

967

42 904

50 839

10.5

1.3

5.4

0.7

0.2

4.6

0.4

1.7

2.0

5.3

1.6

2.0

0.4

1.8

4.8

2.8

12.7

0.0

2.7

11.6

4.4

1.7

2.2

0.8

8.0

2.1

0.2

0.2

2.7

3.2

2.7

1.7

8.2

6.7

4.1

17.8

0.0

7.0

2.9

12.5

11.1

0.0

0.3

0.0

22.0

41.8

0.0

0.2

0.3

0.0

2.4

10.6

1.1

–

27.7

3.7

–

20.1

3.2

1.0

31.4

11.2

39

294

35

6

13

22

49

59

49

1 767

638

142

8

14

106

656

107

0

43

32

11

155

69

153

394

194

8

2

581

175

26

4

136

219

887

2

166

154

1 209

331

0

2

0

368

33 275

1

14

13

1

97

547

531

–

6 136

1 210

–

45 315

6 637

1 016

43 483

51 136

0.9

5.1

1.0

0.3

2.9

0.4

1.7

8.5

1.8

5.1

1.5

2.6

0.2

8.2

4.3

2.1

10.2

0.0

2.8

10.7

4.7

1.8

2.6

0.8

7.3

1.9

0.3

0.2

2.4

3.5

2.5

1.8

10.8

8.8

4.3

17.0

0.1

8.3

3.6

12.5

10.4

0.0

0.6

0.0

22.3

42.6

5.7

0.3

0.3

0.1

2.3

12.1

1.3

–

27.1

3.6

–

20.1

3.0

1.0

31.8

11.2

a  Country/territory/area specific comments are in Annex 5.

b  Cumulative total is the total number of cases reported by the country since the start of reporting.

c  The numbers displayed here may not fully align with the numbers in the country’s national statistics as these are presented by the “date of notification” instead of 

the “date of diagnosis” as here. 

[1]  All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORTTable 4. HIV diagnoses in males who acquired HIV through sex with men, by country and year of diagnosis  
(2014–2023) and cumulative totals, in EU/EEA and other countries of the WHO European Region

Area

Country, territory or areaa

2014

2015

2016

2017

Year of diagnosis
2019

2018

2020

2021

2022

2023

Cumulative 
totalb

EU/EEA
Austria
West
West
Belgium
Centre Bulgaria
Centre Croatia
Centre Cyprus
Centre Czechia
Denmark
West
Estonia
East
Finland
West
France
West
Germany
West
West
Greece
Centre Hungary
Iceland
West
Ireland
West
Italy
West
Latvia
East
Liechtenstein
West
Lithuania
East
Luxembourgc
West
Malta
West
Netherlands
West
Norway
West
Poland
Centre
West
Portugal
Centre Romania
Centre Slovakia
Centre Slovenia
West
West

Spain
Sweden
Total EU/EEA

Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco

Non-EU/EEA
Centre Albania
Andorra
West
Armenia
East
Azerbaijan
East
East
Belarus
Centre Bosnia and Herzegovina
East
West
East
East
West
Centre Montenegro
Centre North Macedonia
East
East
West
Centre Serbia
Centre
Centre
West
East
Centre
East
East
West
East

Serbia excluding Kosovo[1]
Kosovo[1]
Switzerland
Tajikistan
Türkiye
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Total non-EU/EEA

Republic of Moldova
Russian Federation
San Marino

154
456
98
79
39
171
132
3
55
1 671
1 970
417
175
0
178
1 572
29
1
12
57
25
656
115
337
562
145
53
33
2 604
119
11 918

9
4
10
12
53
16
67
151
47
18
1
13
1
9
0
0
92
87
5
223
3
281
–
277
3 250
–
4 537

174
468
111
99
51
211
126
18
53
1 477
1 895
462
134
0
251
1 457
34
0
29
54
45
634
70
358
731
142
55
34
2 457
118
11 748

13
2
12
35
58
10
161
142
82
23
1
14
21
10
0
0
138
136
2
212
3
350
–
368
3 229
–
4 884

180
431
96
95
47
213
121
9
48
1 351
1 737
324
119
8
274
1 419
24
0
29
61
38
613
87
414
694
153
60
49
2 529
136
11 359

11
3
17
17
71
18
131
130
121
37
0
25
18
18
0
0
120
117
3
235
11
403
–
435
2 678
–
4 499

WHO European Region
West
Centre
East
Total WHO European Region

14 372
1 542
540
16 454

14 058
1 741
833
16 632

13 097
1 841
920
15 858

200
372
120
97
47
182
123
16
32
1 429
1 631
320
112
4
261
1 389
24
1
21
46
23
628
88
395
647
177
52
28
2 532
128
11 125

6
2
17
42
72
12
130
150
145
45
2
22
34
29
0
0
126
126

174
13
494
–
490
2 278
–
4 283

12 459
1 904
1 044
15 407

130
378
170
82
44
137
110
11
38
1 500
1 428
306
146
15
296
1 193
20
0
19
53
38
583
73
313
585
172
60
31
2 431
158
10 520

8
4
41
45
103
14
154
134
163
47
0
16
37
32
0
0
144
142
2
163
24
540
–
506
2 163
–
4 338

143
372
122
83
41
150
99
16
37
1 490
1 461
292
168
15
268
1 121
18
0
20
42
0
556
61
351
575
191
51
26
2 401
152
10 322

29
–
50
50
82
23
97
123
206
38
–
15
48
29
0
0
183
180
3
155
11
539
–
467
1 901
–
4 046

84
273
96
57
62
145
80
8
34
1 184
1 014
285
128
19
217
654
11
0
18
24
30
419
63
205
479
150
50
20
1 710
116
7 635

22
–
35
56
79
9
106
136
223
42
–
11
26
18
1 499
0
109
108
1
100
13
297
–
386
1 256
–
4 423

104
322
111
63
80
145
60
9
37
1 156
1 000
271
144
10
185
756
11
1
21
44
20
406
36
237
481
204
49
24
1 726
119
7 832

18
–
42
64
81
16
112
146
273
89
–
6
37
19
1 391
0
147
140
7
111
19
351
–
428
1 292
–
4 642

11 779
1 914
1 165
14 858

11 264
2 020
1 084
14 368

8 177
1 387
2 494
12 058

8 282
1 632
2 559
12 473

106
358
106
70
84
181
71
11
46
1 231
1 060
271
112
19
360
879
9
0
29
22
30
465
59
219
437
202
48
32
1 802
127
8 446

33
–
60
80
88
25
110
151
325
89
–
20
25
20
1 782
0
102
102

98
28
445
–
289
1 294
–
5 064

8 886
1 704
2 920
13 510

92
406
98
64
61
141
68
8
46
1 339
1 037
255
110
23
296
906
9
1
42
21
47
453
71
272
386
210
30
29
1 748
98
8 367

38
–
56
128
69
–
110
135
353
88
–
18
30
15
1 466
–
105
94
11
103
21
282
–
289
1 480
–
4 786

4 608
11 271
1 452
1 434
877
3 051
3 651
215
1 445
29 472
38 670
9 539
2 844
218
4 502
20 807
474
6
408
1 420
349
18 165
2 444
5 202
14 875
2 445
852
704
37 259
4 858
223 517

269
38
380
582
914
201
1 398
3 288
2 114
543
18
229
307
244
6 138
21
2 196
2 152
44
6 122
148
4 588
0
4 899
80 488
29
115 158

9 010
1 488
2 654
13 152

293 528
26 651
18 490
338 669

a   Country/territory/area specific comments are in Annex 5.
b  Cumulative total is the total number of cases reported by the country since the start of reporting.
c  The numbers displayed here may not fully align with the numbers in the country’s national statistics as these are presented by the “date of notification” instead of 

the “date of diagnosis” as here. 

[1]  All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

38

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 dataTable 5. HIV diagnoses in people who acquired HIV through injecting drug use, by country and year of diagnosis 
(2014–2023) and cumulative totals, in EU/EEA and other countries of the WHO European Region

Area

Country, territory or areaa

2014

2015

2016

2017

Year of diagnosis
2019

2018

2020

2021

2022

2023

Cumulative 
totalb

EU/EEA
Austria
West
West
Belgium
Centre Bulgaria
Centre Croatia
Centre Cyprus
Centre Czechia
Denmark
West
Estonia
East
Finland
West
France
West
Germany
West
West
Greece
Centre Hungary
Iceland
West
Ireland
West
Italy
West
Latvia
East
Liechtenstein
West
Lithuania
East
Luxembourgc
West
Malta
West
Netherlands
West
Norway
West
Poland
Centre
West
Portugal
Centre Romania
Centre Slovakia
Centre Slovenia
West
West

Spain
Sweden
Total EU/EEA

Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco

Non-EU/EEA
Centre Albania
Andorra
West
Armenia
East
Azerbaijan
East
East
Belarus
Centre Bosnia and Herzegovina
East
West
East
East
West
Centre Montenegro
Centre North Macedonia
East
East
West
Centre Serbia
Centre
Centre
West
East
Centre
East
East
West
East

Serbia excluding Kosovo[1]
Kosovo[1]
Switzerland
Tajikistan
Türkiye
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Total non-EU/EEA

Republic of Moldova
Russian Federation
San Marino

WHO European Region
West
Centre
East
Total WHO European Region

30
13
48
0
3
10
11
67
7
106
133
122
1
1
27
142
81
0
39
34
0
7
7
51
65
220
1
2
159
14
1 401

1
0
42
185
376
0
194
44
779
178
0
0
0
61
0
0
5
5
–
8
227
10
–
4 670
144
–
6 924

1 074
352
6 899
8 325

34
12
29
2
1
5
8
55
7
80
149
98
2
0
51
121
94
0
46
25
0
5
8
51
67
201
3
1
129
15
1 299

0
0
37
185
790
0
187
39
826
162
0
0
0
38
0
0
4
4
–
9
249
13
–
3 449
191
–
6 179

1 048
312
6 118
7 478

18
5
22
0
2
7
9
31
6
69
138
102
3
9
20
112
63
0
88
34
1
5
8
39
52
141
1
1
148
26
1 160

0
0
35
163
600
0
204
25
900
210
0
0
0
40
0
0
1
1
–
14
202
8
–
3 689
144
–
6 235

945
225
6 225
7 395

19
12
33
0
0
5
6
15
10
75
120
95
1
3
18
103
81
0
143
16
0
10
7
30
38
102
0
0
125
20
1 087

0
0
39
102
485
0
150
34
900
205
0
1
0
42
0
0
4
4
–
20
252
14
–
3 973
140
–
6 361

871
190
6 387
7 448

16
16
34
0
1
8
6
24
6
76
153
123
1
2
14
115
76
0
55
13
0
8
6
22
38
86
1
1
122
23
1 046

0
0
33
108
391
0
96
34
920
142
0
0
0
59
0
0
2
2
–
13
199
24
–
3 730
116
–
5 867

900
180
5 833
6 913

21
11
37
1
3
9
4
20
8
90
167
89
1
2
19
102
46
0
51
4
0
12
8
22
47
76
0
2
98
21
971

0
–
38
102
363
0
115
19
1 219
106
–
0
0
39
0
0
3
3
–
11
135
10
–
4 173
112
–
6 445

845
164
6 407
7 416

15
3
15
3
3
14
1
10
4
59
173
89
1
0
11
55
41
0
32
5
0
6
8
15
35
42
0
1
64
13
718

0
–
22
88
222
0
62
24
1 061
47
–
1
0
17
15 203
0
0
0
–
4
83
14
–
5 905
84
–
22 837

653
109
22 793
23 555

18
14
14
1
5
7
10
5
10
58
123
95
0
1
8
88
27
0
30
5
0
8
4
13
32
57
1
4
55
3
696

1
–
25
97
221
0
69
12
850
37
–
0
0
29
16 702
0
3
3
–
5
76
11
–
5 312
92
–
23 542

641
117
23 480
24 238

14
37
18
3
2
60
18
5
33
88
291
70
3
1
39
97
35
0
32
13
0
37
24
33
25
50
9
3
61
12
1 113

2
–
31
71
287
0
80
30
811
26
–
2
0
35
11 416
0
3
3
–
8
82
17
–
3 812
77
–
16 790

975
205
16 723
17 903

23
36
24
2
6
24
7
4
23
88
271
84
2
1
28
79
22
0
44
5
0
20
31
31
24
57
3
3
55
15
1 012

1
–
17
68
211
–
53
15
716
25
–
13
0
37
10 133
0
3
3
–
5
43
21
–
2 913
71
–
14 345

881
190
14 286
15 357

2 199
903
702
77
35
248
599
4 239
488
2 520
5 297
2 350
38
72
1 772
3 066
3 609
5
2 056
428
10
892
715
6 499
19 632
2 029
31
34
4 073
1 354
65 972

9
11
829
3 632
10 461
19
3 330
1 396
22 256
4 048
8
22
2
3 053
53 454
11
993
991
2
2 867
3 997
241
0
146 841
6 058
11 390
274 976

56 721
10 979
273 243
340 943

a   Country/territory/area specific comments are in Annex 5.
b  Cumulative total is the total number of cases reported by the country since the start of reporting.
c  The numbers displayed here may not fully align with the numbers in the country’s national statistics as these are presented by the “date of notification” instead of 

the “date of diagnosis” as here. 

[1]  All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

39

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORTTable 6. HIV diagnoses in people who acquired HIV through heterosexual contact, by country and year of diagnosis 
(2014–2023) and cumulative totals, in EU/EEA and other countries of the WHO European Region

Area

Country, territory or areaa

2014

2015

2016

2017

Year of diagnosis
2019

2018

2020

2021

2022

2023

Cumulative 
totalb

EU/EEA
Austria
West
West
Belgium
Centre Bulgaria
Centre Croatia
Centre Cyprus
Centre Czechia
Denmark
West
Estonia
East
Finland
West
France
West
Germany
West
West
Greece
Centre Hungary
Iceland
West
Ireland
West
Italy
West
Latvia
East
Liechtenstein
West
Lithuania
East
Luxembourgc
West
Malta
West
Netherlands
West
Norway
West
Poland
Centre
West
Portugal
Centre Romania
Centre Slovakia
Centre Slovenia
West
West

Spain
Sweden
Total EU/EEA

Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco

Non-EU/EEA
Centre Albania
Andorra
West
Armenia
East
Azerbaijan
East
East
Belarus
Centre Bosnia and Herzegovina
East
West
East
East
West
Centre Montenegro
Centre North Macedonia
East
East
West
Centre Serbia
Centre
Centre
West
East
Centre
East
East
West
East

Serbia excluding Kosovo[1]
Kosovo[1]
Switzerland
Tajikistan
Türkiye
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Total non-EU/EEA

Republic of Moldova
Russian Federation
San Marino

WHO European Region
West
Centre
East
Total WHO European Region

114
422
93
12
10
45
102
162
70
2 217
818
144
28
0
127
1 668
133
0
74
64
9
262
140
110
924
442
18
4
1 135
229
9 576

62
0
272
378
1 349
7
294
207
1 391
395
0
4
0
616
0
0
35
34
1
176
628
495
–
10 648
2 382
–
19 339

11 210
1 365
16 340
28 915

110
379
86
13
26
46
126
144
79
1 798
975
128
22
0
132
1 640
156
0
65
61
15
289
138
113
865
494
23
8
1 063
211
9 205

77
0
236
447
1 416
4
357
201
1 439
385
0
3
4
578
0
0
28
28

183
751
583
–
9 043
2 105
–
17 840

10 498
1 530
15 017
27 045

89
363
84
12
27
54
100
116
83
1 666
887
147
28
9
143
1 768
144
1
70
63
21
238
120
110
895
506
18
12
1 094
202
9 070

115
0
244
344
1 671
6
372
195
1 751
428
0
9
10
547
0
0
35
30
5
169
703
646
–
10 004
1 950
–
19 199

10 202
1 672
16 394
28 268

95
374
85
8
32
59
93
89
70
1 732
794
155
23
2
168
1 658
136
0
72
64
17
242
115
105
855
544
15
11
1 149
212
8 974

87
2
290
376
1 868
2
342
188
1 869
491
1
3
8
561
0
0
31
29
2
146
807
775
–
11 024
1 728
–
20 599

9 860
1 788
17 925
29 573

66
349
104
10
32
56
91
67
55
1 975
759
179
13
15
167
1 252
112
0
67
48
14
223
101
74
761
502
19
8
1 058
213
8 390

80
7
343
476
1 861
10
411
220
2 061
549
0
5
6
617
0
0
35
30
5
156
1 051
951
–
11 313
1 785
–
21 937

9 494
1 905
18 928
30 327

83
377
98
13
50
57
87
79
44
1 917
778
195
28
6
167
1 098
112
0
59
52
0
258
100
100
739
496
28
12
1 106
204
8 343

71
–
352
539
1 659
10
445
185
2 127
569
–
4
17
683
0
0
24
22
2
136
970
806
–
11 489
1 718
–
21 804

9 250
1 814
19 083
30 147

64
270
84
11
38
82
65
72
40
1 293
538
135
26
10
102
629
108
1
68
29
14
189
66
69
511
321
16
11
717
148
5 727

73
–
303
407
1 098
6
351
161
2 034
478
–
2
3
404
38 937
0
13
12
1
92
880
536
–
9 080
1 228
–
56 086

6 301
1 291
54 220
61 812

65
258
110
11
59
69
48
34
33
1 365
449
129
22
7
90
847
67
0
56
42
7
179
58
84
618
343
22
10
815
133
6 030

79
–
352
513
1 159
3
341
186
2 289
612
–
2
5
462
38 381
0
12
12
–
101
752
666
–
9 524
1 331
–
56 770

60
415
199
27
128
446
116
98
70
1 575
1 067
138
43
13
315
916
95
0
152
34
12
290
138
214
475
342
61
17
814
199
8 469

51
–
436
592
1 240
4
415
213
2 682
879
–
11
11
650
41 119
0
28
27
1
107
860
789
–
8 032
2 112
–
60 231

6 761
1 497
54 542
62 800

9 079
2 371
57 250
68 700

53
385
130
25
89
181
108
44
107
1 837
1 038
109
52
17
315
1 120
56
0
139
26
21
218
153
169
449
426
44
9
821
113
8 254

74
–
412
709
1 150
–
430
195
2 799
851
–
17
20
778
42 326
0
55
46
9
109
951
723
–
8 391
3 789
–
63 779

10 983
2 014
59 036
72 033

3 568
14 779
2 085
479
962
1 656
3 858
1 962
1 941
44 279
19 803
4 210
674
179
4 451
26 207
2 605
14
1 243
1 508
250
9 260
3 936
2 505
31 583
9 812
397
208
21 373
6 667
222 454

1 338
30
4 225
6 170
23 004
152
5 414
6 053
27 746
7 244
13
123
105
10 989
160 763
23
1 015
939
76
7 687
10 384
10 090
0
189 060
80 277
4 711
556 689

291 935
31 601
455 593
779 129

a   Country/territory/area specific comments are in Annex 5. Due to surveillance human resource constraints associated with the COVID-19 pandemic, some countries 

have higher than normal incomplete data on transmission route for 2020 and trends should be interpreted with care.

b  Cumulative total is the total number of cases reported by the country since the start of reporting.
c  The numbers displayed here may not fully align with the numbers in the country’s national statistics as these are presented by the “date of notification” instead of 

the “date of diagnosis” as here. 

[1]  All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

40

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 dataTable 7. HIV diagnoses in people who acquired HIV through mother-to-child transmission, by country and year of 
diagnosis (2014–2023) and cumulative totals, in EU/EEA and other countries of the WHO European Region

Area

Country, territory or areaa

2014

2015

2016

2017

Year of diagnosis
2019

2018

2020

2021

2022

2023

Cumulative 
totalb

EU/EEA
Austria
West
West
Belgium
Centre Bulgaria
Centre Croatia
Centre Cyprus
Centre Czechia
Denmark
West
Estonia
East
Finland
West
France
West
Germany
West
West
Greece
Centre Hungary
Iceland
West
Ireland
West
Italy
West
Latvia
East
Liechtenstein
West
Lithuania
East
Luxembourg
West
Malta
West
Netherlands
West
Norway
West
Poland
Centre
West
Portugal
Centre Romania
Centre Slovakia
Centre Slovenia
West
West

Spain
Sweden
Total EU/EEA

Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco

Non-EU/EEA
Centre Albania
Andorra
West
Armenia
East
Azerbaijan
East
East
Belarus
Centre Bosnia and Herzegovina
East
West
East
East
West
Centre Montenegro
Centre North Macedonia
East
East
West
Centre Serbia
Centre
Centre
West
East
Centre
East
East
West
East

Serbia excluding Kosovo[1]
Kosovo[1]
Switzerland
Tajikistan
Türkiye
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Total non-EU/EEA

Republic of Moldova
Russian Federation
San Marino

WHO European Region
West
Centre
East
Total WHO European Region

2
9
1
1
0
1
5
5
2
54
27
1
1
0
2
13
4
0
2
3
0
21
3
3
8
18
0
1
4
7
198

3
0
7
18
15
0
5
9
22
18
0
0
0
19
0
0
1
1
0
1
59
22
–
122
89
–
410

260
52
296
608

0
14
1
0
1
0
4
1
3
48
29
0
2
0
5
16
3
0
0
1
0
20
2
8
7
18
0
0
3
15
201

1
0
4
16
26
0
6
4
25
23
0
0
0
14
0
0
1
0
1
4
56
23
–
98
47
–
348

222
55
272
549

2
9
0
0
0
2
1
0
2
30
24
3
1
0
3
11
6
0
1
0
2
16
2
1
6
7
0
0
9
10
148

1
0
1
10
20
0
4
4
24
16
0
0
0
10
0
0
2
2
0
4
54
15
–
77
48
–
290

186
29
223
438

1
4
3
0
0
0
5
0
0
28
18
1
2
0
0
16
3
0
1
0
0
13
2
3
8
15
0
0
4
14
141

1
0
5
12
13
0
3
6
34
16
0
0
0
11
0
0
0
0
0
4
61
12
–
86
61
–
325

185
36
245
466

1
6
3
0
0
0
2
0
2
40
20
2
0
2
4
12
5
0
0
0
2
16
6
2
3
9
0
0
8
12
157

2
0
6
9
4
0
6
7
24
22
0
0
0
13
0
0
1
0
1
2
53
13
–
71
61
–
294

208
30
213
451

0
7
1
0
1
0
0
0
4
55
14
4
0
1
3
3
2
0
0
2
0
11
2
5
0
11
0
0
8
12
146

1
–
3
4
10
0
3
3
26
21
–
0
0
19
0
0
2
2
0
0
47
15
–
79
74
–
307

203
36
214
453

0
8
4
1
0
0
2
3
1
26
11
4
0
0
2
6
5
0
0
1
1
10
0
3
2
7
0
1
1
9
108

1
–
9
2
5
0
3
3
23
12
–
0
0
12
162
0
0
0
0
1
43
12
–
67
30
–
385

118
29
346
493

2
6
2
0
4
0
3
4
1
37
11
2
3
0
4
2
1
0
1
1
0
9
4
2
6
7
0
0
5
12
129

3
–
3
7
5
0
2
9
30
25
–
0
0
12
153
0
2
1
1
0
33
15
–
48
52
–
399

166
38
324
528

0
16
5
1
0
26
7
7
2
50
61
6
1
0
17
11
2
0
15
0
0
17
5
24
6
8
2
1
4
13
307

2
–
3
12
4
1
6
6
22
20
–
0
0
12
129
0
0
0
0
2
30
11
–
35
80
–
375

303
82
297
682

0
9
1
0
1
3
4
3
4
61
39
3
0
0
15
11
3
0
3
0
0
6
12
15
5
5
1
0
4
9
217

2
–
5
5
7
–
2
1
22
13
–
0
0
10
98
–
0
0
0
6
24
4
–
38
158
–
395

347
32
233
612

74
516
40
16
10
38
129
71
45
840
601
82
21
4
130
244
93
1
26
33
5
430
114
269
565
803
3
9
161
316
5 689

44
1
73
160
338
1
121
286
493
311
1
4
2
255
542
1
55
49
6
191
610
224
0
2 488
3 193
363
9 758

7 962
1 539
5 945
15 446

a   Country/territory/area specific comments are in Annex 5. Due to surveillance human resource constraints associated with the COVID-19 pandemic, some countries 

have higher than normal incomplete data on transmission route for 2020 and trends should be interpreted with care.

b  Cumulative total is the total number of cases reported by the country since the start of reporting.

[1]  All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

41

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORTTable 8. HIV diagnoses in 2023, by country of report, transmission mode and sex, in EU/EEA and other countries of the  
WHO European Region

Area

Country, territory or areaa

Sex between men
Transgenderb

Male

Totalc

Female

Injecting drug users
Male

Transgenderb

Totalc

Female

Male

Transgenderb

Totalc

Heterosexual

Mother-to-child transmission
Totalc
Female

Male

Nosocomial

Haemophiliac/transfusion

Unknown

Female

Male

Totalc

Female

Male

Totalc

Female

Male

Transgenderb

Totalc

Totalc Country, territory or areaa

EU/EEA
Austria
West
West
Belgium
Centre Bulgaria
Centre Croatia
Centre Cyprus
Centre Czechia
Denmark
West
Estonia
East
Finland
West
France
West
Germany
West
West
Greece
Centre Hungary
Iceland
West
Ireland
West
Italy
West
Latvia
East
West
Liechtenstein
Lithuania
East
Luxembourgd
West
Malta
West
Netherlands
West
Norway
West
Poland
Centre
West
Portugal
Centre Romania
Centre Slovakia
Centre Slovenia
West
West

Spain
Sweden
Total EU/EEA

Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco

Non-EU/EEA
Centre Albania
Andorra
West
Armenia
East
Azerbaijan
East
East
Belarus
Centre Bosnia and Herzegovina
East
West
East
East
West
Centre Montenegro
Centre North Macedonia
East
East
West
Centre Serbia
Centre
Centre
West
East
Centre
East
East
West
East

Serbia excluding Kosovo[1]
Kosovo[1]
Switzerland
Tajikistan
Türkiye
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Total non-EU/EEA

Republic of Moldova
Russian Federation
San Marino

WHO European Region
West
Centre
East
Total WHO European Region

92
406
98
64
61
141
68
8
46
1 339
1 026
250
110
23
294
906
9
1
42
21
47
453
71
272
384
210
30
29
1 748
98
8 347

38
–
56
128
69
–
110
133
353
88
–
17
30
15
1 466
–
105
94
11
103
21
282
–
289
1 475
–
4 778

8 983
1 487
2 654
13 124

0
0
0
0
0
0
0
0
0
0
11
3
0
0
2
0
0
0
0
0
0
0
0
0
2
0
0
0
0
0
18

0
–
0
0
0
–
0
1
0
0
–
1
0
0
0
–
–
0
–
0
0
0
–
0
0
–
2

92
406
98
64
61
141
68
8
46
1 339
1 037
255
110
23
296
906
9
1
42
21
47
453
71
272
386
210
30
29
1 748
98
8 367

38
–
56
128
69
–
110
135
353
88
–
18
30
15
1 466
–
105
94
11
103
21
282
–
289
1 480
–
4 786

19
1
0
20

9 010
1 488
2 654
13 152

5
7
2
0
0
3
2
1
8
20
59
21
0
0
6
10
4
0
8
0
0
2
8
8
3
11
0
0
10
1
199

0
–
1
3
44
–
1
7
111
1
–
4
0
2
1 585
–
0
0
0
0
2
0
–
453
8
–
2 222

177
28
2 216
2 421

18
29
22
2
6
21
5
3
15
66
211
63
2
1
22
69
18
0
36
5
0
17
23
23
21
46
3
3
45
14
809

1
–
16
65
167
–
52
8
605
24
–
9
0
35
8 548
–
3
3
0
3
41
21
–
2 460
62
–
12 120

697
162
12 070
12 929

0
0
0
0
0
0
0
0
0
2
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
3

0
–
0
0
0
–
0
0
0
0
–
0
0
0
0
–
–
0
–
0
0
0
–
0
0
–
0

3
0
0
3

23
36
24
2
6
24
7
4
23
88
271
84
2
1
28
79
22
0
44
5
0
20
31
31
24
57
3
3
55
15
1 012

1
–
17
68
211
–
53
15
716
25
–
13
0
37
10 133
–
3
3
0
5
43
21
–
2 913
71
–
14 345

881
190
14 286
15 357

25
217
44
12
38
101
58
24
70
1 101
736
68
30
11
191
495
24
0
71
13
3
125
88
101
237
137
17
2
327
71
4 437

27
–
151
256
519
–
136
98
1 100
374
–
8
4
318
20 639
–
11
11
0
49
369
148
–
3 616
2 415
–
30 238

6 398
680
27 597
34 675

28
153
86
13
51
80
50
20
37
736
302
41
22
6
118
625
32
0
68
13
18
93
65
68
212
289
27
7
494
42
3 796

47
–
261
453
631
–
294
97
1 699
477
–
9
16
460
21 687
–
44
35
9
60
582
573
–
4 775
1 370
–
33 535

4 560
1 332
31 439
37 331

0
15
0
0
0
0
0
0
0
0
0
0
0
0
6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
21

0
–
0
0
0
–
0
0
0
0
–
0
0
0
0
–
–
0
–
0
0
0
–
0
0
–
0

21
0
0
21

53
385
130
25
89
181
108
44
107
1 837
1 038
109
52
17
315
1 120
56
0
139
26
21
218
153
169
449
426
44
9
821
113
8 254

74
–
412
709
1 150
–
430
195
2 799
851
–
17
20
778
42 326
–
55
46
9
109
951
723
–
8 391
3 789
–
63 779

10 983
2 014
59 036
72 033

0
4
1
0
0
1
1
2
0
39
21
2
0
0
8
8
2
0
1
0
0
5
4
6
1
2
0
0
3
5
116

1
–
1
4
4
–
0
0
10
9
–
0
0
6
52
–
0
0
0
3
9
3
–
19
103
–
224

207
14
119
340

0
5
0
0
1
2
3
1
4
22
18
1
0
0
7
3
1
0
2
0
0
1
8
9
4
3
1
0
1
4
101

1
–
4
1
3
–
2
1
12
4
–
0
0
4
46
–
0
0
0
3
15
1
–
19
54
–
170

139
18
114
271

0
9
1
0
1
3
4
3
4
61
39
3
0
0
15
11
3
0
3
0
0
6
12
15
5
5
1
0
4
9
217

2
–
5
5
7
–
2
1
22
13
–
0
0
10
98
–
0
0
0
6
24
4
–
38
158
–
395

347
32
233
612

29

1 240

1 700

14

27

16

43

164

6 824

24 731 Total EU/EEA

102

29

1 903

452

36

4 716

0

0

0

0

0

1

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

4

1

0

0

0

0

0

0

0

6

0

–

0

0

0

–

0

0

0

0

–

0

0

0

0

–

0

0

0

0

0

0

–

2

6

–

8

11

1

2

14

0

0

0

0

0

0

0

0

2

0

0

0

0

1

0

0

0

0

0

0

0

4

1

0

0

0

0

0

0

0

8

0

–

0

0

0

–

0

0

0

0

–

0

0

0

0

–

0

0

0

0

0

0

–

1

11

–

12

19

0

1

20

0

0

0

0

0

1

0

0

2

0

0

0

0

1

0

0

0

0

0

0

0

8

2

0

0

0

0

0

0

0

0

–

0

0

0

–

0

0

0

0

–

0

0

0

0

–

0

0

0

0

0

0

–

3

17

–

20

30

1

3

34

0

2

0

0

0

0

2

0

2

8

0

0

0

0

0

2

0

0

0

0

0

0

2

2

2

0

0

0

3

2

0

–

0

0

0

–

0

0

0

0

–

0

0

0

0

–

0

0

0

0

0

1

–

0

19

–

20

44

3

0

47

0

0

0

1

0

1

0

1

1

3

0

0

0

0

0

1

0

0

0

0

0

0

4

0

0

1

0

0

1

2

0

–

0

0

0

–

0

3

0

0

–

0

0

0

0

–

0

0

0

0

0

3

–

0

21

–

27

36

6

1

43

11

0

2

0

1

0

1

2

1

3

0

0

0

0

0

3

0

0

0

0

0

0

6

2

2

1

0

0

4

4

0

–

0

0

0

–

0

3

0

0

–

0

0

0

0

–

0

0

0

0

0

4

–

0

40

–

47

80

9

1

90

109

7

0

2

1

26

10

47

36

576

166

62

108

48

27

8

0

0

9

4

2

14

24

447

18

2

18

1

0

–

1

5

7

–

3

–

1

0

–

7

7

0

–

6

–

31

48

19

41

226

49

27

440

370

19

164

0

3

3

25

28

76

61

941

768

167

44

2

149

182

71

0

30

4

43

86

33

39

46

2

2

8

–

9

4

19

–

14

38

102

58

–

5

0

47

440

–

27

27

0

76

34

2 117

–

18

472

–

3 760

3 522

922

8 204

128

1 645

4 981

France

0

6

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

1

0

0

0

0

0

0

–

0

0

0

–

0

0

0

0

–

0

0

0

0

–

–

0

–

1

0

0

–

0

0

–

1

0

0

26

281

0

5

5

51

38

123

97

936

229

64

2

257

230

98

0

39

8

46

129

57

58

4

64

3

564

65

8

–

10

9

26

–

17

69

150

77

–

6

0

88

666

–

34

34

0

128

61

2 561

–

24

847

–

5 712

4 505

1 388

11 605

EU/EEA

194 Austria

1 119 Belgium

253 Bulgaria

97 Croatia

162 Cyprus

402 Czechia

227 Denmark

183 Estonia

282 Finland

3 321 Germany

680 Greece

228 Hungary

44 Iceland

911

Ireland

2 349 Italy

188 Latvia

1

Liechtenstein

267 Lithuania

60 Luxembourgd

114 Malta

834 Netherlands

332 Norway

2 189 Poland

924 Portugal

703 Romania

142 Slovakia

44 Slovenia

3 196 Spain

304 Sweden

Non-EU/EEA

123 Albania

– Andorra

500 Armenia

919 Azerbaijan

1 463 Belarus

612 Georgia

418 Israel

4 040 Kazakhstan

1 054 Kyrgyzstan

– Monaco

54 Montenegro

– Bosnia and Herzegovina

Serbia excluding Kosovo[1]

50 North Macedonia

928 Republic of Moldova

54 689 Russian Federation

– San Marino

197 Serbia

177

20

Kosovo[1]

351 Switzerland

1 100 Tajikistan

3 595

Türkiye

– Turkmenistan

11 658 Ukraine

6 402 United Kingdom

– Uzbekistan

WHO European Region

27 043 West

8 239 Centre

77 601 East

112 883 Total WHO European Region

1 281

3 488

4 781

88 153 Total non-EU/EEA

1 765

953

466

3 184

165

165

a  Country/territory/area specific comments are in Annex 5.
b  The mode of transmission among transgender people is advised to be classified according to the gender at the time of diagnosis. However, there are discrepancies across countries in 

how the mode of transmission for transgender individuals is classified. Therefore, comparisons between countries should be made with caution.

c  Totals include transgender and persons with unknown gender and may, therefore, not equal the sum of the columns or may differ slightly from the totals presented for 2023 in tables 4–7.
d  The numbers displayed here may not fully align with the numbers in the country’s national statistics as these are presented by the “date of notification” instead of the “date of 

diagnosis” as here. 

[1]  All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

42

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 dataTable 8. HIV diagnoses in 2023, by country of report, transmission mode and sex, in EU/EEA and other countries of the  

WHO European Region

Area

Country, territory or areaa

Sex between men

Injecting drug users

Heterosexual

Mother-to-child transmission

Male

Transgenderb

Totalc

Female

Male

Transgenderb

Totalc

Female

Male

Transgenderb

Totalc

Female

Male

Totalc

Nosocomial
Male

Female

Totalc

Haemophiliac/transfusion
Female

Male

Totalc

Unknown

Female

Male

Transgenderb

Totalc

Totalc Country, territory or areaa

EU/EEA

West

West

Austria

Belgium

Centre Bulgaria

Centre Croatia

Centre Cyprus

Centre Czechia

Denmark

Estonia

Finland

France

Germany

Greece

Iceland

Ireland

Italy

Latvia

Centre Hungary

West

East

West

West

West

West

West

West

West

East

East

West

West

West

West

West

Liechtenstein

Lithuania

Luxembourgd

Malta

Netherlands

Norway

Centre

Poland

West

Portugal

Centre Romania

Centre Slovakia

Centre Slovenia

West

West

Spain

Sweden

Total EU/EEA

Non-EU/EEA

Centre Albania

Andorra

Armenia

Azerbaijan

Belarus

Georgia

Israel

Kazakhstan

Kyrgyzstan

Monaco

West

East

East

East

East

West

East

East

West

East

East

West

Centre

Centre

West

East

East

East

West

East

West

Centre

East

Centre Bosnia and Herzegovina

Centre Montenegro

Centre North Macedonia

Republic of Moldova

Russian Federation

San Marino

Centre Serbia

Serbia excluding Kosovo[1]

Kosovo[1]

Switzerland

Tajikistan

Centre

Türkiye

Turkmenistan

Ukraine

United Kingdom

Uzbekistan

Total non-EU/EEA

WHO European Region

92

406

98

64

61

141

68

8

46

1 339

1 026

250

110

23

294

906

9

1

42

21

47

453

71

272

384

210

30

29

1 748

98

8 347

38

–

56

128

69

–

110

133

353

88

–

17

30

15

–

105

94

11

103

21

282

–

289

1 475

–

4 778

8 983

1 487

2 654

13 124

18

199

809

1 012

4 437

3 796

21

8 254

116

101

217

92

406

98

64

61

141

68

8

46

1 339

1 037

255

110

23

296

906

9

1

42

21

47

453

71

272

386

210

30

29

1 748

98

8 367

38

–

56

128

69

–

110

135

353

88

–

18

30

15

–

105

94

11

103

21

282

–

289

1 480

–

11

0

0

0

0

0

0

0

0

0

0

3

0

0

2

0

0

0

0

0

0

0

0

0

2

0

0

0

0

0

0

–

0

0

0

–

0

1

0

0

–

1

0

0

0

–

–

0

–

0

0

0

–

0

0

–

2

20

59

21

10

11

0

0

10

1

44

111

5

7

2

0

0

3

2

1

8

0

0

6

4

0

8

0

0

2

8

8

3

0

–

1

3

–

1

7

1

–

4

0

2

–

0

0

0

0

2

0

–

8

–

18

29

22

21

2

6

5

3

15

66

211

63

2

1

22

69

18

36

0

5

0

17

23

23

21

46

3

3

45

14

1

–

16

65

167

–

52

8

605

24

35

–

9

0

–

3

3

0

3

41

21

–

62

–

23

36

24

24

2

6

7

4

23

88

271

84

2

1

28

79

22

44

0

5

0

20

31

31

24

57

3

3

55

15

1

–

17

68

211

–

53

15

716

25

–

13

0

37

–

3

3

0

5

43

21

–

71

–

1 101

736

25

217

44

12

38

101

58

24

70

68

30

11

191

495

24

0

71

13

3

125

88

101

237

137

17

2

327

71

27

–

151

256

519

–

136

98

–

8

4

–

11

11

0

49

369

148

–

3 616

2 415

–

28

153

86

13

51

80

50

20

37

736

302

41

22

6

118

625

32

0

68

13

18

93

65

68

212

289

27

7

494

42

47

–

261

453

631

–

294

97

–

9

16

–

44

35

9

60

582

573

–

4 775

1 370

–

0

0

0

0

0

0

0

0

0

2

0

0

0

0

0

0

0

0

0

0

0

1

0

0

0

0

0

0

0

0

3

0

–

0

0

0

–

0

0

0

0

–

0

0

0

0

–

–

0

–

0

0

0

–

0

0

–

0

3

0

0

3

39

21

22

18

0

4

1

0

0

1

1

2

0

2

0

0

8

8

2

0

1

0

0

5

4

6

1

2

0

0

3

5

1

–

1

4

4

–

0

0

9

–

0

0

6

–

0

0

0

3

9

3

–

53

385

130

25

89

181

108

44

107

1 837

1 038

109

52

17

315

1 120

56

0

139

26

21

218

153

169

449

426

44

9

821

113

74

–

412

709

1 150

–

430

195

2 799

851

–

17

20

778

–

55

46

9

109

951

723

–

0

15

0

0

0

0

0

0

0

0

0

0

0

0

6

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

–

0

0

0

–

0

0

0

0

–

0

0

0

0

–

–

0

–

0

0

0

–

0

0

–

0

0

5

0

0

1

2

3

1

4

1

0

0

7

3

1

0

2

0

0

1

8

9

4

3

1

0

1

4

1

–

4

1

3

–

2

1

4

–

0

0

4

–

0

0

0

3

1

–

61

39

3

0

0

15

11

12

15

0

9

1

0

1

3

4

3

4

3

0

3

0

0

6

5

5

1

0

4

9

2

–

5

5

7

–

2

1

–

0

0

–

0

0

0

6

4

–

22

13

10

98

38

158

–

395

347

32

233

612

15

24

1 466

1 466

1 585

8 548

10 133

20 639

21 687

42 326

52

46

10

12

1 100

374

1 699

477

318

460

453

2 460

2 913

4 786

2 222

12 120

14 345

30 238

33 535

19

1

0

20

9 010

1 488

2 654

13 152

177

28

2 216

2 421

697

162

12 070

12 929

881

190

14 286

15 357

6 398

680

27 597

34 675

4 560

1 332

31 439

37 331

8 391

3 789

–

63 779

10 983

2 014

59 036

72 033

21

0

0

21

19

103

–

224

207

14

119

340

19

54

–

170

139

18

114

271

Total WHO European Region

a  Country/territory/area specific comments are in Annex 5.

b  The mode of transmission among transgender people is advised to be classified according to the gender at the time of diagnosis. However, there are discrepancies across countries in 

how the mode of transmission for transgender individuals is classified. Therefore, comparisons between countries should be made with caution.

c  Totals include transgender and persons with unknown gender and may, therefore, not equal the sum of the columns or may differ slightly from the totals presented for 2023 in tables 4–7.

d  The numbers displayed here may not fully align with the numbers in the country’s national statistics as these are presented by the “date of notification” instead of the “date of 

diagnosis” as here. 

[1]  All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4
1
0
0
0
0
0
0
0
6

0
–
0
0
0
–
0
0
0
0
–
0
0
0
0
–
0
0
0
0
0
0
–
2
6
–
8

11
1
2
14

0
0
0
0
0
0
0
0
2
0
0
0
0
1
0
0
0
0
0
0
0
4
1
0
0
0
0
0
0
0
8

0
–
0
0
0
–
0
0
0
0
–
0
0
0
0
–
0
0
0
0
0
0
–
1
11
–
12

19
0
1
20

0
0
0
0
0
1
0
0
2
0
0
0
0
1
0
0
0
0
0
0
0
8
2
0
0
0
0
0
0
0
14

0
–
0
0
0
–
0
0
0
0
–
0
0
0
0
–
0
0
0
0
0
0
–
3
17
–
20

30
1
3
34

0
2
0
0
0
0
2
0
2
8
0
0
0
0
0
2
0
0
0
0
0
0
2
2
2
0
0
0
3
2
27

0
–
0
0
0
–
0
0
0
0
–
0
0
0
0
–
0
0
0
0
0
1
–
0
19
–
20

44
3
0
47

0
0
0
1
0
1
0
1
1
3
0
0
0
0
0
1
0
0
0
0
0
0
4
0
0
1
0
0
1
2
16

0
–
0
0
0
–
0
3
0
0
–
0
0
0
0
–
0
0
0
0
0
3
–
0
21
–
27

36
6
1
43

0
2
0
1
0
1
2
1
3
11
0
0
0
0
0
3
0
0
0
0
0
0
6
2
2
1
0
0
4
4
43

0
–
0
0
0
–
0
3
0
0
–
0
0
0
0
–
0
0
0
0
0
4
–
0
40
–
47

80
9
1
90

7
109
0
2
1
26
10
47
36
576
166
62
8
0
108
48
27
0
9
4
2
14
24
447
18
2
18
1
102
29
1 903

0
–
1
5
7
–
3
31
48
19
–
1
0
41
226
–
7
7
0
49
27
440
–
6
370
–
1 281

1 765
953
466
3 184

19
164
0
3
3
25
28
76
61
941
768
167
44
2
149
182
71
0
30
4
43
86
33
1 240
39
2
46
2
452
36
4 716

8
–
9
4
19
–
14
38
102
58
–
5
0
47
440
–
27
27
0
76
34
2 117
–
18
472
–
3 488

3 760
3 522
922
8 204

0
6
0
0
0
0
0
0
0
128
0
0
0
0
0
0
0
0
0
0
0
29
0
0
1
0
0
0
0
0
164

0
–
0
0
0
–
0
0
0
0
–
0
0
0
0
–
–
0
–
1
0
0
–
0
0
–
1

26
281
0
5
5
51
38
123
97
1 645
936
229
64
2
257
230
98
0
39
8
46
129
57
1 700
58
4
64
3
564
65
6 824

8
–
10
9
26
–
17
69
150
77
–
6
0
88
666
–
34
34
0
128
61
2 561
–
24
847
–
4 781

EU/EEA
194 Austria
1 119 Belgium
253 Bulgaria
97 Croatia
162 Cyprus
402 Czechia
227 Denmark
183 Estonia
282 Finland
France

4 981
3 321 Germany
680 Greece
228 Hungary
44 Iceland
Ireland
911

2 349 Italy

188 Latvia

1

Liechtenstein

267 Lithuania
60 Luxembourgd
114 Malta
834 Netherlands
332 Norway
2 189 Poland

924 Portugal
703 Romania
142 Slovakia
44 Slovenia

3 196 Spain

304 Sweden
24 731 Total EU/EEA
Non-EU/EEA

123 Albania
– Andorra
500 Armenia
919 Azerbaijan

1 463 Belarus

– Bosnia and Herzegovina

612 Georgia
418 Israel

4 040 Kazakhstan
1 054 Kyrgyzstan
– Monaco
54 Montenegro
50 North Macedonia
928 Republic of Moldova
54 689 Russian Federation
– San Marino

197 Serbia
Serbia excluding Kosovo[1]
177
Kosovo[1]
20
351 Switzerland

1 100 Tajikistan
3 595

Türkiye
– Turkmenistan

11 658 Ukraine
6 402 United Kingdom
– Uzbekistan
88 153 Total non-EU/EEA

165
0
0
165

5 712
4 505
1 388
11 605

WHO European Region

27 043 West
8 239 Centre
77 601 East
112 883 Total WHO European Region

[1]  All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

43

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORTTable 9. HIV diagnoses in 2023, by country of report, age and sex, in EU/EEA and other countries of the  
 WHO European Region

Area

Country, territory or areaa

< 15 years
Male

Female

Totalb

Female

Male

Transgenderc

Totalb

Female

Male

Transgenderc

Totalb

Female

Male

Transgenderc

Totalb

Female

Male

Transgenderc

Totalb

Female

Male

Transgenderc

Totalb

Female

Male

Transgenderc

Totalb

Female

Male

Totalb

15–19 years

20–24 years

25–29 years

30–39 years

40–49 years

50+ years

Unknown age

Totalb Country, territory or areaa

EU/EEA
Austria
West
West
Belgium
Centre Bulgaria
Centre Croatia
Centre Cyprus
Centre Czechia
Denmark
West
Estonia
East
Finland
West
France
West
Germany
West
West
Greece
Centre Hungary
Iceland
West
Ireland
West
Italy
West
Latvia
East
Liechtenstein
West
Lithuania
East
Luxembourgd
West
Malta
West
Netherlands
West
Norway
West
Poland
Centre
West
Portugal
Centre Romania
Centre Slovakia
Centre Slovenia
West
West

Spain
Sweden
Total EU/EEA

Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco

Non-EU/EEA
Centre Albania
Andorra
West
Armenia
East
Azerbaijan
East
East
Belarus
Centre Bosnia and Herzegovina
East
West
East
East
West
Centre Montenegro
Centre North Macedonia
East
East
West
Centre Serbia
Centre
Centre
West
East
Centre
East
East
West
East

Serbia excluding Kosovo[1]
Kosovo[1]
Switzerland
Tajikistan
Türkiye
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Total non-EU/EEA

Republic of Moldova
Russian Federation
San Marino

WHO European Region
West
Centre
East
Total WHO European Region

0
4
1
0
0
0
0
2
0
20
11
1
0
0
3
6
2
0
2
0
0
0
2
10
1
2
0
0
3
2
72

1
–
1
4
5
–
0
1
10
9
–
0
0
6
201
–
0
0
0
0
22
3
–
24
13
–
300

67
17
288
372

0
3
0
0
0
0
3
1
1
11
13
0
0
0
4
3
1
0
2
0
0
1
2
11
3
3
0
0
1
5
68

1
–
4
2
5
–
1
0
14
4
–
0
0
4
182
–
0
0
0
0
35
1
–
24
5
–
282

54
16
279
349

0
7
1
0
0
0
3
3
1
31
24
2
0
0
7
9
3
0
4
0
0
1
4
21
4
5
0
0
4
7
141

2
–
5
6
10
–
1
1
24
13
–
0
0
10
383
–
0
0
0
0
57
4
–
48
18
–
582

122
33
567
722

0
10
1
0
1
0
0
1
2
68
18
10
0
2
3
10
1
0
3
0
0
0
2
8
7
13
0
0
2
1
163

0
–
1
10
4
–
1
0
20
10
–
0
0
8
212
–
0
0
0
2
23
8
–
51
17
–
367

154
31
345
530

3
15
2
2
1
2
3
0
3
101
29
4
2
0
1
11
1
0
1
0
1
1
7
25
13
19
1
0
40
0
288

1
–
2
9
12
–
9
2
50
14
–
0
0
1
130
–
3
3
0
3
18
43
–
17
40
–
354

277
101
264
642

0
0
0
0
0
0
0
0
0
2
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3

0
–
0
0
0
–
0
0
0
0
–
0
0
0
0
–
–
0
–
0
0
0
–
0
0
–
0

3
0
0
3

3
25
3
2
2
2
3
1
5
171
47
14
2
2
5
21
2
0
4
0
1
1
9
33
20
32
1
0
42
1
454

1
–
3
19
16
–
10
2
70
24
–
0
0
9
342
–
3
3
0
5
41
51
–
68
58
–
722

435
132
609
1 176

2
17
4
1
4
7
2
5
1
193
70
26
4
0
15
43
2
0
2
1
0
9
1
28
26
14
3
1
28
4
513

4
–
8
23
24
–
7
2
55
17
–
0
1
22
806
–
0
0
0
4
35
51
–
118
116
–
1 293

560
122
1 124
1 806

9
57
26
7
13
16
7
5
11
305
150
34
22
3
28
87
4
0
12
7
4
53
7
163
63
83
14
2
295
10
1 497

14
–
10
53
47
–
43
24
186
67
–
5
4
22
722
–
20
15
5
21
54
363
–
122
235
–
2 012

1 409
752
1 347
3 508

0
6
0
0
0
0
0
0
0
19
1
1
0
0
0
0
0
0
0
0
0
4
0
0
1
0
0
0
0
0
32

0
–
0
0
0
–
0
0
0
0
–
1
0
0
0
–
–
0
–
0
0
0
–
0
0
–
1

11
80
30
8
17
23
9
10
12
517
221
62
26
3
43
130
6
0
14
8
4
66
8
191
90
97
17
3
325
14
2 045

18
–
18
76
71
–
50
26
241
84
–
6
5
44
1 528
–
20
15
5
25
89
414
–
240
354
–
3 309

33
1
0
34

2 008
875
2 471
5 354

4
41
8
1
12
10
8
5
8
245
110
18
2
2
18
72
4
0
3
1
1
13
9
42
41
23
1
0
52
3
757

0
–
12
28
49
–
15
8
99
37
–
2
1
35
1 425
–
2
2
0
8
31
80
–
256
278
–
2 366

940
184
1 999
3 123

26
116
30
15
29
44
11
9
11
429
324
71
28
8
93
187
7
1
18
6
20
90
26
236
145
86
22
5
452
30
2 575

16
–
37
128
58
–
62
23
335
107
–
11
12
52
1 771
–
38
28
10
35
97
569
–
393
557
–
4 301

2 660
1 141
3 074
6 875

0
8
0
0
0
0
0
0
0
33
3
1
0
0
1
0
0
0
0
0
0
3
0
0
1
0
0
0
0
0
50

0
–
0
0
0
–
0
0
0
0
–
0
0
0
0
–
–
0
–
0
0
0
–
0
0
–
0

30
165
38
16
41
54
19
14
19
707
437
90
30
10
112
259
11
1
21
7
21
106
35
279
187
109
23
5
504
33
3 383

16
–
49
156
107
–
77
31
434
144
–
13
13
87
3 196
–
40
30
10
44
128
650
–
649
843
–
6 677

50
0
0
50

3 659
1 327
5 073
10 059

86

8 530

2 607

26 838

2 477

442

10 297

13 216

4 024

1 459

17 632

23 115

28

0

0

6 537

1 904

27 929

28 36 370

1 606

330

6 612

8 548

4 087

957

7 501

12 545

13 073 24 804

86

37 975

33

46

1

80

42

73

1

116

27 040 West

8 239 Centre

77 601 East

10

112 880 Total WHO European Region

2 063

5 561

82

1 767

4 016

28

5 817

1 344

3 709

11

5 064

79

114

24 731 Total EU/EEA

46

1 338

1 068

186

23

1 016

15

20

0

16

17

115

14

4

12

43

26

26

40

473

347

42

13

5

103

151

12

0

27

8

3

55

41

206

65

44

10

1

118

42

7

–

53

94

159

–

38

34

373

114

–

6

1

–

5

5

0

42

247

74

24

32

96

63

31

60

819

713

143

52

14

249

501

38

0

63

16

39

221

61

577

186

176

29

15

912

68

23

–

127

245

317

–

142

82

971

202

–

10

17

198

–

52

50

2

64

31

148

183

–

1 330

1 075

–

236

878

–

2 820

1 147

–

2 789

549

9 735

5 646

2 055

17 103

59

369

88

28

44

139

89

57

100

65

19

355

652

50

0

90

24

42

294

102

784

252

220

39

16

1 034

110

7 713

30

–

180

339

476

–

180

118

1 344

316

–

16

18

–

57

55

2

96

384

1 063

4 150

2 224

–

–

8

84

7

5

4

40

21

24

43

403

269

28

13

2

119

133

16

0

33

2

1

45

40

168

48

34

15

0

130

32

6

–

34

59

184

–

33

52

391

122

–

5

1

–

5

5

0

32

87

139

–

1 335

986

–

36

161

51

20

29

82

38

39

51

590

520

135

44

8

119

449

49

0

49

6

19

163

51

401

121

128

30

11

569

47

15

–

91

121

278

–

109

72

766

150

–

9

5

–

34

33

1

60

154

600

2 918

809

–

–

18

0

7

0

0

0

0

0

0

0

6

1

0

0

3

0

0

0

0

0

0

0

0

1

0

0

0

0

0

0

–

0

0

0

–

0

1

0

0

–

0

0

0

0

–

–

0

–

1

0

0

–

0

0

–

2

0

0

44

246

58

25

33

122

59

63

94

789

163

57

10

240

582

65

0

82

8

20

211

91

570

169

162

45

11

703

79

21

–

125

180

462

–

142

124

1 157

272

–

14

6

279

–

39

38

1

93

241

741

–

4 253

1 797

–

0

0

0

0

0

0

0

0

0

0

0

0

0

2

0

0

0

0

0

0

3

0

0

0

0

0

0

0

0

0

–

0

0

0

–

0

0

0

0

–

0

0

0

–

–

0

–

0

0

0

–

0

0

–

0

6

67

12

3

6

32

16

11

22

342

153

28

6

0

52

148

20

0

19

5

0

28

32

98

73

22

6

1

112

24

10

–

45

50

149

–

46

39

321

94

–

0

0

–

6

6

0

24

61

128

–

982

436

–

41

156

23

15

18

30

29

23

29

852

561

135

26

0

96

548

31

0

33

8

11

125

51

157

129

56

11

8

472

35

25

–

75

93

172

–

106

76

449

107

–

5

8

–

32

30

2

62

99

543

–

1 268

672

–

11 012

19 244

30 263

11 450

19 099

30 554

7 205

8 837

14

15

114 Malta

42

56

0

2

0

0

0

0

0

1

0

0

0

4

0

0

0

0

0

0

0

0

0

0

0

0

0

0

1

0

–

0

0

0

–

0

1

0

0

–

0

0

0

0

–

0

0

0

0

0

0

–

0

0

–

1

0

4

0

0

1

0

0

1

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

1

0

–

0

0

0

–

0

1

0

0

–

0

0

0

0

–

0

0

0

0

0

0

–

0

0

–

1

EU/EEA

194 Austria

1 119 Belgium

253 Bulgaria

97 Croatia

162 Cyprus

402 Czechia

227 Denmark

183 Estonia

282 Finland

4 981

France

3 321 Germany

680 Greece

228 Hungary

44 Iceland

911

Ireland

2 349 Italy

188 Latvia

1

Liechtenstein

267 Lithuania

60 Luxembourgd

834 Netherlands

332 Norway

2 189 Poland

924 Portugal

703 Romania

142 Slovakia

44 Slovenia

3 196 Spain

304 Sweden

Non-EU/EEA

123 Albania

– Andorra

500 Armenia

919 Azerbaijan

1 463 Belarus

612 Georgia

418 Israel

4 040 Kazakhstan

1 054 Kyrgyzstan

– Monaco

54 Montenegro

– Bosnia and Herzegovina

Serbia excluding Kosovo[1]

50 North Macedonia

928 Republic of Moldova

54 689 Russian Federation

– San Marino

197 Serbia

177

20

Kosovo[1]

351 Switzerland

1 100 Tajikistan

3 595

Türkiye

– Turkmenistan

11 658 Ukraine

6 402 United Kingdom

– Uzbekistan

88 153 Total non-EU/EEA

WHO European Region

0

0

0

0

0

0

0

0

0

7

1

0

0

0

1

0

0

0

0

0

0

2

0

0

0

0

0

0

0

0

0

–

0

0

0

–

0

0

0

0

–

0

0

0

0

–

–

0

–

0

0

0

–

0

0

–

0

11

0

0

11

47

223

35

18

24

62

45

34

51

1 201

715

163

32

0

149

696

51

0

52

13

11

155

83

255

202

78

17

9

584

59

35

–

120

143

321

–

152

115

770

201

–

5

8

–

38

36

2

88

160

672

–

2 250

1 108

–

16 045

5 707

1 288

14 113

21 108

0

1

0

0

0

0

0

0

0

0

4

0

0

0

0

0

0

0

0

0

0

0

0

4

0

0

0

0

0

0

9

0

–

0

0

0

–

0

0

0

0

–

0

0

0

0

–

0

0

0

0

0

0

–

0

0

–

0

6

4

0

101

7 260

11 713

299

98

181

18 973

7 881

12 727

97

103

0 20 608

4 717

4 942

200

9 659

a   Country/territory/area specific comments are in Annex 5.
b  Totals include persons with unknown gender and may, therefore, not equal the sum of the columns.
c  The mode of transmission among transgender people is advised to be classified according to the gender at the time of diagnosis. However, there are discrepancies 
across countries in how the mode of transmission for transgender individuals is classified. Therefore, comparisons between countries should be made with caution.
d   The numbers displayed here may not fully align with the numbers in the country’s national statistics as these are presented by the “date of notification” instead of 

the “date of diagnosis” as here. 

[1]  All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

44

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 data20

11

11

13

31

24

19

33

 WHO European Region

Area

Country, territory or areaa

EU/EEA

West

West

Austria

Belgium

Centre Bulgaria

Centre Croatia

Centre Cyprus

Centre Czechia

Centre Hungary

West

East

West

West

West

West

West

West

West

East

West

East

West

West

West

West

Denmark

Estonia

Finland

France

Germany

Greece

Iceland

Ireland

Italy

Latvia

Liechtenstein

Lithuania

Luxembourgd

Malta

Netherlands

Norway

Centre

Poland

West

Portugal

Centre Romania

Centre Slovakia

Centre Slovenia

West

West

Spain

Sweden

Non-EU/EEA

Centre Albania

Andorra

Armenia

Azerbaijan

Belarus

Georgia

Israel

Kazakhstan

Kyrgyzstan

Monaco

Centre Bosnia and Herzegovina

West

East

East

East

East

West

East

East

West

East

East

West

Centre

Centre

West

East

East

East

West

East

West

Centre

East

Centre Montenegro

Centre North Macedonia

Republic of Moldova

Russian Federation

San Marino

Centre Serbia

Serbia excluding Kosovo[1]

Kosovo[1]

Switzerland

Tajikistan

Centre

Türkiye

Turkmenistan

Ukraine

United Kingdom

Uzbekistan

Total non-EU/EEA

WHO European Region

Total WHO European Region

10

11

21

0

4

1

0

0

0

0

2

0

1

0

0

3

6

2

0

2

0

0

0

2

1

2

0

0

3

2

1

–

1

4

5

–

0

1

9

–

0

0

6

–

0

0

0

0

3

–

0

3

0

0

0

0

3

1

1

0

0

0

4

3

1

0

2

0

0

1

2

3

3

0

0

1

5

1

–

4

2

5

–

1

0

4

–

0

0

4

–

0

0

0

0

1

–

5

–

0

7

1

0

0

0

3

3

1

2

0

0

7

9

3

0

4

0

0

1

4

4

5

0

0

4

7

2

–

5

6

–

1

1

–

0

0

–

0

0

0

0

4

–

10

24

13

10

383

48

18

–

122

33

567

722

0

10

3

15

101

29

68

18

10

10

11

2

2

1

2

3

0

3

4

2

0

1

1

0

1

0

1

1

7

25

13

19

1

0

0

40

12

50

14

1

–

2

9

–

9

2

–

0

0

1

–

3

3

0

3

18

43

–

17

40

–

1

0

1

0

0

1

2

0

2

3

1

0

3

0

0

0

2

8

7

0

0

2

1

0

–

1

4

–

1

0

–

0

0

8

–

0

0

0

2

8

–

13

10

20

10

51

17

–

154

31

345

530

10

14

24

13

–

67

17

288

372

24

54

16

279

349

22

35

57

23

3

25

171

47

14

21

3

2

2

2

3

1

5

2

2

5

2

0

4

0

1

1

9

33

20

32

1

0

42

1

1

–

3

19

16

–

10

2

70

24

–

0

0

9

–

3

3

0

5

41

51

–

68

58

–

2

17

4

1

4

7

2

5

1

193

70

26

4

0

15

43

2

0

2

1

0

9

1

28

26

14

3

1

28

4

513

23

24

55

17

4

–

8

–

7

2

–

0

1

–

0

0

0

4

35

51

–

118

116

–

305

150

9

57

26

7

13

16

7

5

11

34

22

3

28

87

12

4

0

7

4

53

7

63

83

14

2

163

14

–

10

53

47

–

43

24

186

67

–

5

4

22

722

–

20

15

5

21

54

363

–

122

235

–

295

10

1 497

0

0

0

0

0

0

0

0

0

2

0

0

0

0

1

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

3

0

–

0

0

0

–

0

0

0

0

–

0

0

0

0

–

–

0

–

0

0

0

–

0

0

–

0

3

0

0

3

11

80

30

8

17

23

9

10

12

517

221

62

26

3

43

130

14

6

0

8

4

8

66

191

90

97

17

3

325

14

18

–

18

76

71

–

50

26

241

84

–

6

5

–

20

15

5

25

89

414

–

240

354

–

4

41

8

1

12

10

8

5

8

245

110

18

2

2

18

72

4

0

3

1

1

13

9

42

41

23

1

0

52

3

0

–

12

28

49

–

15

8

99

37

–

2

1

–

2

2

0

8

31

80

–

256

278

–

26

116

30

15

29

44

11

9

11

429

324

187

71

28

8

93

7

1

18

6

20

90

26

236

145

86

22

5

452

30

128

16

–

37

58

–

62

23

335

107

–

11

12

52

–

38

28

10

35

97

569

–

393

557

–

0

6

0

0

0

0

0

0

0

1

1

0

0

0

0

0

0

0

0

0

4

0

0

1

0

0

0

0

0

0

–

0

0

0

–

0

0

0

0

–

1

0

0

0

–

–

0

–

0

0

0

–

0

0

–

1

0

8

0

0

0

0

0

0

0

3

1

0

0

1

0

0

0

0

0

0

3

0

0

1

0

0

0

0

0

0

–

0

0

0

–

0

0

0

0

–

0

0

0

0

–

–

0

–

0

0

0

–

0

0

–

0

30

165

38

16

41

54

19

14

19

707

437

90

30

10

112

259

11

1

21

7

21

106

35

279

187

109

23

5

504

33

16

–

49

156

107

–

77

31

434

144

–

13

13

87

–

40

30

10

44

3 196

128

650

–

649

843

–

6 677

3 659

1 327

5 073

201

182

212

130

22

806

342

44

1 528

35

1 425

1 771

300

282

582

367

354

722

1 293

2 012

3 309

2 366

4 301

Total EU/EEA

72

68

141

163

288

454

32

2 045

757

2 575

50

3 383

Table 9. HIV diagnoses in 2023, by country of report, age and sex, in EU/EEA and other countries of the  

< 15 years

15–19 years

20–24 years

25–29 years

30–39 years

40–49 years

50+ years

Female

Male

Totalb

Female

Male

Transgenderc

Totalb

Female

Male

Transgenderc

Totalb

Female

Male

Transgenderc

Totalb

Female

Male

Transgenderc

Totalb

Female

Male

Transgenderc

Totalb

Female

Male

Transgenderc

Totalb

Unknown age
Male

Female

Totalb

Totalb Country, territory or areaa

17
115
14
4
12
43
26
26
40
473
347
42
13
5
103
151
12
0
27
8
3
55
41
206
65
44
10
1
118
42
2 063

7
–
53
94
159
–
38
34
373
114
–
6
1
101
7 260
–
5
5
0
31
148
183
–
1 330
1 075
–
11 012

42
247
74
24
32
96
63
31
60
819
713
143
52
14
249
501
38
0
63
16
39
221
61
577
186
176
29
15
912
68
5 561

23
–
127
245
317
–
142
82
971
202
–
10
17
198
11 713
–
52
50
2
64
236
878
–
2 820
1 147
–
19 244

277

101

264

642

435

132

609

1 176

560

122

1 124

1 806

1 409

752

1 347

3 508

33

1

0

34

2 008

875

2 471

5 354

940

184

1 999

3 123

2 660

1 141

3 074

6 875

50

0

0

50

10 059

5 646
2 789
2 055
549
17 103
9 735
13 073 24 804

a   Country/territory/area specific comments are in Annex 5.

b  Totals include persons with unknown gender and may, therefore, not equal the sum of the columns.

c  The mode of transmission among transgender people is advised to be classified according to the gender at the time of diagnosis. However, there are discrepancies 

across countries in how the mode of transmission for transgender individuals is classified. Therefore, comparisons between countries should be made with caution.

d   The numbers displayed here may not fully align with the numbers in the country’s national statistics as these are presented by the “date of notification” instead of 

the “date of diagnosis” as here. 

[1]  All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

0
7
0
0
0
0
0
0
0
46
6
1
0
0
3
0
0
0
0
0
0
18
0
0
1
0
0
0
0
0
82

0
–
0
0
0
–
0
1
0
0
–
0
0
0
0
–
–
0
–
1
0
0
–
0
0
–
2

86
0
0
86

59
369
88
28
44
139
89
57
100
1 338
1 068
186
65
19
355
652
50
0
90
24
42
294
102
784
252
220
39
16
1 034
110
7 713

30
–
180
339
476
–
180
118
1 344
316
–
16
18
299
18 973
–
57
55
2
96
384
1 063
–
4 150
2 224
–
30 263

8 530
2 607
26 838
37 975

8
84
7
5
4
40
21
24
43
403
269
28
13
2
119
133
16
0
33
2
1
45
40
168
48
34
15
0
130
32
1 767

6
–
34
59
184
–
33
52
391
122
–
5
1
98
7 881
–
5
5
0
32
87
139
–
1 335
986
–
11 450

2 477
442
10 297
13 216

36
161
51
20
29
82
38
39
51
590
520
135
44
8
119
449
49
0
49
6
19
163
51
401
121
128
30
11
569
47
4 016

15
–
91
121
278
–
109
72
766
150
–
9
5
181
12 727
–
34
33
1
60
154
600
–
2 918
809
–
19 099

4 024
1 459
17 632
23 115

0
0
0
0
0
0
0
0
0
23
0
0
0
0
2
0
0
0
0
0
0
3
0
0
0
0
0
0
0
0
28

44
246
58
25
33
122
59
63
94
1 016
789
163
57
10
240
582
65
0
82
8
20
211
91
570
169
162
45
11
703
79
5 817

21
0
–
–
125
0
180
0
462
0
–
–
142
0
124
0
1 157
0
272
0
–
–
14
0
6
0
0
279
0 20 608
–
–
39
–
38
0
1
–
93
0
241
0
741
0
–
–
4 253
0
1 797
0
–
–
30 554
0

6
67
12
3
6
32
16
11
22
342
153
28
6
0
52
148
20
0
19
5
0
28
32
98
73
22
6
1
112
24
1 344

10
–
45
50
149
–
46
39
321
94
–
0
0
97
4 717
–
6
6
0
24
61
128
–
982
436
–
7 205

41
156
23
15
18
30
29
23
29
852
561
135
26
0
96
548
31
0
33
8
11
125
51
157
129
56
11
8
472
35
3 709

25
–
75
93
172
–
106
76
449
107
–
5
8
103
4 942
–
32
30
2
62
99
543
–
1 268
672
–
8 837

6 537
28
1 904
0
27 929
0
28 36 370

1 606
330
6 612
8 548

4 087
957
7 501
12 545

0
0
0
0
0
0
0
0
0
7
1
0
0
0
1
0
0
0
0
0
0
2
0
0
0
0
0
0
0
0
11

0
–
0
0
0
–
0
0
0
0
–
0
0
0
0
–
–
0
–
0
0
0
–
0
0
–
0

11
0
0
11

47
223
35
18
24
62
45
34
51
1 201
715
163
32
0
149
696
51
0
52
13
11
155
83
255
202
78
17
9
584
59
5 064

35
–
120
143
321
–
152
115
770
201
–
5
8
200
9 659
–
38
36
2
88
160
672
–
2 250
1 108
–
16 045

5 707
1 288
14 113
21 108

0
1
0
0
0
0
0
0
0
0
4
0
0
0
0
0
0
0
0
0
0
0
0
4
0
0
0
0
0
0
9

0
–
0
0
0
–
0
0
0
0
–
0
0
0
0
–
0
0
0
0
0
0
–
0
0
–
0

0
2
0
0
0
0
0
1
0
0
15
0
4
0
0
0
0
0
0
0
14
0
0
42
0
0
0
0
0
1
79

0
–
0
0
0
–
0
1
0
0
–
0
0
0
0
–
0
0
0
0
0
0
–
0
0
–
1

0
4
0
0
1
0
0
1
0
0
20
0
16
0
0
0
0
0
0
0
15
0
0
56
0
0
0
0
0
1
114

0
–
0
0
0
–
0
1
0
0
–
0
0
0
0
–
0
0
0
0
0
0
–
0
0
–
1

EU/EEA
194 Austria
1 119 Belgium
253 Bulgaria
97 Croatia
162 Cyprus
402 Czechia
227 Denmark
183 Estonia
282 Finland
France

4 981
3 321 Germany
680 Greece
228 Hungary
44 Iceland
Ireland
911

2 349 Italy

188 Latvia

1

Liechtenstein

267 Lithuania
60 Luxembourgd
114 Malta
834 Netherlands
332 Norway
2 189 Poland

924 Portugal
703 Romania
142 Slovakia
44 Slovenia

3 196 Spain

304 Sweden
24 731 Total EU/EEA
Non-EU/EEA

123 Albania
– Andorra
500 Armenia
919 Azerbaijan

1 463 Belarus

– Bosnia and Herzegovina

612 Georgia
418 Israel

4 040 Kazakhstan
1 054 Kyrgyzstan
– Monaco
54 Montenegro
50 North Macedonia
928 Republic of Moldova
54 689 Russian Federation
– San Marino

197 Serbia
Serbia excluding Kosovo[1]
177
Kosovo[1]
20
351 Switzerland

1 100 Tajikistan
3 595

Türkiye
– Turkmenistan

11 658 Ukraine
6 402 United Kingdom
– Uzbekistan
88 153 Total non-EU/EEA

6
4
0
10

33
46
1
80

42
73
1
116

WHO European Region

27 040 West
8 239 Centre
77 601 East
112 880 Total WHO European Region

[1]  All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

45

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORTTable 10. Origin of those diagnosed with HIV in 2023 by country of report or region, in EU/EEA and other countries of 
the WHO European Region 

Area

Country, territory or areaa

Country of report

Western Europe

Central and eastern Europe

Sub-Saharan Africa

Latin America and  

the Caribbean

South and south-east Asia

Other 

Unknown

Totalb  Country, territory or areaa

EU/EEA
West
West
Centre
Centre
Centre
Centre
West
East
West
West
West
West
Centre
West
West
West
East
West
East
West
West
West
West
Centre
West
Centre
Centre
Centre
West
West

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourgc
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Total EU/EEA

Non-EU/EEA
Centre
West
East
East
East
Centre
East
West
East
East
West
Centre
Centre
East
East
West
Centre
Centre
Centre
West
East
Centre
East
East
West
East

Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco
Montenegro
North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia

Serbia excluding Kosovo[1]
Kosovo[1]
Switzerland
Tajikistan
Türkiye
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Total non-EU/EEA

WHO European Region
West
Centre
East
Total WHO European Region

N

92
222
214
53
48
121
35
43
32
1 370
1 156
247
146
2
75
1 469
–
1
167
15
–
193
34
954
417
681
14
24
1 534
34
9 393

121
–
498
886
1 463
–
612
132
3 858
985
–
32
48
922
–
–
197
177
20
89
1 096
3 070
–
11 658
987
–
26 654

8 135
5 723
22 188
36 046

%

47.4
19.8
84.6
54.6
29.6
30.1
15.4
23.5
11.3
27.5
34.8
36.3
64.0
4.5
8.2
62.5
–
100.0
62.5
25.0
–
23.1
10.2
43.6
45.1
96.9
9.9
54.5
48.0
11.2
38.5

98.4
–
99.6
96.4
100.0
–
100.0
31.6
95.5
93.5
–
59.3
96.0
99.4
–
–
100.0
100.0
100.0
25.4
99.6
85.4
–
100.0
15.4
–
79.6

30.2
69.5
97.6
62.3

N

9
81
6
4
13
11
22
0
3
108
83
13
4
4
24
16
–
0
1
12
–
56
2
4
15
2
0
1
96
15
605

1
–
0
0
0
–
0
6
0
4
–
0
0
0
–
–
–
0
–
36
0
72
–
0
134
–
253

735
118
5
858

%

4.6
7.2
2.4
4.1
8.0
2.7
9.7
0.0
1.1
2.2
2.5
1.9
1.8
9.1
2.6
0.7
–
0.0
0.4
20.0
–
6.7
0.6
0.2
1.6
0.3
0.0
2.3
3.0
4.9
2.5

0.8
–
0.0
0.0
0.0
–
0.0
1.4
0.0
0.4
–
0.0
0.0
0.0
–
–
–
0.0
–
10.3
0.0
2.0
–
0.0
2.1
–
0.8

2.7
1.4
0.0
1.5

N

54
131
29
28
23
250
82
65
28
213
945
44
30
9
139
199
–
0
86
1
–
200
214
530
16
8
25
14
99
86
3 548

1
–
2
32
0
–
0
144
161
51
–
21
0
6
–
–
–
0
–
53
3
151
–
0
307
–
932

2 964
1 110
406
4 480

%

27.8
11.7
11.5
28.9
14.2
62.2
36.1
35.5
9.9
4.3
28.5
6.5
13.2
20.5
15.3
8.5
–
0.0
32.2
1.7
–
24.0
64.5
24.2
1.7
1.1
17.6
31.8
3.1
28.3
14.5

0.8
–
0.4
3.5
0.0
–
0.0
34.4
4.0
4.8
–
38.9
0.0
0.6
–
–
–
0.0
–
15.1
0.3
4.2
–
0.0
4.8
–
2.8

11.0
13.5
1.8
7.7

N

11
267
1
3
61
4
32
1
28
1 589
448
68
2
7
283
306
–
0
1
23
–
101
45
14
211
3
0
1
172
88
3 770

0
–
0
0
0
–
0
84
0
0
–
0
2
0
–
–
–
0
–
29
0
75
–
0
3 442
–
3 632

7 234
166
2
7 402

%

5.7
23.9
0.4
3.1
37.7
1.0
14.1
0.5
9.9
31.9
13.5
10.0
0.9
15.9
31.1
13.0
–
0.0
0.4
38.3
–
12.1
13.6
0.6
22.8
0.4
0.0
2.3
5.4
28.9
15.4

0.0
–
0.0
0.0
0.0
–
0.0
20.1
0.0
0.0
–
0.0
4.0
0.0
–
–
–
0.0
–
8.3
0.0
2.1
–
0.0
53.8
–
10.9

26.9
2.0
0.0
12.8

137

N

5

1

5

1

6

0

6

23

348

184

8

12

10

177

211

170

12

6

244

1 101

27

2 703

–

0

4

2

–

1

0

2

0

–

0

0

0

–

0

6

0

0

–

1

0

0

–

–

–

0

–

–

0

–

15

0

20

458

500

3 144

55

4

3 203

%

2.6

12.2

0.4

5.2

0.6

1.5

10.1

0.0

2.1

7.0

5.5

1.2

5.3

22.7

19.4

9.0

–

0.0

1.5

3.3

–

20.4

3.6

0.3

26.4

0.1

0.0

4.5

34.4

8.9

11.1

0.0

–

0.0

0.0

0.0

–

0.0

1.4

0.0

0.0

–

1.9

0.0

0.0

–

–

–

–

0.0

4.3

0.0

0.6

–

0.0

7.2

–

1.5

11.7

0.7

0.0

5.5

N

14

22

1

4

9

8

18

1

22

80

124

13

7

2

33

78

53

19

27

38

587

–

0

0

0

–

5

6

0

1

2

0

–

0

1

0

–

0

3

2

6

–

0

0

0

–

–

–

0

–

–

0

–

10

1

28

457

508

1 019

65

11

1 095

12.5

2.4

%

7.2

2.0

0.4

4.1

5.6

2.0

7.9

0.5

7.8

1.6

3.7

1.9

3.1

4.5

3.6

3.3

–

0.0

0.0

0.0

–

6.4

5.7

0.2

0.6

0.0

0.7

4.5

0.8

0.0

–

0.0

0.1

0.0

–

0.0

0.7

0.0

0.6

–

0.0

0.0

0.0

–

–

–

–

0.0

2.8

0.1

0.8

–

0.0

7.1

–

1.5

3.8

0.8

0.0

1.9

N

8

47

1

0

4

2

9

9

2

177

94

15

1

10

9

48

50

101

15

624

43

19

–

0

8

5

–

6

1

2

0

0

0

0

–

0

0

0

–

0

0

–

0

0

0

–

–

–

0

–

5

0

–

0

–

76

125

268

771

85

36

892

22.7

%

4.1

4.2

0.4

0.0

2.5

0.5

4.0

4.9

0.7

3.6

2.8

2.2

0.4

1.0

2.0

–

0.0

3.0

8.3

–

6.0

1.8

0.0

0.2

0.0

0.0

0.0

3.2

4.9

2.6

0.0

–

0.0

0.0

0.0

–

0.5

0.0

–

0.0

0.0

0.0

–

–

–

–

0.0

1.4

0.0

2.1

–

0.0

2.0

–

0.8

2.9

1.0

0.2

1.5

0.0

10.3

64

161

1 096

212

N

1

0

0

3

0

6

287

272

26

0

171

22

188

0

0

2

114

11

0

675

13

8

102

0

66

1

3 199

0

–

0

0

0

–

0

0

0

8

–

0

0

0

–

–

–

0

–

0

–

0

–

114

103

492

717

2 927

917

72

3 916

%

0.5

18.9

0.0

0.0

1.9

0.0

2.6

35.0

57.1

22.0

8.6

40.0

11.4

0.0

18.8

0.9

100.0

0.0

0.0

3.3

100.0

1.3

0.0

30.8

1.4

1.1

71.8

0.0

2.1

0.3

13.1

0.0

–

0.0

0.0

0.0

–

0.0

0.0

0.0

0.8

–

0.0

0.0

0.0

–

–

–

–

0.0

32.5

0.0

2.9

–

0.0

7.7

–

2.1

10.9

11.1

0.3

6.8

EU/EEA

194 Austria

1 119 Belgium

253 Bulgaria

97 Croatia

162 Cyprus

402 Czechia

227 Denmark

183 Estonia

282 Finland

4 981

France

3 321 Germany

680 Greece

228 Hungary

44 Iceland

911

Ireland

2 349 Italy

188 Latvia

1

Liechtenstein

267 Lithuania

60 Luxembourgc

114 Malta

834 Netherlands

332 Norway

2 189 Poland

924 Portugal

703 Romania

142 Slovakia

44 Slovenia

3 196 Spain

304 Sweden

24 429 Total EU/EEA

Non-EU/EEA

123 Albania

– Andorra

500 Armenia

919 Azerbaijan

1 463 Belarus

612 Georgia

418 Israel

4 040 Kazakhstan

1 054 Kyrgyzstan

– Monaco

54 Montenegro

– Bosnia and Herzegovina

50 North Macedonia

928 Republic of Moldova

– Russian Federation

– San Marino

197 Serbia

177

20

Kosovo[1]

351 Switzerland

1 100 Tajikistan

3 595

Türkiye

Serbia excluding Kosovo[1]

– Turkmenistan

11 658 Ukraine

6 402 United Kingdom

– Uzbekistan

33 464 Total non-EU/EEA

WHO European Region

26 929 West

8 239 Centre

22 724 East

57 892 Total WHO European Region

a   Country/territory/area specific comments are in Annex 5.
b   Cumulative total is the total number of cases reported by the country since the start of reporting.
c 

 The numbers displayed here may not fully align with the numbers in the country’s national statistics as these are presented by the “date of notification” instead of 
the “date of diagnosis” as here. 

[1]  All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

46

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 datathe WHO European Region 

Area

Country, territory or areaa

Centre

Hungary

Austria

Belgium

Bulgaria

Croatia

Cyprus

Czechia

Denmark

Estonia

Finland

France

Germany

Greece

Iceland

Ireland

Italy

Latvia

Liechtenstein

Lithuania

Luxembourgc

Malta

Netherlands

Norway

Poland

Portugal

Romania

Slovakia

Slovenia

Spain

Sweden

Albania

Andorra

Armenia

Azerbaijan

Belarus

Georgia

Israel

Kazakhstan

Kyrgyzstan

Monaco

Montenegro

San Marino

Serbia

Kosovo[1]

Switzerland

Tajikistan

EU/EEA

West

West

Centre

Centre

Centre

Centre

West

East

West

West

West

West

West

West

West

East

West

East

West

West

West

West

Centre

West

Centre

Centre

Centre

West

West

Centre

West

East

East

East

East

West

East

East

West

Centre

Centre

East

East

West

Centre

Centre

Centre

West

East

East

East

West

East

West

Centre

East

Centre

Bosnia and Herzegovina

North Macedonia

Republic of Moldova

Russian Federation

Serbia excluding Kosovo[1]

Centre

Türkiye

Turkmenistan

Ukraine

United Kingdom

Uzbekistan

Total non-EU/EEA

WHO European Region

Total WHO European Region

1 370

1 156

1 469

N

92

222

214

53

48

121

35

43

32

247

146

2

75

–

1

167

15

–

193

34

954

417

681

14

24

1 534

34

9 393

121

–

498

886

1 463

–

612

132

3 858

985

–

32

48

922

–

–

197

177

20

89

1 096

3 070

–

11 658

987

–

26 654

8 135

5 723

22 188

36 046

%

47.4

19.8

84.6

54.6

29.6

30.1

15.4

23.5

11.3

27.5

34.8

36.3

64.0

4.5

8.2

62.5

–

62.5

25.0

–

23.1

10.2

43.6

45.1

96.9

9.9

54.5

48.0

11.2

38.5

100.0

98.4

–

99.6

96.4

100.0

–

100.0

31.6

95.5

93.5

–

59.3

96.0

99.4

–

–

100.0

100.0

100.0

25.4

99.6

85.4

100.0

15.4

–

–

79.6

30.2

69.5

97.6

62.3

108

83

13

N

9

81

6

4

13

11

22

0

3

4

4

24

16

–

0

1

12

–

56

15

2

4

2

0

1

96

15

1

–

0

0

0

–

0

6

0

4

–

0

0

0

–

–

–

0

–

–

0

–

36

0

72

134

253

735

118

5

858

20.0

%

4.6

7.2

2.4

4.1

8.0

2.7

9.7

0.0

1.1

2.2

2.5

1.9

1.8

9.1

2.6

0.7

–

0.0

0.4

–

6.7

0.6

0.2

1.6

0.3

0.0

2.3

3.0

4.9

2.5

0.8

–

0.0

0.0

0.0

–

0.0

1.4

0.0

0.4

–

0.0

0.0

0.0

–

–

–

–

0.0

10.3

0.0

2.0

–

0.0

2.1

–

0.8

2.7

1.4

0.0

1.5

N

54

131

29

28

23

250

82

65

28

213

945

44

30

9

139

199

86

–

0

1

–

200

214

530

16

8

25

14

99

86

32

1

–

2

0

–

0

144

161

51

–

21

0

6

–

–

–

0

–

–

0

–

53

3

151

307

932

2 964

1 110

406

4 480

%

27.8

11.7

11.5

28.9

14.2

62.2

36.1

35.5

9.9

4.3

28.5

6.5

13.2

20.5

15.3

8.5

–

0.0

32.2

1.7

–

24.0

64.5

24.2

1.7

1.1

17.6

31.8

3.1

28.3

14.5

0.8

–

0.4

3.5

0.0

–

0.0

34.4

4.0

4.8

–

38.9

0.0

0.6

–

–

–

–

0.0

15.1

0.3

4.2

–

0.0

4.8

–

2.8

11.0

13.5

1.8

7.7

N

11

267

1

3

61

4

32

1

28

1 589

448

68

283

306

23

–

101

45

14

211

172

88

3 770

84

2

7

–

0

1

3

0

1

0

–

0

0

0

–

0

0

0

–

0

2

0

–

–

–

0

–

–

0

–

29

0

75

3 442

3 632

7 234

166

2

7 402

%

5.7

23.9

0.4

3.1

37.7

1.0

14.1

0.5

9.9

31.9

13.5

10.0

0.9

15.9

31.1

13.0

–

0.0

0.4

38.3

–

12.1

13.6

0.6

22.8

0.4

0.0

2.3

5.4

28.9

15.4

0.0

–

0.0

0.0

0.0

–

0.0

20.1

0.0

0.0

–

0.0

4.0

0.0

–

–

–

–

0.0

8.3

0.0

2.1

–

0.0

53.8

–

10.9

26.9

2.0

0.0

12.8

Total EU/EEA

Non-EU/EEA

605

3 548

a   Country/territory/area specific comments are in Annex 5.

b   Cumulative total is the total number of cases reported by the country since the start of reporting.

c 

 The numbers displayed here may not fully align with the numbers in the country’s national statistics as these are presented by the “date of notification” instead of 

the “date of diagnosis” as here. 

[1]  All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

Table 10. Origin of those diagnosed with HIV in 2023 by country of report or region, in EU/EEA and other countries of 

Country of report

Western Europe

Central and eastern Europe

Sub-Saharan Africa

Latin America and  
the Caribbean

South and south-east Asia

Other 

Unknown

Totalb  Country, territory or areaa

N

5
137
1
5
1
6
23
0
6
348
184
8
12
10
177
211
–
0
4
2
–
170
12
6
244
1
0
2
1 101
27
2 703

0
–
0
0
0
–
0
6
0
0
–
1
0
0
–
–
–
0
–
15
0
20
–
0
458
–
500

3 144
55
4
3 203

%

2.6
12.2
0.4
5.2
0.6
1.5
10.1
0.0
2.1
7.0
5.5
1.2
5.3
22.7
19.4
9.0
–
0.0
1.5
3.3
–
20.4
3.6
0.3
26.4
0.1
0.0
4.5
34.4
8.9
11.1

0.0
–
0.0
0.0
0.0
–
0.0
1.4
0.0
0.0
–
1.9
0.0
0.0
–
–
–
0.0
–
4.3
0.0
0.6
–
0.0
7.2
–
1.5

11.7
0.7
0.0
5.5

N

14
22
1
4
9
8
18
1
22
80
124
13
7
2
33
78
–
0
0
0
–
53
19
5
6
0
1
2
27
38
587

0
–
0
1
0
–
0
3
2
6
–
0
0
0
–
–
–
0
–
10
1
28
–
0
457
–
508

1 019
65
11
1 095

%

7.2
2.0
0.4
4.1
5.6
2.0
7.9
0.5
7.8
1.6
3.7
1.9
3.1
4.5
3.6
3.3
–
0.0
0.0
0.0
–
6.4
5.7
0.2
0.6
0.0
0.7
4.5
0.8
12.5
2.4

0.0
–
0.0
0.1
0.0
–
0.0
0.7
0.0
0.6
–
0.0
0.0
0.0
–
–
–
0.0
–
2.8
0.1
0.8
–
0.0
7.1
–
1.5

3.8
0.8
0.0
1.9

N

8
47
1
0
4
2
9
9
2
177
94
15
1
10
9
48
–
0
8
5
–
50
6
1
2
0
0
0
101
15
624

0
–
0
0
0
–
0
43
19
0
–
0
0
0
–
–
–
0
–
5
0
76
–
0
125
–
268

771
85
36
892

%

4.1
4.2
0.4
0.0
2.5
0.5
4.0
4.9
0.7
3.6
2.8
2.2
0.4
22.7
1.0
2.0
–
0.0
3.0
8.3
–
6.0
1.8
0.0
0.2
0.0
0.0
0.0
3.2
4.9
2.6

0.0
–
0.0
0.0
0.0
–
0.0
10.3
0.5
0.0
–
0.0
0.0
0.0
–
–
–
0.0
–
1.4
0.0
2.1
–
0.0
2.0
–
0.8

2.9
1.0
0.2
1.5

N

1
212
0
0
3
0
6
64
161
1 096
287
272
26
0
171
22
188
0
0
2
114
11
0
675
13
8
102
0
66
1
3 199

0
–
0
0
0
–
0
0
0
8
–
0
0
0
–
–
–
0
–
114
0
103
–
0
492
–
717

2 927
917
72
3 916

%

0.5
18.9
0.0
0.0
1.9
0.0
2.6
35.0
57.1
22.0
8.6
40.0
11.4
0.0
18.8
0.9
100.0
0.0
0.0
3.3
100.0
1.3
0.0
30.8
1.4
1.1
71.8
0.0
2.1
0.3
13.1

0.0
–
0.0
0.0
0.0
–
0.0
0.0
0.0
0.8
–
0.0
0.0
0.0
–
–
–
0.0
–
32.5
0.0
2.9
–
0.0
7.7
–
2.1

10.9
11.1
0.3
6.8

EU/EEA
194 Austria
1 119 Belgium
253 Bulgaria
97 Croatia
162 Cyprus
402 Czechia
227 Denmark
183 Estonia
282 Finland
France

4 981
3 321 Germany
680 Greece
228 Hungary
44 Iceland
Ireland
911

2 349 Italy

188 Latvia

1

Liechtenstein

267 Lithuania
60 Luxembourgc
114 Malta
834 Netherlands
332 Norway
2 189 Poland

924 Portugal
703 Romania
142 Slovakia
44 Slovenia

3 196 Spain

304 Sweden
24 429 Total EU/EEA
Non-EU/EEA

123 Albania
– Andorra
500 Armenia
919 Azerbaijan

1 463 Belarus

– Bosnia and Herzegovina

612 Georgia
418 Israel

4 040 Kazakhstan
1 054 Kyrgyzstan
– Monaco
54 Montenegro
50 North Macedonia
928 Republic of Moldova
– Russian Federation
– San Marino

197 Serbia
Serbia excluding Kosovo[1]
177
Kosovo[1]
20
351 Switzerland

1 100 Tajikistan
3 595

Türkiye
– Turkmenistan

11 658 Ukraine
6 402 United Kingdom
– Uzbekistan
33 464 Total non-EU/EEA

WHO European Region

26 929 West
8 239 Centre
22 724 East
57 892 Total WHO European Region

[1]  All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

47

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORTTable 11. HIV diagnoses, by geographical area, transmission mode and country or region of origin, in cases  
reported in 2023

Country of report

Western Europe

Central and eastern Europe

Sub-Saharan Africa

Latin America and  

the Caribbean

South and south-east Asia

Other 

Unknown

N

4 306
405
2 779
32
3
1
1 867
9 393

2 142
4 118
17 547
137
4
5
2 701
26 654

4 092
295
2 467
29
5
3
1 244
8 135

1 218
129
1 496
14
2
0
2 864
5 723

1 137
4 099
16 363
126
0
3
460
22 188
36 046

%

51.5
40.0
33.7
14.7
7.0
7.1
27.4
38.0

64.5
97.8
81.8
46.1
8.5
25.0
65.6
79.6

45.4
33.5
22.5
8.4
6.3
10.0
21.8
30.1

81.9
67.9
74.3
43.8
22.2
0
63.6
69.5

95.7
98.7
97.9
93.3
0
100.0
63.7
96.8
61.9

N

358
16
123
6
1
0
101
605

93
1
60
2
0
1
96
253

421
17
163
8
0
1
125
735

29
0
17
0
1
0
71
118

1
0
3
0
0
0
1
5
858

%

4.3
1.6
1.5
2.8
2.3
0
1.5
2.4

2.8
0.0
0.3
0.7
0
5.0
2.3
0.8

4.7
1.9
1.5
2.3
0
3.3
2.2
2.7

1.9
0
0.8
0
11.1
0
1.6
1.4

0.1
0
0.0
0
0
0
0.1
0.0
1.5

N

634
404
1 454
62
19
7
968
3 548

189
66
421
11
7
1
237
932

695
390
1 251
53
20
7
548
2 964

100
50
360
15
5
1
579
1 110

28
30
264
5
1
0
78
406
4 480

%

7.6
39.9
17.6
28.6
44.2
50.0
14.2
14.3

5.7
1.6
2.0
3.7
14.9
5.0
5.8
2.8

7.7
44.3
11.4
15.3
25.0
23.3
9.6
11.0

6.7
26.3
17.9
46.9
55.6
100.0
12.9
13.5

2.4
0.7
1.6
3.7
100.0
0
10.8
1.8
7.7

N

392
9
2 738
90
15
0
526
3 770

163
4
2 955
139
18
10
343
3 632

535
13
5 629
227
33
10
787
7 234

18
0
64
2
0
0
82
166

2
0
0
0
0
0
0
2
7 402

%

4.7
0.9
33.2
41.5
34.9
0
7.7
15.2

4.9
0.1
13.8
46.8
38.3
50.0
8.3
10.9

5.9
1.5
51.3
65.4
41.3
33.3
13.8
26.7

1.2
0
3.2
6.3
0
0
1.8
2.0

0.2
0
0
0
0
0
0
0.0
12.7

1 740

13

521

N

5

1

2

421

2 703

275

3

94

2

0

1

125

500

1 984

16

611

522

3 144

27

7

1

3

0

4

0

0

0

4

0

0

0

0

0

0

4

24

55

3 203

%

20.8

1.3

6.3

2.3

2.3

14.3

6.2

10.9

8.3

0.1

0.4

0.7

0

5.0

3.0

1.5

22.0

1.8

5.6

2.0

1.3

10.0

9.1

11.6

1.8

0.2

0

0

0

0

0.5

0.7

0.3

0

0

0

0

0

0

0.0

5.5

N

279

24

149

7

1

0

127

587

271

9

121

2

14

1

90

508

531

29

246

9

15

1

188

1 019

16

4

18

0

0

0

27

65

3

0

6

0

0

0

2

11

1 095

29.8

%

3.3

2.4

1.8

3.2

2.3

0

1.9

2.4

8.2

0.2

0.6

0.7

5.0

2.2

1.5

5.9

3.3

2.2

2.6

1.1

2.1

0.9

0

0

0

0.6

0.8

0.3

0.0

0

0

0

0

0.3

0.0

1.9

18.8

3.3

3.3

3.8

N

309

16

168

1

1

2

127

624

87

6

63

1

3

0

108

268

381

19

208

2

3

2

156

771

12

1

8

0

1

0

63

85

15

3

2

0

0

0

16

36

892

%

3.7

1.6

2.0

0.5

2.3

14.3

1.9

2.5

2.6

0.1

0.3

0.3

6.4

0

2.6

0.8

4.2

2.2

1.9

0.6

3.8

6.7

2.7

2.9

0.8

0.5

0.4

11.1

0

0

1.4

1.0

0.3

0.0

0.1

0

0

0

2.2

0.2

1.5

2 687

3 501

N

349

125

322

14

2

2

100

192

5

3

1

1

415

717

371

102

408

12

3

3

68

6

47

1

0

0

795

917

10

22

59

4

0

0

2 142

3 041

165

260

4 218

%

4.2

12.4

3.9

6.5

4.7

14.3

39.4

14.2

3.0

0.1

0.9

1.0

2.1

5.0

10.1

2.1

4.1

11.6

3.7

3.5

3.8

10.0

37.5

11.2

4.6

3.2

2.3

3.1

0

0

17.6

11.1

0.8

0.5

0.4

3.0

0

0

22.9

1.1

7.2

43 Haemophiliac/transfusion recipient

47 Haemophiliac/transfusion recipient

Total

Transmission mode

EU/EEA

8 367 Sex between men

1 012 Injecting drug use

8 254 Heterosexual contact 

217 Mother-to-child

14 Nosocomial infection

6 824 Other/undetermined

24 731 Total EU/EEA

Non-EU/EEA

3 320 Sex between men

4 212 Injecting drug use

21 453 Heterosexual contact 

297 Mother-to-child

20 Nosocomial infection

4 115 Other/undetermined

33 464 Total non-EU/EEA

West

9 010 Sex between men

881

Injecting drug use

10 983 Heterosexual contact 

347 Mother-to-child

30 Nosocomial infection

5 712 Other/undetermined

27 043 Total west

Centre

1 488 Sex between men

190 Injecting drug use

2 014 Heterosexual contact 

32 Mother-to-child

1 Nosocomial infection

4 505 Other/undetermined

8 239 Total centre

East

1 188 Sex between men

4 153 Injecting drug use

16 710 Heterosexual contact 

135 Mother-to-child

80 Haemophiliac/transfusion recipient

9 Haemophiliac/transfusion recipient

1 Haemophiliac/transfusion recipient

3 Nosocomial infection

722 Other/undetermined

22 912 Total east

58 194 Total WHO European Region

Transmission mode

EU/EEA
Sex between men
Injecting drug use
Heterosexual contact 
Mother-to-child
Haemophiliac/transfusion recipient
Nosocomial infection
Other/undetermined
Total EU/EEA
Non-EU/EEA
Sex between men
Injecting drug use
Heterosexual contact 
Mother-to-child
Haemophiliac/transfusion recipient
Nosocomial infection
Other/undetermined
Total non-EU/EEA
West
Sex between men
Injecting drug use
Heterosexual contact 
Mother-to-child
Haemophiliac/transfusion recipient
Nosocomial infection
Other/undetermined
Total west
Centre
Sex between men
Injecting drug use
Heterosexual contact 
Mother-to-child
Haemophiliac/transfusion recipient
Nosocomial infection
Other/undetermined
Total centre
East
Sex between men
Injecting drug use
Heterosexual contact 
Mother-to-child
Haemophiliac/transfusion recipient
Nosocomial infection
Other/undetermined
Total east
Total WHO European Region

48

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 dataTable 11. HIV diagnoses, by geographical area, transmission mode and country or region of origin, in cases  

reported in 2023

Country of report

Western Europe

Central and eastern Europe

Sub-Saharan Africa

Latin America and  
the Caribbean

South and south-east Asia

Other 

Unknown

N

1 740
13
521
5
1
2
421
2 703

275
3
94
2
0
1
125
500

1 984
16
611
7
1
3
522
3 144

27
0
4
0
0
0
24
55

4
0
0
0
0
0
0
4
3 203

%

20.8
1.3
6.3
2.3
2.3
14.3
6.2
10.9

8.3
0.1
0.4
0.7
0
5.0
3.0
1.5

22.0
1.8
5.6
2.0
1.3
10.0
9.1
11.6

1.8
0
0.2
0
0
0
0.5
0.7

0.3
0
0
0
0
0
0
0.0
5.5

N

279
24
149
7
1
0
127
587

271
9
121
2
14
1
90
508

531
29
246
9
15
1
188
1 019

16
4
18
0
0
0
27
65

3
0
6
0
0
0
2
11
1 095

%

3.3
2.4
1.8
3.2
2.3
0
1.9
2.4

8.2
0.2
0.6
0.7
29.8
5.0
2.2
1.5

5.9
3.3
2.2
2.6
18.8
3.3
3.3
3.8

1.1
2.1
0.9
0
0
0
0.6
0.8

0.3
0
0.0
0
0
0
0.3
0.0
1.9

N

309
16
168
1
1
2
127
624

87
6
63
1
3
0
108
268

381
19
208
2
3
2
156
771

12
1
8
0
1
0
63
85

3
2
15
0
0
0
16
36
892

%

3.7
1.6
2.0
0.5
2.3
14.3
1.9
2.5

2.6
0.1
0.3
0.3
6.4
0
2.6
0.8

4.2
2.2
1.9
0.6
3.8
6.7
2.7
2.9

0.8
0.5
0.4
0
11.1
0
1.4
1.0

0.3
0.0
0.1
0
0
0
2.2
0.2
1.5

N

349
125
322
14
2
2
2 687
3 501

100
5
192
3
1
1
415
717

371
102
408
12
3
3
2 142
3 041

68
6
47
1
0
0
795
917

10
22
59
4
0
0
165
260
4 218

Haemophiliac/transfusion recipient

Haemophiliac/transfusion recipient

Transmission mode

EU/EEA

Sex between men

Injecting drug use

Heterosexual contact 

Mother-to-child

Nosocomial infection

Other/undetermined

Total EU/EEA

Non-EU/EEA

Sex between men

Injecting drug use

Heterosexual contact 

Mother-to-child

Nosocomial infection

Other/undetermined

Total non-EU/EEA

West

Sex between men

Injecting drug use

Heterosexual contact 

Mother-to-child

Nosocomial infection

Other/undetermined

Total west

Centre

Sex between men

Injecting drug use

Heterosexual contact 

Mother-to-child

Nosocomial infection

Other/undetermined

Total centre

East

Sex between men

Injecting drug use

Heterosexual contact 

Mother-to-child

Haemophiliac/transfusion recipient

Haemophiliac/transfusion recipient

Haemophiliac/transfusion recipient

Nosocomial infection

Other/undetermined

Total east

Total WHO European Region

N

4 306

405

2 779

32

3

1

1 867

9 393

2 142

4 118

17 547

137

4

5

2 701

26 654

4 092

295

2 467

29

5

3

1 244

8 135

1 218

129

1 496

14

2

0

2 864

5 723

1 137

4 099

16 363

126

0

3

460

22 188

36 046

%

51.5

40.0

33.7

14.7

7.0

7.1

27.4

38.0

64.5

97.8

81.8

46.1

8.5

25.0

65.6

79.6

45.4

33.5

22.5

8.4

6.3

10.0

21.8

30.1

81.9

67.9

74.3

43.8

22.2

0

63.6

69.5

95.7

98.7

97.9

93.3

0

100.0

63.7

96.8

61.9

N

358

16

123

6

1

0

101

605

93

1

60

2

0

1

96

253

421

17

163

8

0

1

125

735

29

0

17

0

1

0

71

118

1

0

3

0

0

0

1

5

858

%

4.3

1.6

1.5

2.8

2.3

0

1.5

2.4

2.8

0.0

0.3

0.7

0

5.0

2.3

0.8

4.7

1.9

1.5

2.3

0

3.3

2.2

2.7

1.9

0.8

11.1

0

0

0

1.6

1.4

0.1

0.0

0

0

0

0

0.1

0.0

1.5

N

634

404

1 454

62

19

7

968

3 548

189

66

421

11

7

1

237

932

695

390

1 251

53

20

7

548

2 964

100

50

360

15

5

1

579

1 110

28

30

264

5

1

0

78

406

4 480

%

7.6

39.9

17.6

28.6

44.2

50.0

14.2

14.3

5.7

1.6

2.0

3.7

14.9

5.0

5.8

2.8

7.7

44.3

11.4

15.3

25.0

23.3

9.6

11.0

6.7

26.3

17.9

46.9

55.6

100.0

12.9

13.5

2.4

0.7

1.6

3.7

100.0

0

10.8

1.8

7.7

N

392

9

2 738

90

15

0

526

3 770

163

4

2 955

139

18

10

343

3 632

535

13

5 629

227

33

10

787

7 234

18

0

64

82

166

2

0

0

2

0

0

0

0

0

0

2

7 402

%

4.7

0.9

33.2

41.5

34.9

0

7.7

15.2

4.9

0.1

13.8

46.8

38.3

50.0

8.3

10.9

5.9

1.5

51.3

65.4

41.3

33.3

13.8

26.7

1.2

0

3.2

6.3

0

0

1.8

2.0

0.2

0

0

0

0

0

0

0.0

12.7

%

4.2
12.4
3.9
6.5
4.7
14.3
39.4
14.2

3.0
0.1
0.9
1.0
2.1
5.0
10.1
2.1

4.1
11.6
3.7
3.5
3.8
10.0
37.5
11.2

4.6
3.2
2.3
3.1
0
0
17.6
11.1

0.8
0.5
0.4
3.0
0
0
22.9
1.1
7.2

Total

Transmission mode

EU/EEA
8 367 Sex between men
1 012 Injecting drug use
8 254 Heterosexual contact 

217 Mother-to-child
43 Haemophiliac/transfusion recipient
14 Nosocomial infection
6 824 Other/undetermined
24 731 Total EU/EEA
Non-EU/EEA
3 320 Sex between men
4 212 Injecting drug use
21 453 Heterosexual contact 

297 Mother-to-child
47 Haemophiliac/transfusion recipient
20 Nosocomial infection
4 115 Other/undetermined

33 464 Total non-EU/EEA

West

9 010 Sex between men
Injecting drug use

881

10 983 Heterosexual contact 

347 Mother-to-child
80 Haemophiliac/transfusion recipient
30 Nosocomial infection
5 712 Other/undetermined

27 043 Total west

Centre

1 488 Sex between men
190 Injecting drug use
2 014 Heterosexual contact 

32 Mother-to-child
9 Haemophiliac/transfusion recipient
1 Nosocomial infection
4 505 Other/undetermined
8 239 Total centre
East

1 188 Sex between men
4 153 Injecting drug use
16 710 Heterosexual contact 

135 Mother-to-child

1 Haemophiliac/transfusion recipient
3 Nosocomial infection
722 Other/undetermined

22 912 Total east
58 194 Total WHO European Region

49

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORTSURVEILLANCE REPORT

HIV/AIDS surveillance in Europe 2024 – 2023 data

Table 12. Percentage of HIV diagnoses (2023) among individuals over 14 years old, reported with available CD4 cell 
count data, categorized by CD4 cell count levels (< 200 and < 350 cells per mm³ of blood) and by transmission mode for 
cases with CD4 < 350, in the EU/EEA and other countries within the WHO European Regiona

Area

Country, territory or areab

Number of cases 
with CD4c

Completeness 
(%) CD4d 

N

%

N

% Heterosexuald

Injecting 
drug userd

Sex 
between 
mend

CD4 < 200 (%)

CD4 < 350 (%)

CD4 < 350 per mm3 blood (%)

EU/EEA
West
West
Centre
Centre
Centre
Centre
West
East
West
West
West
West
Centre
West
West
West
East
West
East
West
West
West
West
Centre
West
Centre
Centre
Centre
West
West

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Total EU/EEA

Non-EU/EEA
Centre
West
East
East
East
Centre
East
West
East
East
West
Centre
Centre
East
East
West
Centre
Centre
Centre
West
East
Centre
East
East
West
East

Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco
Montenegro
North Macedonia
Republic of Moldova
Russian Federatione
San Marino
Serbia

Serbia excluding Kosovo[1]
Kosovo[1]
Switzerland
Tajikistan
Türkiye
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Total non-EU/EEA

WHO European Region
West
Centre
East
Total WHO European Region

184
332
180
46
102
193
145
98
69
2 048
885
240
–
16
137
2 303
62
–
141
38
–
357
108
–
626
671
26
32
2 833
89
11 961

113
–
–
809
1 273
–
523
159
3 681
894
–
25
48
785
52 547
–
168
154
14
140
978
432
–
9 956
5 637
–
20 153

16 297
2 036
13 732
32 065

97
61
88
90
100
87
97
85
90.0
68
31
37
–
94
35
98
34
–
76
93
–
99
95
–
78
96
33
100
89
65
77

93
–
–
89
88
–
86
74
92
86
–
76
96
86
96
–
95
98
70
55
94
12
–
86
88
–
76

75
38
85
74

51
94
71
20
28
80
52
30
24
666
292
102
–
3
37
955
22
–
45
6
–
101
32
–
211
233
2
12
771
24
3 964

51
–
–
218
346
–
161
39
925
301
–
10
19
281
7 956
–
76
72
4
45
340
111
–
3 827
874
–
6 141

4 420
713
5 013
10 146

27.7
28.3
39.4
43.5
27.5
41.5
48.3
30.6
38.7
32.5
33.0
42.5
–
18.8
27.0
41.5
35.5
–
31.9
15.8
–
28.3
29.6
–
33.7
34.7
7.7
37.5
27.2
27.0
31.6

45.1
–
–
26.9
27.2
–
30.8
24.5
25.1
33.7
–
40.0
39.6
35.8
15.1
–
45.2
46.8
28.6
32.1
34.8
25.7
–
38.4
15.5
–
30.5

27.1
35.0
36.5
31.6

83
160
111
28
42
116
75
45
32
1 171
443
154
–
9
63
1 384
40
–
80
12
–
173
49
–
371
401
7
22
1 380
39
6 490

70
–
–
376
626
–
275
85
1 897
529
–
13
28
458
15 750
–
101
95
6
75
555
222
–
6 119
1 693
–
10 294

7 479
1 161
8 172
16 812

45.1
48.2
61.7
60.9
41.2
60.1
67.8
45.9
51.6
57.2
50.1
64.2
–
56.3
46.0
60.1
64.5
–
56.7
31.6
–
48.5
45.4
–
59.3
59.8
26.9
68.8
48.7
43.8
52.7

61.9
–
–
46.5
49.2
–
52.6
53.5
51.5
59.2
–
52.0
58.3
58.3
30.0
–
60.1
61.7
42.9
53.6
56.7
51.4
–
61.5
30.0
–
51.1

45.9
57.0
59.5
52.4

58.5
57.1
69.1
72.7
43.6
67.8
52.0
56.0
56.3
60.4
47.6
72.7
–
57.1
53.1
65.1
64.5
–
73.4
42.9
–
59.8
55.9
–
63.8
67.6
23.5
75.0
56.1
52.6
58.6

61.8
–
–
45.4
52.0
–
55.3
59.1
54.3
61.4
–
37.5
66.7
59.4
–
–
78.3
80.5
60.0
53.8
56.6
52.6
–
65.0
29.1
–
54.4

46.8
63.7
62.7
56.2

42.1
50.0
55.6
0.0
40.0
70.0
2.6
66.7
40.0
67.9
43.5
69.0
–
100.0
14.3
60.3
66.7
–
39.3
20.0
–
66.7
50.0
–
57.9
52.7
0.0
0.0
47.1
100.0
47.0

100.0
–
–
54.0
39.2
–
70.2
100.0
42.1
58.3
–
33.3
–
44.0
–
–
33.3
33.3
–
–
60.0
100.0
–
52.4
46.7
–
51.7

52.9
54.0
51.7
52.0

36.0
38.2
52.3
59.4
33.3
47.0
32.0
42.9
40.0
48.2
43.1
54.8
–
50.0
38.3
51.4
50.0
–
37.5
10.0
–
40.1
30.6
–
51.1
47.3
37.5
69.6
42.2
37.5
43.1

63.2
–
–
48.3
31.3
–
39.2
45.9
48.8
43.9
–
70.0
53.3
20.0
–
–
52.3
54.4
33.3
47.1
36.8
56.4
–
50.4
29.9
–
36.9

42.0
51.0
43.8
43.0

a  Acute infections and previously positive cases are excluded.
b  Country/territory/area specific comments are in Annex 5.
c  People over 15 years old and previously positive cases reported by some countries are excluded from the data calculations. These data should be interpreted with 
caution, as some countries are unable to distinguish between new and previous positive cases, meaning the numbers and proportions may vary and should not be 
directly compared between countries.

d  There is some variation by country for CD4 cell count completeness by transmission group and numbers of cases by transmission group (heterosexual, injecting 

drug user, sex between men) and therefore percentages based on five or fewer are censored.

e  Data on CD4 cell count reported from the Russian Federation do not include disaggregation by mode of transmission and are excluded from the sub regional  

and regional totals.

[1]  All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

50

HIV/AIDS surveillance in Europe 2024 – 2023 data

SURVEILLANCE REPORT

Table 13. AIDS diagnoses and rates per 100 000 population, by country and year of diagnosis (2014–2023) and 
cumulative totals, in EU/EEA and other countries of the WHO European Region

Area

Country, territory or areaa

Year of 
start of 
reporting 

2014

N

Rate

2015

N

Rate

2016

N

Rate

2017

N

Rate

2018

N

Rate

2019

2020

2021

2022

2023

Rate

Rate

Rate

Cumulative 

totalb Country, territory or areaa

Rate

EU/EEA
West
West
Centre
Centre
Centre
Centre
West
East
West
West
West
West
Centre
West
West
West
East
West
East
West
West
West
West
Centre
West
Centre
Centre
Centre
West
West

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Total EU/EEA

Non-EU/EEA
Centre
West
East
East
East
Centre
East
West
East
East
West
Centre Montenegro
Centre
East
East
West
Centre
Centre
Centre
West
East
Centre
East
East
West
East

Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco

North Macedonia
Repubic of Moldova
Russian Federation
San Marino
Serbia

Serbia excluding Kosovo[1]
Kosovo[1]
Switzerland
Tajikistan
Türkiye
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Total non-EU/EEA

WHO European Region
West
Centre
East
Total WHO European Region

1982
1983
1987
1986
1986
1986
1980
1992
1983
1982
1981
1981
1986
1985
1983
1982
1990
1989
1988
1983
1986
1999
1983
1986
1985
1985
1985
1986
1981
1982

1993
2004
1988
1995
1991
1986
1989
1981
1993
1999
1990
1989
1989
1985
–
1986
1985
1985
2005
1980
1998
1985
2002
1988
1981
1992

85
136
64
1
54
32
30
18
20
656
393
132
51
0
32
932
171
1
37
15
4
224
45
149
398
417
4
17
679
–
4 797

50
0
176
200
474
8
268
70
251
53
1
7
16
299
–
0
49
48
1
79
229
125
–
9 844
368
–
12 567

4 299
1 044
12 020
17 363

1.0
1.2
0.9
0.0
6.3
0.3
0.5
1.4
0.4
1.0
0.5
1.2
0.5
0.0
0.7
1.5
8.5
2.7
1.2
2.7
0.9
1.3
0.9
0.4
3.8
2.1
0.1
0.8
1.5
–
1.1

1.7
0.0
6.1
2.1
4.9
0.2
7.1
0.9
1.4
0.9
2.8
1.1
0.8
9.0
–
0.0
0.5
0.6
0.1
1.0
2.8
0.2
–
21.8
0.6
–
4.4

1.0
0.5
10.7
2.4

76
105
45
3
70
38
40
18
19
615
362
139
43
0
21
874
132
0
35
19
2
263
22
128
357
367
8
11
609
–
4 421

65
3
163
193
490
8
270
45
273
35
0
11
6
293
–
0
50
47
3
64
281
118
–
8 468
401
–
11 237

4 036
971
10 651
15 658

0.9
0.9
0.6
0.1
8.3
0.4
0.7
1.4
0.3
0.9
0.4
1.3
0.4
0.0
0.4
1.4
6.6
0.0
1.2
3.4
0.5
1.6
0.4
0.3
3.4
1.8
0.1
0.5
1.3
–
1.0

2.3
4.2
5.7
2.0
5.1
0.2
7.2
0.6
1.5
0.6
0.0
1.7
0.3
8.9
–
0.0
0.5
0.6
0.2
0.8
3.3
0.1
–
19.8
0.6
–
4.0

1.0
0.5
9.6
2.2

67
78
42
22
74
45
24
40
30
523
310
149
53
4
15
874
114
0
48
19
5
220
22
102
401
355
10
10
541
–
4 197

58
0
163
161
512
8
269
47
350
33
0
15
9
366
–
0
61
56
5
71
238
99
–
8 852
297
–
11 609

3 697
963
11 146
15 806

0.8
0.7
0.6
0.5
8.7
0.4
0.4
3.0
0.5
0.8
0.4
1.4
0.5
1.2
0.3
1.5
5.8
0.0
1.6
3.3
1.1
1.3
0.4
0.3
3.9
1.8
0.2
0.5
1.2
–
0.9

2.0
0.0
5.7
1.6
5.3
0.2
7.1
0.6
1.9
0.5
0.0
2.4
0.4
11.3
–
0.0
0.7
0.7
0.3
0.8
2.7
0.1
–
20.8
0.5
–
4.1

0.9
0.5
10.0
2.1

68
64
49
21
67
55
29
20
18
511
295
129
52
0
21
803
118
0
54
9
0
212
14
109
321
335
9
7
513
–
3 903

33
2
144
168
439
4
257
33
361
46
0
13
2
274
–
0
65
59
6
74
265
121
–
9 308
260
–
11 869

3 376
942
11 454
15 772

0.8
0.6
0.7
0.5
7.8
0.5
0.5
1.5
0.3
0.8
0.4
1.2
0.5
0.0
0.4
1.3
6.1
0.0
1.9
1.5
0.0
1.2
0.3
0.3
3.1
1.7
0.2
0.3
1.1
–
0.9

1.1
2.7
5.0
1.7
4.5
0.1
6.8
0.4
2.0
0.8
0.0
2.1
0.1
8.6
–
0.0
0.7
0.8
0.3
0.9
3.0
0.1
–
21.9
0.4
–
4.1

0.8
0.5
10.3
2.1

53
60
57
30
73
39
26
25
22
553
242
107
57
2
13
722
99
0
37
8
0
197
12
111
290
326
11
10
384
–
3 566

47
0
211
182
382
13
273
42
433
47
0
14
4
365
–
0
70
62
8
66
212
108
–
8 839
256
–
11 564

3 055
970
11 105
15 130

0.6
0.5
0.8
0.7
8.4
0.4
0.4
1.9
0.4
0.8
0.3
1.0
0.6
0.6
0.3
1.2
5.1
0.0
1.3
1.3
0.0
1.1
0.2
0.3
2.8
1.7
0.2
0.5
0.8
–
0.8

1.6
0.0
7.4
1.8
3.9
0.4
7.2
0.5
2.3
0.8
0.0
2.2
0.2
11.6
–
0.0
0.8
0.8
0.4
0.8
2.3
0.1
–
20.9
0.4
–
4.0

0.7
0.5
9.9
2.0

a   Country/territory/area specific comments are in Annex 5.
b   Cumulative total is the total number of cases reported by the country since the start of reporting.

[1]  All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

51

3 175

2 499

2 540

2 643

2 690

349 976 Total EU-EEA

N

61

87

68

20

84

38

22

30

19

74

97

53

4

11

90

0

21

5

0

580

647

183

19

95

259

314

3

9

–

282

38

–

173

196

380

10

264

29

451

20

285

–

10

–

–

0

77

72

5

71

157

112

–

7 511

261

–

10 045

2 711

931

9 578

13 220

N

47

63

42

12

70

45

25

23

12

452

–

105

42

2

10

415

55

0

23

13

0

164

11

53

226

204

4

6

–

375

18

–

152

105

220

–

181

34

469

28

–

4

–

–

0

199

34

32

2

43

110

46

–

4 139

182

–

5 964

2 179

580

5 704

8 463

0.7

0.8

1.0

0.5

9.6

0.4

0.4

2.3

0.3

0.9

0.1

0.9

0.5

1.1

0.2

1.1

4.7

0.0

0.7

0.8

0.0

1.1

0.4

0.3

2.5

1.6

0.1

0.4

0.6

–

0.7

1.3

–

6.1

1.9

3.9

0.3

7.0

0.3

2.4

0.3

1.6

9.2

–

–

–

0.0

0.8

1.0

0.3

0.8

1.7

0.1

–

17.9

0.4

–

3.4

0.6

0.5

8.5

1.8

487

507

545

453

444

532

N

54

76

38

25

92

55

17

11

16

–

86

50

2

16

39

0

38

19

0

141

23

64

257

220

3

5

–

253

48

–

197

109

286

–

217

35

459

33

–

8

–

–

0

199

53

50

3

39

129

80

–

4 151

193

–

6 236

2 167

741

5 868

8 776

0.5

0.5

0.6

0.3

7.9

0.4

0.4

1.7

0.2

0.7

–

1.0

0.4

0.5

0.2

0.7

2.9

0.0

0.8

2.1

0.0

0.9

0.2

0.1

2.2

1.1

0.1

0.3

0.8

–

0.7

0.6

–

5.4

1.0

2.3

–

4.8

0.4

2.5

0.4

0.6

6.5

–

–

–

0.0

0.4

0.4

0.1

0.5

1.2

0.1

–

9.9

0.3

–

2.0

0.6

0.3

5.1

1.3

Rate

0.6

0.7

0.6

0.6

10.3

0.5

0.3

0.8

0.3

0.7

–

0.8

0.5

0.5

0.3

0.8

2.1

0.0

1.4

3.0

0.0

0.8

0.4

0.2

2.5

1.1

0.1

0.2

0.5

–

0.7

1.7

–

7.1

1.1

3.0

–

5.8

0.4

2.4

0.5

1.3

6.5

–

–

–

0.0

0.6

0.7

0.2

0.4

1.3

0.1

–

10.0

0.3

–

2.1

0.6

0.4

5.2

1.3

N

51

70

54

20

43

66

20

14

15

–

75

43

2

20

58

–

25

9

0

144

20

137

171

286

5

9

–

335

46

–

230

91

–

–

215

17

430

259

39

–

16

–

–

0

54

54

–

43

109

84

–

3 010

203

–

4 846

2 146

863

4 480

7 489

N

41

92

66

17

–

78

25

10

10

–

74

46

2

17

45

–

37

8

0

130

19

156

129

267

3

10

299

–

53

–

221

173

–

–

249

19

367

252

27

–

12

–

–

–

54

49

5

30

104

80

–

3 351

196

–

5 188

2 168

874

4 836

7 878

0.2

0.4

0.8

0.5

4.8

0.6

0.3

1.1

0.3

0.7

–

0.7

0.4

0.5

0.4

0.8

3.1

–

0.9

1.4

0.0

0.8

0.4

0.4

1.7

1.5

0.1

0.4

0.7

–

0.7

1.6

–

8.3

0.9

–

–

5.7

0.2

2.2

0.6

2.6

–

–

–

7.9

0.0

0.6

0.7

0.0

0.5

1.1

0.1

–

7.3

0.3

–

1.7

0.6

0.4

4.3

1.1

EU/EEA

3 530 Austria

5 620 Belgium

990 Bulgaria

368 Croatia

945 Cyprus

923 Czechia

2 844 Denmark

625 Estonia

800 Finland

75 356 France

32 203 Germany

4 480 Greece

1 235 Hungary

85

Iceland

1 371

Ireland

73 150 Italy

2 274 Latvia

12 Liechtenstein

734 Lithuania

604 Luxembourg

114 Malta

8 405 Netherlands

1 276 Norway

4 192 Poland

23 955 Portugal

11 748 Romania

134 Slovakia

309 Slovenia

89 477 Spain

2 190 Sweden

Non-EU/EEA

812 Albania

15 Andorra

2 669 Armenia

2 897 Azerbaijan

7 253 Belarus

5 127 Georgia

1 860 Israel

5 840 Kazakhstan

794 Kyrgyzstan

51 Monaco

202 Montenegro

178 Bosnia and Herzegovina

170 North Macedonia

5 344 Repubic of Moldova

0 Russian Federation

23 San Marino

2 320 Serbia

2 225

Serbia excluding Kosovo[1]

95

Kosovo[1]

10 288 Switzerland

2 668 Tajikistan

2 087 Türkiye

1

Turkmenistan

133 208 Ukraine

30 880 United Kingdom

651 Uzbekistan

215 443 Total non-EU/EEA

WHO European Region

368 577 West

26 640 Centre

170 190 East

565 407 Total WHO European Region

0.5

0.8

1.0

0.4

–

0.7

0.4

0.7

0.2

0.8

–

0.7

0.5

0.5

0.3

0.9

2.4

–

1.3

1.2

0.0

0.7

0.3

0.4

1.2

1.4

0.1

0.5

0.7

–

0.7

1.9

–

8.0

1.7

–

–

6.7

0.2

1.9

0.4

1.9

7.3

–

–

–

–

0.6

0.7

0.3

0.3

1.0

0.1

–

9.1

0.3

–

1.9

0.6

0.4

4.9

1.2

Area

Country, territory or areaa

Year of 

start of 

reporting 

2014

N

Rate

2015

N

Rate

2016

2017

2018

Rate

Rate

Rate

2019

N

Rate

2020

N

Rate

2021

N

Rate

2022

N

Rate

2023

N

Cumulative 

totalb Country, territory or areaa

Rate

SURVEILLANCE REPORT

HIV/AIDS surveillance in Europe 2024 – 2023 data

61
87
68
20
84
38
22
30
19
580
74
97
53
4
11
647
90
0
21
5
0
183
19
95
259
314
3
9
282
–
3 175

38
–
173
196
380
10
264
29
451
20
–
10
–
285
–
0
77
72
5
71
157
112
–
7 511
261
–
10 045

2 711
931
9 578
13 220

0.7
0.8
1.0
0.5
9.6
0.4
0.4
2.3
0.3
0.9
0.1
0.9
0.5
1.1
0.2
1.1
4.7
0.0
0.7
0.8
0.0
1.1
0.4
0.3
2.5
1.6
0.1
0.4
0.6
–
0.7

1.3
–
6.1
1.9
3.9
0.3
7.0
0.3
2.4
0.3
–
1.6
–
9.2
–
0.0
0.8
1.0
0.3
0.8
1.7
0.1
–
17.9
0.4
–
3.4

0.6
0.5
8.5
1.8

47
63
42
12
70
45
25
23
12
452
–
105
42
2
10
415
55
0
23
13
0
164
11
53
226
204
4
6
375
–
2 499

18
–
152
105
220
–
181
34
469
28
–
4
–
199
–
0
34
32
2
43
110
46
–
4 139
182
–
5 964

2 179
580
5 704
8 463

0.5
0.5
0.6
0.3
7.9
0.4
0.4
1.7
0.2
0.7
–
1.0
0.4
0.5
0.2
0.7
2.9
0.0
0.8
2.1
0.0
0.9
0.2
0.1
2.2
1.1
0.1
0.3
0.8
–
0.7

0.6
–
5.4
1.0
2.3
–
4.8
0.4
2.5
0.4
–
0.6
–
6.5
–
0.0
0.4
0.4
0.1
0.5
1.2
0.1
–
9.9
0.3
–
2.0

0.6
0.3
5.1
1.3

54
76
38
25
92
55
17
11
16
487
–
86
50
2
16
453
39
0
38
19
0
141
23
64
257
220
3
5
253
–
2 540

48
–
197
109
286
–
217
35
459
33
–
8
–
199
–
0
53
50
3
39
129
80
–
4 151
193
–
6 236

2 167
741
5 868
8 776

0.6
0.7
0.6
0.6
10.3
0.5
0.3
0.8
0.3
0.7
–
0.8
0.5
0.5
0.3
0.8
2.1
0.0
1.4
3.0
0.0
0.8
0.4
0.2
2.5
1.1
0.1
0.2
0.5
–
0.7

1.7
–
7.1
1.1
3.0
–
5.8
0.4
2.4
0.5
–
1.3
–
6.5
–
0.0
0.6
0.7
0.2
0.4
1.3
0.1
–
10.0
0.3
–
2.1

0.6
0.4
5.2
1.3

51
70
54
20
43
66
20
14
15
507
–
75
43
2
20
444
58
–
25
9
0
144
20
137
171
286
5
9
335
–
2 643

46
–
230
91
–
–
215
17
430
39
–
16
–
259
–
0
54
54
–
43
109
84
–
3 010
203
–
4 846

2 146
863
4 480
7 489

0.2
0.4
0.8
0.5
4.8
0.6
0.3
1.1
0.3
0.7
–
0.7
0.4
0.5
0.4
0.8
3.1
–
0.9
1.4
0.0
0.8
0.4
0.4
1.7
1.5
0.1
0.4
0.7
–
0.7

1.6
–
8.3
0.9
–
–
5.7
0.2
2.2
0.6
–
2.6
–
7.9
–
0.0
0.6
0.7
0.0
0.5
1.1
0.1
–
7.3
0.3
–
1.7

0.6
0.4
4.3
1.1

41
92
66
17
–
78
25
10
10
545
–
74
46
2
17
532
45
–
37
8
0
130
19
156
129
267
3
10
299
–
2 690

53
–
221
173
–
–
249
19
367
27
–
12
–
252
–
–
54
49
5
30
104
80
–
3 351
196
–
5 188

2 168
874
4 836
7 878

0.5
0.8
1.0
0.4
–
0.7
0.4
0.7
0.2
0.8
–
0.7
0.5
0.5
0.3
0.9
2.4
–
1.3
1.2
0.0
0.7
0.3
0.4
1.2
1.4
0.1
0.5
0.7
–
0.7

1.9
–
8.0
1.7
–
–
6.7
0.2
1.9
0.4
–
1.9
–
7.3
–
–
0.6
0.7
0.3
0.3
1.0
0.1
–
9.1
0.3
–
1.9

0.6
0.4
4.9
1.2

EU/EEA
3 530 Austria
5 620 Belgium
990 Bulgaria
368 Croatia
945 Cyprus
923 Czechia
2 844 Denmark
625 Estonia
800 Finland
75 356 France
32 203 Germany
4 480 Greece
1 235 Hungary
Iceland
Ireland

85
1 371

73 150 Italy
2 274 Latvia

12 Liechtenstein

734 Lithuania
604 Luxembourg
114 Malta

8 405 Netherlands
1 276 Norway
4 192 Poland
23 955 Portugal
11 748 Romania
134 Slovakia
309 Slovenia

89 477 Spain

2 190 Sweden
349 976 Total EU-EEA
Non-EU/EEA

812 Albania
15 Andorra
2 669 Armenia
2 897 Azerbaijan
7 253 Belarus

178 Bosnia and Herzegovina

5 127 Georgia
1 860 Israel
5 840 Kazakhstan
794 Kyrgyzstan
51 Monaco
202 Montenegro
170 North Macedonia
5 344 Repubic of Moldova
0 Russian Federation
23 San Marino

2 320 Serbia
2 225
95

Serbia excluding Kosovo[1]
Kosovo[1]
10 288 Switzerland
2 668 Tajikistan
2 087 Türkiye

1

Turkmenistan

133 208 Ukraine
30 880 United Kingdom
651 Uzbekistan
215 443 Total non-EU/EEA

WHO European Region

368 577 West
26 640 Centre
170 190 East
565 407 Total WHO European Region

Table 13. AIDS diagnoses and rates per 100 000 population, by country and year of diagnosis (2014–2023) and 

cumulative totals, in EU/EEA and other countries of the WHO European Region

1982

1983

1987

1986

1986

1986

1980

1992

1983

1982

1981

1981

1986

1985

1983

1982

1990

1989

1988

1983

1986

1999

1983

1986

1985

1985

1985

1986

1981

1982

1993

2004

1988

1995

1991

1986

1989

1981

1993

1999

1990

1989

1989

1985

–

1986

1985

1985

2005

1980

1998

1985

2002

1988

1981

1992

Centre

Hungary

Austria

Belgium

Bulgaria

Croatia

Cyprus

Czechia

Denmark

Estonia

Finland

France

Germany

Greece

Iceland

Ireland

Italy

Latvia

Liechtenstein

Lithuania

Luxembourg

Malta

Netherlands

Norway

Poland

Portugal

Romania

Slovakia

Slovenia

Spain

Sweden

Albania

Andorra

Armenia

Azerbaijan

Belarus

Georgia

Israel

Kazakhstan

Kyrgyzstan

Monaco

EU/EEA

West

West

Centre

Centre

Centre

Centre

West

East

West

West

West

West

West

West

West

East

West

East

West

West

West

West

Centre

West

Centre

Centre

Centre

West

West

Centre

West

East

East

East

East

West

East

East

West

East

East

West

Centre

Centre

Centre

West

East

East

East

West

East

West

Centre

East

Centre

Bosnia and Herzegovina

Centre Montenegro

Centre

North Macedonia

Repubic of Moldova

Russian Federation

Serbia excluding Kosovo[1]

San Marino

Serbia

Kosovo[1]

Switzerland

Tajikistan

Turkmenistan

Ukraine

United Kingdom

Uzbekistan

Total non-EU/EEA

Centre

Türkiye

WHO European Region

Total WHO European Region

85

136

64

1

54

32

30

18

20

656

393

132

51

0

32

932

171

1

37

15

4

224

45

149

398

417

4

17

679

–

50

0

176

200

474

8

268

70

251

53

1

7

16

299

–

0

49

48

1

79

229

125

–

9 844

368

–

12 567

4 299

1 044

12 020

17 363

1.0

1.2

0.9

0.0

6.3

0.3

0.5

1.4

0.4

1.0

0.5

1.2

0.5

0.0

0.7

1.5

8.5

2.7

1.2

2.7

0.9

1.3

0.9

0.4

3.8

2.1

0.1

0.8

1.5

–

1.1

1.7

0.0

6.1

2.1

4.9

0.2

7.1

0.9

1.4

0.9

2.8

1.1

0.8

9.0

–

0.0

0.5

0.6

0.1

1.0

2.8

0.2

–

21.8

0.6

–

4.4

1.0

0.5

10.7

2.4

76

105

45

3

70

38

40

18

19

615

362

139

43

0

21

874

132

0

35

19

2

263

22

128

357

367

8

11

–

609

65

3

163

193

490

8

270

45

273

293

35

0

11

6

–

0

50

47

3

64

281

118

–

401

–

8 468

11 237

4 036

971

10 651

15 658

N

67

78

42

22

74

45

24

40

30

523

310

149

53

4

15

874

114

0

48

19

5

220

22

102

401

355

10

10

541

–

58

0

163

161

512

8

269

47

350

33

0

15

9

–

0

61

56

5

71

238

99

–

8 852

297

–

11 609

3 697

963

11 146

15 806

0.9

0.9

0.6

0.1

8.3

0.4

0.7

1.4

0.3

0.9

0.4

1.3

0.4

0.0

0.4

1.4

6.6

0.0

1.2

3.4

0.5

1.6

0.4

0.3

3.4

1.8

0.1

0.5

1.3

–

1.0

2.3

4.2

5.7

2.0

5.1

0.2

7.2

0.6

1.5

0.6

0.0

1.7

0.3

8.9

–

0.0

0.5

0.6

0.2

0.8

3.3

0.1

–

19.8

0.6

–

4.0

1.0

0.5

9.6

2.2

N

68

64

49

21

67

55

29

20

18

511

295

129

52

0

21

803

118

0

54

9

0

212

14

109

321

335

9

7

–

513

33

2

144

168

439

4

257

33

361

46

0

13

2

–

0

65

59

6

74

265

121

–

9 308

260

–

11 869

3 376

942

11 454

15 772

0.8

0.7

0.6

0.5

8.7

0.4

0.4

3.0

0.5

0.8

0.4

1.4

0.5

1.2

0.3

1.5

5.8

0.0

1.6

3.3

1.1

1.3

0.4

0.3

3.9

1.8

0.2

0.5

1.2

–

0.9

2.0

0.0

5.7

1.6

5.3

0.2

7.1

0.6

1.9

0.5

0.0

2.4

0.4

–

0.0

0.7

0.7

0.3

0.8

2.7

0.1

–

0.5

–

4.1

20.8

0.9

0.5

10.0

2.1

N

53

60

57

30

73

39

26

25

22

553

242

107

722

57

2

13

99

0

37

8

0

197

12

111

290

326

11

10

384

–

47

0

211

182

382

13

273

42

433

47

0

14

4

–

0

70

62

8

66

212

108

–

8 839

256

–

11 564

3 055

970

11 105

15 130

0.8

0.6

0.7

0.5

7.8

0.5

0.5

1.5

0.3

0.8

0.4

1.2

0.5

0.0

0.4

1.3

6.1

0.0

1.9

1.5

0.0

1.2

0.3

0.3

3.1

1.7

0.2

0.3

1.1

–

0.9

1.1

2.7

5.0

1.7

4.5

0.1

6.8

0.4

2.0

0.8

0.0

2.1

0.1

8.6

–

0.0

0.7

0.8

0.3

0.9

3.0

0.1

–

21.9

0.4

–

4.1

0.8

0.5

10.3

2.1

0.6

0.5

0.8

0.7

8.4

0.4

0.4

1.9

0.4

0.8

0.3

1.0

0.6

0.6

0.3

1.2

5.1

0.0

1.3

1.3

0.0

1.1

0.2

0.3

2.8

1.7

0.2

0.5

0.8

–

0.8

1.6

0.0

7.4

1.8

3.9

0.4

7.2

0.5

2.3

0.8

0.0

2.2

0.2

–

0.0

0.8

0.8

0.4

0.8

2.3

0.1

–

20.9

0.4

–

4.0

0.7

0.5

9.9

2.0

366

11.3

274

365

11.6

Total EU/EEA

Non-EU/EEA

4 797

4 421

4 197

3 903

3 566

a   Country/territory/area specific comments are in Annex 5.

b   Cumulative total is the total number of cases reported by the country since the start of reporting.

[1]  All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

[1]  All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

5 2

Table 14. AIDS diagnoses in males and rates per 100 000 male population, by country and year of AIDS diagnosis 
(2014–2023) and cumulative totals, in EU/EEA and other countries of the WHO European Region

Area

Country, territory or areaa

2014
N

Rate

2015
N

Rate

2016
N

Rate

2017
N

Rate

2018
N

Rate

2019

2020

N

2021

N

Rate

2022

N

Rate

2023

N

Rate

Cumulative 

totalb Country, territory or areaa

EU/EEA
West
West
Centre
Centre
Centre
Centre
West
East
West
West
West
West
Centre
West
West
West
East
West
East
West
West
West
West
Centre
West
Centre
Centre
Centre
West
West

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Total EU/EEA

Non-EU/EEA
Centre

Albania

West
East
East
East
Centre
East
West
East
East
West
Centre Montenegro
Centre
East
East
West
Centre
Centre
Centre
West
East
Centre
East
East
West
East

Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco

North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia

Serbia excluding Kosovo[1]
Kosovo[1]
Switzerland
Tajikistan
Türkiye
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Total non-EU/EEA

WHO European Region
West
Centre
East
Total WHO European Region

59
84
52
1
51
23
24
13
14
443
335
107
41
0
22
714
110
1
29
10
4
185
36
115
307
295
3
16
547
–
3 641

36

0
129
162
308
7
201
48
185
35
1
4
13
183
–
0
43
42
1
63
157
99
–
6 119
248
–
8 041

3 251
799
7 631
11 681

1.4
1.5
1.5
0.0
12.2
0.4
0.9
2.1
0.5
1.4
0.8
2.0
0.9
0.0
1.0
2.4
12.0
5.4
2.1
3.6
1.9
2.2
1.4
0.6
6.2
3.0
0.1
1.6
2.4
–
1.7

2.5

0.0
9.8
3.4
6.9
0.4
11.3
1.2
2.2
1.2
5.6
1.3
1.2
11.5
–
0.0
1.0
1.2
0.1
1.6
3.8
0.3
–
29.3
0.8
–
5.8

1.6
0.8
14.3
3.3

57
64
39
3
62
30
28
11
13
426
297
114
37
0
16
687
89
0
26
11
2
212
15
97
257
256
7
11
492
–
3 359

50

2
129
150
278
7
196
26
181
19
0
11
5
179
–
0
47
45
2
52
187
92
–
5 328
299
–
7 238

3 070
754
6 773
10 597

1.4
1.2
1.1
0.1
15.1
0.6
1.0
1.8
0.5
1.3
0.7
2.2
0.8
0.0
0.7
2.4
9.8
0.0
1.9
3.9
0.9
2.5
0.6
0.5
5.2
2.6
0.3
1.1
2.2
–
1.6

3.5

5.5
9.8
3.1
6.2
0.4
11.0
0.7
2.1
0.7
0.0
3.6
0.5
11.5
–
0.0
1.0
1.2
0.2
1.3
4.4
0.2
–
23.2
0.9
–
5.1

1.5
0.8
12.2
3.0

49
44
39
21
62
39
19
23
25
345
249
115
45
4
12
669
90
0
41
16
5
171
15
90
288
257
10
8
438
–
3 189

50

0
116
125
311
7
196
29
231
23
0
15
6
210
–
0
57
52
5
49
173
86
–
5 462
223
–
7 369

2 765
792
7 001
10 558

1.1
0.8
1.2
1.1
15.0
0.8
0.7
3.7
0.9
1.1
0.6
2.2
1.0
2.4
0.5
2.3
10.0
0.0
3.0
5.5
2.2
2.0
0.6
0.5
5.9
2.7
0.4
0.8
1.9
–
1.5

3.5

0.0
8.9
2.5
6.9
0.4
11.0
0.7
2.7
0.8
0.0
4.9
0.6
13.7
–
0.0
1.3
1.4
0.6
1.2
3.9
0.2
–
27.7
0.7
–
5.3

1.3
0.8
13.3
2.9

55
43
39
19
50
45
25
15
10
364
231
98
36
0
15
588
73
0
46
7
0
169
11
94
231
247
9
7
409
–
2 936

24

1
111
114
274
4
193
23
225
29
0
12
2
167
–
0
59
53
6
56
182
103
–
5 612
184
–
7 375

2 520
750
7 041
10 311

1.3
0.8
1.2
1.0
12.0
0.9
0.9
2.4
0.4
1.1
0.6
1.9
0.8
0.0
0.6
2.0
8.2
0.0
3.5
2.4
0.0
2.0
0.4
0.5
4.7
2.6
0.3
0.7
1.8
–
1.3

1.7

2.7
8.6
2.3
6.1
0.2
10.9
0.6
2.6
1.0
0.0
3.9
0.2
11.0
–
0.0
1.3
1.5
0.7
1.3
4.1
0.3
–
28.6
0.6
–
5.2

1.2
0.8
13.3
2.9

43
35
48
28
63
35
21
19
18
394
191
93
54
0
12
565
63
0
29
7
0
152
9
86
192
239
11
10
318
–
2 735

35

0
147
122
229
13
172
32
279
30
0
14
4
213
–
0
62
55
7
50
149
91
–
5 405
190
–
7 237

2 322
793
6 857
9 972

1.0
0.6
1.5
1.5
14.9
0.7
0.7
3.1
0.7
1.2
0.5
1.8
1.2
0.0
0.5
1.9
7.1
0.0
2.2
2.3
0.0
1.8
0.3
0.5
3.9
2.5
0.4
1.0
1.4
–
1.2

2.4

0.0
11.4
2.4
5.1
0.8
9.7
0.8
3.1
1.0
0.0
4.5
0.4
14.3
–
0.0
1.4
1.5
0.8
1.2
3.2
0.2
–
27.6
0.6
–
5.1

1.1
0.8
12.9
2.8

a   Country/territory/area specific comments are in Annex 5.
b   Cumulative total is the total number of cases reported by the country since the start of reporting.

[1]  All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

54

2 353

1 881

1 870

1 981

274 186 Total EU-EEA

403

320

330

357

524

305

332

418

N

47

57

56

18

58

27

15

21

13

55

70

46

3

7

53

0

16

3

0

144

14

80

171

218

3

5

–

226

25

–

127

150

241

8

198

20

293

180

11

–

10

–

–

0

61

57

4

57

109

92

–

4 661

202

–

6 445

2 031

707

6 060

8 798

Rate

1.1

1.0

1.7

0.9

13.6

0.5

0.5

3.4

0.5

1.2

0.1

1.3

1.0

1.6

0.3

1.8

6.0

0.0

1.2

1.0

0.0

1.7

0.5

0.4

3.5

2.3

0.1

0.5

1.0

–

1.1

1.7

–

10.0

3.0

5.4

0.5

11.2

0.5

3.3

0.4

3.3

12.2

–

–

–

0.0

1.4

1.6

0.5

1.3

2.3

0.2

–

24.0

0.6

–

4.5

1.0

0.7

11.4

2.4

36

40

31

11

56

37

21

18

7

–

88

35

2

7

39

0

18

7

0

123

10

39

166

148

4

4

–

309

16

–

113

77

143

–

134

26

293

13

123

–

3

–

–

0

28

27

1

37

87

33

–

2 479

146

–

3 751

1 650

445

3 537

5 632

Rate

0.8

0.7

1.0

0.6

12.9

0.7

0.7

2.9

0.3

1.0

–

1.7

0.7

1.1

0.3

1.0

4.4

0.0

1.4

2.2

0.0

1.4

0.4

0.2

3.4

1.6

0.2

0.4

1.3

–

1.0

1.1

–

8.9

1.5

3.2

–

7.6

0.6

3.2

0.4

1.0

–

–

–

8.4

0.0

0.6

0.8

0.1

0.9

1.8

0.1

–

11.1

0.4

–

2.6

1.0

0.5

6.3

1.7

43

44

35

23

70

45

14

9

9

–

63

39

2

15

337

351

24

0

29

15

0

114

13

52

163

156

3

3

–

199

37

–

146

82

184

–

163

25

289

18

120

–

7

–

–

0

52

49

3

29

97

73

–

2 513

147

–

3 982

1 583

595

3 674

5 852

16.0

1.0

0.8

1.1

1.2

0.9

0.5

1.4

0.3

1.0

–

1.2

0.8

1.1

0.6

1.2

2.7

0.0

2.2

4.7

0.0

1.3

0.5

0.3

3.4

1.7

0.1

0.3

0.9

–

1.0

2.6

–

11.6

1.6

4.2

–

9.2

0.6

3.1

0.6

2.3

8.3

–

–

–

0.0

1.2

1.4

0.3

0.7

2.0

0.2

–

13.1

0.4

–

2.8

0.9

0.6

6.9

1.8

34

46

45

19

23

50

11

12

12

–

57

32

1

17

42

–

17

6

0

113

11

104

130

228

2

8

–

273

1 955

33

–

173

63

–

–

9

168

274

26

–

15

–

152

–

0

50

50

–

31

79

71

–

1 895

133

–

3 172

1 546

680

2 901

5 127

0.8

0.8

1.4

1.0

5.2

1.0

0.4

1.9

0.4

1.0

–

1.1

0.7

0.5

0.7

1.2

4.8

–

1.3

1.8

0.0

1.3

0.4

0.6

2.6

2.5

0.1

0.8

1.2

–

1.1

2.3

–

13.8

1.2

–

–

9.5

0.2

2.9

0.8

4.9

–

–

–

9.8

0.0

1.2

1.4

0.0

0.7

1.6

0.2

–

10.0

0.4

–

2.3

0.9

0.7

5.9

1.6

30

61

51

15

–

56

13

7

2

–

66

33

1

9

32

–

23

5

0

107

13

116

91

206

3

10

237

–

42

–

162

120

–

–

188

12

229

17

159

–

9

–

–

–

45

40

5

20

65

70

–

2 081

130

–

3 349

1 572

675

3 083

5 330

EU/EEA

2 681 Austria

3 697 Belgium

783 Bulgaria

329 Croatia

741 Cyprus

740 Czechia

2 402 Denmark

455 Estonia

629 Finland

58 787 France

27 494 Germany

3 715 Greece

1 053 Hungary

71

Iceland

1 051

Ireland

56 398 Italy

1 565

Latvia

11

Liechtenstein

581

Lithuania

454 Luxembourg

100 Malta

6 678 Netherlands

982 Norway

3 306 Poland

18 741 Portugal

7 218 Romania

118 Slovakia

270 Slovenia

71 332 Spain

1 785 Sweden

Non-EU/EEA

624 Albania

11 Andorra

1 982 Armenia

2 323 Azerbaijan

4 590 Belarus

3 783 Georgia

1 331

Israel

3 908 Kazakhstan

566 Kyrgyzstan

40 Monaco

175 Montenegro

148 Bosnia and Herzegovina

127 North Macedonia

3 242 Republic of Moldova

0 Russian Federation

21 San Marino

1 827 Serbia

1 752

75

Kosovo[1]

7 671 Switzerland

1 941

1 741

Tajikistan

Türkiye

Serbia excluding Kosovo[1]

0 Turkmenistan

64 696 Ukraine

24 049 United Kingdom

494 Uzbekistan

125 384 Total non-EU/EEA

WHO European Region

290 120 West

19 219 Centre

90 220 East

399 559 Total WHO European Region

0.7

1.1

1.6

0.8

–

1.1

0.4

1.1

0.1

1.1

–

1.3

0.7

0.5

0.3

1.5

3.7

–

1.7

1.5

0.0

1.2

0.5

0.7

1.8

2.2

0.1

0.9

1.2

–

1.1

3.0

–

13.0

2.3

–

–

10.7

0.3

2.4

0.5

3.0

9.7

–

–

–

–

1.0

1.2

0.6

0.5

1.3

0.2

–

12.4

0.4

–

2.4

0.9

0.7

6.5

1.7

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 dataTable 14. AIDS diagnoses in males and rates per 100 000 male population, by country and year of AIDS diagnosis 

(2014–2023) and cumulative totals, in EU/EEA and other countries of the WHO European Region

Total EU/EEA

3 641

3 359

3 189

2 936

2 735

Centre

Hungary

Austria

Belgium

Bulgaria

Croatia

Cyprus

Czechia

Denmark

Estonia

Finland

France

Germany

Greece

Iceland

Ireland

Italy

Latvia

Liechtenstein

Lithuania

Luxembourg

Malta

Netherlands

Norway

Poland

Portugal

Romania

Slovakia

Slovenia

Spain

Sweden

Andorra

Armenia

Azerbaijan

Belarus

Georgia

Israel

Kazakhstan

Kyrgyzstan

Monaco

San Marino

Serbia

Kosovo[1]

Switzerland

Tajikistan

EU/EEA

West

West

Centre

Centre

Centre

Centre

West

East

West

West

West

West

West

West

West

East

West

East

West

West

West

West

Centre

West

Centre

Centre

Centre

West

West

West

East

East

East

East

West

East

East

West

East

East

West

Centre

Centre

Centre

West

East

East

East

West

East

West

Centre

East

Non-EU/EEA

Centre

Albania

Centre

Bosnia and Herzegovina

Centre Montenegro

Centre

North Macedonia

Republic of Moldova

Russian Federation

Serbia excluding Kosovo[1]

Centre

Türkiye

Turkmenistan

Ukraine

United Kingdom

Uzbekistan

Total non-EU/EEA

WHO European Region

Total WHO European Region

Rate

1.4

1.5

1.5

0.0

12.2

12.0

0.4

0.9

2.1

0.5

1.4

0.8

2.0

0.9

0.0

1.0

2.4

5.4

2.1

3.6

1.9

2.2

1.4

0.6

6.2

3.0

0.1

1.6

2.4

–

1.7

2.5

0.0

9.8

3.4

6.9

0.4

11.3

1.2

2.2

1.2

5.6

1.3

1.2

11.5

–

0.0

1.0

1.2

0.1

1.6

3.8

0.3

–

29.3

0.8

–

5.8

1.6

0.8

14.3

3.3

57

64

39

3

62

30

28

11

13

426

297

114

687

37

0

16

89

0

26

11

2

212

15

97

257

256

7

11

–

492

50

2

129

150

278

7

196

26

181

179

19

0

11

5

–

0

47

45

2

52

187

92

–

5 328

299

–

7 238

3 070

754

6 773

10 597

59

84

52

1

51

23

24

13

14

443

335

107

41

0

22

714

110

1

29

10

4

185

36

115

307

295

3

16

547

–

36

0

129

162

308

7

201

48

185

35

1

4

13

183

–

0

43

42

1

63

157

99

–

6 119

248

–

8 041

3 251

799

7 631

11 681

1.4

1.2

1.1

0.1

15.1

0.6

1.0

1.8

0.5

1.3

0.7

2.2

0.8

0.0

0.7

2.4

9.8

0.0

1.9

3.9

0.9

2.5

0.6

0.5

5.2

2.6

0.3

1.1

2.2

–

1.6

3.5

5.5

9.8

3.1

6.2

0.4

11.0

0.7

2.1

0.7

0.0

3.6

0.5

11.5

–

0.0

1.0

1.2

0.2

1.3

4.4

0.2

–

0.9

–

5.1

1.5

0.8

12.2

3.0

23.2

49

44

39

21

62

39

19

23

25

345

249

115

45

4

12

669

90

0

41

16

5

171

15

90

288

257

10

8

438

–

50

0

116

125

311

7

196

29

231

23

210

0

15

6

–

0

57

52

5

49

173

86

–

5 462

223

–

7 369

2 765

792

7 001

10 558

Rate

1.1

0.8

1.2

1.1

15.0

10.0

0.8

0.7

3.7

0.9

1.1

0.6

2.2

1.0

2.4

0.5

2.3

0.0

3.0

5.5

2.2

2.0

0.6

0.5

5.9

2.7

0.4

0.8

1.9

–

1.5

3.5

0.0

8.9

2.5

6.9

0.4

11.0

0.7

2.7

0.8

0.0

4.9

0.6

13.7

–

0.0

1.3

1.4

0.6

1.2

3.9

0.2

–

27.7

0.7

–

5.3

1.3

0.8

13.3

2.9

55

43

39

19

50

45

25

15

10

98

36

0

15

73

0

46

7

0

364

231

588

169

11

94

231

247

9

7

–

409

24

1

111

114

274

4

193

23

225

29

167

0

12

2

–

0

59

53

6

56

182

103

–

5 612

184

–

7 375

2 520

750

7 041

10 311

Rate

1.3

0.8

1.2

1.0

12.0

0.9

0.9

2.4

0.4

1.1

0.6

1.9

0.8

0.0

0.6

2.0

8.2

0.0

3.5

2.4

0.0

2.0

0.4

0.5

4.7

2.6

0.3

0.7

1.8

–

1.3

1.7

2.7

8.6

2.3

6.1

0.2

0.6

2.6

1.0

0.0

3.9

0.2

–

0.0

1.3

1.5

0.7

1.3

4.1

0.3

–

11.0

10.9

28.6

0.6

–

5.2

1.2

0.8

13.3

2.9

43

35

48

28

63

35

21

19

18

394

191

93

54

0

12

63

0

29

565

7

0

9

152

86

192

239

11

10

318

–

35

0

147

122

229

13

172

32

279

213

30

0

14

4

–

0

62

55

7

50

149

91

–

190

–

5 405

7 237

2 322

793

6 857

9 972

14.9

1.0

0.6

1.5

1.5

0.7

0.7

3.1

0.7

1.2

0.5

1.8

1.2

0.0

0.5

1.9

7.1

0.0

2.2

2.3

0.0

1.8

0.3

0.5

3.9

2.5

0.4

1.0

1.4

–

1.2

2.4

0.0

11.4

2.4

5.1

0.8

9.7

0.8

3.1

1.0

0.0

4.5

0.4

–

0.0

1.4

1.5

0.8

1.2

3.2

0.2

–

14.3

27.6

0.6

–

5.1

1.1

0.8

12.9

2.8

Area

Country, territory or areaa

2014

N

2015

N

Rate

2016

N

2017

N

2018

N

Rate

2019
N

Rate

2020
N

Rate

2021
N

Rate

2022
N

Rate

2023
N

Rate

Cumulative 

totalb Country, territory or areaa

47
57
56
18
58
27
15
21
13
403
55
70
46
3
7
524
53
0
16
3
0
144
14
80
171
218
3
5
226
–
2 353

25

–
127
150
241
8
198
20
293
11
–
10
–
180
–
0
61
57
4
57
109
92
–
4 661
202
–
6 445

2 031
707
6 060
8 798

1.1
1.0
1.7
0.9
13.6
0.5
0.5
3.4
0.5
1.2
0.1
1.3
1.0
1.6
0.3
1.8
6.0
0.0
1.2
1.0
0.0
1.7
0.5
0.4
3.5
2.3
0.1
0.5
1.0
–
1.1

1.7

–
10.0
3.0
5.4
0.5
11.2
0.5
3.3
0.4
–
3.3
–
12.2
–
0.0
1.4
1.6
0.5
1.3
2.3
0.2
–
24.0
0.6
–
4.5

1.0
0.7
11.4
2.4

36
40
31
11
56
37
21
18
7
320
–
88
35
2
7
305
39
0
18
7
0
123
10
39
166
148
4
4
309
–
1 881

16

–
113
77
143
–
134
26
293
13
–
3
–
123
–
0
28
27
1
37
87
33
–
2 479
146
–
3 751

1 650
445
3 537
5 632

0.8
0.7
1.0
0.6
12.9
0.7
0.7
2.9
0.3
1.0
–
1.7
0.7
1.1
0.3
1.0
4.4
0.0
1.4
2.2
0.0
1.4
0.4
0.2
3.4
1.6
0.2
0.4
1.3
–
1.0

1.1

–
8.9
1.5
3.2
–
7.6
0.6
3.2
0.4
–
1.0
–
8.4
–
0.0
0.6
0.8
0.1
0.9
1.8
0.1
–
11.1
0.4
–
2.6

1.0
0.5
6.3
1.7

43
44
35
23
70
45
14
9
9
337
–
63
39
2
15
351
24
0
29
15
0
114
13
52
163
156
3
3
199
–
1 870

37

–
146
82
184
–
163
25
289
18
–
7
–
120
–
0
52
49
3
29
97
73
–
2 513
147
–
3 982

1 583
595
3 674
5 852

1.0
0.8
1.1
1.2
16.0
0.9
0.5
1.4
0.3
1.0
–
1.2
0.8
1.1
0.6
1.2
2.7
0.0
2.2
4.7
0.0
1.3
0.5
0.3
3.4
1.7
0.1
0.3
0.9
–
1.0

2.6

–
11.6
1.6
4.2
–
9.2
0.6
3.1
0.6
–
2.3
–
8.3
–
0.0
1.2
1.4
0.3
0.7
2.0
0.2
–
13.1
0.4
–
2.8

0.9
0.6
6.9
1.8

34
46
45
19
23
50
11
12
12
330
–
57
32
1
17
332
42
–
17
6
0
113
11
104
130
228
2
8
273
–
1 955

33

–
173
63
–
–
168
9
274
26
–
15
–
152
–
0
50
50
–
31
79
71
–
1 895
133
–
3 172

1 546
680
2 901
5 127

0.8
0.8
1.4
1.0
5.2
1.0
0.4
1.9
0.4
1.0
–
1.1
0.7
0.5
0.7
1.2
4.8
–
1.3
1.8
0.0
1.3
0.4
0.6
2.6
2.5
0.1
0.8
1.2
–
1.1

2.3

–
13.8
1.2
–
–
9.5
0.2
2.9
0.8
–
4.9
–
9.8
–
0.0
1.2
1.4
0.0
0.7
1.6
0.2
–
10.0
0.4
–
2.3

0.9
0.7
5.9
1.6

30
61
51
15
–
56
13
7
2
357
–
66
33
1
9
418
32
–
23
5
0
107
13
116
91
206
3
10
237
–
1 981

42

–
162
120
–
–
188
12
229
17
–
9
–
159
–
–
45
40
5
20
65
70
–
2 081
130
–
3 349

1 572
675
3 083
5 330

0.7
1.1
1.6
0.8
–
1.1
0.4
1.1
0.1
1.1
–
1.3
0.7
0.5
0.3
1.5
3.7
–
1.7
1.5
0.0
1.2
0.5
0.7
1.8
2.2
0.1
0.9
1.2
–
1.1

3.0

–
13.0
2.3
–
–
10.7
0.3
2.4
0.5
–
3.0
–
9.7
–
–
1.0
1.2
0.6
0.5
1.3
0.2
–
12.4
0.4
–
2.4

0.9
0.7
6.5
1.7

EU/EEA
2 681 Austria
3 697 Belgium
783 Bulgaria
329 Croatia
741 Cyprus
740 Czechia
2 402 Denmark
455 Estonia
629 Finland
58 787 France
27 494 Germany
3 715 Greece
1 053 Hungary
Iceland
Ireland

71
1 051

56 398 Italy

Latvia
Liechtenstein
Lithuania

1 565
11
581
454 Luxembourg
100 Malta

6 678 Netherlands

982 Norway
3 306 Poland
18 741 Portugal
7 218 Romania
118 Slovakia
270 Slovenia

71 332 Spain
1 785 Sweden
274 186 Total EU-EEA
Non-EU/EEA

624 Albania

11 Andorra
1 982 Armenia
2 323 Azerbaijan
4 590 Belarus

148 Bosnia and Herzegovina

3 783 Georgia
Israel
1 331
3 908 Kazakhstan
566 Kyrgyzstan
40 Monaco
175 Montenegro
127 North Macedonia
3 242 Republic of Moldova
0 Russian Federation
21 San Marino

1 827 Serbia
1 752
75

Serbia excluding Kosovo[1]
Kosovo[1]
7 671 Switzerland
1 941
1 741

Tajikistan
Türkiye
0 Turkmenistan

64 696 Ukraine
24 049 United Kingdom
494 Uzbekistan
125 384 Total non-EU/EEA

WHO European Region

290 120 West

19 219 Centre
90 220 East
399 559 Total WHO European Region

a   Country/territory/area specific comments are in Annex 5.

b   Cumulative total is the total number of cases reported by the country since the start of reporting.

[1]  All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

[1]  All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

55

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORTTable 15. AIDS diagnoses in females and rates per female 100 000 population, by country and year of diagnosis  
(2014–2023) and cumulative totals, in EU/EEA and other countries of the WHO European Region

Area

Country, territory or areaa

2014
N

Rate

2015
N

Rate

2016
N

Rate

2017
N

Rate

2018
N

Rate

2019

N

Rate

2020

2021

Rate

Rate

2022

N

Rate

2023

Cumulative 

totalb Country, territory or areaa

Rate

EU/EEA
West
West
Centre
Centre
Centre
Centre
West
East
West
West
West
West
Centre
West
West
West
East
West
East
West
West
West
West
Centre
West
Centre
Centre
Centre
West
West

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Total EU/EEA

Non-EU/EEA
Centre
West
East
East
East
Centre
East
West
East
East
West
Centre Montenegro
Centre
East
East
West
Centre
Centre
Centre
West
East
Centre
East
East
West
East

Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco

North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia

Serbia excluding Kosovo[1]
Kosovo[1]
Switzerland
Tajikistan
Türkiye
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Total non-EU/EEA

WHO European Region
West
Centre
East
Total WHO European Region

26
51
12
0
3
9
6
5
6
212
58
23
10
0
10
218
61
0
8
5
0
38
9
34
91
122
1
1
132
–
1 151

14
0
47
38
166
1
67
22
66
18
0
3
3
116
–
0
6
6
–
16
72
26
–
3 725
120
–
4 526

1 043
245
4 389
5 677

0.6
0.9
0.3
0.0
0.7
0.2
0.2
0.7
0.2
0.6
0.1
0.4
0.2
0.0
0.4
0.7
5.6
0.0
0.5
1.8
0.0
0.4
0.4
0.2
1.7
1.2
0.0
0.1
0.6
–
0.5

1.0
0.0
3.0
0.8
3.2
0.1
3.4
0.6
0.7
0.6
0.0
0.9
0.3
6.6
–
0.0
0.1
0.2
–
0.4
1.7
0.1
–
15.4
0.4
–
3.1

0.5
0.3
7.4
1.5

18
41
6
0
8
8
12
7
6
185
65
25
6
0
5
187
43
0
9
8
0
49
7
31
100
111
1
0
117
–
1 055

15
1
34
43
212
1
74
19
92
16
0
0
1
114
–
0
3
2
1
12
94
26
–
3 140
100
–
3 997

957
217
3 878
5 052

0.4
0.7
0.2
0.0
1.8
0.1
0.4
1.0
0.2
0.5
0.2
0.4
0.1
0.0
0.2
0.6
4.0
0.0
0.6
2.8
0.0
0.6
0.3
0.2
1.8
1.1
0.0
0.0
0.5
–
0.5

1.0
2.8
2.2
0.9
4.1
0.1
3.7
0.5
1.0
0.5
0.0
0.0
0.1
6.6
–
0.0
0.1
0.1
0.1
0.3
2.2
0.1
–
15.9
0.3
–
2.8

0.5
0.2
7.0
1.4

18
34
3
1
12
6
5
17
5
174
61
32
8
0
3
205
24
0
7
3
0
46
7
12
113
98
0
2
103
–
999

8
0
47
36
201
1
73
18
119
10
0
0
2
156
–
0
4
4
–
21
65
13
–
3 390
73
–
4 237

921
170
4 145
5 236

0.4
0.6
0.1
0.0
2.8
0.1
0.2
2.4
0.2
0.5
0.1
0.6
0.2
0.0
0.1
0.7
2.3
0.0
0.4
1.0
0.0
0.5
0.3
0.1
2.1
1.0
0.0
0.2
0.4
–
0.4

0.6
0.0
3.0
0.7
3.9
0.1
3.7
0.4
1.3
0.3
0.0
0.0
0.2
9.2
–
0.0
0.1
0.1
–
0.5
1.5
0.0
–
14.8
0.2
–
2.9

0.4
0.2
7.1
1.4

13
21
10
2
17
10
4
5
8
143
64
28
16
0
6
215
45
0
8
2
0
41
3
15
90
88
0
0
104
–
958

9
1
33
54
165
0
64
10
136
17
0
1
0
107
–
0
6
6
–
17
83
18
–
3 696
75
–
4 492

845
192
4 413
5 450

0.3
0.4
0.3
0.1
3.9
0.2
0.1
0.7
0.3
0.4
0.2
0.5
0.3
0.0
0.2
0.7
4.3
0.0
0.5
0.7
0.0
0.5
0.1
0.1
1.7
0.9
0.0
0.0
0.4
–
0.4

0.6
2.7
2.1
1.1
3.2
0.0
3.2
0.2
1.4
0.5
0.0
0.3
0.0
6.4
–
0.0
0.1
0.2
–
0.4
1.9
0.0
–
16.2
0.2
–
3.1

0.4
0.2
7.5
1.5

10
25
9
2
10
4
5
6
4
156
51
13
3
2
1
157
36
0
8
1
0
38
3
25
98
87
0
0
64
–
818

12
0
64
60
153
0
101
10
154
17
0
0
0
152
–
0
8
7
1
15
63
17
–
3 434
66
–
4 326

719
177
4 248
5 144

0.2
0.4
0.3
0.1
2.3
0.1
0.2
0.9
0.1
0.5
0.1
0.2
0.1
1.2
0.0
0.5
3.4
0.0
0.5
0.3
0.0
0.4
0.1
0.1
1.8
0.9
0.0
0.0
0.3
–
0.4

0.8
0.0
4.1
1.2
2.9
0.0
5.1
0.2
1.6
0.5
0.0
0.0
0.0
9.2
–
0.0
0.2
0.2
0.1
0.3
1.4
0.0
–
15.2
0.2
–
3.0

0.3
0.2
7.2
1.4

a   Country/territory/area specific comments are in Annex 5.
b   Cumulative total is the total number of cases reported by the country since the start of reporting.

[1]  All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

56

N

11

23

11

1

14

8

4

5

5

–

17

7

0

3

127

110

16

0

5

6

0

38

1

14

60

56

0

2

66

–

610

2

–

39

28

77

–

47

8

176

15

76

–

1

–

–

0

6

5

1

6

23

13

–

36

–

1 660

2 213

521

135

2 167

2 823

0.3

0.5

0.3

0.1

5.8

0.2

0.2

1.3

0.2

0.5

0.0

0.5

0.1

0.6

0.2

0.4

3.6

0.0

0.3

0.7

0.0

0.4

0.2

0.1

1.6

1.0

0.0

0.4

0.2

–

0.4

0.9

–

3.0

0.9

2.7

0.1

3.3

0.2

1.6

0.3

0.0

–

–

–

6.4

0.0

0.3

0.4

0.1

0.3

1.0

0.0

–

12.7

0.2

–

2.4

0.3

0.2

6.0

1.2

14

29

12

2

26

11

7

9

6

168

19

27

123

37

7

1

4

0

5

2

0

35

5

15

88

96

0

4

56

–

13

–

46

46

139

66

2

9

158

105

9

–

0

–

–

0

16

15

1

13

48

20

–

59

–

808

2 850

3 599

665

224

3 518

4 407

144

102

15

N

11

31

3

2

22

10

3

2

7

–

23

11

0

1

0

9

4

0

24

10

12

94

64

0

2

54

–

660

11

–

51

27

102

–

54

10

170

15

79

–

1

–

–

0

1

1

0

10

32

7

–

46

–

1 638

2 254

574

146

2 194

2 914

0.2

0.4

0.3

0.0

3.1

0.1

0.1

0.7

0.2

0.4

–

0.3

0.1

0.0

0.1

0.4

1.6

0.0

0.3

1.9

0.0

0.4

0.0

0.1

1.1

0.6

0.0

0.2

0.3

–

0.3

0.1

–

2.5

0.5

1.5

–

2.4

0.2

1.8

0.5

0.3

–

–

–

4.7

0.0

0.1

0.1

0.1

0.1

0.5

0.0

–

8.6

0.1

–

1.5

0.3

0.1

3.9

0.9

0.2

0.5

0.1

0.1

4.8

0.2

0.1

0.3

0.3

0.4

–

0.4

0.2

0.0

0.0

0.3

1.5

0.0

0.6

1.3

0.0

0.3

0.4

0.1

1.7

0.7

0.0

0.2

0.2

–

0.4

0.8

–

3.3

0.5

2.0

–

2.7

0.2

1.7

0.5

0.3

4.9

–

–

–

0.0

0.0

0.0

0.0

0.2

0.7

0.0

–

7.4

0.1

–

1.5

0.3

0.2

3.7

0.9

17

23

9

1

20

16

9

2

3

170

–

18

11

1

3

112

16

–

8

3

0

30

9

33

41

58

3

0

61

–

13

–

57

28

–

–

47

8

156

13

107

–

1

–

–

0

4

4

0

12

30

13

–

70

–

1 115

1 674

590

182

1 579

2 351

179

114

N

11

31

15

2

–

22

12

3

8

–

8

1

8

13

13

–

14

3

0

22

6

40

38

61

0

0

61

–

11

–

59

53

–

–

61

7

93

–

2

–

–

–

9

9

0

10

39

10

–

66

–

138

10

1 270

1 838

585

198

1 753

2 536

0.4

0.4

0.3

0.0

4.3

0.3

0.3

0.3

0.1

0.5

–

0.3

0.2

0.5

0.1

0.4

1.6

–

0.5

0.9

0.0

0.3

0.3

0.2

0.8

0.6

0.1

0.0

0.3

–

0.4

0.9

–

3.7

0.5

–

–

2.4

0.2

1.6

0.4

0.3

6.2

–

–

–

0.0

0.1

0.1

0.0

0.3

0.6

0.0

–

5.1

0.2

–

1.2

0.3

0.2

2.9

0.7

677

698

EU/EEA

846 Austria

1 913 Belgium

207 Bulgaria

39 Croatia

199 Cyprus

183 Czechia

442 Denmark

170 Estonia

171

Finland

16 478 France

4 709 Germany

757 Greece

182 Hungary

14 Iceland

318 Ireland

16 752 Italy

709 Latvia

1

Liechtenstein

153 Lithuania

148 Luxembourg

14 Malta

1 650 Netherlands

294 Norway

886 Poland

5 207 Portugal

4 530 Romania

16 Slovakia

38 Slovenia

18 137 Spain

405 Sweden

75 581 Total EU-EEA

Non-EU/EEA

188 Albania

4 Andorra

687 Armenia

574 Azerbaijan

2 663 Belarus

1 344 Georgia

529 Israel

1 932 Kazakhstan

228 Kyrgyzstan

11 Monaco

26 Montenegro

28 Bosnia and Herzegovina

Serbia excluding Kosovo[1]

36 North Macedonia

2 102 Republic of Moldova

0 Russian Federation

2 San Marino

493 Serbia

473

20

Kosovo[1]

2 612 Switzerland

727 Tajikistan

346 Türkiye

1

Turkmenistan

37 578 Ukraine

6 827 United Kingdom

157 Uzbekistan

59 106 Total non-EU/EEA

WHO European Region

78 240 West

7 410 Centre

49 036 East

134 686 Total WHO European Region

0.2

0.5

0.4

0.1

–

0.4

0.4

0.4

0.3

0.5

–

0.2

0.3

0.5

0.3

0.4

1.3

–

0.9

0.9

0.0

0.2

0.2

0.2

0.7

0.6

0.0

0.0

0.3

–

0.4

0.8

–

3.9

1.0

–

–

3.1

0.2

1.4

0.3

0.6

5.2

–

–

–

–

0.2

0.2

0.0

0.2

0.8

0.0

–

6.4

0.2

–

1.3

0.3

0.2

3.3

0.8

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 dataTable 15. AIDS diagnoses in females and rates per female 100 000 population, by country and year of diagnosis  

(2014–2023) and cumulative totals, in EU/EEA and other countries of the WHO European Region

Centre

Hungary

Austria

Belgium

Bulgaria

Croatia

Cyprus

Czechia

Denmark

Estonia

Finland

France

Germany

Greece

Iceland

Ireland

Italy

Latvia

Liechtenstein

Lithuania

Luxembourg

Malta

Netherlands

Norway

Poland

Portugal

Romania

Slovakia

Slovenia

Spain

Sweden

Andorra

Armenia

Azerbaijan

Belarus

Georgia

Israel

Kazakhstan

Kyrgyzstan

Monaco

San Marino

Serbia

Kosovo[1]

Switzerland

Tajikistan

EU/EEA

West

West

Centre

Centre

Centre

Centre

West

East

West

West

West

West

West

West

West

East

West

East

West

West

West

West

Centre

West

Centre

Centre

Centre

West

West

West

East

East

East

East

West

East

East

West

East

East

West

Centre

Centre

Centre

West

East

East

East

West

East

West

Centre

East

Total EU/EEA

Non-EU/EEA

Centre

Albania

Centre

Bosnia and Herzegovina

Centre Montenegro

Centre

North Macedonia

Republic of Moldova

Russian Federation

Serbia excluding Kosovo[1]

Centre

Türkiye

Turkmenistan

Ukraine

United Kingdom

Uzbekistan

Total non-EU/EEA

WHO European Region

Total WHO European Region

N

18

41

6

0

8

8

7

6

12

185

65

25

187

43

6

0

5

0

9

8

0

49

7

31

100

111

1

0

–

117

212

15

1

34

43

1

74

19

92

16

114

0

0

1

–

0

3

2

1

12

94

26

–

1 055

3 140

100

–

3 997

957

217

3 878

5 052

0.6

0.9

0.3

0.0

0.7

0.2

0.2

0.7

0.2

0.6

0.1

0.4

0.2

0.0

0.4

0.7

5.6

0.0

0.5

1.8

0.0

0.4

0.4

0.2

1.7

1.2

0.0

0.1

0.6

–

0.5

1.0

0.0

3.0

0.8

3.2

0.1

3.4

0.6

0.7

0.6

0.0

0.9

0.3

6.6

–

0.0

0.1

0.2

–

0.4

1.7

0.1

–

15.4

0.4

–

3.1

0.5

0.3

7.4

1.5

26

51

12

0

3

9

6

5

6

212

58

23

10

0

10

218

61

0

8

5

0

38

9

34

91

122

1

1

166

14

0

47

38

1

67

22

66

18

116

0

3

3

–

0

6

6

–

16

72

26

–

132

–

1 151

3 725

120

–

4 526

1 043

245

4 389

5 677

0.4

0.7

0.2

0.0

1.8

0.1

0.4

1.0

0.2

0.5

0.2

0.4

0.1

0.0

0.2

0.6

4.0

0.0

0.6

2.8

0.0

0.6

0.3

0.2

1.8

1.1

0.0

0.0

0.5

–

0.5

1.0

2.8

2.2

0.9

4.1

0.1

3.7

0.5

1.0

0.5

0.0

0.0

0.1

6.6

–

0.0

0.1

0.1

0.1

0.3

2.2

0.1

–

15.9

0.3

–

2.8

0.5

0.2

7.0

1.4

18

34

12

3

1

6

5

17

5

174

61

32

205

24

46

7

12

113

98

103

999

8

0

3

0

7

3

0

0

2

–

8

0

47

36

201

1

73

18

119

10

156

0

0

2

–

0

4

4

–

21

65

13

–

73

–

3 390

4 237

921

170

4 145

5 236

N

13

21

10

2

17

10

4

5

8

143

64

28

16

0

6

215

45

0

8

2

0

41

3

15

90

88

104

958

0

0

–

9

1

33

54

165

0

64

10

136

17

107

0

1

0

–

0

6

6

–

17

83

18

–

75

–

3 696

4 492

845

192

4 413

5 450

0.4

0.6

0.1

0.0

2.8

0.1

0.2

2.4

0.2

0.5

0.1

0.6

0.2

0.0

0.1

0.7

2.3

0.0

0.4

1.0

0.0

0.5

0.3

0.1

2.1

1.0

0.0

0.2

0.4

–

0.4

0.6

0.0

3.0

0.7

3.9

0.1

3.7

0.4

1.3

0.3

0.0

0.0

0.2

9.2

–

0.0

0.1

0.1

–

0.5

1.5

0.0

–

14.8

0.2

–

2.9

0.4

0.2

7.1

1.4

N

10

25

10

9

2

4

5

6

4

51

13

3

2

1

156

157

36

0

8

1

0

38

3

25

98

87

0

0

64

–

818

12

0

64

60

153

0

101

10

154

17

152

0

0

0

–

0

8

7

1

15

63

17

–

66

–

3 434

4 326

719

177

4 248

5 144

0.3

0.4

0.3

0.1

3.9

0.2

0.1

0.7

0.3

0.4

0.2

0.5

0.3

0.0

0.2

0.7

4.3

0.0

0.5

0.7

0.0

0.5

0.1

0.1

1.7

0.9

0.0

0.0

0.4

–

0.4

0.6

2.7

2.1

1.1

3.2

0.0

3.2

0.2

1.4

0.5

0.0

0.3

0.0

6.4

–

0.0

0.1

0.2

–

0.4

1.9

0.0

–

16.2

0.2

–

3.1

0.4

0.2

7.5

1.5

0.2

0.4

0.3

0.1

2.3

0.1

0.2

0.9

0.1

0.5

0.1

0.2

0.1

1.2

0.0

0.5

3.4

0.0

0.5

0.3

0.0

0.4

0.1

0.1

1.8

0.9

0.0

0.0

0.3

–

0.4

0.8

0.0

4.1

1.2

2.9

0.0

5.1

0.2

1.6

0.5

0.0

0.0

0.0

9.2

–

0.0

0.2

0.2

0.1

0.3

1.4

0.0

–

15.2

0.2

–

3.0

0.3

0.2

7.2

1.4

Area

Country, territory or areaa

2014

N

Rate

2015

Rate

2016

N

Rate

2017

2018

Rate

Rate

2019
N

Rate

2020
N

Rate

2021
N

Rate

2022
N

Rate

2023
N

Rate

Cumulative 

totalb Country, territory or areaa

14
29
12
2
26
11
7
9
6
168
19
27
7
1
4
123
37
0
5
2
0
35
5
15
88
96
0
4
56
–
808

13
–
46
46
139
2
66
9
158
9
–
0
–
105
–
0
16
15
1
13
48
20
–
2 850
59
–
3 599

665
224
3 518
4 407

0.3
0.5
0.3
0.1
5.8
0.2
0.2
1.3
0.2
0.5
0.0
0.5
0.1
0.6
0.2
0.4
3.6
0.0
0.3
0.7
0.0
0.4
0.2
0.1
1.6
1.0
0.0
0.4
0.2
–
0.4

0.9
–
3.0
0.9
2.7
0.1
3.3
0.2
1.6
0.3
–
0.0
–
6.4
–
0.0
0.3
0.4
0.1
0.3
1.0
0.0
–
12.7
0.2
–
2.4

0.3
0.2
6.0
1.2

11
23
11
1
14
8
4
5
5
127
–
17
7
0
3
110
16
0
5
6
0
38
1
14
60
56
0
2
66
–
610

2
–
39
28
77
–
47
8
176
15
–
1
–
76
–
0
6
5
1
6
23
13
–
1 660
36
–
2 213

521
135
2 167
2 823

0.2
0.4
0.3
0.0
3.1
0.1
0.1
0.7
0.2
0.4
–
0.3
0.1
0.0
0.1
0.4
1.6
0.0
0.3
1.9
0.0
0.4
0.0
0.1
1.1
0.6
0.0
0.2
0.3
–
0.3

0.1
–
2.5
0.5
1.5
–
2.4
0.2
1.8
0.5
–
0.3
–
4.7
–
0.0
0.1
0.1
0.1
0.1
0.5
0.0
–
8.6
0.1
–
1.5

0.3
0.1
3.9
0.9

11
31
3
2
22
10
3
2
7
144
–
23
11
0
1
102
15
0
9
4
0
24
10
12
94
64
0
2
54
–
660

11
–
51
27
102
–
54
10
170
15
–
1
–
79
–
0
1
1
0
10
32
7
–
1 638
46
–
2 254

574
146
2 194
2 914

0.2
0.5
0.1
0.1
4.8
0.2
0.1
0.3
0.3
0.4
–
0.4
0.2
0.0
0.0
0.3
1.5
0.0
0.6
1.3
0.0
0.3
0.4
0.1
1.7
0.7
0.0
0.2
0.2
–
0.4

0.8
–
3.3
0.5
2.0
–
2.7
0.2
1.7
0.5
–
0.3
–
4.9
–
0.0
0.0
0.0
0.0
0.2
0.7
0.0
–
7.4
0.1
–
1.5

0.3
0.2
3.7
0.9

17
23
9
1
20
16
9
2
3
170
–
18
11
1
3
112
16
–
8
3
0
30
9
33
41
58
3
0
61
–
677

13
–
57
28
–
–
47
8
156
13
–
1
–
107
–
0
4
4
0
12
30
13
–
1 115
70
–
1 674

590
182
1 579
2 351

0.4
0.4
0.3
0.0
4.3
0.3
0.3
0.3
0.1
0.5
–
0.3
0.2
0.5
0.1
0.4
1.6
–
0.5
0.9
0.0
0.3
0.3
0.2
0.8
0.6
0.1
0.0
0.3
–
0.4

0.9
–
3.7
0.5
–
–
2.4
0.2
1.6
0.4
–
0.3
–
6.2
–
0.0
0.1
0.1
0.0
0.3
0.6
0.0
–
5.1
0.2
–
1.2

0.3
0.2
2.9
0.7

11
31
15
2
–
22
12
3
8
179
–
8
13
1
8
114
13
–
14
3
0
22
6
40
38
61
0
0
61
–
698

11
–
59
53
–
–
61
7
138
10
–
2
–
93
–
–
9
9
0
10
39
10
–
1 270
66
–
1 838

585
198
1 753
2 536

0.2
0.5
0.4
0.1
–
0.4
0.4
0.4
0.3
0.5
–
0.2
0.3
0.5
0.3
0.4
1.3
–
0.9
0.9
0.0
0.2
0.2
0.2
0.7
0.6
0.0
0.0
0.3
–
0.4

0.8
–
3.9
1.0
–
–
3.1
0.2
1.4
0.3
–
0.6
–
5.2
–
–
0.2
0.2
0.0
0.2
0.8
0.0
–
6.4
0.2
–
1.3

0.3
0.2
3.3
0.8

EU/EEA
846 Austria
1 913 Belgium
207 Bulgaria
39 Croatia
199 Cyprus
183 Czechia
442 Denmark
170 Estonia
Finland
171
16 478 France
4 709 Germany
757 Greece
182 Hungary
14 Iceland
318 Ireland

16 752 Italy

709 Latvia

1

Liechtenstein

153 Lithuania
148 Luxembourg
14 Malta

1 650 Netherlands

294 Norway
886 Poland
5 207 Portugal
4 530 Romania
16 Slovakia
38 Slovenia

18 137 Spain

405 Sweden
75 581 Total EU-EEA
Non-EU/EEA

188 Albania
4 Andorra
687 Armenia
574 Azerbaijan

2 663 Belarus

28 Bosnia and Herzegovina

1 344 Georgia
529 Israel

1 932 Kazakhstan
228 Kyrgyzstan
11 Monaco
26 Montenegro
36 North Macedonia
2 102 Republic of Moldova
0 Russian Federation
2 San Marino

493 Serbia
473
20

Serbia excluding Kosovo[1]
Kosovo[1]
2 612 Switzerland
727 Tajikistan
346 Türkiye

1

Turkmenistan

37 578 Ukraine
6 827 United Kingdom
157 Uzbekistan

59 106 Total non-EU/EEA

WHO European Region

78 240 West

7 410 Centre

49 036 East
134 686 Total WHO European Region

a   Country/territory/area specific comments are in Annex 5.

b   Cumulative total is the total number of cases reported by the country since the start of reporting.

[1]  All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

[1]  All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

57

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORTTable 16. The most common AIDS-indicative diseases diagnosed in 2023 ordered by frequencya 

Diseases

EU/EEA
Pneumocystis carinii pneumonia
Wasting syndrome due to HIV
Candidiasis; oesophageal
Mycobacterium tuberculosis; pulmonary in an adult or an adolescent (aged 13 
years or over)
Cytomegalovirus disease (other than liver; spleen; or nodes) in a patient over 
one month of age
Kaposi sarcoma
Toxoplasmosis of brain in a patient over one month of age
Mycobacterium tuberculosis; extrapulmonary
Encephalopathy; HIV-related
Cryptococcosis; extrapulmonary
Non-EU/EEA
Wasting syndrome due to HIV
Candidiasis; oesophageal
Mycobacterium tuberculosis; pulmonary in an adult or an adolescent (aged 13 
years or over)
Pneumocystis carinii pneumonia
Mycobacterium tuberculosis; extrapulmonary
Kaposi sarcoma
Encephalopathy; HIV-related
Candidiasis of bronchi; trachea; or lungs
Pneumonia; recurrent in an adult or an adolescent (aged 13 years or over)
Cervical cancer; invasive in an adult or an adolescent (aged 13 years or over)
West
Pneumocystis carinii pneumonia
Candidiasis; oesophageal
Kaposi sarcoma
Wasting syndrome due to HIV
Cytomegalovirus disease (other than liver; spleen; or nodes) in a patient over 
one month of age
Toxoplasmosis of brain in a patient over one month of age
Mycobacterium tuberculosis; pulmonary in an adult or an adolescent (aged 13 
years or over)
Mycobacterium tuberculosis; extrapulmonary
Encephalopathy; HIV-related
Cryptococcosis; extrapulmonary
Centre
Wasting syndrome due to HIV
Pneumocystis carinii pneumonia
Mycobacterium tuberculosis; pulmonary in an adult or an adolescent (aged 13 
years or over)
Candidiasis; oesophageal
Kaposi sarcoma
Encephalopathy; HIV-related
Pneumonia; recurrent in an adult or an adolescent (aged 13 years or over)
Cytomegalovirus disease (other than liver; spleen; or nodes) in a patient over 
one month of age
Mycobacterium tuberculosis; extrapulmonary
Toxoplasmosis of brain in a patient over one month of age
East
Wasting syndrome due to HIV
Candidiasis; oesophageal
Mycobacterium tuberculosis; pulmonary in an adult or an adolescent (aged 13 
years or over)
Pneumocystis carinii pneumonia
Mycobacterium tuberculosis; extrapulmonary
Encephalopathy; HIV-related
Pneumonia; recurrent in an adult or an adolescent (aged 13 years or over)
Candidiasis of bronchi; trachea; or lungs
Kaposi sarcoma
Cervical cancer; invasive in an adult or an adolescent (aged 13 years or over)

Men
N

577
297
276

217

204

208
134
109
105
55

201
194

150

131
125
83
64
54
42
10

447
231
216
177

171

115

101

85
68
41

149
146

112

65
54
45
31

39

31
30

172
174

154

115
118
56
28
26
21
0

%

22.4
11.5
10.7

8.4

7.9

8.1
5.2
4.2
4.1
2.1

12.5
12.1

9.3

8.1
7.8
5.2
4.0
3.4
2.6
0.6

22.4
11.6
10.8
8.9

8.6

5.8

5.1

4.3
3.4
2.1

16.6
16.2

12.4

7.2
6.0
5.0
3.4

4.3

3.4
3.3

13.3
13.5

11.9

8.9
9.1
4.3
2.2
2.0
1.6
0.0

Women
N

189
97
106

87

62

15
59
57
21
23

121
100

45

44
34
25
22
23
25
36

148
85
32
58

53

55

52

48
16
18

42
37

36

23
3
7
15

8

12
8

118
98

44

48
31
20
17
14
5
24

%

21.4
11.0
12.0

9.9

7.0

1.7
6.7
6.5
2.4
2.6

16.6
13.7

6.2

6.0
4.7
3.4
3.0
3.2
3.4
4.9

20.6
11.8
4.5
8.1

7.4

7.6

7.2

6.7
2.2
2.5

16.5
14.6

14.2

9.1
1.2
2.8
5.9

3.1

4.7
3.1

18.5
15.3

6.9

7.5
4.9
3.1
2.7
2.2
0.8
3.8

Children

N

3
3
2

1

2

1
0
2
4
1

1
0

0

0
1
0
1
0
0
0

2
2
1
2

2

0

1

1
1
1

1
1

0

0
0
3
2

0

0
0

1
0

0

0
2
1
0
0
0
0

%

11.5
11.5
7.7

3.8

7.7

3.8
0.0
7.7
15.4
3.8

14.3
0.0

0.0

0.0
14.3
0.0
14.3
0.0
0.0
0.0

13.3
13.3
6.7
13.3

13.3

0.0

6.7

6.7
6.7
6.7

10.0
10.0

0.0

0.0
0.0
30.0
20.0

0.0

0.0
0.0

12.5
0.0

0.0

0.0
25.0
12.5
0.0
0.0
0.0
0.0

Total
N

769
397
384

305

268

224
193
168
130
79

323
294

195

175
160
108
87
77
67
46

597
318
249
237

226

170

154

134
85
60

192
184

148

88
57
55
48

47

43
38

291
272

198

163
151
77
45
40
26
24

%

22.1
11.4
11.0

8.7

7.7

6.4
5.5
4.8
3.7
2.3

13.8
12.5

8.3

7.5
6.8
4.6
3.7
3.3
2.9
2.0

21.9
11.7
9.1
8.7

8.3

6.2

5.6

4.9
3.1
2.2

16.5
15.8

12.7

7.6
4.9
4.7
4.1

4.0

3.7
3.3

15.0
14.0

10.2

8.4
7.8
4.0
2.3
2.1
1.3
1.2

a  Numbers and percentages relate to AIDS indicative disease events reported: some people diagnosed with AIDS have more than one event reported at the time of 

diagnosis.

58

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 dataTable 17. AIDS-related deaths, by country and year of death (2014–2023) and cumulative totals in EU/EEA and other 
countries of the WHO European Regiona

Area

Country, territory or areab

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

Year of diagnosis

Cumulative 
totalc

EU/EEA
West
West
Centre
Centre
Centre
Centre
West
East
West
West
West
West
Centre
West
West
West
East
West
East
West
West
West
West
Centre
West
Centre
Centre
Centre
West
West

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italyb
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spainb
Sweden
Total EU/EEA

Non-EU/EEA
Centre
West
East
East
East
Centre
East
West
East
East
West
Centre Montenegro
Centre
East
East
West
Centre
Centre
Centre
West
East
Centre
East
East
West
East

Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco

North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia

Serbia excluding Kosovo[1]
Kosovo[1]
Switzerland
Tajikistan
Türkiye
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Total non-EU/EEA

WHO European Region
West
Centre
East
Total WHO European Region

15
34
13
0
4
14
0
2
5
127
101
45
15
0
0
573
72
0
10
5
1
36
3
31
208
240
0
4
234
–
1 792

13
0
50
57
170
1
48
33
141
47
0
2
0
102
–
0
10
10
0
0
75
11
–
3 426
128
–
4 313

1 548
357
4 200
6 105

15
21
8
2
2
12
1
2
6
103
76
47
11
0
1
535
38
0
7
5
1
44
2
33
177
200
4
5
185
–
1 543

12
3
62
44
127
5
52
25
169
50
0
6
0
89
–
0
16
15
1
0
92
4
–
3 032
77
–
3 865

1 324
317
3 767
5 408

15
27
9
3
0
17
2
2
5
129
77
41
11
0
1
487
37
0
23
7
3
46
0
24
189
199
2
3
179
–
1 538

12
0
53
41
127
2
107
30
180
56
0
2
0
98
–
0
13
10
3
0
111
4
–
3 253
76
–
4 165

1 314
301
4 088
5 703

16
20
10
2
0
15
1
4
9
134
71
46
8
0
1
298
31
0
15
2
0
35
2
18
168
201
1
1
110
–
1 219

4
0
74
34
88
0
78
18
213
59
0
4
2
81
–
0
14
14
0
0
152
4
–
3 298
68
–
4 191

999
282
4 129
5 410

15
16
9
2
0
16
2
4
6
193
71
42
16
0
0
262
29
0
14
2
0
30
1
17
159
181
3
1
81
–
1 172

11
0
61
40
120
2
76
19
251
60
0
2
1
78
–
0
26
25
1
0
121
8
–
3 448
59
–
4 383

958
295
4 302
5 555

14
32
17
9
0
5
1
1
1
207
34
39
16
0
2
240
29
0
5
7
0
30
1
12
116
177
2
0
29
–
1 026

8
–
61
37
117
2
51
17
263
36

4
–
61
–
0
23
21
2
0
104
4
–
2 977
49
–
3 814

819
279
3 742
4 840

7
28
6
6
0
20
2
6
0
200
–
35
10
1
2
218
12
0
12
7
0
30
0
14
76
149
1
0
48
–
890

4
–
52
33
63
–
63
20
251
36
–
1
–
102
–
0
16
16
0
0
72
1
–
2 114
81
–
2 909

755
228
2 816
3 799

14
24
13
5
1
22
4
5
2
196
–
25
12
0
1
194
6
0
18
3
0
28
0
6
97
158
0
1
39
–
874

11
–
65
31
33
–
38
14
207
46
–
4
–
51
–
0
14
14
0
0
55
1
–
1 928
123
–
2 621

764
248
2 483
3 495

20
35
11
3
0
16
4
2
2
203
–
23
19
0
3
0
16
–
16
8
0
36
1
24
74
213
0
1
40
–
770

10
–
52
23
–
–
53
16
186
51
–
2
–
47
–
0
21
21
0
0
45
7
–
1 293
128
–
1 934

593
326
1 785
2 704

12
30
7
7
0
22
0
0
0
195
–
34
13
0
1
0
16
–
14
3
0
66
0
19
58
130
1
2
33
–
663

10
–
57
13
–
–
62
7
138
57
–
2
–
93
–
–
13
13
0
0
60
6
–
1 474
120
–
2 112

559
232
1 984
2 775

1 256
2 296
246
138
73
365
1 802
134
242
37 970
14 970
1 918
474
40
426
44 539
927
6
256
263
65
1 413
635
1 416
11 121
5 623
53
109
49 161
1 323
179 260

216
4
869
1 434
2 291
69
1 210
884
3 485
770
18
69
67
1 621
0
8
1 268
1 220
48
0
1 244
134
1
58 242
7 821
323
82 048

178 175
10 303
72 830
261 308

a  This table includes deaths reported as due to AIDS and excludes deaths reported as not due to AIDS-related cases. In countries and years for which cause of death 

(AIDS or non-AIDS related) was unknown or could not be reported, deaths among persons (ever) diagnosed with AIDS were included. 

b  Country/territory/area-specific comments are in Annex 5. Spain has changing national coverage of AIDS reporting during the period (see Annex 5) and trends should 

be interpreted with caution. Mortality statistics for 2021–2022 were unavailable in Italy.

c  Cumulative total is the total number of deaths reported by country since the start of reporting.

[1]  All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

59

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORTTable 18. Number of HIV tests performed, excluding unlinked anonymous testing and testing of blood donations, by 
country and year (2014–2023) and number of tests per 1000 population in 2023, in EU/EEA and other countries of the 
WHO European Region

Area

Country, territory or areaa

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

Number of HIV tests

Tests/1000 
population 
in 2023

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden

EU/EEA
West
West
Centre
Centre
Centre
Centre
West
East
West
West
West
West
Centre
West
West
West
East
West
East
West
West
West
West
Centre
West
Centre
Centre
Centre
West
West
Non-EU/EEA
Centre
West
East
East
East
Centre
East
West
East
East
West
Centre Montenegro
Centre
East
East
West
Centre
Centre
Centre
West
East
Centre
East
East
West
East

Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco

North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia

Serbia excluding Kosovo[1]
Kosovo[1]
Switzerland
Tajikistan
Türkiye
Turkmenistan
Ukraine
United Kingdom
Uzbekistan

–
697 684
230 000
–
–
349 448
151 970
82 266
–
5 336 653
–
240 116
93 289
–
168 028
–
60 614
–
108 781
–
–
–
–
272 102
260 437
332 422
126 187
35 498
–
–

4 156
2 378
94 122
612 860
1 157 072
–
86 290
–
2 190 757
410 331
–
6 571
27 430
133 476
29 878 681
3 427
56 282
56 282
–
–
634 791
6 663 547
–
1 853 626
–
–

–
692 679
290 000
–
–
345 274
153 050
87 587
–
5 449 230
–
192 150
91 793
–
178 267
–
65 552
–
105 486
–
–
–
–
318 458
282 800
346 032
127 109
34 366
–
–

5 442
2 212
117 012
714 621
1 249 712
–
78 261
–
2 388 347
376 284
–
6 607
28 601
146 762
30 750 547
1 548
63 189
61 877
1 312
–
597 426
7 203 959
–
1 695 926
–
–

–
726 457
–
–
52 385
350 234
163 779
90 136
–
5 555 386
–
196 257
–
–
192 956
–
79 715
–
104 132
71 200
–
–
–
440 365
281 992
360 893
104 876
35 788
–
–

5 582
2 340
99 270
500 469
1 464 386
–
119 868
–
2 587 065
331 609
–
6 324
30 211
124 010
32 855 597
3 600
68 426
65 827
2 599
–
509 092
6 263 020
–
1 697 479
–
–

–
715 536
–
–
–
351 650
158 331
102 863
–
5 699 670
–
176 966
–
–
223 609
–
82 608
–
113 917
100 529
–
–
–
430 662
291 305
338 898
111 340
37 315
–
–

–
734 506
360 000
–
–
353 425
155 609
112 487
–
5 916 036
–
187 627
–
–
239 571
–
90 368
–
109 825
–
–
–
–
385 173
308 328
323 468
177 498
38 570
–
–

7 149
2 591
119 628
657 704
1 514 635
–
207 175
–
2 742 741
376 431
–
5 606
36 248
160 947

11 219
2 712
132 509
753 568
1 627 169
–
188 142
–
2 760 324
356 765
–
6 890
34 634
154 575
36 445 059 40 485 246
3 411
81 530
76 653
4 877
–
780 688
7 457 674
–
1 868 565
–
–

3 685
80 918
76 367
4 551
–
612 123
7 107 551
–
1 816 023
–
–

–
763 413
360 000
–
–
359 327
158 009
125 273
–
6 337 548
–
305 433
–
–
247 490
–
98 651
–
133 810
–
–
–
–
432 929
352 926
334 410
–
40 462
–
–

13 261
–
164 933
722 136
1 488 199
–
441 119
–
2 877 706
424 087
–
6 575
40 596
182 196
41 900 729
2 200
90 508
88 490
2 018
–
1 062 509
10 257 015
–
1 961 711
–
–

–
629 063
340 000
–
37 326
329 433
144 859
105 285
–
5 457 414
–
250 450
–
12 253
206 516
–
93 036
–
112 489
–
–
–
–
432 074
272 310
234 520
–
23 798
–
–

159 281
–
159 281
665 000
1 242 389
–
–
–
2 877 706
367 948
–
5 375
34 439
152 500
36 110 128
1 550
64 332
63 090
1 242
–
836 487
7 067 571
–
1 501 984
–
–

–
694 792
–
–
41 900
386 943
146 263
106 051
–
5 999 391
–
263 046
–
13 947
224 072
–
103 843
–
125 918
–
–
–
–
460 882
333 382
243 718
–
40 147
–
–

–
706 294
–
–
–
431 832
149 263
115 538
–
6 501 139
–
236 911
–
16 835
243 870
–
119 274
–
129 082
–
–
–
–
699 717
437 645
287 865
–
51 143
–
–

156 175
–
156 175
664 614
1 316 274
–
422 900
–
3 315 560
546 133
–
6 372
40 879
141 100
41 277 712
630
86 166
82 737
3 429
–
909 536

208 833
–
208 833
774 714
1 488 640
–
298 500
–
3 581 123
612 785
–
6 831
39 596
273 666
47 205 207
2 627
96 389
89 317
7 072
–
919 083
9 379 998 10 092 464
–
1 068 483
–
–

–
1 428 952
–
–

–
745 514
–
–
–
387 381
175 440
115 229
–
7 513 155
–
336 812
–
18 928
260 355
–
122 647
–
129 545
–
–
–
–
415 021
 460323 
285 629
–
53 992
–
–

214 595
–
214 595
693 236
1 478 722
–
554 060
–
4 117 260
675 151
–
8 092
47 308
269 466
51 002 495
1 570
114 015
107 312
6 703
–
105 6582
7 689 302
–
1 622 466
–
–

–
63.5
–
–
–
35.8
29.4
84.4
–
110.2
–
32.3
–
50.3
49.4
–
65.1
–
45.3
–
–
–
–
11.3
44.7
14.83
–
25.5
–
–

–
–
–
66.6
155.7
–
148.6
–
210.0
100.2
–
12.9
22.7
78.4
353.1
46.7
–
16.0
3.8
–
–
89.6
–
44.2
–
–

a   Country/territory/area specific comments are in Annex 5.

[1]  All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

60

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 dataMaps

61

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORTMap 1a. HIV diagnoses per 100 000 population, 2023

< 3
3 to < 5
5 to < 10
10 to < 20
> 20  
Missing or excluded data

Non-visible countries

Andorra
Liechtenstein
Luxembourg
Malta
Monaco
San Marino

0

1000

2000 km

Map 1b. HIV diagnoses per 100 000 population, 2023, EU/EEA

< 3
3 to < 5
5 to < 10
10 to < 15
> 15  
Missing or excluded data

Non-visible countries

Andorra
Liechtenstein
Luxembourg
Malta
Monaco
San Marino

62

0

1000

2000 km

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 dataMap 2. HIV diagnoses in men per 100 000 male population, 2023

< 5
5 to < 10
10 to < 20
20 to < 30
> 30  
Missing or excluded data

Non-visible countries

Andorra
Liechtenstein
Luxembourg
Malta
Monaco
San Marino

0

1000

2000 km

Map 3. HIV diagnoses in women per 100 000 female population, 2023

< 3
3 to < 5
5 to < 10
10 to < 15
> 15  
Missing or excluded data

Non-visible countries

Andorra
Liechtenstein
Luxembourg
Malta
Monaco
San Marino

0

1000

2000 km

63

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORTMap 4. HIV diagnoses in men who have sex with men per 100 000 male population, 2023

< 3
3 to < 5
5 to < 10
10 to < 15
> 15  
Missing or excluded data

Non-visible countries

Andorra
Liechtenstein
Luxembourg
Malta
Monaco
San Marino

0

1000

2000 km

Map 5. HIV diagnoses acquired through heterosexual transmission per 100 000 population, 2023

< 3
3 to < 5
5 to < 10
10 to < 15
> 15  
Missing or excluded data

Non-visible countries

Andorra
Liechtenstein
Luxembourg
Malta
Monaco
San Marino

64

0

1000

2000 km

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 dataMap 6. HIV diagnoses acquired through injecting drug use per 100 000 population, 2023

< 0.3
0.3 to < 1
1 to < 3
3 to < 5
> 5  
Missing or excluded data

Non-visible countries

Andorra
Liechtenstein
Luxembourg
Malta
Monaco
San Marino

0

1000

2000 km

Map 7. AIDS diagnoses reported per 100 000 population, 2023

< 0.5
0.5 to < 1
1 to < 3
3 to < 5
> 5  
Missing or excluded data

Non-visible countries

Andorra
Liechtenstein
Luxembourg
Malta
Monaco
San Marino

0

1000

2000 km

65

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORTAnnexes

66

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 dataAnnex 1. Framework for data collection, 
validation and presentation

Reporting
The  Member  States’  Coordinating  Competent  Bodies  in 
European Union (EU) and European Economic Area (EEA) 
(jointly referred to as EU/EEA) countries have nominated 
national  operational  contact  points 
for  HIV/AIDS 
surveillance  to  work  on  reporting  surveillance  data  to 
the  joint  European  Centre  for  Disease  Prevention  and 
Control  (ECDC)  and  the  WHO  Regional  Office  for  Europe 
database  for  HIV/AIDS  surveillance.  For  non-EU/EEA 
countries, 
HIV/AIDS 
surveillance  focal  points  were  received  directly  by  the 
WHO  Regional  Office  for  Europe  via  the  respective 
ministries of health. 

nominations 

national 

for 

Data  are  submitted  directly  by  reporting  countries 
through a web-based platform to a joint database known 
as  The  European  Surveillance  System  (TESSy).  Four 
types  of  data  are  collected:  HIV  (case-based  and 
aggregate),  AIDS  (case-based  and  aggregate),  HIVAIDS 
(case-based data that link HIV and AIDS diagnoses) and 
number of HIV tests performed (aggregate). AIDS-related 
deaths  are  reported  as  part  of  case-based  AIDS  or 
HIVAIDS  data.  All  new  HIV  diagnoses,  irrespective  of 
whether the case is diagnosed simultaneously with AIDS 
or  reported  as  a  new  AIDS  diagnosis,  are  classified  as 
HIV cases. 

Implementation of WHO and EU case definitions for HIV 
and AIDS surveillance means that only confirmed cases 
are reported at European level (1,2). It is recognized that 
the  HIV  and  AIDS  case  definitions  currently  used  in  a 
number of countries may differ across the WHO European 
Region,  but  the  EU  and  WHO  case  definitions  are 
compatible  for  surveillance  purposes.  Since  2016,  the 
case  definitions  have  been  changed  in  the  Russian 
Federation. Updated forms (N61) of the Federal Statistical 
Surveillance  are  submitted  by  medical  facilities  to  the 
Ministry of Health and include the number of individuals 
newly  diagnosed  with  HIV  infection;  2009–2015  data 
therefore  cannot  be  directly  compared  to  2016–2023 
data.  A  built-in  set  of  validation  rules  in  TESSy  ensures 
verification  of  the  data  within  the  database  during  the 
data-uploading  process,  improving  data  quality  and 
allowing  each  country  to  test  their  datasets  prior  to 
submission. Further validation checks are carried out by 
ECDC  and  the  WHO  Regional  Office  for  Europe  in 
collaboration  with  countries  before 
the  data  are 
considered of sufficient quality to be used for analysis.

Andorra, Monaco, Turkmenistan and Uzbekistan did not 
report any HIV data through TESSy for 2023 (or previous 
years for some of the countries − see Table 1). Andorra, 
Germany, 
Bosnia 
Liechtenstein,  Monaco,  North  Macedonia,  the  Russian 

Herzegovina, 

Cyprus, 

and 

Federation,  Sweden,  Turkmenistan  and  Uzbekistan  did 
not report any AIDS data for 2023 (or previous years for 
some of the countries − see Table 13). 

The  completeness  of  key  variables  is  presented  for  the 
EU/EEA  and  the  WHO  European  Region  as  a  whole  in 
Annex 2 and by country in Annex 3.

Surveillance systems – data sources 

To  describe  the  national  source  of  data  and  specify  the 
national  surveillance  system  from  which  the  reported 
data originate, information on the country data source is 
included  as  a  compulsory  part  of  reporting  (detailed  in 
Annex 4a and 4b.) Some cross-country data comparisons 
are  hampered  by  differences  in  surveillance  systems, 
and by the quality and coverage of national surveillance. 
These  issues  are  detailed  in  Annex  5  and  should  be 
taken  into  account  when  interpreting  and  comparing 
trends across countries.

Data collection and validation
Data collection 2024

The 2023 data submission for HIV and AIDS surveillance 
took  place  between  25  April  and  3  October  2024.  Data 
presented in this report were extracted from TESSy on 5 
October 2024

Individual country datasets

Data were uploaded, validated and approved in the joint 
database  for  HIV/AIDS  surveillance  by  the  reporting 
countries.  Once  the  data  were  submitted,  individual 
datasets were reviewed by ECDC and the WHO Regional 
Office  for  Europe  and  validated  by  countries.  The 
HIVAIDS record type was used for the first time in 2014 
to  collect  case-based  joined  HIV  and  AIDS  data  (Annex 
4a and 4b). The joined record type allows understanding 
of the relationship between the HIV and AIDS events and 
diagnosis dates. Additional details on record type used 
per country can be found in Annexes 4a and 4b. 

Reporting  of  aggregated  HIV  and  AIDS  data  has  an 
impact  on  the  data  presentation  and  analysis  and  the 
epidemiological overview of HIV/AIDS in Europe because 
fewer  variables  are  available  from  the  aggregated 
datasets,  reducing  the  amount  of  data  that  can  be 
presented in certain tables and figures.

67

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORTData re-coding and adjustments
Dates used for data presentation

HIV and AIDS data are presented in this report by date of 
diagnosis.  If  countries  could  not  provide  this  date  or 
preferred to present their data by the date of statistics to 
avoid  discrepancies  with  their  national  surveillance 
reports,  this  date  was  used  instead.  This  was  the  case 
for  four  countries:  Armenia,  Belarus,  Türkiye  and 
Ukraine. 

Region of origin 

Where  available,  countries  were  encouraged  to  provide 
data  on  the  specific  country  of  origin  or  nationality  of 
the case. This information was used first and, if absent, 
the variable “region of origin” was used to group cases 
into region of origin, presented in Table 10 (stratified by 
reporting  country)  and  Table  11  (all  countries  stratified 
by mode of transmission). 

Origin of reported cases 

Cases originating from countries outside of the reporting 
country  are  highlighted 
in  some  of  the  analyses 
presented here. This approach has been taken to inform 
epidemiological  understanding  and  guide  public  health 
resource allocation and prevention efforts. 

Reporting delay

The  data  in  this  report  has  not  been  adjusted  for 
reporting  delays.  This  is  primarily  due  to  the  impact  of 
the  COVID-19  pandemic  and  the 
incorporation  of 
previously reported positive diagnoses into the analysis. 

Data presentation
Geographical presentation

Data  are  presented  for  the  WHO  European  Region  and 
the  EU/EEA.  The  EU  comprises  27  Member  States  and 
(Iceland, 
the  EEA  an  additional 

three  countries 

Fig. A1.1. Geographical/epidemiological division of the WHO European Region

West
Centre
East

Non-visible countries

Andorra
Liechtenstein
Luxembourg
Malta
Monaco
San Marino

0

1000

2000 km

Note: the countries covered by the report are grouped as follows:

•  west, 23 countries: Andorra, Austria*, Belgium*, Denmark*, Finland*, France*, Germany*, Greece*, Iceland, Ireland*, Israel, Italy*, Luxembourg*, Malta*, Monaco, 

Netherlands*, Norway, Portugal*, San Marino, Spain*, Sweden*, Switzerland, the United Kingdom;

•  centre, 15 countries: Albania, Bosnia and Herzegovina, Bulgaria*, Croatia*, Cyprus*, Czechia*, Hungary*, North Macedonia, Montenegro, Poland*, Romania*, Serbia, 

Slovakia*, Slovenia*, Türkiye and;

•  east, 15 countries: Armenia, Azerbaijan, Belarus, Estonia*, Georgia, Kazakhstan, Kyrgyzstan, Latvia*, Lithuania*, Republic of Moldova, the Russian Federation, 

Tajikistan, Turkmenistan, Ukraine, Uzbekistan.

*  Countries constituting the European Union as of 2022.

68

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 dataLiechtenstein  and  Norway)  which  are  included  in  the 
overview of the EU/EEA. 

on 

into 

areas, 

The tables are presented for EU/EEA countries, non-EU/
EEA countries and as totals. The 53 countries of the WHO 
European  Region  are  also  subdivided 
three 
geographical 
epidemiological 
based 
considerations and in accordance with the division used 
in  previous  reports  on  HIV/AIDS  surveillance  in  Europe: 
west  (23  countries),  centre  (15  countries)  and  east  (15 
countries) (Fig. A1.1). The division reflects similarities in 
epidemiological  dynamics,  such  as  epidemic  levels, 
trends  over  time  and  transmission  patterns.  Among  the 
EU/EEA  countries,  18  Member  States  are  classified  as 
being  in  the  west,  nine  in  the  centre  and  three  in  the 
east. 

Liechtenstein is not a WHO Member State, so its data are 
included in the totals for the EU/EEA but not for the WHO 
European  Region.  Totals  for  west,  centre  and  east 
therefore may not always equal the EU/EEA and non-EU/
EEA  totals.  Data  from  Serbia  include  HIV  cases  notified 
in Kosovo[1] in all figures, although these are stratified in 
tables to allow separate epidemiological presentation of 
the reported data. 

Population data and rates 

Data  are  presented  in  absolute  numbers  and  rates  as 
cases per 100 000 population.

The population estimates up to 2023 were derived from 
Eurostat  for  all  EU/EEA  countries  and  from  the  United 
Nations  Population  Division  for  non-EU/EEA  countries23 
(3).  The  Eurostat  data  are  from  May  2023  (4)  and  the 
United  Nations  Population  Division  statistics  are  from 
the 2023 round of estimates (5). 

The  population  data  used  for  AIDS  in  Spain  were 
adjusted according to the extent of subnational coverage 
for  the  relevant  years  historically  (see  Annex  5  for 
details). 

Rates  for  data  presented  by  gender  and  age  were 
calculated  using  relevant  male  and  female  population 
denominators  from  the  sources  described  above.  For 
maps  presenting  figures  for  men  who  have  sex  with 
men, rates were calculated using the male population.

Data are presented by year but also as cumulative totals 
per  country.  The  cumulative  total  includes  all  data 
reported  by  that  particular  country  since  the  beginning 
of  national  reporting  and  is  not  limited  to  the  selected 
number of years presented in that given table.

23 Due to discrepancies in the methodology used for calculating the 

population rates by the Russian Federal Statistics Service and the United 
Nations Population Division, rates on overall HIV diagnoses, as well as 
data disaggregated by sex presented in Tables 1, 2, 3 and elsewhere in the 
report may differ from the data presented in national statistics.

[1]  All references to Kosovo in this document should be understood to be in the 

context of the United Nations Security Council resolution 1244 (1999). 

Trend data

Only  countries  reporting  consistently  were  included  for 
presentation of the overall trends; these are noted in the 
footnotes to the trend graphs.

inconsistently 

When  presenting  HIV  trends  for  2014−2023  countries 
reporting  data 
(Andorra,  Monaco, 
Turkmenistan  and  Uzbekistan)  and  those  reporting  on 
transmission mode inconsistently or incompletely (such 
as  Estonia,  Latvia,  Poland,  the  Russian  Federation  and 
Türkiye)  were  excluded  from  relevant  figures  reporting 
trends by transmission mode. 

AIDS  trends  for  2014−2023  excluded  countries  not 
reporting consistently over the period (Andorra, Cyprus, 
Germany,  Monaco,  the  Russian  Federation,  Sweden, 
Turkmenistan and Uzbekistan).

When  analysing  trends  for  AIDS  deaths,  only  countries 
reporting consistently were included (Andorra, Germany, 
Italy,  Monaco, 
the  Russian  Federation,  Sweden, 
Turkmenistan and Uzbekistan were not included). 

Data limitations
Surveillance  systems  are  not  identical  across  Europe, 
and  differences  in  testing  policies  and  data  collection 
methods could affect the results and introduce bias into 
comparisons between countries. Factors such as under-
reporting and reporting delay may influence the country 
figures and rankings presented in the report.

The  data  in  the  report  for  recent  years  are  to  be 
considered  as  provisional  because  they  are  subject  to 
regular  updates  (such  as  detection  and  deletion  of 
duplicate cases, and inclusion of new information about 
limitations  described 
cases  already  reported).  The 
below,  the  country  comments  in  Annex  5  and  the 
information  on  HIV  and  AIDS  case  reporting  systems 
available in Annex 4 and 5 should be taken into account 
when interpreting the data presented here.

Official  reports  of  HIV  diagnoses  do  not  represent  true 
incidence.  Reported  HIV  diagnoses  include  recently 
infected  people,  as  well  as  those  who  were  previously 
positive, or infected several years ago but only recently 
tested  for  HIV.  These  reports  are  also  influenced  by 
several  factors,  such  as  the  uptake  of  HIV  testing, 
patterns  of  reporting,  the  long  incubation  period  and  a 
slow  progression  of  the  disease.  To  better  interpret 
trends  in  HIV  case-reporting  data,  the  total  numbers  of 
HIV  tests  performed  annually  for  diagnostic  purposes 
(excluding  unlinked  anonymous  tests  and  screening  of 
blood  donations)  are  presented  to  help  provide  some 
background  on  HIV  testing  patterns.  The  absence  of 
standardization  and  consistent  collection  of  the  HIV 
status  variable,  which  distinguishes  between  first-time 
diagnoses  and  previous  positive  diagnoses,  has 
presented challenges in interpreting the data from 2023.

In  2023,  although  it  was  not  feasible  to  account  for 
reporting delays, it is essential to emphasize that only a 
limited  number  of  European  countries  have  assessed 

69

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORTEuropean Commission; 2022 (http://eur-lex.europa.eu/LexUriServ/
LexUriServ.do?uri=CONSLEG:2002D0253:20120927:EN:PDF). 

3.  World population prospects: the 2017 revision, DVD edition. New 
York: United Nations, Department of Economic and Social Affairs, 
Population Division; 2017.

4. 

Eurostat [online database]. Brussels: Eurostat; 2022 (http://
ec.europa.eu/eurostat/data/database).

5.  World population prospects 2024 [website]. United Nations 

Department of Economic and Social Affairs, Population Division; 
2022 (https://population.un.org/wpp/).

6. 

EuroHIV 2006 survey on HIV and AIDS surveillance in the WHO 
European Region. Saint-Maurice: Santé publique France; 2007 
(https://www.santepubliquefrance.fr/maladies-et-traumatismes/
infections-sexuellement-transmissibles/vih-sida/documents/rap-
port-synthese/eurohiv-2006-survey-on-hiv-and-aids-surveillance-
in-the-who-european-region).

their  surveillance  systems  for  under-reporting  and 
subsequently shared the findings (3). Previous estimates 
of  under-reporting  range  from  0%  to  41%  for  AIDS 
cases,24  while  national  estimates  of  under-reporting  for 
HIV  can  range  from  10%  (Iceland  and  Italy)  to  around 
40% (Germany and the United Kingdom) (6). 

Estimates on the under-reporting of AIDS-related deaths 
are not available, but according to a country survey from 
2006,  only  around  one  third  of  countries  were  able  to 
comprehensively  link  HIV  and  AIDS  surveillance  death 
registries  with  national  statistics  or  death  certificate 
information,  which  results  in  under-reporting  of  AIDS-
related deaths.25

References26

1.  WHO case definitions of HIV for surveillance and revised clinical 
staging and immunological classification of HIV-related disease 
in adults and children. Geneva: World Health Organization; 2007 
(https://iris.who.int/handle/10665/43699).

2. 

European Commission Decision 2002/253/EC laying down 
case definitions for reporting communicable diseases to the 
Community network under Decision No 2119/98/EC of the European 
Parliament and of the Council. OJ L 27.09.12:6–7. Brussels: 

24 F. Cazein, Santé Publique France, personal communication, 2021.

25  Ibid. 

26  All references were accessed 14 November 2024.

70

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 dataAnnex 2

Table A2.1. Completeness of variables for data reported in 2022 and 2023 

Number of 
countries 

2022

Completeness 
%

Minimal 

Maximal 

Number of 
countries 

2023

Completeness 
%

Minimal 

Maximal 

EU/EEA Countries
Age
Gender
Transmission
Country of birth or region of origin 
CD4 cell count
HIV status 
WHO European Region
Age
Gender
Transmission
Country of birth or region of origin
CD4 cell count
HIV status

30
30
30
28
27
25

48
48
47
40
45
34

99.5
99.8
73.2
87.8
60.5
58.5

99.8
99.9
81.0
82.7
68.4
35.9

88.8
91.5
31.2
50.7
6.4
2.1

88.8
91.5
18.9
15.1
6.4
2.1

100
100
100
100
99.6
100

100
100
100
100
99.6
100

30
30
30
28
27
26

48
48
48
41
44
34

99.5
99.8
72.4
85.8
59.8
57.1

99.8
99.9
81.2
82.8
70.1
34.6

86.8
94.5
62.9
28.2
15.9
11.5

86.8
94.7
22.3
10.2
12.0
11.5

100
100
100
100
100
100

100
100
100
100
100
100

71

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORTAnnex 3

Table A3.1 Completeness by country and variable, 2023

Area

Country, territory or areaa

Age

Gender

Transmission

CD4 cell count

Country of birth/
region of originb

HIV status 

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden

EU/EEA
West
West
Centre
Centre
Centre
Centre
West
East
West
West
West
West
Centre
West
West
West
East
West
East
West
West
West
West
Centre
West
Centre
Centre
Centre
West
West
Non-EU/EEA
Centre
West
East
East
East
Centre
East
West
East
East
West
Centre Montenegro
Centre
East
East
West
Centre
Centre
Centre
West
East
Centre
East
East
West
East

Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco

North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia
 Serbia excluding Kosovo[1]
 Kosovo[1]
Switzerland
Tajikistan
Türkiye
Turkmenistan
Ukraine
United Kingdom
Uzbekistan

100
99.6
100
100
99.4
100
100
99.5
100
100
99.4
100
93
100
100
100
100
100
100
100
86.8
100
100
97.4
100
100
100
100
100
99.7

100
–
100
100
100
–
100
100
100
100
–
100
100
100
100
–
100
100
100
100
100
100
–
100
100
–

100
99.8
100
100
99.4
100
100
100
100
100
99.9
99.7
94.7
100
100
100
100
100
100
100
99.1
100
100
99.4
100
100
100
100
99.7
100

100
–
100
100
100
–
100
100
100
100
–
100
100
100
100
–
100
100
100
98.9
100
100
–
100
100
–

92.1
84.1
100
97.3
98.0
93.8
89.7
63.3
79.9
78.5
83.1
79.9
84.4
97.2
82.6
93.6
69.6
100
89.4
92.2
71.6
91.6
87.0
62.9
96.0
99.6
77.5
96.4
90.1
88.2

93.5
–
98.0
99.0
98.2
–
97.2
83.5
96.3
92.7
–
88.9
100.0
90.5
100.0
–
–
82.7
–
63.5
94.5
28.8
–
99.8
86.8
–

97.4
70.0
87.0
56.7
100
87.8
47.6
86.9
67.4
56.9
31.9
37.2
0.0
36.4
15.9
98.3
34.0
100
77.2
85.0
0.0
98.9
95.8
0.0
77.1
96.2
25.4
81.8
88.8
65.1

93.5
–
0.0
88.7
87.7
–
85.6
69.4
91.7
86.1
–
46.3
96.0
85.5
96.1
–
94.9
98.1
70.0
59.3
93.8
12.0
–
85.5
88.3
–

99.5
79.6
100
100
98.0
100
97.1
65.0
42.3
77.5
91.1
59.2
88.4
100
80.7
99.1
0.0
100
100
95.8
0.0
98.6
100
69.1
98.6
98.9
28.2
100
97.9
99.7

100
–
99.8
100
100
–
100
91.9
99.5
99.2
–
100
100
100
100
–
100
100
100
0.0
99.7
85.3
–
0.0
92.3
–

100
100
14.6
75.3
95.7
99.8
100
100
52.5
75.9
100
100
0.0
100.0
73.1
0.0
100
100
29.6
100
40.4
100
89.8
11.5
100
0.0
64.1
54.5
0.0
95.7

100
–
–
–
0.0
–
0.0
99.0
–
0.0
–
100
0.0
0.0
–
–
–
–
–
24.5
0.0
0.0
–
0.0
0.0
–

a   Completeness not computed on countries, territories or areas with fewer than five diagnoses reported in 2023 or countries that reported in the aggregated record 

type which did not allow reporting of all variables (Russian Federation).

b  Completeness provided is based on country of birth, region of origin or, for Italy and Switzerland, country of nationality.

[1]  All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

72

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 dataAnnex 4a

Table A4.1. HIV surveillance system overview: data source information

Country, territory  
or area

HIV data source

Record typea 
for 2023 
reporting

Period

Legalb

Coveragec

Comments

V

C
C
C
C
C
C
C

C
C

C

C
C
C
C

C

C
C

C

V
C
V
C
C
C
C

C
C
C
C

C
V
V
V
C

EU/EEA
Austria

Belgium
Bulgaria
Cyprus
Croatia
Czechia
Denmark
Estonia

Finland
France

Germany

Greece
Hungary
Iceland
Ireland

Italy

AT-HIV

HIVAIDS

1980–2023

BE-HIV/AIDS
BG-HIV
CY-HIV/AIDS
HR-CNIPH
CZ-HIV/AIDS
DK-HIV
EE-NAKIS 

FI-NIDR
FR-HIVAIDS

HIVAIDS
HIVAIDS
HIVAIDS
HIVAIDS
HIVAIDS
HIVAIDS
HIVAIDS

HIVAIDS
HIVAIDS

DE-SURVNET@RKI7.3-HIV

EL-HIV/AIDS
HU-HIV/AIDS
IS-SUBJECT_TO_REGISTRATION
IE-CIDR 

HIVAIDS
HIVAIDS
HIVAIDS
HIVAIDS

1985–2023
1986–2023
1986–2023
1985–2023
1985–2023
1990–2023
1988–2023

1980–2023
2003–2023

1993–2023

1984–2023
1985–2023
1983–2023
1985–2023

IT-COA-ISS

HIV

1985–2023

Latvia
Liechtenstein

LV-HIV/AIDS
LI-HIVAIDS

HIVAIDS
HIVAIDS

1987–2023
2021–2023

Lithuania

LT-NPHC 

HIVAIDS

1988–2023

Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania

Slovakia
Slovenia
Spain
Sweden

non-EU/EEA
Albania
Andorra
Armenia
Azerbaijan
Belarus

Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Montenegro
Monaco
North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia
Switzerland
Tajikistan
Türkiye
Turkmenistan
Ukraine

LU-HIVAIDS
MT-DISEASE_SURVEILLANCE
NL-HIV/AIDS
NO-MSIS_B
PL-HIV
PT-HIVAIDS
RO-RSS

SK-EPIS
SI-HIVAIDS
ES-HIV
SE-SmiNet

AL-NIoPH
AD-MoHWFH
AM-NAC
AZ-AIDS-CENTER-NEW
BY-NAC

BA-FMoH-MoHSWRS
GE-IDACIRC
IL-MOH
KZ-RCfAPC
KG-HIV KG 2008
ME-IOPH
MC-MoSH-GEN
MK-NHASS
MD-NAC
RU-MOH
SM-AIDS/HIV
RS-NAC
CH-FOPH
TJ-RHAC
TR-MOH
TM-NAC
UA-NAC

United Kingdom
Uzbekistan
Kosovo[1]

UK-HIVAIDS
UZ-RAC
XK-IPH

HIVAIDS
HIVAIDS
HIVAIDS
HIVAIDS
HIVAIDS
HIVAIDS
HIVAIDS

HIVAIDS
HIVAIDS
HIV
HIVAIDS

HIVAIDS
HIVAIDS
HIVAIDS
HIVAIDS
HIVAIDS

HIVAIDS
HIVAIDS
HIVAIDS
HIVAIDS
HIVAIDS
HIVAIDS
HIV
HIVAIDS
HIVAIDS
HIVAGGR
HIVAGGR
HIVAIDS
HIV
HIVAIDS
HIV
–
HIVAIDS

HIVAIDS
–
HIVAIDS

1983–2023
2001–2023
1980–2023
1984–2023
1985–2023
1985–2023
1987–2023

1985–2023
1985–2023
2003–2023
1983–2023

1993–2023
2004–2018
1988–2023
1987–2023
1981–2023

C
C
C

1986–2022
1989–2023
1981–2023
1987–2023 NS/unk
1987–2023
1989–2023
1987–2018
1993–2023
1987–2023
2009-2023
1985–2022
1984–2023
1985–2023
1991–2023
1985–2023
1990–2012
1987–2023

V
C
C
C
V
C
C
C
C
C
C
V
V

1981–2023
1981–2010
1986–2023

V
V
V

Co

Co
Co
Co
Co
Co
Co
Co

Co
Co

Co

Co
Co
Co
Co

Co

Co
Co

Co

Co
Co
Co
Co
Co
Co
Co

Co
Co
Co
Co

Co
Co
Co
Se
Co

Co
Co
Co
NS/unk
Co
Co
Co
Co
Other
Co
Co
Co
Co
Co
Co
Co
Other

Co
Co
Co

HIV surveillance in Austria is based on the AHIVCOS (Austrian HIV cohort 
study), which in 2022 represented 64% of people who had ever received 
antiretroviral therapy in Austria. 
–
HIV aggregate record type used through 2006; HIV record type 2007–2013
–
HIV record type used prior to 2016
–
HIV record type used 1990–2013
Data source EE-HIV used 1988–2012; HIV aggregate record type used through 
2006; HIV record type prior to 2015
HIV record type used prior to 2016
Although compulsory, HIV diagnoses are not exhaustively reported; 
underreporting was estimated between 23% and 27% until 2018, then 
increased during the coronavirus diease pandemic years (42% in 2021), then 
decreased (30% in 2023). This underreporting is lower in hospitals (21% in 
2023).
Data source DE-HIV-Pre-IfSG used 1993–2001; HIV recordtype used to report 
data up to 2016
–
HIV record type used 1985–2013
HIV record type used prior to 2017
Data source IE-HIV/AIDS used for years 1981–2011; HIV aggregate used for 
reporting through 2002; HIV record type 2003–2011
See country comments about historical coverage (Annex 5); HIV aggregate 
record type used through 2009. Mortality statistics for 2022-2023 were 
unavailable.
HIV record type used 1987–2013; HIVAIDS record type used from 2014
Cases reported through Switzerland's surveillance system using another data 
source through 2020
New data source LT_NPHC (National Public Health Centre under the Ministry of 
Health) from 2021

–
HIV record type used in years 1986–2014
–
HIV record type used in years 1980–2013
–
–
Data source: Compartment for Monitoring and Evaluation of HIV/AIDS Data 
in Romania, National Institute for Infectious Diseases "Prof. Dr. Matei Bals". 
National coverage. 
HIV record type used in years 1985–2013
–
See country comments about historical coverage (Annex 5) 
Data source SE-SweHIVReg used 1983–2009; HIV record type used prior to 
2014

–
–
–
–
HIVAIDS record type used only for HIV reporting (no linked HIV and AIDS 
reporting); HIV record type used in years 1981–2013
HIV record type used in years 1993–2013
–
–
–
HIV record type used in years 1987–2000
–
–
HIV record type used in years 1993–2016
–
–
–
HIV aggregate record type used in years 1984–2001
–
–
–
–
HIVAIDS record type used only for HIV reporting (no linked HIV and AIDS 
reporting); HIVAGGR record type used in years 1987–2015.
–
Did not report data 2011–2020; used HIV record type in years 1981–2010
HIVAIDS record type used for all years

a   Type: HIVAIDS: HIV and AIDS joined case-based record type; HIV: HIV case-based record type; AIDS: AIDS case-based record type; HIVAGGR: HIV aggregate record 

type; AIDSAGGR: AIDS aggregate record type.

b  Legal: V: voluntary reporting; C: compulsory reporting; NS/unk: not-specified/unknown.
c   Coverage: Se: sentinel system; Co: comprehensive; NS/unk: not-specified/unknown.

73

[1]  All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORTAnnex 4b

Table A4.2. AIDS surveillance system overview: data source information

Country, territory 
or area

AIDS Data source

Record 
typea 
for 2023 
reporting

Period

Legalb

Coveragec

Comments

EU/EEA
Austria

Belgium
Bulgaria
Cyprus
Croatia
Czechia
Denmark
Estonia
Finland
France

Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein

AT-AIDS

HIVAIDS

1982–2023

BE-HIV/AIDS
BG-AIDS
CY-HIV/AIDS
HR-CNIPH
CZ-HIV/AIDS
DK-HIV
EE-NAKIS 
FI-NIDR
FR-HIVAIDS; FR-AIDS

DE-AIDS
EL-HIV/AIDS
HU-HIV/AIDS
IS-SUBJECT_TO_REGISTRATION
IE-CIDR
IT-COA-ISS
LV-AIDS
LI-HIVAIDS

HIVAIDS
HIVAIDS
HIVAIDS
HIVAIDS
HIVAIDS
HIVAIDS
HIVAIDS
HIVAIDS
HIVAIDS

–
HIVAIDS
HIVAIDS
HIVAIDS
HIVAIDS
AIDS
HIVAIDS
HIVAIDS

1983–2023
1987–2023
1986–2023
1986–2023
1986–2023
1980–2023
1992–2023
1983–2023
1982–2023

1981–2019
1981–2023
1986–2023
1985–2023
1983–2023
1982–2023
1990–2023
2021–2023

Lithuania

LT-NPHC 

HIVAIDS

1988–2023

Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania

LU-HIVAIDS
MT-DISEASE_SURVEILLANCE
NL-HIV/AIDS
NO-MSIS_B
PL-HIV
PT-HIVAIDS
RO-RSS

Slovakia
Slovenia
Spain
Sweden
non-EU/EEA
Albania
Andorra
Armenia
Azerbaijan
Belarus
Bosnia and Herzegovina
Georgia
Israel
Kazakhstan
Kyrgyzstan
Montenegro
Monaco
North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia
Switzerland
Tajikistan
Türkiye
Turkmenistan
Ukraine

SK-EPIS
SI-HIVAIDS
ES-AIDS

AL-NIoPH
AD-MoHWFH
AM-NAC
AZ-AIDS-CENTER-NEW
BY-NAC
BA-FMoH-MoHSWRS
GE-IDACIRC
IL-MOH
KZ-RCfAPC
KG-HIV KG 2008
ME-IOPH
MC-MoSH-GEN
MK-NHASS
MD-NAC
-
SM-AIDS/HIV
RS-NAC
CH-FOPH
TJ-RHAC
TR-MOH
TM-NAC
UA-NAC

HIVAIDS
HIVAIDS
HIVAIDS
HIVAIDS
HIVAIDS
HIVAIDS
HIVAIDS

HIVAIDS
HIVAIDS
AIDS
–

HIVAIDS
HIVAIDS
HIVAIDS
HIVAIDS
AIDS
HIVAIDS
HIVAIDS
HIVAIDS
HIVAIDS
HIVAIDS
HIVAIDS
AIDS
HIVAIDS
HIVAIDS
–
AIDS
HIVAIDS
AIDS
HIVAIDS
AIDS
–
AIDSAGGR

1983–2023
1986–2023
1999–2023
1983–2023
1986–2023
1985–2023
1985–2023

1985–2023
1986–2023
1981–2023
1982–2007

1993–2023
2004–2018
1988–2023
1995–2022
1991–2023
1986–2019
1989–2023
1981–2023
1993–2023
1999–2023
1990–2023
1985–2018
1989–2018
1989–2023
–
1986–2023
1985–2023
1980–2023
1998–2023
1985–2023
2002–2012
1988–2023

United Kingdom
Uzbekistan

UK-HIVAIDS
UZ-RAC

HIVAIDS
–

1981–2023
1992–2010

Kosovo[1]

XK-IPH

HIVAIDS

1986–2023

V

V
C
C
C
C
C
C
C
C

V
C
C
C
V
C
C
C

C

V
C
V
C
C
C
C

C
C
C
V

C
V
V
V
C
C
C
C
NS
V
C
C
C
V
–
C
C
C
C
C
V
V

V
V

V

Co

Co
Co
Co
Co
Co
Co
Co
Co
Co

Co
Co
Co
Co
Co
Co
Co
Co

Co

Co
Co
Co
Co
Co
Co
Co

Co
Co
Co
Co

Co
Co
Se
Co
Co
Co
Co
Co
NS
Co
Co
Co
Co
Co
–
Co
Co
Co
Co
Co
Co
Co

Co
Co

Co

HIV surveillance in Austria is based on the AHIVCOS (Austrian HIV cohort 
study), which in 2022 represented 64% of people who had ever received 
antiretroviral therapy in Austria. 
–
AIDS record type was used for cases prior to 2014
–
AIDS record type used prior to 2016
–
AIDS record type from data source DK-MIS used 1980–2013
AIDS record type used prior to 2015
AIDS record type used prior to 2016
Additional data from record type AIDS used for the years 1978–2023. 
Although compulsory, AIDS diagnoses are not exhaustively reported. 
Underreporting was estimated at 41% in 2007–2009, then increased to 
46% in 2016–2017. It was estimated at 42% in 2023.
Did not report 2020 data, AIDS record type used through 2016
–
AIDS record type used 1986–2013
AIDS record type used prior to 2017
Data source IE-HIV/AIDS and AIDS record type used for years 1981–2011 
Mortality statistics for 2022–2023 were unavailable.
Same data source in AIDS record type used for 1990–2013
Cases reported through Switzerland's surveillance system using another 
data source through 2020
New data source LT_NPHC (National Public Health Centre under the 
Ministry of Health) from 2021
–
Same data source and AIDS record type used 1986–2014
–
Data source NO-MSIS-A and record type AIDS used in years 1980–2013
–
–
Data source: Compartment for Monitoring and Evaluation of HIV/AIDS 
Data in Romania, National Institute for Infectious Diseases "Prof. Dr. 
Matei Bals". National coverage. 
AIDS record type used in years 1985–2013
–
See country comments about coverage
AIDS surveillance discontinued in 2008

–
–
–
–
–
AIDS record type used in years 1986–2013
–
–
–
AIDS record type used in years 1987-2000
–
–
AIDS record type used in years 1993–2016
–
–
–
AIDS record type used in years 1985–2001
–
–
–
–
HIVAIDS record type used only for HIV reporting (i.e. no linked HIV and 
AIDS reporting)
–
Did not report data 2011–2020; used AIDS record type in years 
1992–2010
HIVAIDS record type used for all years

a  Type: HIVAIDS: HIV and AIDS joined case-based record type; HIV: HIV case-based record type; AIDS: AIDS case-based record type; HIVAGGR: HIV aggregate record 

type; AIDSAGGR: AIDS aggregate record type.

b   Legal: V: voluntary reporting; C: compulsory reporting; NS/unk: not-specified/unknown.
c  Coverage: Se: sentinel system; Co: comprehensive; NS/unk: not-specified/unknown.
74

[1]  All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 dataAnnex 5

Table A5.1. Country-specific comments regarding national HIV and AIDS reporting

Country, territory or area

Comments

EU/EEA

Austria

Belgium

Bulgaria

Croatia

Cyprus

Czechia

Denmark

Estonia

Finland

France

Germany

Greece

Hungary

Iceland

Ireland

Italy

Latvia

Liechtenstein

Lithuania

Luxembourg

Malta

Netherlands

Norway

Poland

Portugal

HIV surveillance in Austria is based on the AHIVCOS (Austrian HIV cohort study), which in 2022 represented 64% of people who had ever 
received antiretroviral therapy in Austria. 

–

Case-based reporting of HIV is available from 2007 onwards.

–

–

Foreigners with short-term stays in Czechia are not included in cases notified. The increase in the number of cases in 2022 and 2023 compared 
to the previous years is clearly due to the arrival of Ukrainians in connection with the war in Ukraine, who account for 77.7% and 52.7% of the 
cases reported in 2022 and 2023, respectively.

–

The surveillance system was modified substantially in 2008. Previously, the probable mode of HIV transmission was not reported by Estonia 
(from 2003 to 2007, Estonia supplied partial information on people who inject drugs only).

–

Since 2016, HIV and AIDS diagnoses should be reported online, and physicians should report HIV diagnoses spontaneously, without waiting for 
the laboratory report. 
Case-based data reported through The European Surveillance System (TESSy) are not exhaustive because of reporting delays (cases reported 
several months or years after the diagnosis) and underreporting (cases that are diagnosed but never reported). The coronavirus disease 
pandemic has affected French HIV surveillance by increasing the underreporting in 2020 and 2021, which affects the reliability of adjusted 
number of HIV and AIDS diagnoses. 
The most recent estimates of underreporting in France are 42% in 2023 for AIDS and 30% in 2023 for HIV. Considering only reports in hospitals, 
HIV underreporting would be estimated at 21% in 2023.  
To assess the real numbers and trends of HIV and AIDS diagnoses in France, it is essential to use adjusted data, which take into account 
reporting delays, underreporting and missing data (incomplete reports). The actual number of new HIV diagnoses in 2023, after adjustment, 
is estimated at 5 473, 95% confidence interval (CI): 5 343–5 603. The actual number of AIDS diagnoses in 2023 is estimated at 937 (95% CI: 
862–1013.  
Transgender people known to be infected by sexual intercourse are not classified as men who have sex with men nor heterosexual, but as 
"Sexual transmission" in French surveillance data. This category does not exist in TESSy, so transgender people infected through sexual 
intercourse are listed as "unknown transmission mode".

–

Previous positive cases are classified, according to the year of diagnosis abroad. In case the date of HIV diagnosis abroad is not available, the 
date of the first positive HIV test in Greece is used

Case report for HIV has been available since 1985 and for AIDS since 1986.

–

HIV was made a notifiable disease in September 2011. The HIV reporting system was modified substantially in 2012. AIDS cases and deaths 
among AIDS cases are now only reported at the time of HIV diagnosis. HIV diagnoses include a growing proportion of so-called previous-
positive people, who are transferring their HIV care when moving to Ireland and tested positive and were notified within the Irish system 
when moving to the country. These people are excluded when reviewing late diagnosis. There was a change in the implementation of the case 
definition in 2015 (requiring confirmatory testing on a single sample rather than two samples) which resulted in more people being notified to 
the surveillance system. 

Data on new HIV diagnoses have been collected since 1985 in some regions of Italy. New HIV diagnoses were reported by 10 of the 21 Italian 
regions between 2004 and 2006, 11 regions in 2007, 12 in 2008, 18 in 2009 and all of the 21 regions of Italy since 2012. Between 2004 and 
2011, population denominators were based on the annual resident population in the regions reporting cases. From 2012, the coverage of the 
surveillance system has been national, so the total Italian population is used as a denominator. AIDS deaths are not reported after 2017 due to 
lack of updated data from the national mortality register.

–

Liechtenstein is a small country with about 39 000 inhabitants. Due to a customs treaty with Switzerland, Liechtenstein adopted the Swiss Law 
of Epidemiology in 2015. Since then, all communicable diseases collected in Liechtenstein are reported to a Swiss database.  

–

HIV tests reported through 2010 include only tests performed at two major public laboratories, so underestimate the total number of HIV tests 
performed during those years. From 2011, tests reported include all laboratories in the country. 

A new HIV reporting system started in 2004. Due to the different data cut-off times between the European Centre for Disease Prevention and 
Control (ECDC) and national data collection, there are some discrepancies between ECDC data and the national reports. These differences are 
explained as follows: 
HIV diagnosis in men who acquired HIV through sex with men should read 41 in 2019 
HIV diagnosis in men who acquired HIV through intersexual contact should read 15 in 2019  
AIDS diagnosis and rates per 100 000 population should read 1 in 2020 and 2 in 2023 
AIDS diagnosis in males and rates per 100 000 population should read 2 in 2023 
AIDS diagnosis in females and rates per 100 000 population should read 1 in 2020.

HIV surveillance is based on the ATHENA cohort, which includes 98% of people who entered HIV care in the Netherlands. Data collection 
started from 1996 onwards and HIV diagnoses before 1996 are incomplete. The national Dutch HIV monitoring report publishes slightly 
different figures than those displayed in the European report because migrants with a documented HIV diagnosis before arrival in Netherlands 
are excluded in the national report. 

–

There were an increased in the number of cases in Poland due to the arrival of Ukraine war refugees, who account for 22.3% of reported cases 
in 2023. 

The PT-HIV database is fully case-based, containing details of HIV and AIDS cases diagnosed from 1983. Strategies to address underreporting 
and reporting delay implemented in 2013 and 2017, by the Portuguese HIV/AIDS Programme, resulted in a significant increase in the number of 
reported cases and deaths for all previous years.

75

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORTTable A5.1. contd.

Country, territory or area

Comments

Romania

Slovakia

Slovenia

Spain

Sweden

Non-EU/EEA

Albania

Andorra

Armenia

Azerbaijan

Belarus

The Romanian surveillance and reporting system has been implemented since the beginning of the 1990s, in real time. The data is collected 
in the National HIV/AIDS Registry, where the patients are recorded one-time only, wihout duplicates. Updates in the patients' data are made 
constantly with changes from HIV to AIDS. The national reporting addressess to the Ministry of Health, the National Public Health Institute , 
on a quarterly basis. Also, the information is available, in-real time, for the respective year. Annually, the data is transmitted to ECDC and any 
other international entity involved in the field, including the Joint United Nations Programme on HIV/AIDS and WHO, in the case where they are 
sollicited. The statistical evaluation is made with SPECTRUM. The national HIV/AIDS Regsitry is stored at The National Institute for Infectious 
Diseases "Prof. Dr. matei Bals" through the Compartment for Monitoring and Evaluation of HIV/AIDS. 

–

–

HIV reporting has existed since the 1980s in some of the 19 Autonomous Regions of Spain. For 2003–2011 data are available only for nine 
Regions: Asturias, Balearic Islands, Basque Country, Canary Islands, Catalonia, Ceuta, Extremadura, La Rioja, and Navarre; since 2004, data 
are available for 10 Regions (+Galicia); since 2007, data are available for 11 Regions (+Madrid); since 2008, data are available for 14 Regions 
(+ Aragón, Castilla-La Mancha and Melilla); since 2009, data are available for 17 Regions (+Cantabria, Castilla-León and Murcia); since 2012 
data are available for 18 Regions (+Valencia); and since 2013 data are available for all the 19 Regions of Spain (+Andalucía). In 2018, data 
from Catalonia are not available. AIDS data: For technical reasons, it has not been possible to include AIDS data from one region in 2014, two 
regions from 2015 to 2022, and three in 2023. Rates are based on the corresponding population for each year.

Due to changes in the HIV/AIDS surveillance system, AIDS reporting has not been mandatory since 2005. Since 2008, AIDS data are not 
reported from Sweden because the national AIDS surveillance system had been discontinued. 

–

–

–

All data are presented by "date of statistics" (instead of "date of diagnosis").

All data are presented by "date of statistics" (instead of "date of diagnosis").

Bosnia and Herzegovina

–

Georgia

Israel

Kazakhstan

Kyrgyzstan

Monaco

Montenegro

Data are presented by "date of statistics" (instead of "date of diagnosis").

Discrepancies may exist between the figures displayed in the report and those presented in the country's national statistics.

–

–

–

Data on HIV tests refer to the number of people tested and do not include people tested in the private laboratories. 

North Macedonia

AIDS cases include only people diagnosed with AIDS at the time of HIV diagnosis.

Republic of Moldova

–

Russian Federation

San Marino

Serbia

Switzerland

Tajikistan

Türkiye

Turkmenistan

Ukraine

United Kingdom

The Russian Federation reported an aggregated dataset with new HIV diagnoses registered in 2023 disaggregated by sex, age group and 
mode of transmission and data on testing for 2023, whereas data reported for 2009–2019 was limited to new HIV diagnoses by sex only. This 
enabled the inclusion of the country’s data in Tables 1–12 and 18 and in the figures showing the trend of HIV diagnosis but not in the rest of 
the trend figures due to inconsistent reporting. The country also reported separately information about CD4 cell count at the time of diagnosis. 
These data were manually entered into Table 12. 
Since 2016, case definitions have been changed in the Russian Federation. Updated Forms (N61) of the Federal Statistical Surveillance are 
submitted by medical facilities to the Ministry of Health and include the number of individuals newly diagnosed with HIV infection. Data for 
2009–2015 cannot therefore be compared directly with those for 2016–2023. 
Due to discrepancies in the methodology used for calculating the population rates by the Russian Federal Statistics Service and the United 
Nations Population Division, rates on overall HIV diagnoses, as well as data disaggregated by sex, presented in the report in Tables 1, 2 and 3 
and elsewhere in the report may differ from the data presented in national statistics.

–

Data on HIV tests refer to the number of people tested and do not include people tested in the reference laboratory or private laboratories. 

–

Due to technical problems, no data export for 2018 from Tajikistan was available.

Reported HIV cases exclude people diagnosed with AIDS at the time of HIV diagnosis. Reported AIDS cases only include people diagnosed with 
AIDS at the time of HIV diagnosis. Table 14 (see Tables section): CD4 cell count data exclude people diagnosed with AIDS at the time of HIV 
diagnosis. All data are presented by "date of statistics" (instead of "date of diagnosis").

–

Ukraine’s national HIV and AIDS case notification system was established in 1987. It is a mandatory reporting system where health 
facilities routinely collect data from all 25 regions of Ukraine and, since 2018, report the data to the information system for monitoring 
socially significant diseases. The major gap in HIV Surveillance in Ukraine is that there is no HIV case electronic registration right after the 
confirmation of positive test results, so all data for TESSy are presented by “date of statistics” (instead of “date of diagnosis”). The war in 
Ukraine starting in 2022 caused a significant population migration, which has had a negative impact on the completeness and quality of data.

Data for the United Kingdom in 2023 excludes diagnoses made in Northern Ireland which were not available at the time of publication. Rises 
in HIV diagnoses in 2022 and 2023 have largely been driven by increases in people previously diagnosed abroad arriving in the United 
Kingdom and subsequently diagnosed in the United Kingdom. The majority of these people were rapidly linked to care, on treatment and virally 
suppressed.

Uzbekistan

Kosovo[1]

–

–

[1]  All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

76

SURVEILLANCE REPORTHIV/AIDS surveillance in Europe 2024 – 2023 dataAnnex 6

Table A6.1. HIV/AIDS surveillance in Europe: participating countries and national institutions

Country, territory or area

National institutions

EU/EEA
Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland

Portugal

Romania
Slovakia
Slovenia
Spain
Sweden
Non-EU/EEA
Albania
Andorra
Armenia
Azerbaijan
Belarus

Bosnia and Herzegovina

Georgia
Israel
Kazakhstan
Kyrgyzstan
Monaco
Montenegro
North Macedonia
Republic of Moldova
Russian Federation
San Marino
Serbia
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdom
Uzbekistan
Kosovo[1]

Austrian Agency for Health and Food Safety; Federal Ministry of Social Affairs, Health, Care and Consumer Protection
Sciensano 
Ministry of Health
Croatian National Institute of Public Health
Ministry of Health
National Institute of Public Health
Statens Serum Institut
Health Board 
National Institute for Health and Welfare (THL).
Santé Publique France (French National Public Health Agency)
Robert Koch Institute
Hellenic Center for Disease Control and Prevention
National Center for Public Health and Pharmacy
Directorate of Health, Centre for Health Security and Communicable Disease Control
Health Protection Surveillance Centre (HPSC)
Ministry of Health DG Prevention - Unit V
Centre for Disease Prevention and Control of Latvia 
Principality of Liechtenstein
National Public Health Center under the Ministry of Health
National Service of Infectious Diseases, Centre Hospitalier
Department of Health Promotion and Disease Prevention
National Institute for Public Health and the Environment (RIVM)
Norwegian Institute of Public Health
National Institute of Public Health NIH - National Research Institute
Directorate-General of Health (Direção-Geral da Saúde) and National Institute of Health Dr Ricardo Jorge (Instituto Nacional de Saúde Doutor 
Ricardo Jorge, I.P.)
Institute of Public Health and National Institute for Infectious Diseases "Prof. Dr. Matei Bals"
Regional Public Health Authority of capital Bratislava
National Institute of Public Health
Instituto de Salud Carlos III - Centro Nacional de Epidemiología
Public Health Agency of Sweden

National Institute of Public Health
Ministry of Health, Social Welfare and Family
National Center For Infectious Diseases
Azerbaijan AIDS Center
National Centre for Hygiene, Epidemiology and Public Health
Ministry of Civil Affairs of Bosnia and Herzegovina; Federal Ministry of Health; Ministry of Health and Social Welfare the Republica Srpska; and 
Public Health Institutes of the Federation of Bosnia and Herzegovina and Republica Srpska
Infectious Diseases, AIDS & Clinical Immunology Research Center
Ministry of Health
National Center for the Prevention and Control of AIDS
Republic Centre for AIDS Prevention and Control
Ministry of Social Health
Institute of Public Health of Montenegro
Public Health Institute
National AIDS Center; National Center for Preventative Care
Ministry of Health of the Russian Federation
Ospedale di Stato
Institute of Public Health of Serbia
Bundesamt für Gesundheit
Republican HIV/AIDS Center
General Directorate of Public Health, Ministry of Health
National AIDS Prevention Center
State Institution "Public Health Center of the Ministry of Health of Ukraine"
UK Health Security Agency
Republican AIDS Center
Institute of Public Health

[1]  All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council resolution 1244 (1999).

77

HIV/AIDS surveillance in Europe 2024 – 2023 dataSURVEILLANCE REPORTEU publications
You can download or order free and priced EU publications 
from  EU  Bookshop  at:  http://publications.europa.eu/
eubookshop.  Multiple  copies  of  free  publications  may 
be  obtained  by  contacting  Europe  Direct  or  your  local 
information centre (see http://europa.eu/contact).

Address requests about publications of the WHO 
Regional Office for Europe to:  
Publications  
WHO Regional Office for Europe  
UN City, Marmorvej 51  
DK-2100 Copenhagen Ø, Denmark 

European Centre for Disease 
Prevention and Control (ECDC)

Gustav III:s Boulevard 40 
SE-169 73 Solna, Sweden

Tel. +46 858 60 10 00
Fax +46 858 60 10 01
www.ecdc.europa.eu 

Contact us 
ECDC.Info@ecdc.europa.eu

 Follow us on Twitter 

@ECDC_EU

 Like our Facebook page 
www.facebook.com/ECDC.EU

World Health Organization 
Regional Office for Europe

UN City, Marmorvej 51 
DK-2100 Copenhagen Ø, Denmark

Tel. +45 45 33 70 00
Fax +45 45 33 70 01
www.who.int/europe

Contact us 
eucontact@who.int

 Follow us on Twitter 

@WHO_EUROPE

 Like our Facebook page 

www.facebook.com/WHOEurope

ECDC PDF

ISBN 978-92-9498-757-0

ISSN 2363-3085

doi 10.2900/3113714

TQ-01-24-013-EN-N

WHO  PDF

ISBN 978-92-8906-155-1